<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2678792-A2" country="EP" doc-number="2678792" kind="A2" date="20140101" family-id="45809682" file-reference-id="299490" date-produced="20180826" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146551277" ucid="EP-2678792-A2"><document-id><country>EP</country><doc-number>2678792</doc-number><kind>A2</kind><date>20140101</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-12707449-A" is-representative="NO"><document-id mxw-id="PAPP154825200" load-source="docdb" format="epo"><country>EP</country><doc-number>12707449</doc-number><kind>A</kind><date>20120222</date><lang>EN</lang></document-id><document-id mxw-id="PAPP186997019" load-source="docdb" format="original"><country>EP</country><doc-number>12707449.0</doc-number><date>20120222</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140447662" ucid="US-201161445315-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>201161445315</doc-number><kind>P</kind><date>20110222</date></document-id></priority-claim><priority-claim mxw-id="PPC140445943" ucid="US-2012026145-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>2012026145</doc-number><kind>W</kind><date>20120222</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1988130910" load-source="docdb">G06F  19/18        20110101AFI20120913BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-2012758012" load-source="docdb" scheme="CPC">G06F  19/28        20130101 LI20151017BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2012758081" load-source="docdb" scheme="CPC">C12Q   1/6883      20130101 FI20151017BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2012758495" load-source="docdb" scheme="CPC">G06F  19/18        20130101 LI20151017BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2012758714" load-source="docdb" scheme="CPC">G06F  19/20        20130101 LI20151017BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2012760505" load-source="docdb" scheme="CPC">C12Q2600/158       20130101 LA20151017BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2012760932" load-source="docdb" scheme="CPC">C12Q2600/148       20130101 LA20151017BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132186315" lang="DE" load-source="patent-office">VERFAHREN ZUR IDENTIFIKATION KOSMETISCHER MITTEL FÜR HAUTPFLEGEZUSAMMENSETZUNGEN</invention-title><invention-title mxw-id="PT132186316" lang="EN" load-source="patent-office">METHODS FOR IDENTIFYING COSMETIC AGENTS FOR SKIN CARE COMPOSITIONS</invention-title><invention-title mxw-id="PT132186317" lang="FR" load-source="patent-office">PROCÉDÉS D'IDENTIFICATION D'AGENTS COSMÉTIQUES POUR DES COMPOSITIONS DE SOINS DE LA PEAU</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR918167094" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>PROCTER &amp; GAMBLE</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR918152653" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>THE PROCTER &amp; GAMBLE COMPANY</last-name></addressbook></applicant><applicant mxw-id="PPAR918985415" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>The Procter and Gamble Company</last-name><iid>100236799</iid><address><street>One Procter &amp; Gamble Plaza</street><city>Cincinnati, OH 45202</city><country>US</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR918173907" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>BINDER ROBERT LLOYD</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918154883" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>BINDER, ROBERT, LLOYD</last-name></addressbook></inventor><inventor mxw-id="PPAR918982973" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>BINDER, ROBERT, LLOYD</last-name><address><street>10371 Birkemeyer Drive</street><city>Montgomery, Ohio 45242</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918162203" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>YOUNGQUIST ROBERT SCOTT</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918164379" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>YOUNGQUIST, ROBERT, SCOTT</last-name></addressbook></inventor><inventor mxw-id="PPAR918986025" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>YOUNGQUIST, ROBERT, SCOTT</last-name><address><street>8511 Charleston Knoll Court</street><city>Mason, Ohio 45040</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918166126" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>XU JUN</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918146662" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>XU, JUN</last-name></addressbook></inventor><inventor mxw-id="PPAR918989158" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>XU, JUN</last-name><address><street>7867 Winding Creek Court</street><city>Mason, Ohio 45040</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918170617" load-source="docdb" sequence="4" format="epo"><addressbook><last-name>JUHLIN KENTON DUANE</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918173523" load-source="docdb" sequence="4" format="intermediate"><addressbook><last-name>JUHLIN, KENTON, DUANE</last-name></addressbook></inventor><inventor mxw-id="PPAR918988649" load-source="patent-office" sequence="4" format="original"><addressbook><last-name>JUHLIN, KENTON, DUANE</last-name><address><street>5920 Woodspoint Drive</street><city>Milford, Ohio 45150</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918158863" load-source="docdb" sequence="5" format="epo"><addressbook><last-name>OSBORNE ROSEMARIE</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918163738" load-source="docdb" sequence="5" format="intermediate"><addressbook><last-name>OSBORNE, ROSEMARIE</last-name></addressbook></inventor><inventor mxw-id="PPAR918993250" load-source="patent-office" sequence="5" format="original"><addressbook><last-name>OSBORNE, ROSEMARIE</last-name><address><street>6370 Brown Road</street><city>Oxford, Ohio 45056</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918163961" load-source="docdb" sequence="6" format="epo"><addressbook><last-name>HARTMAN SCOTT MICHAEL</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918164233" load-source="docdb" sequence="6" format="intermediate"><addressbook><last-name>HARTMAN, Scott, Michael</last-name></addressbook></inventor><inventor mxw-id="PPAR918993871" load-source="patent-office" sequence="6" format="original"><addressbook><last-name>HARTMAN, Scott, Michael</last-name><address><street>6859 OBannon Bluff</street><city>Loveland, Ohio 45140</city><country>US</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR918984356" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Holmes, Rosalind</last-name><iid>101328030</iid><address><street>Procter &amp; Gamble Service GmbH Patent Department Berliner Allee 65</street><city>64274 Darmstadt</city><country>DE</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="US-2012026145-W"><document-id><country>US</country><doc-number>2012026145</doc-number><kind>W</kind><date>20120222</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2012116081-A2"><document-id><country>WO</country><doc-number>2012116081</doc-number><kind>A2</kind><date>20120830</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS548837099" load-source="docdb">AL</country><country mxw-id="DS548929329" load-source="docdb">AT</country><country mxw-id="DS548930624" load-source="docdb">BE</country><country mxw-id="DS548927039" load-source="docdb">BG</country><country mxw-id="DS548934735" load-source="docdb">CH</country><country mxw-id="DS548930625" load-source="docdb">CY</country><country mxw-id="DS548865670" load-source="docdb">CZ</country><country mxw-id="DS548837100" load-source="docdb">DE</country><country mxw-id="DS548930630" load-source="docdb">DK</country><country mxw-id="DS548930631" load-source="docdb">EE</country><country mxw-id="DS548816093" load-source="docdb">ES</country><country mxw-id="DS548927040" load-source="docdb">FI</country><country mxw-id="DS548927041" load-source="docdb">FR</country><country mxw-id="DS548837101" load-source="docdb">GB</country><country mxw-id="DS548930632" load-source="docdb">GR</country><country mxw-id="DS548837102" load-source="docdb">HR</country><country mxw-id="DS548865671" load-source="docdb">HU</country><country mxw-id="DS548934736" load-source="docdb">IE</country><country mxw-id="DS548930633" load-source="docdb">IS</country><country mxw-id="DS548927042" load-source="docdb">IT</country><country mxw-id="DS548930638" load-source="docdb">LI</country><country mxw-id="DS548837103" load-source="docdb">LT</country><country mxw-id="DS548929334" load-source="docdb">LU</country><country mxw-id="DS548927043" load-source="docdb">LV</country><country mxw-id="DS548927044" load-source="docdb">MC</country><country mxw-id="DS548929335" load-source="docdb">MK</country><country mxw-id="DS548929336" load-source="docdb">MT</country><country mxw-id="DS548816094" load-source="docdb">NL</country><country mxw-id="DS548914056" load-source="docdb">NO</country><country mxw-id="DS548816095" load-source="docdb">PL</country><country mxw-id="DS548927045" load-source="docdb">PT</country><country mxw-id="DS548865672" load-source="docdb">RO</country><country mxw-id="DS548927050" load-source="docdb">RS</country><country mxw-id="DS548816096" load-source="docdb">SE</country><country mxw-id="DS548934737" load-source="docdb">SI</country><country mxw-id="DS548914057" load-source="docdb">SK</country><country mxw-id="DS548914062" load-source="docdb">SM</country><country mxw-id="DS548929337" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><abstract mxw-id="PA99618872" ref-ucid="WO-2012116081-A2" lang="EN" load-source="patent-office"><p num="0000">Provided are methods for determining functional relationships between a cosmetic agent and a skin tissue condition of interest. Also provided are methods for identifying cosmetic agents that affect a skin aging tissue condition, as well as the use of agents identified by such methods for the preparation of cosmetic compositions, personal care products, or both.</p></abstract><abstract mxw-id="PA99818557" ref-ucid="WO-2012116081-A2" lang="EN" source="national office" load-source="docdb"><p>Provided are methods for determining functional relationships between a cosmetic agent and a skin tissue condition of interest. Also provided are methods for identifying cosmetic agents that affect a skin aging tissue condition, as well as the use of agents identified by such methods for the preparation of cosmetic compositions, personal care products, or both.</p></abstract><abstract mxw-id="PA99618873" ref-ucid="WO-2012116081-A2" lang="FR" load-source="patent-office"><p num="0000">L'invention concerne des procédés visant à déterminer des relations fonctionnelles entre un agent cosmétique et un état de tissu cutané d'intérêt. L'invention concerne également des procédés d'identification d'agents cosmétiques affectant un état de tissu cutané vieillissant, ainsi que l'utilisation d'agents identifiés par de tels procédés pour la préparation de compositions cosmétiques et / ou de produits de soins personnels.</p></abstract><abstract mxw-id="PA99818558" ref-ucid="WO-2012116081-A2" lang="FR" source="national office" load-source="docdb"><p>L'invention concerne des procédés visant à déterminer des relations fonctionnelles entre un agent cosmétique et un état de tissu cutané d'intérêt. L'invention concerne également des procédés d'identification d'agents cosmétiques affectant un état de tissu cutané vieillissant, ainsi que l'utilisation d'agents identifiés par de tels procédés pour la préparation de compositions cosmétiques et / ou de produits de soins personnels.</p></abstract><description mxw-id="PDES50929982" ref-ucid="WO-2012116081-A2" lang="EN" load-source="patent-office"><!-- EPO <DP n="2"/>--><p id="p0001" num="0001"> METHODS FOR IDENTIFYING COSMETIC AGENTS FOR SKIN CARE COMPOSITIONS </p><p id="p0002" num="0002">BACKGROUND OF THE INVENTION </p><p id="p0003" num="0003"> Connectivity mapping is a well-known hypothesis generating and testing tool having successful application in the fields of operations research, computer networking and telecommunications. The undertaking and completion of the Human Genome Project, and the parallel development of very high throughput high-density DNA microarray technologies enabling rapid and simultaneous quantization of cellular mRNA expression levels, resulted in the generation of an enormous genetic database. At the same time, the search for new pharmaceutical actives via in silica methods such as molecular modeling and docking studies stimulated the generation of vast libraries of potential small molecule actives. The amount of information linking disease to genetic profile, genetic profile to drugs, and disease to drugs grew exponentially, and application of connectivity mapping as a hypothesis testing tool in the medicinal sciences ripened. </p><p id="p0004" num="0004"> The general notion that functionality could be accurately determined for previously uncharacterized genes, and that potential targets of drug agents could be identified by mapping connections in a data base of gene expression profiles for drug-treated cells, was spearheaded in 2000 with publication of a seminal paper by T.R. Hughes et al. ["Functional discovery via a compendium of expression profiles" Cell 102, 109- 126 (2000)], followed shortly thereafter with the launch of The Connectivity Map (-map Project by Justin Lamb and researchers at MIT ("Connectivity Map: Gene Expression Signatures to Connect Small Molecules, Genes, and Disease", Science, Vol 313, 2006.) In 2006, Lamb's group began publishing a detailed synopsis of the mechanics of C-map construction and installments of the reference collection of gene expression profiles used to create the first generation C-map and the initiation of an on-going large scale community C-map project, which is available under the "supporting materials" hyperlink at http://www.sciencemag.Org/content 313/5795/1929/suppl/DC 1. </p><p id="p0005" num="0005"> The basic paradigm of predicting novel relationships between disease, disease phenotype, and drags employed to modify the disease phenotype, by comparison to known relationships has been practiced for centuries as an intuitive science by medical clinicians. Modern connectivity mapping, with its rigorous mathematical underpinnings and aided by modern computational power, has resulted in confirmed medical successes with identification of new agents for the treatment of various diseases including cancer. Nonetheless, certain limiting presumptions challenge application of C-map with respect to diseases of polygenic origin or syndromic conditions characterized by diverse and often apparently unrelated cellular phenotypic 
<!-- EPO <DP n="3"/>-->
 manifestations. According to Lamb, the challenge to constructing a useful C-map is in the selection of input reference data which permit generation of clinically salient and useful output upon query. For the drug-related C-map of Lamb, strong associations comprise the reference associations, and strong associations are the desired output identified as hits. </p><p id="p0006" num="0006"> Noting the benefit of high-throughput, high density profiling platforms which permit automated amplification, labeling hybridization and scanning of 96 samples in parallel a day, Lamb nonetheless cautioned: "[e]ven this much firepower is insufficient to enable the analysis of every one of the estimated 200 different cell types exposed to every known perturbagen at every possible concentration for every possible duration... compromises are therefore required" (page 54, column 3, last paragraph). Hence, Lamb confined his C-map to data from a very small number of established cell lines. This leads to heightened potential for in vitro to in vivo mismatch, and limits information to the context of a particular cell line. Selection of cell line, therefore, may be critical to the utility of a resulting C-map. </p><p id="p0007" num="0007"> Lamb stresses that particular difficulty is encountered if reference connections are extremely sensitive and at the same time difficult to detect (weak), and Lamb adopted compromises aimed at minimizing numerous, diffuse associations. Since the regulatory scheme for drug products requires high degrees of specificity between a purported drug agent and disease state, and modulation of disease by impacting a single protein with a minimum of tangential associations is desired in development of pharmaceutical actives, the Lamb C-map is well-suited for screening for potential pharmaceutical agents despite the Lamb compromises. </p><p id="p0008" num="0008"> The connectivity mapping protocols of Lamb would not be predicted, therefore, to have utility for hypothesis testing generating in the field of cosmetics. Cosmetic formulators seek agents or compositions of agents capable of modulating multiple targets and having effects across complex phenotypes and conditions. Further, the phenotypic impact of a cosmetic agent must be relatively low by definition, so that the agent avoids being subject to the regulatory scheme for pharmaceutical actives. Nonetheless, the impact must be perceptible to the consumer and preferably empirically confirmable by scientific methods. Gene transcription/expression profiles for cosmetic conditions are generally diffuse, comprising many genes with low to moderate fold differentials. Cosmetic agents, therefore, provide more diverse and less acute effects on cellular phenotype and generate the sort of associations expressly taught by Lamb as unsuitable for generating connectivity maps useful for confident hypothesis testing. </p><p id="p0009" num="0009"> Contrary to the teachings of Lamb and the prior art in general, the present inventors surprisingly discovered that useful connectivity maps could be developed from cosmetic active - cellular phenotype - gene expression data associations in particular with respect to skin care 
<!-- EPO <DP n="4"/>-->
 cosmetics. Specifically, certain aspects of the present invention are based on the surprising discovery that selection of human dermal fibroblast cells as the relevant cell line resulted in construction of connectivity maps useful for hypothesis generating and testing relating to cosmetic agents in treatment of photo-damaged/photo-aged skin, while a combination of fibroblast and keratinocyte cells appeared most suitable for intrinsically aged skin. Skin is a highly complex system, and the effects of aging conditions, whether intrinsic or photo-induced, on skin are diffuse and not fully understood. Therefore, it could not be predicted that a fibroblast cell or a keratinocyte cell, or any combination thereof, could be used to construct a connectivity map effective for generating and testing hypotheses relating to cosmetic actives and genes associated with skin aging. </p><p id="p0010" num="0010"> Skin is a complex, multi-layered and dynamic system that provides a protective covering defining the interactive boundary between an organism and the environment. It is the largest organ of the body and is vitally important to both our health and our self image. As shown in Fig. 1, skin comprises three principal layers, the epidermis, the dermis, and a layer of subcutaneous fat. The majority of cells in the epidermis are keratinocytes that produce a family of proteins called keratins. Keratins contribute to the strength of the epidermis. The epidermis itself may be divided into multiple layers with the outermost layer referred to as the stratum corneum, and the innermost layer referred to as the basal layer. All epidermal cells originate from the basal layer and undergo a process known as differentiation as they gradually displace outward to the stratum corneum, where they fuse into squamous sheets and are eventually shed. In healthy, normal skin, the rate of production equals the rate of shedding (desquamation). </p><p id="p0011" num="0011"> The differentiating epidermal cells form distinct though naturally blended layers. As the cells displace outward, they flatten and become joined by spiny processes forming the stratum spinosum, or spinous layer. The cells manufacture specialized fats called sphingolipids, and begin to express keratins associated with terminal differentiation. As keratin is produced, it is incorporated into the cellular matrix, strengthening the skin and providing structural support to the outer layers. As the cells migrate further outward and develop characteristic granules that contain proteins which contribute to the aggregation of keratins; they now form part of the granular layer. Cells lose their nuclei in the outer part of this layer, and the granules release their contents contributing to comification. Vesicles containing lipids discharge into the spaces between the cells, creating a barrier structure that has been suggested to function like bricks (cells) and mortar (lipids). As the cells rise into the outermost layer of the epidermis - the stratum corneum, sometimes called the horny layer or the cornified layer - they take the form of flattened discs, tightly packed together. These flattened cells, called corneocytes, are effectively dead. The 
<!-- EPO <DP n="5"/>-->
 lipids of the epidermis play an important role in maintaining skin health, as they help the stratum corneum to regulate water loss while providing a virtually impermeable hydrophobic barrier to the environment. Fully mature keratinocytes function to protect the skin from UV light damage, and help effectuate immune response to environmental stimuli. </p><p id="p0012" num="0012"> The dermis, which lies just beneath the epidermis, is composed largely of the protein collagen. Most of the collagen is organized in bundles which run horizontally through the dermis and which are buried in a jelly-like material called the ground substance. Collagen accounts for up to 75% of the weight of the dermis, and is responsible for the resilience and elasticity of skin. The collagen bundles are held together by elastic fibers running through the dermis. The fibers are comprised of a protein called elastin, and make up less than 5% of the weight of the dermis. Fibroblasts function to synthesize collagen and the dermis ground substance, including components glycoproteins and glycosaminoglycans such as hyaluronic acid (which is able to bind water). The junction between the epidermis and the dermis is not straight but undulates - more markedly so in some areas of the body than others. A series of finger-like structures called rete pegs project up from the dermis, and similar structures project down from the epidermis. These projections increase the area of contact between the layers of skin, and help to prevent the epidermis from being sheared off. As skin ages, the projections get smaller and flatter. Networks of tiny blood vessels run through the rete pegs, bringing nutrients, vitamins and oxygen to the epidermis, although the epidermis itself is avascular and nourished by diffusion from the rete pegs. The dermis also contains the pilobaceous units comprising hair follicles and sebaceous glands, apocrine and eccrine sweat glands, lymphatic vessels, nerves, and various sensory structures, including the mechano-sensing Pacinian and Meissner's corpuscles. </p><p id="p0013" num="0013"> Beneath the dermis lies the hypodermis, which comprises subcutaneous fat that cushions the dermis from underlying tissues such as muscle and bones. The fat is contained in adipose cells embedded in a connective tissue matrix. This layer may also house the hair follicles when they are in the growing phase. </p><p id="p0014" num="0014"> Thus, skin is a multilayered complex organ comprising a wide variety of cellular types and structures, including epidermal and dermal connective tissue with blood and lymphatic vessels, the pilosebaceous units, glands, nerves, various sensory structures, the hypodermal adipose tissue, and the elastic fascia beneath the hypodermis. In turn, these structures are composed of a number of different cell types including keratinocytes, melanocytes, neuroendocrine Merkel cells, sebocytes, fibroblasts, endothelial cells, pericytes, neurons, adipocytes, myocytes and resident irnmunocytes including Langerhans cells, other dendritic cells, T cells and mast cells. Two of the main cell lineages in the skin are epithelial cells, which in 
<!-- EPO <DP n="6"/>-->
 W 201 </p><p id="p0015" num="0015"> 5 general form the linings of the body and the parenchyma of many organs and glands, and mesenchymal cells, which form connective tissue, blood vessels and muscle. Dermal fibroblasts are mesenchymal cells, and keratinocytes are epithelial cells, which comprise most of the structure of the epidermis. </p><p id="p0016" num="0016"> Skin aging is likewise a complex multi-factorial process that results from unrepaired cellular and tissue damage leading to impaired functional capacity. The aging process in skin is the result of both intrinsic and extrinsic factors occurring over decades. Skin is subject to many of the same intrinsic aging processes as other organs, but is also exposed to solar radiation, an important extrinsic factor that contributes to premature skin aging or photo-aging. Another important extrinsic factor potentially contributing to skin aging is smoking. There have been major advances in the understanding of the aging process with the identification of cellular pathways and genes associated with longevity and aging. Several theories have been proposed to explain intrinsic aging, including cellular senescence resulting from telomere shortening, mutations in nuclear and mitochondrial DNA, hormonal insufficiency and oxidative stress. Reactive active oxygen species and the direct effects of ultraviolet radiation (UVR) appear to play major roles in photo-aging. As is the case for aging in general, an integrated understanding of skin aging has not been developed. </p><p id="p0017" num="0017"> Skin researchers have categorized age-inducing factors as either intrinsic or extrinsic, although these are interdependent, reflected for example by the fact that extrinsic factors may accelerate intrinsic aging. One example of the complex interplay of factors involves free radicals, which are both generated internally through normal metabolic processes and produced as a consequence of external factors, including UVR exposure. As a result of the age-associated decline in protective internal antioxidant mechanisms, free radicals can reach higher and sustained levels in cells and alter both proteins and DNA in skin. Levels of altered protein and DNA may accumulate causing damage. In addition, ongoing accumulation of damage secondary to internally-generated free radicals combined with those generated from UVR and other external assaults (surfactants, allergens, and other irritants) can promote a chronic inflammatory state. This chronic inflammation compromises skin health and may accelerate the aging process: for example, proteolytic enzymes are produced, resulting in collagen degradation. Activated inflammatory cells resulting from elevations in circulating pro-inflammatory mediators (e.g., prostaglandins, cytokines, histamines) produce reactive oxygen species that can cause oxidative damage to nucleic acids, cellular proteins and lipids. Accumulated damage caused by reactive oxygen species may stimulate a host of cytokine cascades that results in photo-aging and photo- carcinogenesis. These changes may be tied to the appearance of aging skin. 
<!-- EPO <DP n="7"/>-->
 Other changes resulting from the complex interplay between intrinsic and extrinsic factors that may impact the appearance of fine lines, wrinkles and texture include the following: </p><p id="p0018" num="0018"> • Epidermal thickness and cellular turnover rate of both the epidermis and the stratum </p><p id="p0019" num="0019"> corneum declines and epidermal differentiation is altered. </p><p id="p0020" num="0020"> • The dermis becomes thinner as major structural molecules including collagen, elastin and glycosaminoglycans decrease in amount. The elastic network in photo-damaged skin becomes disorganized and aggregated and the various structural proteins may be modified by glycation. Metalloproteinase activity increases in photo-damaged skin, contributing to the degradation of collagen and elastin. </p><p id="p0021" num="0021"> • Convolution of dermal-epidermal junction (rete ridges) flattens with age, resulting in a loss of mechanical strength. This also leads to decreased microcirculation to the upper dermis and, thus, decreased nourishment to the epidermis. </p><p id="p0022" num="0022"> • Age-related changes in inter- and intra-cellular signaling lead to decreases in collagen synthesis. </p><p id="p0023" num="0023"> • Changes in hyaluronic acid content within the skin occur with age. Hyaluronic acid is a natural moisturizer within the skin, binding up to 1000 times its weight in water. Age- related declines result in compromised moisturization and firmness. </p><p id="p0024" num="0024"> • Decreased intracellular energy sources including ATP and NADH lead to an inability of skin cells to sustain youthful skin biochemistry, thereby reducing the skin's ability to maintain and restore youthful skin structure. </p><p id="p0025" num="0025"> • In the epidermis, a lack of estrogen slows the activity of the basal keratinocytes, and </p><p id="p0026" num="0026"> consequently leads to epidermal atrophy. This atrophic, fragile skin is less well protected by the normal surface film of lipids, because of the slow decline in sebum secretion experienced by everyone as they age. The stratum corneum barrier is less effective, and the skin may develop reactions to irritants, particularly if skin care has been inadequate or too aggressive, </p><p id="p0027" num="0027"> • The time necessary to repair the stratum corneum barrier increases considerably with age: the replacement of skin cells takes about twice as long for people over 75 as for those around 30. </p><p id="p0028" num="0028"> These changes may compromise skin's elasticity, firmness and structure - contributing to areas of collapse and irregularity and ultimately manifesting as fine lines, wrinkles and texture problems. 
<!-- EPO <DP n="8"/>-->
 There are many skin care products available to consumers which are directed to improving the health and/or physical appearance of skin tissue, such as keratinous tissue. Many of such products are directed to delaying, minimizing or even eliminating changes typically associated with one or both of aging and environmental damage to skin. Such products may include one or more of the numerous cosmetic agents known to be useful in improving the health and/or appearance of keratinous tissue. Although many such agents are known, an ongoing need exists to identify cosmetic agents that can provide new or improved benefits to skin tissue. There is also a need to identify additional cosmetic agents that provide similar or improved benefits as compared to existing products but which are easier to formulate, produce, and/or market. </p><p id="p0029" num="0029"> Successful identification of anti-aging cosmetic agents has proven to be difficult due to the multi-cellular, multi-factorial processes that occur in skin over the course of decades. In addition, many desirable cosmetic agents may comprise a mixture of compounds with effects and interactions that may not be fully understood. This is often the case with a botanical or other natural extract that may affect many cellular/pathways. An additional challenge for cosmetic formulators is that cosmetics must be very safe and adverse effects generally are not acceptable. Further, while much is known about skin aging, there is much that is still poorly understood or unknown. Conventional in vitro studies of biological responses to potential cosmetic agents involve testing hundreds or thousands of potential agents in various cell types before an agent that gives the desired result can be identified and moved into a next stage of testing. However, such studies can be hindered by the complex or weakly detectable responses typically induced and/or caused by cosmetic agents. Such weak responses arise, in part, due to the great number of genes and gene products involved, and cosmetic agents may affect multiple genes in multiple ways. Moreover, the degree of bioactivity of cosmetic agents may differ for each gene and be difficult to quantify. </p><p id="p0030" num="0030"> For example, niacinamide is a well-known cosmetic agent producing skin benefits such as improved barrier function and anti-inflammatory activity. Niacinamide is a precursor of NADH, which is involved in more than 100 reactions in cellular metabolism. In contrast to drug agents, which are selected for specificity and which are intended to have measurable effects on structure and function of the body, cosmetic agents are selected for effect on appearance and may not effect structure and function of the body to a measurable degree. Cosmetic agents tend to be nonspecific with respect to effect on cellular phenotype, and administration to the body is generally limited to application on or close to the body surface. </p><p id="p0031" num="0031"> The value of a connectivity map approach to discover functional connections among cosmetic phenotypes such as aged skin, gene expression perturbation, and cosmetic agent action 
<!-- EPO <DP n="9"/>-->
 is counter-indicated by the progenors of the drug-based C-map. The relevant phenotypes are very complex, the genetic perturbations are numerous and weak, and cosmetic agent action is likewise diffuse and by definition, relatively weak. It is unclear whether statistically valid data may be generated from cosmetic C-maps and it is further unclear whether a cell line exists which may provide salient or detectable cosmetic data. </p><p id="p0032" num="0032"> Surprisingly, the present inventors have provided a C-map approach that is generalizable and biologically relevant for identification of potential cosmetic actives, and demonstrate that the C-map concept is viable by use of benchmark cosmetic actives to query the reference data and by identification of new cosmetic actives. </p><p id="p0033" num="0033">SUMMARY OF THE INVENTION </p><p id="p0034" num="0034"> Accordingly, the present invention provides novel methods useful for generating potential new actives for the treatment of aged and photo-damaged skin. In particular, by careful selection of cell type, and by generation of a reference collection of gene-expression profiles for known cosmetic actives, the present inventors were surprisingly able to create a connectivity map useful for testing and generating hypotheses about cosmetic actives and cosmetic conditions. The present investigators confirmed the validity of connectivity mapping as a tool for identifying cosmetic agents efficacious in the treatment of aged and photo-damaged skin. Potentially efficacious cosmetic agents were identified using gene expression signatures derived from multi- cellular, full thickness human skin biopsies that were compared to short term in vitro experiments of simple cell culture systems. Based on the counter-intuitive and surprising discovery that a fibroblast cell line appears particularly predicative for use with some skin aging gene expression signatures (e.g., a photo-aging gene expression signature), while a combination of fibroblast and keratinocyte cell lines appears more predictive for other skin aging conditions (e.g., intrinsically aged skin), the invention provides methods and systems uniquely suited for desired treatment targets. </p><p id="p0035" num="0035"> The present inventors discovered that it is possible to derive unique photo-aging and intrinsic aging gene expression signatures for use in a connectivity map, particularly where the photo- aging gene expression signature is derived from a full thickness biopsy of skin that was chronologically or intrinsically aged. The present inventors have also surprisingly discovered methods that utilize a plurality of unique skin aging gene expression signatures in a connectivity map to identify useful cosmetic skin care agents. </p><p id="p0036" num="0036"> The present invention provides embodiments which broadly include methods and systems for determining relationships between a skin aging tissue condition of interest and one or more 
<!-- EPO <DP n="10"/>-->
 cosmetic agents, one or more genes associated with the skin aging tissue condition, and one or more cells associated with the skin aging tissue condition. Such methods may be used to identify cosmetic agents without detailed knowledge of the mechanisms of biological processes associated with a skin aging condition of interest, all of the genes associated with such a condition, or the cell types associated with such a condition. </p><p id="p0037" num="0037"> According to one embodiment of the invention, a method for constructing a data architecture for use in identifying connections between perturbagens and genes associated with one or more skin aging conditions is provided. The method comprises: (a) providing a gene expression profile for a control human dermal fibroblast cell; (b) generating a gene expression profile for a human dermal fibroblast cell exposed to at least one perturbagen; (c) identifying genes differentially expressed in response to the at least one perturbagen by comparing the gene expression profiles of (a) and (b); (d) creating an ordered list comprising identifiers representing the differentially expressed genes, wherein the identifiers are ordered according to the differential expression of the genes; (e) storing the ordered list as a fibroblast instance on at least one computer readable medium; and (f) constructing a data architecture of stored fibroblast instances by repeating (a) through (e), wherein the at least one perturbagen of step (a) is different for each fibroblast instance. In another embodiment, the method further requires (g) providing a gene expression profile for a control human keratinocyte cell; (h) generating a gene expression profile for a human keratinocyte cell exposed to at least one perturbagen; (i) identifying genes differentially expressed in response to the at least one perturbagen by comparing the gene expression profiles of (g) and (h); (j) creating an ordered list comprising identifiers representing the differentially expressed genes, wherein the identifiers are ordered according to the differential expression of the genes identified in (i); (k) storing the ordered list created in step (j) as a keratinocyte instance on the at least one computer readable medium; and (1) constructing a data architecture of stored keratinocyte instances by repeating (g) through (k), wherein the at least one perturbagen of step (h) is different for each keratinocyte instance. </p><p id="p0038" num="0038"> Other embodiments provide that the inventive methods are implemented to generate connections useful for identifying cosmetic agents effective for treating aged skin. According to one embodiment, the method comprises querying the data architecture with at least one skin aging gene expression signature, wherein querying comprises comparison of at least one skin aging gene expression signature to each instance in a data architecture of stored instances, wherein the skin aging gene expression signature represents genes differentially expressed in association with at least one skin aging condition. Examples of skin aging conditions include 
<!-- EPO <DP n="11"/>-->
 intrinsic skin aging conditions, which are generally age-dependent, and photo-aged skin conditions, which are a form of extrinsic skin aging where the skin is exposed to UV radiation. </p><p id="p0039" num="0039"> Additional embodiments provide methods for formulating a skin care composition by identifying connections between perturbagens and genes associated with one or more skin aging conditions. The methods comprise: (a) accessing a plurality of instances stored in a data architecture, wherein each instance is associated with a perturbagen and a skin cell type and wherein each instance comprises an ordered list comprising a plurality of identifiers representing a plurality of up-regulated and a plurality of down-regulated genes; (b) accessing at least one skin aging gene expression signature stored in a data architecture, wherein the at least one skin aging gene expression signature comprises one or more lists comprising a plurality of identifiers representing a plurality of up-regulated genes and a plurality of down-regulated genes associated with a skin aging condition. According to one embodiment, a skin aging gene expression signature is selected from up-regulated genes set forth in Tables A and C, and down-regulated genes set forth inn Tables B and D. In more specific embodiments, about 25- 100 percent of the up-regulated genes are selected from the genes set forth in Tables A or C, and about 25-100 percent of the down-regulated genes are selected from the genes set forth in Tables B and D; (c) comparing the at least one skin aging gene expression signature to the plurality of the instances, wherein the comparison comprises comparing each identifier in the gene expression signature list(s) with the position of the same identifier in the ordered lists for each of the plurality of instances; (d) assigning a connectivity score to each of the plurality of instances, wherein the connectivity score of each instance represents how strongly the gene expression profile represented by the ordered list of an instance correlates to the skin aging gene expression signature; and (e) formulating a skin care composition comprising a dermatologically acceptable carrier and at least one perturbagen, wherein the connectivity score of the instance associated with the at least one perturbagen has a negative correlation or connectivity score. </p><p id="p0040" num="0040"> In other embodiments, methods for generating a gene expression signature for use in identifying connections between perturbagens and genes associated with one or more skin aging conditions are provided. In a specific embodiment, the method comprises: (a) providing a gene expression profile for a reference sample of human skin cells; (b) generating a gene expression profile for at least one sample of human skin cells from a subject exhibiting at least one skin aging condition, (c) comparing the expression profiles of (a) and (b) to determine a gene expression signature comprising a set of genes differentially expressed in (a) and (b); (d) assigning an identifier to each gene constituting the gene expression signature and ordering the identifiers according to magnitude of differential expression to create one or more gene 
<!-- EPO <DP n="12"/>-->
 expression signature lists; and (e) storing the gene expression signature list(s) in a data architecture. </p><p id="p0041" num="0041"> Systems useful for identifying connections between perturbagens and genes associated with one or more skin aging conditions are also provided. According to one embodiment, the system comprises (a) a data architecture having stored therein a plurality of instances, and at least one skin aging gene expression signature, wherein the instances and the gene expression signature are derived from a human dermal fibroblast cell, wherein each instance comprises an instance list of rank-ordered identifiers of differentially expressed genes, and wherein the at least one skin aging gene expression signature comprises one or more gene expression signature lists of identifiers representing differentially expressed genes associated with a skin aging condition; (b) a programmable computer comprising computer-readable instructions that cause the programmable computer to execute one or more of the following: (i) accessing the plurality of instances and the at least one skin aging gene expression signature stored in the data architecture; (ii) comparing the at least one skin aging gene expression signature to the plurality of the instances, wherein the comparison comprises comparing the each identifier in the gene expression signature list(s) with the position of the same identifier in the instance list for each of the plurality of instances; and (iii) assigning a connectivity score to each of the plurality of instances, wherein the connectivity score of each instance represents how strongly the gene expression profile represented by the ordered list of an instance correlates to the skin aging gene expression signature. In other embodiments, the system may comprise a microarray scanner for receiving a sample comprising human dermal fibroblast cells and/or human keratinocyte cells; and a second programmable computer for transmitting gene expression data from the scanner to the first programmable computer. </p><p id="p0042" num="0042"> In other aspects, the invention provides inventive gene expression signatures which may exist tangibly in various forms known in the art. For example, a gene expression signature may exist as a set of immobilized oligonucleotides wherein each oligonucleotide uniquely hybridizes to a nucleotide sequence identifying a region of a gene in the signature. In a specific embodiment, a gene expression signature for intrinsically aged skin consisting of genes selected from the genes set forth in Table E is provided. In another specific embodiment, a gene expression signature for photoaged skin consisting of genes selected from the genes set forth in Table F is provided. It is understood that the "genes set forth" in a table refers to gene identifiers designating the genes, and that a genetic signature as set forth herein is set forth according to a gene identifier. 
<!-- EPO <DP n="13"/>-->
 According to yet another embodiment, a computer readable medium comprising the inventive data architecture is provided. The computer readable medium comprises a first digital file stored in a spreadsheet file format, a word processing file format, or a database file format suitable to be read by a respective spreadsheet, word processing, or database computer program, the first digital file comprising data arranged to provide one or more gene expression signature lists comprising a plurality of identifiers when read by the respective spreadsheet, word processing, or database computer program; and wherein each identifier is selected from the group consisting of a microarray probe set ID, a human gene name, a human gene symbol, and combinations thereof representing a gene set forth in Table E and wherein the gene expression signature list comprises between about 50 and about 600 identifiers. </p><p id="p0043" num="0043"> These and additional objects, embodiments, and aspects of the invention will become apparent by reference to the Figures and Detailed Description below. </p><p id="p0044" num="0044">BRIEF DESCRIPTION OF THE FIGURES </p><p id="p0045" num="0045"> Figure 1 is a schematic illustration of the epidermal, dermal, and subcutaneous skin layers; </p><p id="p0046" num="0046"> Figure 2 is a schematic illustration of a computer system suitable for use with the present invention; </p><p id="p0047" num="0047"> Figure 3 is a schematic illustration of an instance associated with a computer readable medium of the computer system of Figure 2; </p><p id="p0048" num="0048"> Figure 4 is a schematic illustration of a programmable computer suitable for use with the present invention; </p><p id="p0049" num="0049"> Figure 5 is a schematic illustration of an exemplary system for generating an instance;</p><p id="p0050" num="0050">Figure 6 is a schematic illustration of a comparison between a gene expression signature and an instance, wherein there is a positive correlation between the lists; </p><p id="p0051" num="0051"> Figure 7 is a schematic illustration of a comparison between a gene expression signature and an instance, wherein there is a negative correlation between the lists; and </p><p id="p0052" num="0052"> Figure 8 is a schematic illustration of a comparison between a gene expression signature and an instance, wherein there is a neutral correlation between the lists. </p><p id="p0053" num="0053"> Figure 9 illustrates morphology of A: telomerized-keratinocytes treated with 0.1 % </p><p id="p0054" num="0054"> DMSO for 6 hr (vehicle control): B: telomerized-keratinocytes treated with 10 μΜ al ra/w- retinoic acid (tRA) in DMSO for 6 hr; C: BJ fibroblasts treated with 0.1 % DMSO for 6 hr 
<!-- EPO <DP n="14"/>-->
 W </p><p id="p0055" num="0055"> 13 </p><p id="p0056" num="0056">(vehicle control); and D: BJ fibroblasts treated with 10 μΜ tRA in DMSO for 6 hr; wherein the control keratinocytes are observed to have a cobblestone-like morphology, the control fibroblasts are observed to have a spindly morphology; and wherein treatment with 10 μΜ tRA caused dramatic morphologic changes in the keratinocytes (B compared to A) but had no apparent morphologic effect on the fibroblasts (D compared to C). </p><p id="p0057" num="0057">DETAILED DESCRIPTION </p><p id="p0058" num="0058"> The present invention will now be described with occasional reference to the specific embodiments of the invention. This invention may, however, be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and to fully convey the scope of the invention to those skilled in the art. </p><p id="p0059" num="0059"> Tables A through J are submitted herewith as .txt files in accordance with large tabled data submission guidelines. Tables A through J in the .txt file format are incorporated herein, in their entirety, by this reference. Table A is a table of 300 identifiers for genes up-regulated in response to skin intrinsic aging conditions. Table B is a table of 300 identifiers for genes down- regulated in response to skin intrinsic aging conditions. Table C is a table of 300 identifiers for genes up-regulated in response to skin photo-aging conditions. Table D is a table of 300 identifiers for genes down-regulated in response to skin photo-aging conditions. Table E reflects an exemplary instance according to certain embodiments of the invention and includes a rank- ordered list of identifiers (chip probe set ID) for an illustrative number of high, middle and low ranked genes profiled by the 22,214 probe sets on Affymetrix chip model HG-U133A2.0 in response to exposure of human dermal fibroblast cells to the perturbagen Cynara scolymus (artichoke) leaf extract (instance CMP_62_13). Table F reflects an exemplary instance according to certain embodiments of the invention and includes a rank-ordered list of the identifiers (chip probe set ID) for an illustrative number of high, middle and low ranked genes profiled by the 22,214 probe sets on Affymetrix chip model HG-U133A2.0 in response to exposure of human keratin ocyte cells to the perturbagen artichoke leaf extract (instance CMP_62_13). Table G reflects an exemplary instance according to certain embodiments of the invention and includes a rank-ordered list of the identifiers (chip probe et ID) for an illustrative number of high, middle and low ranked genes profiled by the 22,214 probe sets on Affymetrix chip model HG-U133A2.0 in response to exposure of human dermal fibroblast cells to the perturbagen carob leaf extract (instance CMP_62_24). Table H reflects an exemplary instance according to certain embodiments of the invention and includes a rank-ordered list of the identifiers (chip probe set ID) for an illustrative number of high, middle and low ranked genes 
<!-- EPO <DP n="15"/>-->
 profiled by the 22,214 probe sets on Affymetrix chip model HG-U133A2.0 in response to exposure of human keratinocyte cells to the perturbagen carob leaf extract (instance CMP_61_23). Table I is a list of identifiers for up-regulated Signature 3, a set of genes up- regulated under photo-aging conditions, optimized for fibroblasts. Table J is a list of identifiers for down-regulated Signature 3, a set of genes down-regulated under photo-aging conditions, optimized for fibroblasts. </p><p id="p0060" num="0060"> Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. The terminology used in the description of the invention herein is for describing particular embodiments only and is not intended to be limiting of the invention. As used in the description of the invention and the appended claims, the singular forms "a," "an," and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. </p><p id="p0061" num="0061"> As used interchangeably herein, the terms "connectivity map" and "C-map" refer broadly to devices, systems, articles of manufacture, and methodologies for identifying relationships between cellular phenotypes or cosmetic conditions, gene expression, and perturbagens, such as cosmetic actives. </p><p id="p0062" num="0062"> As used herein, the term "cosmetic agent" means any substance, as well any component thereof, intended to be rubbed, poured, sprinkled, sprayed, introduced into, or otherwise applied to a mammalian body or any part thereof. Cosmetic agents may include substances that are Generally Recognized as Safe (GRAS) by the US Food and Drug Administration, food additives, and materials used in non-cosmetic consumer products including over-the-counter medications. In some embodiments, cosmetic agents may be incorporated in a cosmetic composition comprising a dermatologically acceptable carrier suitable for topical application to skin. A cosmetic agent includes, but is not limited to, (i) chemicals, compounds, small or large molecules, extracts, formulations, or combinations thereof that are known to induce or cause at least one effect (positive or negative) on skin tissue; (ii) chemicals, compounds, small molecules, extracts, formulations, or combinations thereof that are known to induce or cause at least one effect (positive or negative) on skin tissue and are discovered, using the provided methods and systems, to induce or cause at least one previously unknown effect (positive or negative) on the skin tissue; and (iii) chemicals, compounds, small molecules, extracts, formulations, or combinations thereof that are not known have an effect on skin tissue and are discovered, using the provided methods and systems, to induce or cause an effect on skin tissue. </p><p id="p0063" num="0063"> Some examples of cosmetic agents or cosmetically actionable materials can be found in: the PubChem database associated with the National Institutes of Health, USA 
<!-- EPO <DP n="16"/>-->
 W </p><p id="p0064" num="0064"> 15 </p><p id="p0065" num="0065">(http://pubchem.ncbi.nlm.nih. gov): the Ingredient Database of the Personal Care Products Council (http://online, personalcarecouncil.org/jsp/Home.jsp); and the 2010 International Cosmetic Ingredient Dictionary and Handbook, 13<sup>lh</sup> Edition, published by The Personal Care Products Council; the EU Cosmetic Ingredients and Substances list; the Japan Cosmetic Ingredients List; the Personal Care Products Council, the SkinDeep database (URL: http://www.cosmeticsdatabase.com); the FDA Approved Excipients List; the FDA OTC List; the Japan Quasi Drug List; the US FDA Everything Added to Food database; EU Food Additive list; Japan Existing Food Additives, Flavor GRAS list; US FDA Select Committee on GRAS Substances; US Household Products Database; the Global New Products Database (GNPD) Personal Care, Health Care, Food/Drink/Pet and Household database (URL: http://www.gnpd.com); and from suppliers of cosmetic ingredients and botanicals. </p><p id="p0066" num="0066"> Other non-limiting examples of cosmetic agents include botanicals (which may be derived from one or more of a root, stem bark, leaf, seed or fruit of a plant). Some botanicals may be extracted from a plant biomass (e.g., root, stem, bark, leaf, etc.) using one more solvents. Botanicals may comprise a complex mixture of compounds and lack a distinct active ingredient. Another categor of cosmetic agents are vitamin compounds and derivatives and combinations thereof, such as a vitamin B3 compound, a vitamin B5 compound, a vitamin B6 compound, a vitamin B9 compound, a vitamin A compound, a vitamin C compound, a vitamin E compound, and derivatives and combinations thereof (e.g., retinol, retinyl esters, niacinamide, folic acid, panthenol, ascorbic acid, tocopherol, and tocopherol acetate). Other non-limiting examples of cosmetic agents include sugar amines, phytosterols, hexamidine, hydroxy acids, ceramides, amino acids, and polyols. </p><p id="p0067" num="0067"> The terms "gene expression signature," and "gene-expression signature" refer to a rationally derived list, or plurality of lists, of genes representative of a skin tissue condition or a skin agent. In specific contexts, the skin agent may be a benchmark skin agent or a potential skin agent. Thus, the gene expression signature may serve as a proxy for a phenotype of interest for skin tissue. A gene expression signature may comprise genes whose expression, relative to a normal or control state, is increased (up-regulated), whose expression is decreased (down- regulated), and combinations thereof. Generally, a gene expression signature for a modified cellular phenotype may be described as a set of genes differentially expressed in the modified cellular phenotype over the cellular phenotype. A gene expression signature can be derived from various sources of data, including but not limited to, from in vitro testing, in vivo testing and combinations thereof. In some embodiments, a gene expression signature may comprise a first 
<!-- EPO <DP n="17"/>-->
 list representative of a plurality of up-regulated genes of the condition of interest and a second list representative of a plurality of down-regulated genes of the condition of interest. </p><p id="p0068" num="0068"> As used herein, the term "benchmark skin agent" refers to any chemical, compound, small or large molecule, extract, formulation, or combinations thereof that is known to induce or cause a superior effect (positive or negative) on skin tissue. Non-limiting examples of benchmark skin agents include niacinamide, trans-retinoic acid, and hexamidine. </p><p id="p0069" num="0069"> As used herein, the term "query" refers to data that is used as an input to a Connectivity Map and against which a plurality of instances are compared. A query may include a gene expression signature associated with one or both of a skin aging condition and a benchmark skin agent. </p><p id="p0070" num="0070"> The term "instance," as used herein, refers to data from a gene expression profiling experiment in which skin cells are dosed with a perturbagen. In some embodiments, the data comprises a list of identifiers representing the genes that are part of the gene expression profiling experiment. The identifiers may include gene names, gene symbols, microarray probe set IDs, or any other identifier. In some embodiments, an instance may comprise data from a microarray experiment and comprises a list of probe set IDs of the microarray ordered by their extent of differential expression relative to a control. The data may also comprise metadata, including but not limited to data relating to one or more of the perturbagen, the gene expression profiling test conditions, the skin cells, and the microarray. </p><p id="p0071" num="0071"> The term "keratinous tissue," as used herein, refers to keratin-containing layers disposed as the outermost protective covering of mammals which includes, but is not limited to, skin, hair, nails, cuticles, horns, claws, beaks, and hooves. With respect to skin, the term refers to one or all of the dermal, hypodermal, and epidermal layers, which includes, in part, keratinous tissue. </p><p id="p0072" num="0072"> As used herein, the term "skin aging" refers to a human skin tissue condition resulting from the expression or repression of genes, environmental factors (e.g., sun exposure, UVA and/or UVB exposure, smoking), intrinsic factors (e.g. endogenous free radical production or cellular senescence) or interactions there between that produces one or more of fine lines and/or wrinkles, dry skin, inflamed skin, rough skin, sallow skin, telangectasia, sagging skin, enlarged pores, and combinations thereof. </p><p id="p0073" num="0073"> The term "perturbagen," as used herein, means anything used as a challenge in a gene expression profiling experiment to generate gene expression data for use in the present invention. In some embodiments, the perturbagen is applied to fibroblast and/or keratinocyte cells and the gene expression data derived from the gene expression profiling experiment may be stored as an instance in a data architecture. Any substance, chemical, compound, active, natural product. 
<!-- EPO <DP n="18"/>-->
 extract, drug [e.g. Sigma-Aldrich LOPAC (Library of Pharmacologically Active Compounds) collection], small molecule, and combinations thereof used as to generate gene expression data can be a perturbagen. A perturbagen can also be any other stimulus used to generate differential gene expression data. For example, a perturbagen may also be UV radiation, heat, osmotic stress, pH, a microbe, a virus, and small interfering RNA. A perturbagen may be. but is not required to be, any cosmetic agent. </p><p id="p0074" num="0074"> The term "dermatologieally acceptable.<sup>"</sup> as used herein, means that the compositions or components described are suitable for use in contact with human skin tissue. </p><p id="p0075" num="0075"> As used herein, the term "computer readable medium" refers to any electronic storage medium and includes but is not limited to any volatile, nonvolatile, removable, and nonremovable media implemented in any method or technology for storage of information such as computer readable instructions, data and data structures, digital files, software programs and applications, or other digital information. Computer readable media includes, but are not limited to, application-specific integrated circuit (ASIC), a compact disk (CD), a digital versatile disk (DVD), a random access memory (RAM), a synchronous RAM (SRAM), a dynamic RAM (DRAM), a synchronous DRAM (SDRAM), double data rate SDRAM (DDR SDRAM), a direct RAM bus RAM (DRRAM), a read only memory (ROM), a programmable read only memory (PROM), an electronically erasable programmable read only memory (EEPROM), a disk, a carrier wave, and a memory stick. Examples of volatile memory include, but are not limited to, random access memory (RAM), synchronous RAM (SRAM), dynamic RAM (DRAM), synchronous DRAM (SDRAM), double data rate SDRAM (DDR SDRAM), and direct RAM bus RAM (DRRAM). Examples of non-volatile memory include, but are not limited to, read only memory (ROM), programmable read only memory (PROM), erasable programmable read only memory (EPROM), and electrically erasable programmable read only memory (EEPROM). A memory can store processes and/or data. Still other computer readable media include any suitable disk media, including but not limited to, magnetic disk drives, floppy disk drives, tape drives, Zip drives, flash memory cards, memory sticks, compact disk ROM (CD-ROM), CD recordable drive (CD-R drive). CD rewriteable drive (CD-RW drive), and digital versatile ROM drive (DVD ROM). </p><p id="p0076" num="0076"> As used herein, the terms "software" and "softw are application" refer to one or more computer readable and/or executable instructions that cause a computing device or other electronic device to perform functions, actions, and/or behave in a desired manner. The instructions may be embodied in one or more various forms like routines, algorithms, modules, libraries, methods, and/or programs. Software may be implemented in a variety of executable 
<!-- EPO <DP n="19"/>-->
 and/or loadable forms and can be located in one computer component and/or distributed between two or more communicating, co-operating, and/or parallel processing computer components and thus can be loaded and/or executed in serial, parallel, and other manners. Software can be stored on one or more computer readable medium and may implement, in whole or part, the methods and functionalities of the present invention. </p><p id="p0077" num="0077"> As used herein, the term "intrinsic aging gene expression signature" refers to a gene expression signature derived from gene expression profiling of an intrinsic aging skin condition. </p><p id="p0078" num="0078"> As used herein, the term "intrinsic aging skin condition" refers to a skin aging condition that derives, in whole or part, from chronological aging of the skin. </p><p id="p0079" num="0079"> As used herein, the term "photo-aging skin condition" refers to a skin aging condition that derives, in whole or part, from exposure to sunlight and/or ultraviolet light (e.g., UVR, UVA, UVB, and/or UVC). </p><p id="p0080" num="0080"> As used herein, the term "photo-aging gene expression signature" refers to a gene expression signature derived from gene expression profiling of a photo-aging skin condition. </p><p id="p0081" num="0081"> As used herein, the term "connectivity score" refers to a derived value representing the degree to which an instance correlates to a query. </p><p id="p0082" num="0082"> As used herein, the term "data architecture" refers generally to one or more digital data structures comprising an organized collection of data. In some embodiments, the digital data structures can be stored as a digital file (e.g., a spreadsheet file, a text file, a word processing file, a database file, etc.) on a computer readable medium. In some embodiments, the data architecture is provided in the form of a database that may be managed by a database management system (DBMS) that is be used to access, organize, and select data (e.g., instances and gene expression signatures) stored in a database. </p><p id="p0083" num="0083"> As used herein, the terms "gene expression profiling" and "gene expression profiling experiment" refer to the measurement of the expression of multiple genes in a biological sample using an suitable profiling technology. For example, the mRNA expression of thousands of genes may be determined using microarray techniques. Other emerging technologies that may be used include RNA-Seq or whole transcriptome sequencing using NextGen sequencing techniques. </p><p id="p0084" num="0084"> As used herein, the term "microarray" refers broadly to any ordered array of nucleic acids, oligonucleotides, proteins, small molecules, large molecules, and/or combinations thereof on a substrate that enables gene expression profiling of a biological sample. Non-limiting examples of microarrays are available from Affymetrix, Inc.; Agilent Technologies, Inc.; Ilumina (two "F"s?), Inc.; GE Healthcare, Inc.; Applied Biosystems, Inc.; Bee km an Coulter. Inc.; etc. 
<!-- EPO <DP n="20"/>-->
 Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth as used in the specification and claims are to be understood as being modified in all instances by the term "about". Additionally, the disclosure of any ranges in the specification and claims are to be understood as including the range itself and also anything subsumed therein, as well as endpoints. All numeric ranges are inclusive of narrower ranges; delineated upper and lower range limits are interchangeable to create further ranges not explicitly delineated. Unless otherwise indicated, the numerical properties set forth in the specification and claims are approximations that may vary depending on the desired properties sought to be obtained in embodiments of the present invention. Notwithstanding that numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical values, however, inherently contain certain errors necessarily resulting from error found in their respective measurements. </p><p id="p0085" num="0085"> In accordance with one aspect of the present invention, provided are devices, systems and methods for implementing a connectivity map utilizing one or more query signatures associated with a skin aging condition. The query signatures may be derived in variety of ways. In some embodiments, the query signatures may be gene expression signatures derived from gene expression profiling of full thickness skin biopsies of skin exhibiting a skin aging condition of interest compared to a control (e.g., photo-damaged skin compared to sun protected skin). The gene expression profiling can be carried out using any suitable technology, including but not limited to microarray analysis or NextGen sequencing. Some examples of gene expression signatures include a photo-aging gene expression signature and an intrinsic aging gene expression signature, examples of which are described more fully hereafter. In other embodiments, the query signature may be derived from benchmark agents known to positively affect, treat, or reverse a skin aging condition, wherein the query signature is derived from a fibroblast and/or keratinocyte cell line exposed to the benchmark skin agent. These query signatures may be used singularly or in combination. </p><p id="p0086" num="0086"> In accordance with another aspect of the present invention, provided are devices, systems, and methods for implementing a connectivity map utilizing one or more instances derived from a perturbagen, such as a cosmetic agent, exposed to a fibroblast (e.g., BJ fibroblasts) and/or keratinocyte (e.g., telomerized human keratinocytes) skin cell line. Instances from more complex cell culture systems may also be used, such as skin organotypic cultures containing both keratinocytes and fibroblasts or ex vivo human skin. Instances from a plurality of cell lines may be used with the present invention. 
<!-- EPO <DP n="21"/>-->
 In accordance with yet another aspect of the present invention, provided are devices, systems and methods for identification of relationships between a skin aging query signature and a plurality of instances. For example, it may be possible to ascertain perturbagens that give rise to a statistically significant activity on a statistically significant number of genes associated with a skin aging tissue condition of interest, leading to the identification of new cosmetic agents for treating a skin condition or new uses of known cosmetic agents. </p><p id="p0087" num="0087"> I. Systems and Devices </p><p id="p0088" num="0088"> Referring to FIGS. 2, 4 and 5, some examples of systems and devices in accordance with the present invention for use in identifying relationships between perturbagens, skin aging tissue conditions, and genes associated with the skin aging tissue condition will now be described. System 10 comprises one or more of computing devices 12, 14, a computer readable medium 16 associated with the computing device 12, and communication network 18. </p><p id="p0089" num="0089"> The computer readable medium 16, which may be provided as a hard disk drive, comprises a digital file 20, such as a database file, comprising a plurality of instances 22, 24, and 26 stored in a data structure associated with the digital file 20. The plurality of instances may be stored in relational tables and indexes or in other types of computer readable media. The instances 22, 24, and 26 may also be distributed across a plurality of digital files, a single digital file 20 being described herein however for simplicity. </p><p id="p0090" num="0090"> The digital file 20 can be provided in wide variety of formats, including but not limited to a word processing file format (e.g., Microsoft Word), a spreadsheet file format (e.g., Microsoft Excel), and a database file format. Some common examples of suitable file formats include, but are not limited to, those associated with file extensions such as *.xls, *.xld, *.xlk, *.xll, *.xlt, *.xlxs, *.dif, *.db, *.dbf, *.accdb, *.mdb, *.mdf, *.cdb, *.fdb, *.csv, *sql, *.xml, *.doc, *.txt, <sup>'</sup> *.rtf, *.log, *.docx, *.ans, *.pages, *.wps, etc. </p><p id="p0091" num="0091"> Referring to FIG. 3, in some embodiments the instance 22 may comprise an ordered listing of microarray probe set IDs, wherein the value of N is equal to the total number of probes on the microarray used in analysis. Common microarrays include Affymetrix GeneChips and Illumina BeadChips, both of which comprise probe sets and custom probe sets. To generate the reference gene profiles according to the invention, preferred chips are those designed for profiling the human genome. Examples of Affymetrix chips with utility in the instant invention include model Human Genome (HG)-U133 Plus 2.0. A specific Affymetrix chip employed by the instant investigators is HG-U133A2.0, however it will be understood by a person or ordinary skill in the art that any chip or microarray, regardless of proprietary origin, is suitable so long as the probe 
<!-- EPO <DP n="22"/>-->
 W </p><p id="p0092" num="0092"> 21 sets of the chips used to construct a data architecture according to the invention are substantially similar. </p><p id="p0093" num="0093"> Instances derived from microarray analyses utilizing Affymetrix GeneChips may comprise an ordered listing of gene probe set IDs where the list comprises 22,000+ IDs. The ordered listing may be stored in a data structure of the digital file 20 and the data arranged so that, when the digital file is read by the software application 28, a plurality of character strings are reproduced representing the ordered listing of probe set IDs. An example of an ordered listing of probe set IDs for a perturbagen having the INCI name Cynara scolymus (artichoke leaf extract) is set forth in Table E, which specifically includes an ordered list derived from a microarray analysis of fibroblast cells dosed with Cynara scolymus. Table F is a table of rank-ordered identifiers in association with the rank as derived from a microarray analysis of keratinocyte cells dosed with Cynara scolymus. While it is preferred that each instance comprise a full list of the probe set IDs, it is contemplated that one or more of the instances may comprise less than all of the probe set IDs of a microarray. It is also contemplated that the instances may include other data in addition to or in place of the ordered listing of probe set IDs. For example, an ordered listing of equivalent gene names and/or gene symbols may be substituted for the ordered listing of probe set IDs. Additional data may be stored with an instance and/or the digital file 20. In some embodiments, the additional data is referred to as metadata and can include one or more of cell line identification, batch number, exposure duration, and other empirical data, as well as any other descriptive material associated with an instance ID. The ordered list may also comprise a numeric value associated with each identifier that represents the ranked position of that identifier in the ordered list. </p><p id="p0094" num="0094"> Referring again to FIGS. 2, 3 and 4, the computer readable medium 16 may also have a second digital file 30 stored thereon. The second digital file 30 comprises one or more lists 32 of microarray probe set IDs associated with one or more skin aging gene expression signatures. The listing 32 of microarray probe set IDs typically comprises a much smaller list of probe set IDs than the instances of the first digital file 20. In some embodiments, the list comprises between 2 and 1000 probe set IDs. In other embodiments the list comprises greater than 10, 50, 100, 200. or 300 and/or less than about 800, 600, or about 400 probe set IDs. The listing 32 of probe set IDs of the second digital file 30 comprises a list of probe set IDs representing up,and/or down- regulated genes selected to represent a skin aging condition of interest. In some embodiments, a first list may represent the up-regulated genes and a second list may represent the down-regulated genes of the gene expression signature. The listing(s) may be stored in a data structure of the digital file 30 and the data arranged so that, when the digital file is read by the software 
<!-- EPO <DP n="23"/>-->
 application 28, a plurality of character strings are reproduced representing the list of probe set IDs. Instead of probe set IDs, equivalent gene names and/or gene symbols (or another nomenclature) may be substituted for a list of probe set IDs. Additional data may be stored with the gene expression signature and/or the digital file 30 and this is commonly referred to as metadata, which may include any associated information, for example, cell line or sample source, and microarray identification. Examples of listings of probe set IDs for intrinsic aging gene expression signatures are set forth in Tables A (up-regulated) and B (down-regulated), and an example of listings of probe set IDs for photo-aging gene expression signatures are set forth in Tables C (up-regulated) and D(down-regulated). In some embodiments, one or more skin aging gene expression signatures may be stored in a plurality of digital files and/or stored on a plurality of computer readable media. In other embodiments, a plurality of gene expression signatures (e.g., 32, 34) may be stored in the same digital file (e.g., 30) or stored in the same digital file or database that comprises the instances 22, 24, and 26. </p><p id="p0095" num="0095"> As previously described, the data stored in the first and second digital files may be stored in a wide variety of data structures and/or formats. In some embodiments, the data is stored in one or more searchable databases, such as free databases, commercial databases, or a company's internal proprietary database. The database may be provided or structured according to any model known in the art, such as for example and without limitation, a flat model, a hierarchical model, a network model, a relational model, a dimensional model, or an object-oriented model. In some embodiments, at least one searchable database is a company's internal proprietary database. A user of the system 10 may use a graphical user interface associated with a database management system to access and retrieve data from the one or more databases or other data sources to which the system is operably connected. In some embodiments, the first digital file 20 is provided in the form of a first database and the second digital file 30 is provided in the form of a second database. In other embodiments, the first and second digital files may be combined and provided in the form of a single file. </p><p id="p0096" num="0096"> In some embodiments, the first digital file 20 may include data that is transmitted across the communication network 18 from a digital file 36 stored on the computer readable medium 38. In one embodiment, the first digital file 20 may comprise gene expression data obtained from a cell line (e.g., a fibroblast cell line and/or a keratinocyte cell line) as well as data from the digital file 36, such as gene expression data from other cell lines or cell types, gene expression signatures, perturbagen information, clinical trial data, scientific literature, chemical databases, pharmaceutical databases, and other such data and metadata. The digital file 36 may be provided 
<!-- EPO <DP n="24"/>-->
 in the form of a database, including but not limited to Sigma-Aldrich LOPAC collection, Broad Institute C-MAP collection. GEO collection, and Chemical Abstracts Service (CAS) databases. </p><p id="p0097" num="0097"> The computer readable medium 16 (or another computer readable media, such as 16) may also have stored thereon one or more digital files 28 comprising computer readable instructions or software for reading, writing to, or otherwise managing and/or accessing the digital files 20, 30. The computer readable medium 16 may also comprise software or computer readable and/or executable instructions that cause the computing device 12 to perform one or more steps of the methods of the present invention, including for example and without limitation, the step(s) associated with comparing a gene expression signature stored in digital file 30 to instances 22, 24, and 26 stored in digital file 20. In some embodiments, the one or more digital files 28 may form part of a database management system for managing the digital files 20, 28. Non-limiting examples of database management systems are described in United States Patent Serial Nos. 4,967,341 and 5,297,279. </p><p id="p0098" num="0098"> The computer readable medium 16 may form part of or otherwise be connected to the computing device 12. The computing device 12 can be provided in a wide variety of forms, including but not limited to any general or special purpose computer such as a server, a desktop computer, a laptop computer, a tower computer, a microcomputer, a mini computer, and a mainframe computer. While various computing devices may be suitable for use with the present invention, a generic computing device 12 is illustrated in FIG. 4. The computing device 12 may comprise one or more components selected from a processor 40, system memory 42, and a system bus 44. The system bus 44 provides an interface for system components including but not limited to the system memory 42 and processor 40. The system bus 36 can be any of several types of bus structures that may further interconnect to a memory bus (with or without a memory controller), a peripheral bus, and a local bus using any of a variety of commercially available bus architectures. Examples of a local bus include an industrial standard architecture (ISA) bus, a microchannel architecture (MSA) bus, an extended ISA (EISA) bus, a peripheral component interconnect (PCI) bus, a universal serial (USB) bus, and a small computer systems interface (SCSI) bus. The processor 40 may be selected from any suitable processor, including but not limited to, dual microprocessor and other multi -processor architectures. The processor executes a set of stored instructions associated with one or more program applications or software. </p><p id="p0099" num="0099"> The system memory 42 can include non-volatile memory 46 (e.g., read only memory (ROM), erasable programmable read only memory (EPROM), electrically erasable programmable read only memory (EEPROM), etc.) and/or volatile memory 48 (e.g., random access memory (RAM)). A basic input/output system (BIOS) can be stored in the non- volatile 
<!-- EPO <DP n="25"/>-->
 memory 38, and can include the basic routines that help to transfer information between elements within the computing device 12. The volatile memory 48 can also include a high-speed RAM such as static RAM for caching data. </p><p id="p0100" num="0100"> The computing device 12 may further include a storage 44, which may comprise, for example, an internal hard disk drive [HDD,e.g., enhanced integrated drive electronics (EIDE) or serial advanced technology attachment (SATA)] for storage. The computing device 12 may further include an optical disk drive 46 (e.g., for reading a CD-ROM or DVD-ROM 48). The drives and associated computer- readable media provide non-volatile storage of data, data structures and the data architecture of the present invention, computer-executable instructions, and so forth. For the computing device 12, the drives and media accommodate the storage of any data in a suitable digital format. Although the description of computer- readable media above refers to an HDD and optical media such as a CD-ROM or DVD-ROM, it should be appreciated by those skilled in the art that other types of media which are readable by a computer, such as Zip disks, magnetic cassettes, flash memory cards, cartridges, and the like may also be used, and further, that any such media may contain computer-executable instructions for performing the methods of the present invention. </p><p id="p0101" num="0101"> A number of software applications can be stored on the drives 44 and volatile memory 48, including an operating system and one or more software applications, which implement, in whole or part, the functionality and/or methods described herein. It is to be appreciated that the embodiments can be implemented with various commercially available operating systems or combinations of operating systems. The central processing unit 40, in conjunction with the software applications in the volatile memory 48, may serve as a control system for the computing device 12 that is configured to, or adapted to, implement the functionality described herein. </p><p id="p0102" num="0102"> A user may be able to enter commands and information into the computing device 12 through one or more wired or wireless input devices 50, for example, a keyboard, a pointing device, such as a mouse (not illustrated), or a touch screen. These and other input devices are often connected to the central processing unit 40 through an input device interface 52 that is coupled to the system bus 44 but can be connected by other interfaces, such as a parallel port, an IEEE 1394 serial port, a game port, a universal serial bus (USB) port, an IR interface, etc. The computing device 12 may drive a separate or integral display device 54, which may also be connected to the system bus 44 via an interface, such as a video port 56. </p><p id="p0103" num="0103"> The computing devices 12, 14 may operate in a networked environment across network 18 using a wired and/or wireless network communications interface 58. The network interface port 58 can facilitate wired and/or wireless communications. The network interface port can be 
<!-- EPO <DP n="26"/>-->
 W </p><p id="p0104" num="0104"> 25 part of a network interface card, network interface controller (NIC), network adapter, or LAN adapter. The communication network 18 can be a wide area network (WAN) such as the Internet, or a local area network (LAN). The communication network 18 can comprise a fiber optic network, a twisted-pair network, a Tl/El line-based network or other links of the T-carrier/E carrier protocol, or a wireless local area or wide area network (operating through multiple protocols such as ultra-mobile band (UMB), long term evolution (LTE), etc.). Additionally, communication network 1 8 can comprise base stations for wireless communications, which include transceivers, associated electronic devices for modulation/demodulation, and switches and ports to connect to a backbone network for backhaul communication such as in the case of packet-switched communications. </p><p id="p0105" num="0105"> II. Methods for Creating a Plurality of Instances </p><p id="p0106" num="0106"> In some embodiments, the methods of the present invention may comprise populating at least the first digital file 20 with a plurality of instances (e.g., 22, 24, 26) comprising data derived from a plurality of gene expression profiling experiments, wherein one or more of the experiments comprise exposing dermal fibroblast cells and/or keratinocyte cells (or other skin cells such as human skin equivalent cultures or ex vivo cultured human skin) to at least one perturbagen. For simplicity of discussion, the gene expression profiling discussed hereafter will be in the context of a microarray experiment. </p><p id="p0107" num="0107"> Referring to FIG. 5, one embodiment of a method of the present invention is illustrated. The method 58 comprises exposing a fibroblast cells 60 and/or keratinocyte cells 62 to a perturbagen 64. The perturbagen may be dissolved in a carrier, such as dimethyl sulfoxide (DMSO). After exposure, mRNA is extracted from the cells exposed to the perturbagen and reference cells 66 (e.g., fibroblast or keratinocyte cells) which are exposed to only the carrier. The mRNA 68, 70, 72 may be reverse transcribed to cDNA 64, 76, 78 and marked with different fluorescent dyes (e.g., red and green) if a two color microarray analysis is to be performed. Alternatively, the samples may be prepped for a one color microarray analysis as described in Example 1 , and further a plurality of replicates may be processed if desired. The cDNA samples may be co-hybridized to the microarray 80 comprising a plurality of probes 82. The microarray may comprise thousands of probes 82, In some embodiments, there are between 10,000 and 50,000 gene probes 82 present on the microarray 80. The microarray is scanned by a scanner 84, which excites the dyes and measures the amount fluorescence. A computing device 86 may be used to analyze the raw images to determine the expression levels of a gene in the cells 60, 62 relative to the reference cells 66. The scanner 84 may incorporate the functionality of the computing device 86. The expression levels include: i) up-regulation [e.g., greater binding of 
<!-- EPO <DP n="27"/>-->
 the test material (e.g., cDNA 74, 76) to the probe than the reference material (e.g.. cDNA 78)], or ii) down-regulation [e.g., greater binding of the reference material (e.g., cDNA 78) to the probe than the test material (e.g., cDNA 74, 76)], iii) expressed but not differentially [e.g., similar binding of the reference material (e.g., cDNA 78) to the probe than the test material (e.g., cDNA 74. 76)], and iv) no detectable signal or noise. The up- and down-regulated genes are referred to as differentially expressed. Microarrays and microarray analysis techniques are well known in the art, and it is contemplated that other microarray techniques may be used with the methods, devices and systems of the present invention. For example, any suitable commercial or noncommercial microarray technology and associated techniques may used. Good results have been obtained with Affymetrix GeneChip© technology and Illumina BeadChip™ technology. One illustrative technique is described in Example 1. However, one of skill in the art will appreciate that the present invention is not limited to the methodology of the example and that other methods and techniques are also contemplated to be within its scope. </p><p id="p0108" num="0108"> In a very specific embodiment, an instance consists of the rank ordered data for all of the probe sets on the Affymetrix HG-U133A2.0 GeneChip wherein each probe on the chip has a unique probe set IDentifier. The probe sets are rank ordered by the fold change relative to the controls in the same C-map batch (single instance/average of controls). The probe set IDentifiers are rank-ordered to reflect the most up-regulated to the most down-regulated. </p><p id="p0109" num="0109"> Notably, even for the non-differentially regulated genes the signal values for a particular probe set are unlikely to be identical for the instance and control so a fold change different from 1 will be calculated that can be used for comprehensive rank ordering. In accordance with methods disclosed by Lamb et al. (2006), data are adjusted using 2 thresholds to minimize the effects of genes that may have very low noisy signal values, which can lead to spurious large fold changes. The thresholding is preferably done before the rank ordering. An example for illustrative purposes includes a process wherein a first threshold is set at 20. If the signal for a probe set is below 20, it is adjusted to 20. Ties for ranking are broken with a second threshold wherein the fold changes are recalculated and any values less than 2 are set to 2. For any remaining ties the order depends on the specific sorting algorithm used but is essentially random. The probe sets in the middle of the list do not meaningfully contribute to an actual connectivity score. </p><p id="p0110" num="0110"> The rank ordered data are stored as an instance. The probes may be sorted into a list according to the level of gene expression regulation detected, wherein the list progresses from up- regulated to marginal or no regulation to down-regulated, and this rank ordered listing of probe IDs is stored as an instance (e.g., 22) in the first digital file 20. Referring to FIG. 3, the data associated with an instance comprises the probe ID 80 and a value 82 representing its ranking in 
<!-- EPO <DP n="28"/>-->
 the list (e.g., 1 , 2, 3, 4 . . . N, where N represents the total number of probes on the microarray). The ordered list 84 may generally comprise approximately three groupings of probe IDs: a first grouping 86 of probe IDs associated with up-regulated genes, a second group 88 of probe IDs associated with genes with marginal regulation or no detectable signal or noise, and a third group 90 of probe IDs associated with down-regulated genes. The most up regulated genes are at or near the top of the list 84 and the most down-regulated genes are at or near the bottom of the list 84. The groupings are shown for illustration, but the lists for each instance may be continuous and the number of regulated genes will depend on the strength of the effect of the perturbagen associated with the instance. Other arrangements within the list 84 may be provided. For example, the probe IDs associated with the down-regulated genes may be arranged at the top of the list 84. This instance data may also further comprise metadata such as perturbagen identification, perturbagen concentration, cell line or sample source, and microarray identification. </p><p id="p0111" num="0111"> In some embodiments, one or more instances comprise at least about 1 ,000, 2,500, 5,000, 10,000, or 20,000 identifiers and/or less than about 30,000, 25,000, or 20,000 identifiers. In some embodiments, the database comprises at least about 50, 100, 250, 500, or 1 ,000 instances and/or less than about 50,000, 20,000, 15,000, 10,000, 7,500, 5,000, or 2,500 instances. Replicates of an instance may created, and the same perturbagen may be used to derive a first instance from fibroblast cells and a second instance from keratinocyte cells and a third instance from another skin cell type, such as melanocytes or complex tissue, for example ex vivo human skin. </p><p id="p0112" num="0112"> The present inventors have surprisingly discovered that instances derived from fibroblast cells appear to be more predictive than other cell types when used in combination with a photo- aging gene expression signature. As described more fully hereafter in Example 6, the present inventors compared instances derived from BJ fibroblast cells and keratinocyte cells with a photo-aging gene expression signature and found that instances derived from the fibroblast cells were dramatically over represented in the highest ranking results (the higher the ranking, the more likely the perturbagen is to have a beneficial affect upon the photo aging condition) compared to keratinocyte cells. The inventors also discovered that the up-regulated genes of a photo-aging gene expression signature most closely correlated with instances derived from fibroblast cells. In comparison, the present inventors discovered that a combination of instances derived from fibroblast cells and keratinocyte cells using the same set of perturbagens correlated more closely with an intrinsic aging gene expression signature, with the instances derived from the fibroblast cells being slightly more preferential. The inventors were surprised to find that instances derived from keratinocyte cells were under represented in the top ranking results of the 
<!-- EPO <DP n="29"/>-->
 photo-aging gene expression signature, while more equal representation was observed with respect to an intrinsic aging gene expression signature. Still further, both results are surprising considering that the gene expression signatures were derived from full thickness biopsies representing complex, multi-factorial skin aging conditions and further that the photo-aging gene expression signature was derived from a full thickness skin biopsy that was also intrinsically aged. In other words, a photo-aging gene expression signature could be differentiated from biopsy samples containing both intrinsic aging and photo aging phenotypes. </p><p id="p0113" num="0113"> III. Methods for Deriving Skin Aging Gene expression signatures </p><p id="p0114" num="0114"> Some methods of the present invention comprise identifying a gene expression signature that represents the up-regulated and down-regulated genes associated with a skin aging condition of interest. A skin aging condition typically involves complex processes involving numerous known and unknown extrinsic and intrinsic factors, as well as responses to such factors that are subtle over a relatively short period of time but non-subtle over a longer period of time. This is in contrast to what is typically observed in drug screening methods, wherein a specific target, gene, or mechanism of action is of interest. Due to the unique screening challenges associated with a skin aging condition, the quality of the gene expression signature representing the condition of interest can be important for distinguishing between the gene expression data actually associated with a response to a perturbagen from the background expression data. One challenge in developing skin aging gene expression signatures is that the number of genes selected needs to be adequate to reflect the dominant and key biology but not so large as to include many genes that have achieved a level of statistical significance by random chance and are non-informative. Thus, query signatures should be carefully derived since the predictive value may be dependent upon the quality of the gene expression signature. </p><p id="p0115" num="0115"> One factor that can impact the quality of the query signature is the number of genes included in the signature. The present inventors have found that, with respect to a cosmetic data architecture and connectivity map, too few genes can result in a signature that is unstable with regard to the highest scoring instances. In other words, small changes to the gene expression signature can result significant differences in the highest scoring instance. Conversely, too many genes may tend to partially mask the dominant biological responses and will include a higher fraction of genes meeting statistical cutoffs by random chance - thereby adding undesirable noise to the signature. The inventors have found that the number of genes desirable in a gene expression signature is also a function of the strength of the biological response associated with the condition and the number of genes needed to meet minimal values (e.g.. a p-value less than about 0.05) for statistical significance. When the biology is weaker, such as is the case typically 
<!-- EPO <DP n="30"/>-->
 W </p><p id="p0116" num="0116"> 29 with cosmetic condition phenotypes, fewer genes than those which may meet the statistical requisite for inclusion in the prior art. may be used to avoid adding noisy genes. For example, the gene expression profiling analysis of a photo aging skin condition yielded approximately 4000 genes having a statistical p- value of less than 0.05 and approximately 1000 genes having a p- value of less than 0.001 , which could be considered a very strong biological response. The gene expression profiling analysis of an intrinsic aging skin condition yielded approximately 1000 genes have a statistical p-value of less than 0.05 and approximately 400 genes have a p-value of less than 0.001 , which could be considered a moderately strong biological response. In these cases, a gene expression signature comprises between about 100 and about 600 genes. Weaker biology may be better represented by a gene expression signature comprising fewer genes. </p><p id="p0117" num="0117"> While a gene expression signature may represent all significantly regulated genes associated with skin aging condition of interest; typically it represents a subset of such genes. The present inventors have discovered that skin aging gene expression signatures comprising between about 200 and about 800 genes of approximately equal numbers of up-regulated and/or down-regulated genes are stable, reliable, and can provide predictive results. For example, a suitable gene expression signature may have from about 200-250 genes, 250-300 genes, 300-350 genes, 350-400 genes, 400-450 genes, 450-500 genes, 500-550 genes, 550-600 genes, 600-650 genes, 650-700 genes, 700-750 genes, and 750-800 genes. However, one of skill in the art will appreciate that gene expression signatures comprising fewer or more genes are also within the scope of the various embodiments of the invention. For purposes of depicting a gene expression signature, the probe set IDs associated with the genes are preferably separated into a first list comprising the most up-regulated genes and a second list comprising the most down-regulated. </p><p id="p0118" num="0118"> Gene expression signatures may be generated from full thickness skin biopsies from skin having the skin aging condition of interest compared to a control. Two gene expression signature types for skin aging can include an intrinsic aging gene expression signature and a photo-aging gene expression signature, which may be derived by comparing gene expression data from a full thickness skin biopsy from skin having the condition of interest and a control. Examples 2 and 3 below describe in greater detail non-limiting methods for deriving these gene expression signatures. Generally, for a photo-aging gene expression signature, biopsies may be taken from sun exposed skin (e.g., extensor forearm) and sun protected skin (e.g., buttocks) of a plurality of older subjects. The subjects may vary in age. but one age range is between about 45 years of age and 70 years of age. A gene expression profiling analysis of the biopsy samples may be performed and one or more photo-aging gene expression signatures derived from a statistical analysis of the results. In some embodiments, the photo-aging gene expression signature 
<!-- EPO <DP n="31"/>-->
 comprises about equal numbers of up-regulated and down-regulated genes. In an alternate embodiment, a photo-aging gene expression signature may be derived by comparing a sun exposed site of an older individual (e.g., 45 to 80 y.o.) to a sun exposed site of a younger individual (e.g., 18 to 25 y.o.) </p><p id="p0119" num="0119"> Generally, for an intrinsic aging gene expression signature, biopsies may be taken from sun protected sites (e.g., buttocks) of a plurality of older and younger subjects. The subjects may vary in age, but one age range is between about 45 years of age and 80 years of age for the older subjects and 18 years of age and 25 years of age for the younger subjects. A gene expression profiling analysis of the biopsy samples may be performed and one or more intrinsic aging gene expression signatures derived from a statistical analysis of the microarray results. In some embodiments, the intrinsic aging gene expression signature comprises about equal numbers of up- regulated and down-regulated genes. </p><p id="p0120" num="0120"> In some embodiments, the photo-aging and intrinsic aging gene expression signatures have fewer than 20% of their genes in common, and they reflect different aspects of the biology of aging skin as described. The intrinsic aging gene expression signatures may capture decreased expression of epidermal differentiation markers and down-regulation of pathways involved in the synthesis of lipids important in epidermal barrier function as well as changes related to the dermis, while the photo-aging signatures may be much more reflective of modified biology of the dermis and fibroblasts. Therefore, both photo-aging and intrinsic aging gene expression signatures are useful for identification of cosmetic agents to improve the appearance of aging skin and allow identification of potential perturbagens with differing biological activities. </p><p id="p0121" num="0121"> In other embodiments of the present invention, a gene expression signature may be derived from a gene expression profiling analysis of fibroblast and/or keratinocyte cells treated with a benchmark skin agent to represent cellular perturbations leading to improvement in the skin tissue condition treated with that benchmark skin agent, said signature comprising a plurality of genes up-regulated and down-regulated by the benchmark skin agent in cells in vitro. As one illustrative example, microarray gene expression profile data where the perturbagen is the known skin anti-aging agent all ?r n.v-retinoic acid (tRA) may be analyzed using the present invention to determine from the rank-ordered instances in the query results, the genes associated with the highest scoring instances. Thus, a list of genes strongly up-regulated and strongly down- regulated in response to challenge with tRA can be derived, and said list of genes (a proxy for skin anti-aging) can be used as a query signature to screen for skin anti-aging agents. In another embodiment, a signature may be derived to represent more than one aspect of the condition of</p><p id="p0122" num="0122">1 ΙΊ St» 
<!-- EPO <DP n="32"/>-->
 W </p><p id="p0123" num="0123"> 31 </p><p id="p0124" num="0124">IV. Methods for Comparing a Plurality of Instances to One or More Skin Aging Gene expression signatures </p><p id="p0125" num="0125"> Referring to FIG. 6 and FIG. 7, a method for querying a plurality of instances with one or more skin aging gene signatures will now be described. Broadly, the method comprises querying a plurality of instances with one or more skin aging gene signatures and applying a statistical method to determine how strongly the signature genes match the regulated genes in an instance. Positive connectivity occurs when the genes in the up-regulated signature list are enriched among the up-regulated genes in an instance and the genes in the down-regulated signature list are enriched among the down-regulated genes in an instance. On the other hand, if the up-regulated genes of the signature are predominantly found among the down-regulated genes of the instance, and vice versa, this is scored as negative connectivity. FIG. 6 schematically illustrates an extreme example of a positive connectivity between signature 90 and the instance 104 comprising the probe IDs 102, wherein the probe IDs of the instance are ordered from most up-regulated to most down-regulated. In this example, the probe IDs 100 (e.g., Xj, X<sub>2</sub> X<sub>3</sub>, X<sub>4</sub>, Xs, X<sub>6*</sub> X<sub>?</sub>, Xg) of the gene signature 90, comprising an up list 97 and a down list 99, have a one to one positive correspondence with the most up-regulated and down-regulated probe IDs 102 of the instance 104, respectively. Similarly, FIG. 7 schematically illustrates an extreme example of a negative connectivity between signature 94 and the instance 88 comprising the probe IDs 90, wherein the probe IDs of the instance are ordered from most up-regulated to most down-regulated. In this example, the probe IDs of the up list 93 (e.g., Xi, X<sub>2</sub> X<sub>3</sub>, X<sub>4</sub>) correspond exactly with the most down-regulated genes of the instance 88, and the probe IDs of the down list 95 (e.g.,X<sub>5</sub>, X<sub>6</sub>, X<sub>?</sub>, X<sub>8</sub>) correspond exactly to the most up-regulated probe IDs of the instance 88. FIG. 8 schematically illustrates an extreme example of neutral connectivity, wherein there is no consistent enrichment of the up- and down-regulated genes of the signature among the up- and down-regulated genes of the instance, either positive or negative. Hence the probe IDs 106 (e.g., X i . X; X;.. X<sub>4</sub>, X.5, X(„ X<sub>7</sub>, X ) of a gene signature 108 (comprising an up list 107 and a down list 109) are scattered with respect to rank with the probe IDs 1 10 of the instance 1 12, wherein the probe IDs of the instance are ordered from most up-regulated to most down-regulated. While the above embodiments illustrate process where the gene signature comprises a both an up list and a down list representative of the most significantly up- and down-regulated genes of a skin condition, it is contemplated that the gene signature may comprise only an up list or a down list when the dominant biology associated with a condition of interest shows gene regulation in predominantly one direction. 
<!-- EPO <DP n="33"/>-->
 In some embodiments, the connectivity score can be a combination of an up-score and a down score, wherein the up-score represents the correlation between the up-regulated genes of a gene signature and an instance and the down-score represents the correlation between the down- regulated genes of a gene signature and an instance. The up score and down score may have values between + 1 and -1 . For an up score (and down score) a high positive value indicates that the corresponding perturbagen of an instance induced the expression of the microarray probes of the up-regulated (or down-regulated) genes of the gene signature, and a high negative value indicates that the corresponding perturbagen associated with the instance repressed the expression of the microarray probes of the up-regulated (or down-regulated) genes of the gene signature. The up-score can be calculated by comparing each identifier of an up list of a gene signature comprising the up-regulated genes (e.g., Tables A, C, I and lists 93, 97, and 107) to an ordered instance list (e.g., Tables E, F, G, H) while the down-score can be calculated by comparing each identifier of a down list of a gene signature comprising the down-regulated genes (see, e.g., Tables B, D, J and down lists 95, 99, and 109) to an ordered instance list (e.g., Tables E, F, G, H). In these embodiments, the gene signature comprises the combination of the up list and the down list. </p><p id="p0126" num="0126"> In some embodiments, the connectivity score value may range from +2 (greatest positive connectivity) to -2 (greatest negative connectivity), wherein the connectivity score (e.g., 101 , 103, and 105) is the combination of the up score (e.g., I l l , 1 13, 1 15) and the down score (e.g., 1 17, 1 19, 121 ) derived by comparing each identifier of a gene signature to the identifiers of an ordered instance list. In other embodiments the connectivity range may be between +1 and - 1. Examples of the scores are illustrated in FIGS. 6, 7 and 8 as reference numerals 101 , 103, 105, 1 1 1 , 1 13, 1 15, 1 17, 1 19, and 121. The strength of matching between a signature and an instance represented by the up scores and down scores and/or the connectivity score may be derived by one or more approaches known in the art and include, but are not limited to, parametric and non- parametric approaches. Examples of parametric approaches include Pearson correlation (or Pearson r) and cosine correlation. Examples of non-parametric approaches include Spearman's Rank (or rank-order) correlation. Kendall's Tau correlation, and the Gamma statistic. Generally, in order to eliminate a requirement that all profiles be generated on the same microarray platform, a non-parametric, rank-based pattern matching strategy based on the Kol mogoro -S mirnov statistic (see M. Hollander et al. "Nonparametric Statistical Methods": Wiley. New York, ed. 2, 1999)(see, e.g., pp. 178- 185). It is noted, however, that where all expression profiles are derived from a single technology platform, similar results may be obtained using conventional measures of correlation, for example, the Pearson correlation coefficient. 
<!-- EPO <DP n="34"/>-->
 W 201 </p><p id="p0127" num="0127"> 33 </p><p id="p0128" num="0128">In specific embodiments, the methods and systems of the present invention employ the nonparametric. rank-based pattern-matching strategy based on the Kolmogorov-Smirnov statistic, which has been refined for gene profiling data by Lamb's group, commonly known in the art as Gene Set Enrichment Analysis (GSEA) (see, e.g., Lamb et al. 2006 and Subramanian, A. et al. (2005) Proc.Natl.Acad Sci U.S. A, 102, 15545-15550). For each instance, a down score is calculated to reflect the match between the down-regulated genes of the query and the instance, and an up score is calculated to reflect the correlation between the up-regulated genes of the query and the instance. In certain embodiments the down score and up score each may range between - 1 and +1. The combination represents the strength of the overall match between the query signature and the instance. </p><p id="p0129" num="0129"> The combination of the up score and down score is used to calculate an overall connectivity score for each instance, and in embodiments where up and down score ranges are set between - 1 and + 1 , the connectivity score ranges from -2 to +2, and represents the strength of match between a query signature and the instance. The sign of the overall score is determined by whether the instance links positivity or negatively to the signature. Positive connectivity occurs when the perturbagen associated with an instance tends to up-regulate the genes in the up list of the signature and down-regulate the genes in the down list. Conversely, negative connectivity occurs when the perturbagen tends to reverse the up and down signature gene expression changes, The magnitude of the connectivity score is the sum of the absolute values of the up and down scores when the up and down scores have different signs. A high positive connectivity score predicts that the perturbagen will tend to induce the condition that was used to generate the query signature, and a high negative connectivity score predicts that the perturbagen will tend to reverse the condition associated with the query signature. A zero score is assigned where the the up and down scores have the same sign, indicating that a perturbagen did not have a consistent impact the condition signature (e.g., up-regulating both the up and down lists). </p><p id="p0130" num="0130"> According to Lamb et al. (2006), there is no standard for estimating statistical significance of connections observed. Lamb teaches that the power to detect connections may be greater for compounds with many replicates. Replicating in this context means that the same perturbagen is profiled multiple times. Where batch to batch variation must be avoided, a perturbagen should be profiled multiple times in each batch. However, since microarray experiments tend to have strong batch effects it is desirable to replicate instances in different batches (i.e., experiments) to have the highest confidence that connectivity scores are meaningful and reproducible. 
<!-- EPO <DP n="35"/>-->
 Each instance may be rank ordered according to its connectivity score to the query signature and the resulting rank ordered list displayed to a user using any suitable software and computer hardware allowing for visualization of data. </p><p id="p0131" num="0131"> In some embodiments, the methods may comprise identifying from the displayed rank- ordered list of instances (i) the one or more perturbagens associated with the instances of interest (thereby correlating activation or inhibition of a plurality of genes listed in the query signature to the one or more perturbagens); (ii) the differentially expressed genes associated with any instances of interest (thereby correlating such genes with the one or more perturbagens, the skin tissue condition of interest, or both); (iii) the cells associated with any instance of interest (thereby correlating such cells with one or more of the differentially expressed genes, the one or more perturbagens, and the skin tissue condition of interest); or (iv) combinations thereof. The one or more perturbagens associated with an instance may be identified from the metadata stored in the database for that instance. However, one of skill in the art will appreciate that perturbagen data for an instance may be retrievably stored in and by other means. Because the identified perturbagens statistically correlate to activation or inhibition of genes listed in the query signature, and because the query signature is a proxy for a skin tissue condition of interest, the identified perturbagens may be candidates for new cosmetic agents, new uses of known cosmetic agents, or to validate known agents for known uses. </p><p id="p0132" num="0132"> In some embodiments, the methods of the present invention may further comprise testing the selected candidate cosmetic agent, using in vitro assays and/or in vivo testing, to validate the activity of the agent and usefulness as a cosmetic agent. Any suitable in vitro test method can be used, including those known in the art, and most preferably in vitro models having an established nexus to the desired in vivo result. For example, MatTek human skin equivalent cultures and skin biopsy assays may be used to evaluate candidate cosmetic agents. In some embodiments, evaluation of selected agents using in vitro assays may reveal, confirm, or both, that one or more new candidate cosmetic agents may be used in conjunction with a known cosmetic agent (or a combination of known cosmetic agents) to regulate a skin aging tissue condition of interest. </p><p id="p0133" num="0133"> V. Cosmetic Compositions and Personal Care Products </p><p id="p0134" num="0134"> Because of the desirability of providing various cosmetic skin anti-aging benefits to a consumer, it may be beneficial to incorporate test agents or compounds identified by one or more of the screening methods described herein into a cosmetic composition suitable for topical application to skin. That is, it may be desirable to include the test agent as an ingredient in the cosmetic composition. In certain embodiments, the cosmetic composition may include a 
<!-- EPO <DP n="36"/>-->
 dermatological acceptable earner, the test agent, and one or more optional ingredients of the kind commonly included in the particular cosmetic compositing being provided. </p><p id="p0135" num="0135"> Dermatological ly acceptable carriers should be safe for use in contact with human skin tissue. Suitable carriers may include water and/or water miscible solvents. The cosmetic skin care composition may comprise from about 1 % to about 95 % by weight of water and/or water miscible solvent. The composition may comprise from about 1 %, 3%, 5%, 10%, 15%, 20%, 25%, 30%. 35%. 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, or 85% to about 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10% , or 5% water and/or water miscible solvents. Suitable water miscible solvents include monohydric alcohols, dihydric alcohols, polyhydric alcohols, glycerol, glycols, polyalkylene glycols such as polyethylene glycol, and mixtures thereof. When the skin care composition is in the form of an emulsion, water and/or water miscible solvents are carriers typically associated with the aqueous phase. </p><p id="p0136" num="0136"> Suitable carriers also include oils. The skin care composition may comprise from about 1 % to about 95 % by weight of one or more oils. The composition may comprise from about 0.1%, 0.5%, 1 %, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90% to about 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or 3% of one or more oils. Oils may be used to solubilize, disperse, or carry materials that are not suitable for water or water soluble solvents. Suitable oils include silicones, hydrocarbons, esters, amides, ethers, and mixtures thereof. The oils may be volatile or nonvolatile. </p><p id="p0137" num="0137"> Suitable silicone oils include polysiloxanes. Commercially available polysiloxanes include the polydimethylsiloxanes, which are also known as dimethicones, examples of which include the DM-Fluid series from Shin-Etsu, the Vicasif' series sold by Momentive Performance Materials Inc., and the Dow Corning<sup>®</sup> 200 series sold by Dow Corning Corporation. Specific examples of suitable polydimethylsiloxanes include Dow Corning* 200 fluids (also sold as Xiameter" PMX-200 Silicone Fluids) having viscosities of 0.65, 1.5, 50, 100, 350, 10.000, 12,500 100,000, and 300,000 centistokes. </p><p id="p0138" num="0138"> Suitable hydrocarbon oils include straight, branched, or cyclic alkanes and alkenes. The chain length may be selected based on desired functional characteristics such as volatility. Suitable volatile hydrocarbons may have between 5-20 carbon atoms or, alternately, between 8- 16 carbon atoms. </p><p id="p0139" num="0139"> Other suitable oils include esters. The suitable esters typically contained at least 10 carbon atoms. These esters include esters with hydrocarbyl chains derived from fatty acids or 
<!-- EPO <DP n="37"/>-->
 alcohols (e.g. , mono-esters, polyhydric alcohol esters, and di- and tri-carboxylic acid esters). The hydrocarbyl radicals of the esters hereof may include or have covalently bonded thereto other compatible functionalities, such as amides and alkoxy moieties (e.g. , ethoxy or ether linkages, etc.). </p><p id="p0140" num="0140"> Other suitable oils include amides. Amides include compounds having an amide functional group while being liquid at 25 °C and insoluble in water. Suitable amides include N- acetyl-N-butylaminopropionate, isopropyl N-lauroylsarcosinate. and Ν,Ν,-diethyltoluamide. Other suitable amides are disclosed in U.S. Patent No. 6,872,401. </p><p id="p0141" num="0141"> Other suitable oils include ethers. Suitable ethers include saturated and unsaturated fatty ethers of a polyhydric alcohol, and alkoxylated derivatives thereof. Exemplary ethers include C<sub>4</sub>. 20 alkyl ethers of polypropylene glycols, and di-Cs<sub>-3</sub>o alkyl ethers. Suitable examples of these materials include PPG- 14 butyl ether, PPG- 15 stearyl ether, dioctyl ether, dodecyl octyl ether, and mixtures thereof. </p><p id="p0142" num="0142"> The skin care composition may comprise an emulsifier. An emulsifier is particularly suitable when the composition is in the form of an emulsion or if immiscible materials are being combined. The skin care composition may comprise from about 0.05%, 0.1%, 0.2%, 0.3%, 0.5%, or 1 % to about 20%, 10%, 5%, 3%, 2%, or 1 % emulsifier. Emulsifiers may be nonionic, anionic or cationic. Non-limiting examples of emulsifiers are disclosed in U.S. Patent 3,755,560, U.S. Patent 4,421 ,769, and McCutcheon's, Emulsifiers and Detergents, 2010 Annual Ed., published by M. C. Publishing Co.. Other suitable emulsifiers are further described in the Persona] Care Product Council's International Cosmetic Ingredient Dictionary and Handbook, Thirteenth Edition, 2006, under the functional category of "Surfactants - Emulsifying Agents."</p><p id="p0143" num="0143">Linear or branched type silicone emulsifiers may also be used. Particularly useful polyether modified silicones include KF-601 1 , KF-6012, KF-6013, KF-6015, KF-6015, KF- 6017, KF-6043. KF-6028, and F-6038 from Shin Etsu. Also particularly useful are the polyglycerolated linear or branched siloxane emulsifiers including KF-6100, KF-6104, and KF- 6105 from Shin Etsu. Emulsifiers also include emulsifying silicone elastomers. Suitable silicone elastomers may be in the powder form, or dispersed or solubilized in solvents such as volatile or nonvolatile silicones, or silicone compatible vehicles such as paraffinic hydrocarbons or esters. Suitable emulsifying silicone elastomers may include at least one polyalkyl ether or polyglycerolated unit. </p><p id="p0144" num="0144"> Structuring agents may be used to increase viscosity, thicken, solidify, or provide solid or crystalline structure to the skin care composition. Structuring agents are typically grouped based on solubility, dispersibility. or phase compatibility. Examples of aqueous or water structuring 
<!-- EPO <DP n="38"/>-->
 agents include polymeric agents, natural or synthetic gums, polysaccharides, and the like. In one embodiment, the composition may comprises from about 0.0001 %, 0.001 %, 0.01 %, 0.05%, 0.1 %, 0.5%, 1 %, 2%, 3%, 5% to about 25%, 20%, 10%), 7%, 5%, 4%, or 2%, by weight of the composition, of one or more structuring agents. </p><p id="p0145" num="0145"> Polysaccharides and gums may be suitable aqueous phase thickening agents. Suitable classes of polymeric structuring agents include but are not limited to carboxylic acid polymers, polyacrylamide polymers, sulfonated polymers, high molecular weight polyalkylglycols or polyglycerins, copolymers thereof, hydrophobically modified derivatives thereof, and mixtures thereof. Silicone gums are another oil phase structuring agent. Another type of oily phase structuring agent includes silicone waxes. Silicone waxes may be referred to as alkyl silicone waxes which and are semi-solids or solids at room temperature. Other oil phase structuring agents may be one or more natural or synthetic waxes such as animal, vegetable, or mineral waxes. </p><p id="p0146" num="0146"> The skin care compositions may be generally prepared by conventional methods such as known in the art of making compositions and topical compositions. Such methods typically involve mixing of ingredients in or more steps to a relatively uniform state, with or without heating, cooling, application of vacuum, and the like. Typically, emulsions are prepared by first mixing the aqueous phase materials separately from the fatty phase materials and then combining the two phases as appropriate to yield the desired continuous phase. The compositions are preferably prepared such as to optimize stability (physical stability, chemical stability, photostability, etc.) and/or delivery of active materials. The composition may be provided in a package sized to store a sufficient amount of the composition for a treatment period. The size, shape, and design of the package may vary widely. Certain package examples are described in USPNs D570J07; D391 , 162; D516.436; D535.191 ; D542,660; D547J 93; D547.661 ; D558.591 ; D563.221 ; 2009/0017080; 2007/0205226; and 2007/0040306. </p><p id="p0147" num="0147"> EXAMPLES </p><p id="p0148" num="0148"> The present invention will be better understood by reference to the following examples which are offered by way of illustration not limitation. </p><p id="p0149" num="0149"> Example 1 </p><p id="p0150" num="0150"> Generating Instances </p><p id="p0151" num="0151"> Individual experiments (referred to as batches) generally comprise 30 to 96 samples analyzed using Affymetrix GeneChip® technology platforms, containing 6 replicates of the vehicle control (e.g.. DSMO), 2 replicate samples of a positive control that gives a strong reproducible effect in the cell type used (e.g.,all mmv-retinoic acid for fibroblast cells), and 
<!-- EPO <DP n="39"/>-->
 samples of the test material/perturbagen. Replication of the test material is done in separate batches due to batch effects. In vitro testing was performed in 6-well plates to provide sufficient RNA for GeneChip® analysis (2-4 ,ug total RNA yield/well). </p><p id="p0152" num="0152"> Human telomerized keratinocytes (t C) were obtained from the University of Texas, Southwestern Medical Center, Dallas, TX. tKC cells were grown in EpiLife® media with IX Human Keratinocyte Growth Supplement (Invitrogen, Carlsbad, CA) on collagen I coated cell culture flasks and plates (Becton Dickinson, Franklin Lakes, NJ). Keratinocytes were seeded into 6-well plates at 20,000 cells /cm<sup>2</sup> 24 hours before chemical exposure. Human skin fibroblasts (BJ cell line from ATCC, Manassas, VA) were grown in Eagle's Minimal Essential Medium (ATCC) supplemented with 10% fetal bovine serum (HyClone, Logan, UT) in normal cell culture flasks and plates (Corning, Lowell, MA). BJ fibroblasts were seeded into 6-well plates at 12,000 cells/cm<sup>2</sup> 24 hours before chemical exposure. </p><p id="p0153" num="0153"> All cells were incubated at 37°C in a humidified incubator with 5% CC At t= -24 hours cells were trypsinized from T-75 flasks and plated into 6-well plates in basal growth medium. At t=0 media was removed and replaced with the appropriate dosing solution as per the experimental design. Dosing solutions were prepared the previous day in sterile 4 ml Falcon snap cap tubes. Pure test materials may be prepared at a concentration of 1 -200 μΜ, and botanical extracts may be prepared at a concentration of 0.001 to 1% by weight of the dosing solution. After 6 to 24 hours of chemical exposure, cells were viewed and imaged. The wells were examined with a microscope before cell lysis and RNA isolation to evaluate for morphologic evidence of toxicity. If morphological changes were sufficient to suggest cytotoxicity, a lower concentration of the perturbagen was tested. Cells were then lysed with 350ul/well of RLT buffer containing β- mercaptoethanol (Qiagen, Valencia, CA), transferred to a 96-well plate, and stored at -20° C. </p><p id="p0154" num="0154"> RNA from cell culture batches was isolated from the RLT buffer using Agencourt® RNAdvance Tissue-Bind magnetic beads (Beckman Coulter) according to manufacturer's instructions. 1 g of total RNA per sample was labeled using Ambion Message Amp™ II Biotin Enhanced kit (Applied Biosystems Incorporated) according to manufacturer's instructions. The resultant biotin labeled and fragmented cRNA was hybridized to an Affymetrix HG-U133A 2.0 GeneChip®, which was then washed, stained and scanned using the protocol provided by Affymetrix. </p><p id="p0155" num="0155"> In one embodiment, an exemplary test perturbagen was Cynara scolymus (artichoke) leaf extract obtained from Ichimaru Pharcos, JP. Following generally the procedure described above, a resultant rank-ordered listing of 22,214 probe set IDs (e.g., an instance) for the artichoke leaf perturbagen applied to fibroblast cells was generated and are set forth in Table E. Following 
<!-- EPO <DP n="40"/>-->
 W 201 </p><p id="p0156" num="0156"> 39 generally the procedure described above, a resultant rank-ordered listing of 22,214 probe set IDs (e.g.. an instance) for the artichoke leaf extract perturbagen applied to keratinocyte cells was generated and illustrative portions are set forth in Table F. In another aspect, an exemplary test perturbagen was Hydrolyzed Ceratonia siliqua (carob) seed extract. Following generally the procedure described above, a resultant rank-ordered listing of 22,214 probe set IDs (e.g., an instance) for the carob seed extract perturbagen applied to fibroblast cells was generated and illustrative portions are set forth in Table G. Following generally the procedure described above, a resultant rank-ordered listing of 22,214 probe set IDs (e.g., an instance) for the carob seed extract perturbagen applied to keratinocyte cells was generated and illustrative portions are set forth in Table H. </p><p id="p0157" num="0157"> Example 2 </p><p id="p0158" num="0158"> Deriving a Photo-Aging Gene expression signature </p><p id="p0159" num="0159"> A clinical survey study to obtain biopsy specimens for use in the investigation of gene expression patterns associated with sun light-mediated skin aging (photo-aging) was performed. Baseline gene expression patterns were examined in sun-protected and sun-exposed skin from young and aged women to examine gene expression profiles associated with photo-aging. A total of 3 full thickness skin biopsies (~4mm) were taken from sun-protected (buttocks) and sun- exposed (extensor forearm) body sites from each of 10 young women (aged 18 to 20 years) and 10 older women (aged 60 to 67 years). The older women were selected to have moderate to severe forearm photo-damage. Biopsies were flash frozen in liquid nitrogen and stored at -80°C until RNA isolation. </p><p id="p0160" num="0160"> Frozen skin biopsies were homogenized in Trizol (Invitrogen) and RNA extracted using the protocol provided by Invitrogen. Since the tissue samples were from full thickness biopsies, RNA was extracted from a variety of cell types within the full-thickness skin sample, including keratinocytes, fibroblasts, melanocytes, endothelial cells, pericytes, nerves, smooth muscle, sebocytes, adipocytes, and immunocytes). R A was further purified using RNEasy spin columns (Qiagen). Total RNA was quantified using a NanoDrop spectrophotometer (Thermo Scientific, Waltham, MA) and quality was confirmed using an Agilent (Santa Clara, CA) 2100 BioAnalyzer. Total RNA (5 iig) was converted to GeneChip targets using the Enzo BioArray labeling procedure (Enzo Life Sciences. Farmingdale. NY) and protocol provided. All biotin- labeled GeneChip targets were hybridized to Affymetrix Human Genome HG-U 133 Plus 2.0 GeneChips overnight, which were then washed, stained and scanned using the protocol provided by Affymetrix. Forearm and buttock samples were processed on the same day using the same manufacturing lot of GeneChips. 
<!-- EPO <DP n="41"/>-->
 The samples were analyzed on the Affymetrix HG-U 133 Plus 2.0 GeneChips, which contain 54,613 probe sets complementary to the transcripts of more than 20,000 genes. However, instances in the provided database used were derived from gene expression profiling experiments using Affymetrix HG-U133A 2.0 GeneChips, containing 22,214 probe sets, which are a subset of those present on the Plus 2.0 GeneChip. Therefore, in developing gene expression signatures from the clinical data, the probe sets were filtered for those included in the HG-U133A 2.0 gene chips. </p><p id="p0161" num="0161"> Using, generally the following selection process, a statistical analysis of the microarray data was performed to derive a plurality of photo-aging gene expression signatures comprising between about 200 and about 600 up-regulated and down-regulated genes. </p><p id="p0162" num="0162"> a. Filtering based on Absent/Margin/Present Calls. This filter creates a list of potential genes for inclusion in the gene expression signature. For example, a suitable filter may be that at least 50% of the samples in one treatment group must have a Present call for each probe set. Present calls are derived from processing the raw GeneChip data and provide evidence that the gene transcript complementary to a probe set that is actually expressed in the biological sample. The probes that are absent from all samples are likely to be just noisy measurements. This step is important to filter out probe sets that do not contribute meaningful data to the signature. For both photo-aging and intrinsic aging gene expression signatures, the data was filtered for probe sets with at least 10% Present calls provided by the Affymetrix MAS 5 software. </p><p id="p0163" num="0163"> b. Filtering According to a Statistical Measure. For example, a suitable statistical measure may be p-values from a t-test, ANOVA, correlation coefficient, or other model-based analysis. As one example, p-values may be chosen as the statistical measure and a cutoff value of p=0.05 may be chosen. Limiting the signature list to genes that meet some reasonable cutoff for statistical significance compared to an appropriate control is important to allow selection of genes that are characteristic of the biological state of interest. This is preferable to using a fold change value, which does not take into account the noise around the measurements. The t-statistic was used to select the probe sets in the signatures because it is signed and provides an indication of the directionality of the gene expression changes (i.e. up- or down-regulated) as well as statistical significance. </p><p id="p0164" num="0164"> c. Sorting the Probe Sets. All the probe sets are sorted into sets of up-regulated and down-regulated sets using the statistical measure. For example, if a t-test was used to compute p-values, the values (positive and negative) of the t-statistic are used to sort the list since p-values are always positive. The sorted t-statistics will place the sets with the 
<!-- EPO <DP n="42"/>-->
 most significant p-values at the top and bottom of the list with the non-significant ones near the middle. </p><p id="p0165" num="0165"> d. Creation of the Gene expression signature. Using the filtered and sorted list created, a suitable number of probe sets from the top and bottom are selected to create a gene expression signature that preferably has approximately the same number of sets chosen from the top as chosen from the bottom. For example, the gene expression signature created may have at least about 10, 50, 100, 200, or 300 and/or less than about 800, 600, or about 400 genes corresponding to a probe set on the chip. The number of probe sets approximately corresponds to the number of genes, but a single gene may be represented by more than one probe set. It is understood that the phrase "number of genes" as used herein, corresponds generally with the phrase "number of probe sets." The number of genes included in the signature was based upon the observations in preliminary studies that indicated signatures with from 200 to 800 probe sets equally divided between up- and down-regulated genes provide stable results with regard to the top scoring chemical instances when using the signature to query the provided database. </p><p id="p0166" num="0166"> For photo-aging, three gene expression signatures were selected as follows: </p><p id="p0167" num="0167"> (i) "Photo-aging 200" signature (P200), which comprises 100 most significant up- and 100 most significant down-regulated probe sets comparing older arm to younger arm as set forth in Tables C and D, respectively; </p><p id="p0168" num="0168"> (ii) "Photo-aging 400" signature (P400), which comprises 200 most significant up- and 200 most significant down-regulated probe sets comparing older arm to younger arm as set forth in Tables C and D, respectively; and </p><p id="p0169" num="0169"> (iii) "Photo-aging 600" signature (P600), which comprises 300 most significant up- and 300 most significant down-regulated probe sets comparing older arm to younger arm as set forth in Tables C and D, respectively. </p><p id="p0170" num="0170">Example 3 </p><p id="p0171" num="0171"> Deriving an Intrinsic Aging Gene expression signature </p><p id="p0172" num="0172"> A clinical survey study to obtain biopsy specimens for use in the investigation of gene expression patterns associated with chronological (intrinsic) skin aging was performed. Baseline gene expression patterns were examined in sun-protected skin from young and aged women to examine gene expression profiles associated with intrinsic aging. A total of 3 full thickness skin biopsies (~4mm) were taken from sun-protected (buttocks) body sites from each of 10 young 
<!-- EPO <DP n="43"/>-->
 women (aged 1 8 to 20 years) and 10 older women (aged 60 to 67 years). Biopsies were flash frozen in liquid nitrogen and stored at -80°C until RNA isolation. </p><p id="p0173" num="0173"> Frozen skin biopsies were homogenized in Trizol (Invitrogen) and RNA extracted using the protocol provided by nvitrogen. Since the tissue samples were from full thickness biopsies, RNA was extracted from a variety of cell types within the full-thickness skin sample, including keratinocytes, fibroblasts, melanocytes, endothelial cells, pericytes, nerves, smooth muscle, sebocytes, adipocytes, and immunocytes). RNA was further purified using RNEasy spin columns (Qiagen). Total RNA was quantified using a NanoDrop spectrophotometer (Thermo Scientific, Waltham, MA) and quality was confirmed using an Agilent (Santa Clara, CA) 2100 BioAnalyzer. Total RNA (5 ,ug) was converted to GeneChip targets using the Enzo BioArray labeling procedure (Enzo Life Sciences, Farmingdale, NY) and protocol provided. All biotin- labeled GeneChip targets were hybridized to Affymetrix Human Genome HG-U133 Plus 2.0 gene chips overnight, which were then washed, stained and scanned using the protocol provided by Affymetrix. Samples were processed on the same day using the same manufacturing lot of gene chips. </p><p id="p0174" num="0174"> Using, generally the same sorting process as set forth in Example 2, a statistical analysis of the microarray data was performed to derive intrinsic aging gene expression signatures comprising between about 200 genes and about 600 genes. </p><p id="p0175" num="0175"> (i) "Intrinsic Aging 200" signature (1200), which comprises 100 most significant up- and 100 most significant down-regulated probe sets comparing older buttock to younger buttock as set forth in Table A and B, respectively. </p><p id="p0176" num="0176"> (ii) "Intrinsic Aging 400" signature (1400), which comprises 200 most significant up- and 200 most significant down-regulated probe sets older buttock to younger buttock as set forth in Table A and B, respectively. </p><p id="p0177" num="0177"> (iii) "Intrinsic Aging 600" signature (1600), which comprises 300 most significant up- and 300 most significant down-regulated probe sets older buttock to younger buttock as set forth in Table A and B, respectively. </p><p id="p0178" num="0178"> The photo-aging gene expression signatures and the intrinsic aging gene expression signatures may be used in whole or part, or they may be used in combination as a query in the present invention. In some embodiments, the gene expression signature comprises the set of most up-regulated or most down-regulated genes. In some embodiments, the photo-aging gene expression signature and intrinsic aging gene expression signature may have between about 10 and 50% of their probe set IDs in common. In other embodiments, the photo-aging gene 
<!-- EPO <DP n="44"/>-->
 W </p><p id="p0179" num="0179"> 43 expression signature and the intrinsic aging gene expression signature may have between about 20% and 30% of their probe set IDs in common. Some materials tested in C-map link to only to gene expression signatures developed for one of the types of skin aging because these agents may be affecting different biology. For example, the inventors have found that the photo-aging gene expression signatures show strong preferential linkage to perturbagen instances tested in fibroblasts and the gene expression changes are more reflective of changes in the dermal connective tissue. In contrast, the intrinsic aging gene expression signatures reflect changes in both the epidermis and dermis that occur with aging. Therefore, it is useful to query the connectivity map with separate signatures derived for both intrinsic aging and photo-aging. Also, it is desirable to use signatures with different numbers of genes. Predictions of biological activity based on multiple signatures are more likely to be correct. </p><p id="p0180" num="0180"> Example 4 </p><p id="p0181" num="0181"> Photo- Aging Gene expression signature and Intrinsic Aging Gene expression signature </p><p id="p0182" num="0182"> Comparison to Fibroblast and Keratinocyte Instances </p><p id="p0183" num="0183"> The inventors observed that photo-aging gene signatures (e.g., Example 2) have a strong preferential connectivity toperturbagen instances tested in BJ fibroblasts. In other words, among the top ranked instances (i.e., with high connectivity scores) resulting from queries with photo- aging signatures BJ fibroblast instances were strongly over-represented. This effect was most dramatic when the genes up-regulated in photoaged skin were used as the query signatures. A similar result, but less strong, was obtained with the intrinsic aging signatures (e.g., Example 3). A summary of the results of comparing a plurality of instances with the Photo-aging 600 signature is shown in Table 1. These results are completely unpredicted and surprising considering that: i) the gene signatures derived from full thickness biopsies comprising a variety of cell types expected to contribute to the skin aging phenotype, and ii) skin aging is a complex multi-factorial condition involving changes in most of the tissues and structures of skin, </p><p id="p0184" num="0184"> Table 1. </p><p id="p0185" num="0185"> Distribution of fibroblast (BJ and keratinocyte (tKC) instances in the top ranked instances from a </p><p id="p0186" num="0186"> C-map query with the Photo-aging 600 signature<sup>1</sup> </p><p id="p0187" num="0187">Rank <sup>2</sup> ; Chemical instances tested in each cell type </p><p id="p0188" num="0188"> Complete Up list <sup>3</sup> Down list <sup>3</sup> </p><p id="p0189" num="0189"> signature </p><p id="p0190" num="0190"> BJ tKC BJ tKC BJ tKC </p><p id="p0191" num="0191"> 1 -100 ; 79 21 100 0 36 64 </p><p id="p0192" num="0192"> 101 -200 Ϊ 60 40 100 0 36 <sup>:</sup> 64 </p><p id="p0193" num="0193"> 201 -300 57 <sup>;</sup> 43 : 100 0 41 \ 59 
<!-- EPO <DP n="45"/>-->
 301 -400 51 49 96 4 34 66 </p><p id="p0194" num="0194"> 401 -500 38 62 85 15 15 72 </p><p id="p0195" num="0195"> 'This signature comprises the 300 most statistically significant up-regulated and the 300 most significant down-regulated Affymetrix probe sets in the older arm to younger arm comparison described in Example 2, above. </p><p id="p0196" num="0196"> instances were ranked from the most negatively scoring to most positive (i.e., 1 was the most negatively scoring instance). Chemicals scoring negatively are predicted to have beneficial effects on photo-aging.</p><p id="p0197" num="0197"> The up list results are from querying a database of instances with only up-regulated probe sets in the gene expression signature. Similarly, the down list results are from querying with a gene expression signature comprising only probe sets that are down-regulated. </p><p id="p0198" num="0198"> Among the top 300 ranked instances linking to the complete photo-aging signature, 196</p><p id="p0199" num="0199">(65.3%) were with respect to BJ fibroblasts and only 34.7% were with respect to keratinocytes. This was more than a 2-fold over-representation of fibroblasts, since they comprised only 31 % of the instances in the database. The preferential connectivity of fibroblasts to the photo-aging signature was much more dramatic when only the up list was used for the query. Remarkably, in that case all of the top 300 instances were in fibroblasts. The up signature contribution accounted for the preferential connectivity of fibroblasts to the complete photo-aging signature, because querying with the down signature alone gave a distribution of top scoring instances more proportional to the percentages of the two cell lines instances in the database. Similar results were obtained with the Photo-aging P200 and P400 signatures described in Example 2. Overall, the strong preferential connectivity of fibroblast instances to the photo-aging signatures is surprising because keratinocytes are expected to contribute to the photo-aging phenotype and all of the materials tested in BJ fibroblasts were also tested in keratinocytes (i.e., the effect is not due to any chemical specificity). </p><p id="p0200" num="0200"> A similar but subtly different pattern was observed when the provided database was queried with intrinsic aging gene expression signatures. Table 2 shows results obtained with the Intrinsic Aging 600 signature (Example 3). Again there was an over-representation of fibroblasts among the top ranked instances with the complete signature, and this effect was due to the up- regulated probe sets in the signature, but the effect was not as strong as with the photo-aging signatures. Furthermore, the top ranking instances connecting to the down list showed some over-representation of keratinocytes relative to their proportion of the samples tested (Table 2). </p><p id="p0201" num="0201"> Table 2 </p><p id="p0202" num="0202"> Distribution of fibroblast (BJ) and keratinocyte (tKC)instances in the top ranked instances from a </p><p id="p0203" num="0203"> C-map query with the Intrinsic Aging 600 signature. ' </p><p id="p0204" num="0204">Rank <sup>2</sup> Chemical instances tested in each cell type </p><p id="p0205" num="0205"> Complete Up list <sup>3</sup> Down list <sup>3</sup> 
<!-- EPO <DP n="46"/>-->
 signature </p><p id="p0206" num="0206"> BJ tKC BJ tKC BJ tKC </p><p id="p0207" num="0207"> 1 -100 i 68 32 95 5 13 87 </p><p id="p0208" num="0208"> 101 -200 55 45 84 16 17 83 </p><p id="p0209" num="0209"> 201 -300 38 62 72 28 17 83 </p><p id="p0210" num="0210"> 301 -400 37 63 67 33 21 79 </p><p id="p0211" num="0211"> 401 -500 31 69 57 43 26 74 </p><p id="p0212" num="0212"><sup>1</sup> This signature comprises the 300 most statistically significant up- and 300 most significant down-regulated Affymetrix probe sets in the older buttock to younger buttock comparison in the clinical study described in Example 3. </p><p id="p0213" num="0213"> ' Instances were ranked as in Table 1 . </p><p id="p0214" num="0214"><sup>3</sup> The up list results are from querying the C-Map database with only the up-regulated probe sets in the signature. Similarly, the down list results are from querying only with the down list. </p><p id="p0215" num="0215"> Unexpectedly, the gene expression signatures generated from clinical samples of photo- aged skin show very strong preferential connectivity to chemical instances tested in dermal fibroblasts compared to epidermal keratinocytes. Furthermore, this preferential connectivity was observed with signatures generated from gene expression profiling done on RNA extracted from full thickness biopsies of skin, which comprise a composite sample of all of the cell types within the complex structure of skin. Analysis of the biological processes associated with the genes differentially expressed in photo-aged skin indicated that many of the processes were related to the dermis and fibroblasts including wound healing (see Theme Analysis, Example 5). These results support the hypothesis that the dominant gene expression changes in photo-aged skin occur in dermal fibroblasts. Furthermore, in clinical testing statistically significant anti-wrinkle results were obtained with two botanical extracts predicted to have skin anti-aging activity based on C-Map queries of fibroblast instances (e.g. Examples 6 and 7). In contrast, the keratinocytes instances of these materials did not predict their anti-aging activities. </p><p id="p0216" num="0216"> These differences between the photo-aging and intrinsic aging signatures may be accounted for by the fact that they represent overlapping but different biological changes in aging skin (see Theme Analysis, Example 5). Photo-aging is due to a combination of the effects of UV radiation exposure and intrinsic factors, while intrinsic aging lacks the solar/UV component. Fewer than 20% of the genes in the photo-aging and intrinsic aging signatures were observed to be in common. These results point to the value of using both photo-aging and intrinsic aging signatures when applying C-map to identify cosmetic agents to improve aging skin, because the signatures will allow detection of materials that affect different aspects of the complex aging process. 
<!-- EPO <DP n="47"/>-->
 The under-representation of telomerized keratinocytes in the top ranked C-map instances with queries using the complete photo-aging and intrinsic aging gene expression signatures was not due to a lack of responsiveness of the cells under the conditions of testing. Table 3 sets forth gene expression outlier numbers for 493 chemicals that were tested in both BJ fibroblasts and telomerized keratinocytes using the same stock solutions. Outlier numbers were calculated for each singleton C-map instance and are a measure of the number of probe sets regulated by treatment. In this probe set-by-probe set analysis, the 6 vehicle control samples in a C-map batch are used to form a prediction interval for each probe set, and then for each chemical instance in the batch the probe sets falling outside the interval are counted. This statistic is used because chemical replication is usually done in different C-map batches due to batch effects on the scoring. </p><p id="p0217" num="0217">Table 3. </p><p id="p0218" num="0218"> Gene expression outlier numbers for 493 materials tested in both BJ fibroblasts and telomerized keratinocytes. <sup>1</sup> </p><p id="p0219" num="0219">Number of C-MAP instances </p><p id="p0220" num="0220">Range of BJ fibroblasts Telomerized- outliers keratinocytes </p><p id="p0221" num="0221"> ≥2000 123 245 </p><p id="p0222" num="0222"> 1000 - 1999 Γ 71 1 725 </p><p id="p0223" num="0223"> &lt;1000 292 234 </p><p id="p0224" num="0224"> Totals: 1 126 1204 </p><p id="p0225" num="0225"> 'Materials from the same stock tubes were tested in both types of cells. Outlier numbers were calculated for each singleton C-map instance and are a measure of the number of probe sets regulated by treatment. In this probe set-by-probe set analysis, the 6 vehicle control samples in a C-map batch are used to form a prediction interval for each probe set, and then for each chemical instance in the batch the probe sets falling outside the interval are counted. This statistic is used because chemical replication is usually done in different C-map batches due to batch effects on the scoring. </p><p id="p0226" num="0226"> Based on outlier numbers, the keratinocytes tended to be more responsive to treatment than fibroblasts and there were about twice as many keratin ocyte instances with high outlier numbers (&gt;2,000) compared to those with fibroblasts. Additional indications of cellular responsiveness to treatment are morphologic changes. Altered morphology in telomerized keratinocytes treated with various chemicals has been observed. In contrast, morphologic changes in BJ fibroblasts have rarely been observed under the same conditions. A fairly dramatic comparative example is shown in Figure 9, which documents the morphology of cells treated 
<!-- EPO <DP n="48"/>-->
 Table 4. </p><p id="p0227" num="0227"> Theme analysis of genes regulated in photo-aging. </p><p id="p0228" num="0228">Gene Ontology Biological Process Terms Old Arm to Terms </p><p id="p0229" num="0229"> Young Arm related to Comparison dermis</p><p id="p0230" num="0230">Up Down</p><p id="p0231" num="0231"> O:0006956 complement activation</p><p id="p0232" num="0232">:0032501 multicellular organismal process</p><p id="p0233" num="0233"> :0007275 multicellular organismal development</p><p id="p0234" num="0234"> 0:6035295 tube development </p><p id="p0235" num="0235">GO:0030323 respiratory tube development </p><p id="p0236" num="0236"> GO:0048754 branching morphogenesis of a tube</p><p id="p0237" num="0237"> O:0048731 system development </p><p id="p0238" num="0238">GO.0048513 organ development </p><p id="p0239" num="0239"> GO:0048568 embryonic organ development </p><p id="p0240" num="0240"> GO:0009887 organ morphogenesis </p><p id="p0241" num="0241"> GO.0009888 tissue development </p><p id="p0242" num="0242">GO:0007399 nervous system development </p><p id="p0243" num="0243">GO:0001501 skeletal system development X GO:0048706 embryonic skeletal system development XO:0048736 appendage development X GO:0035107 appendage morphogenesis X GO:0060173 limb development XO:0007389 pattern specification process</p><p id="p0244" num="0244">0032502 developmental process</p><p id="p0245" num="0245"> :0048856 anatomical structure development</p><p id="p0246" num="0246">O:0009653 anatomical structure morphogenesis</p><p id="p0247" num="0247">O:0016477 cell migration </p><p id="p0248" num="0248"> GO:0002541 activation of plasma proteins involved</p><p id="p0249" num="0249"> te inflammat...</p><p id="p0250" num="0250">O:0009611 response to wounding X O:0042060 wound healing X :0009605 response to external stimulus</p><p id="p0251" num="0251">O:0019222 regulation of metabolic process </p><p id="p0252" num="0252"> GO:0045941 positive regulation of transcription </p><p id="p0253" num="0253"> GO:0045893 positive regulation of transcription, 
<!-- EPO <DP n="49"/>-->
 DNA-dependent </p><p id="p0254" num="0254"> . . . . . . . . . GO:0045944 positive regulation of transcription from RNA polym... </p><p id="p0255" num="0255"> GO:0006355 regulation of transcription, DNA- dependent </p><p id="p0256" num="0256"> GO:0045892 negative regulation of transcription,</p><p id="p0257" num="0257">DNA-dependent </p><p id="p0258" num="0258"> GO;0000122 negative regulation of transcription from RNA polym... </p><p id="p0259" num="0259"> GO:0006357 regulation of transcription from RNA polymerase II pr... </p><p id="p0260" num="0260"> GO:0016481 negative regulation of transcription GO:0051253 negative regulation of RNA metabolic process </p><p id="p0261" num="0261"> GO:0051252 regulation of RNA metabolic process GO:0051254 positive regulation of RNA metabolic process </p><p id="p0262" num="0262"> GO:0045935 positive regulation of nucleobase, nucleoside, nucleotide... </p><p id="p0263" num="0263"> GO:0031324 negative regulation of cellular metabolic process </p><p id="p0264" num="0264"> GO:0031327 negative regulation of cellular biosynthetic process </p><p id="p0265" num="0265"> GO:0031325 positive regulation of cellular metabolic process </p><p id="p0266" num="0266"> GO:0031328 positive regulation of cellular biosynthetic process </p><p id="p0267" num="0267"> GO:0051 173 positive regulation of nitrogen compound metabolic process </p><p id="p0268" num="0268"> . . . . GO:0060255 regulation of macromolecule metabolic process </p><p id="p0269" num="0269"> GO:0010628 positive regulation of gene expression GO:0010629 negative regulation of gene expression GO:0010557 positive regulation of macromolecule biosynthetic process </p><p id="p0270" num="0270"> GO:0010558 negative regulation of macromolecule biosynthetic process </p><p id="p0271" num="0271"> GO:0010604 positive regulation of macromolecule metabolic process </p><p id="p0272" num="0272"> GO.O010605 negative regulation of macromolecule metabolic process </p><p id="p0273" num="0273"> GO:0009890 negative regulation of biosynthetic 
<!-- EPO <DP n="50"/>-->
 process </p><p id="p0274" num="0274"> GO:0009891 positive regulation of biosynthetic process </p><p id="p0275" num="0275"> . . . . GO:0009892 negative regulation of metabolic process</p><p id="p0276" num="0276">. . . . GO:0048522 positive regulation of cellular process GO:0002053 positive regulation of mesenchymal cell proliferation </p><p id="p0277" num="0277"> . . . . GO:0048634 regulation of muscle organ development GO:0016202 regulation of striated muscle tissue development </p><p id="p0278" num="0278"> GO:0010464 regulation of mesenchymal cell proliferation </p><p id="p0279" num="0279"> . . . . GO:0007165 signal transduction </p><p id="p0280" num="0280"> GO:0009966 regulation of signal transduction</p><p id="p0281" num="0281">. . GO:0043062 extracellular structure organization </p><p id="p0282" num="0282"> . . . GO:0030198 extracellular matrix organization </p><p id="p0283" num="0283"> GO:0006350 transcription </p><p id="p0284" num="0284"> . . GO:0006928 cellular component movement </p><p id="p0285" num="0285"> . . . . GO:0006325 chromatin organization </p><p id="p0286" num="0286"> GO:0016568 chromatin modification </p><p id="p0287" num="0287"> . . GO:0007154 cell communication </p><p id="p0288" num="0288"> GO:0016485 protein processing </p><p id="p0289" num="0289"> GO:0051605 protein maturation by peptide bond cleavage </p><p id="p0290" num="0290"><sup>1</sup> Statistical significance is as follows. </p><p id="p0291" num="0291"> P-Value Legend </p><p id="p0292" num="0292"> P </p><p id="p0293" num="0293"> 1.00E-4 </p><p id="p0294" num="0294"> &lt; </p><p id="p0295" num="0295"> p &lt;= 1.00E- * </p><p id="p0296" num="0296">1.00E-5 4 </p><p id="p0297" num="0297">&lt; </p><p id="p0298" num="0298"> 1 .00E-6 p &lt;= 1 .00E- ** </p><p id="p0299" num="0299"> &lt; 5 </p><p id="p0300" num="0300"> : p ;&lt;= 1 .00E- *** </p><p id="p0301" num="0301">1.00E-7 ; 6 </p><p id="p0302" num="0302">&lt; </p><p id="p0303" num="0303"> p &lt;= 1.00E- **** </p><p id="p0304" num="0304"> 7 
<!-- EPO <DP n="51"/>-->
 This analysis revealed that up- and down-regulated genes in photo-aging were associated with quite distinct biological processes. A number of biological processes closely associated with fibroblasts and connective tissue were up-regulated in photo-aging. It is notable that the Gene Ontology terms "response to wounding" and "wound healing" were among the most statistically significant terms (p &lt; 1 X 10<sup>~7</sup>) for the up-regulated gene list. Other terms clearly associated with fibroblasts or mesenchymal cells are marked in Table 4 and these all were significant for the up list. Most of these other terms associated with the up-regulated list relate to developmental processes in which mesenchymal cells play important roles. The genes down- regulated in photo-aging were associated with more general processes such as gene transcription and various aspects of metabolism and signal transduction that relate to various cell types. </p><p id="p0305" num="0305"> The Photo-aging 600 signature gene lists (see Example 2) were also subject to theme analysis (not shown), which revealed a pattern of significant terms quite similar to that obtained with the entire photo-aging data set. The up-regulated gene list contains genes involved in biological processes closely associated with fibroblasts or mesenchymal cells. Again among the most significant terms for the up list included "response to wounding" and "wound healing" (P &lt; 1 X 10<sup>"5</sup>). The results of these theme analyses provide a clear rationale for the specific linkage of fibroblasts to the photo-aging up-regulated gene expression signature and the strong linkage to the overall signature.photo-aging It appears that the dominant processes that are up-regulated in photo-aging involve the dermis and fibroblasts. Overall, the photo-aging gene signatures reflect this dominant biology observed in the gene expression profiling of the photo-aging skin condition. </p><p id="p0306" num="0306"> Theme analysis was also performed on the genes regulated in intrinsic aging, which involved approximately 12,500 expressed genes. Table 5 shows GO Biological Process terms that are significantly enriched in the comparison of the older buttock to younger buttock (intrinsic aging) from the clinical gene expression study described in Example 3. Similarly with respect to Table 4. only the most highly significant themes are shown (p &lt; 1 X 10<sup>"4</sup>) to keep the size of this table manageable. </p><p id="p0307" num="0307"> Table 5 </p><p id="p0308" num="0308"> Theme analysis of genes regulated in intrinsic aging </p><p id="p0309" num="0309">Gene Ontology Biological Process Terms </p><p id="p0310" num="0310">. GO:0032501 multicellular organismal </p><p id="p0311" num="0311">process 
<img id="imgf000051_0001" he="34" wi="56" file="imgf000051_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 
<!-- EPO <DP n="52"/>-->
. . . GO:0022600 digestive system </p><p id="p0312" num="0312">process </p><p id="p0313" num="0313"> . . . GO:0003012 muscle system process </p><p id="p0314" num="0314"> . . GO:0007275 multicellular organismal </p><p id="p0315" num="0315">development </p><p id="p0316" num="0316"> . . , GO:0048731 system development </p><p id="p0317" num="0317"> . . . . (30:0048513 organ development </p><p id="p0318" num="0318"> GO;0007398 ectoderm X development </p><p id="p0319" num="0319"> GO:0021846 cell proliferation in </p><p id="p0320" num="0320">fore brain </p><p id="p0321" num="0321"> . . . . GO:0007399 nervous system </p><p id="p0322" num="0322">development </p><p id="p0323" num="0323"> GO:0007417 central nervous </p><p id="p0324" num="0324">system development </p><p id="p0325" num="0325"> . . GO:0007586 digestion </p><p id="p0326" num="0326"> . . GO:0001503 ossification </p><p id="p0327" num="0327"> . GO:0032502 developmental process </p><p id="p0328" num="0328"> . . GO:0048856 anatomical structure </p><p id="p0329" num="0329">development </p><p id="p0330" num="0330"> . . . GO:0060021 palate development </p><p id="p0331" num="0331"> . . . GO:0061061 muscle structure </p><p id="p0332" num="0332">development </p><p id="p0333" num="0333"> GO:0043434 response to peptide </p><p id="p0334" num="0334">hormone stimulus </p><p id="p0335" num="0335"> . . . . GO:0042127 regulation of cell </p><p id="p0336" num="0336">proliferation </p><p id="p0337" num="0337"> . . . GO:0042180 cellular ketone metabolic </p><p id="p0338" num="0338">process </p><p id="p0339" num="0339"> . . . . GO:0043436 oxoacid metabolic X process </p><p id="p0340" num="0340"> GO:0019752 carboxylic acid X metabolic process </p><p id="p0341" num="0341"> GO:0006631 fatty acid metabolic X process </p><p id="p0342" num="0342"> . . . . . . . . GO:0006633 fatty acid X biosynthetic process </p><p id="p0343" num="0343"> GO:0046394 carboxylic acid X biosynthetic process </p><p id="p0344" num="0344"> GO:0042438 melanin biosynthetic </p><p id="p0345" num="0345">process </p><p id="p0346" num="0346"> . . . . GO:0051 188 cofactor biosynthetic 
<!-- EPO <DP n="53"/>-->
 process </p><p id="p0347" num="0347"> GO:0016053 organic acid * X </p><p id="p0348" num="0348"> biosynthetic process </p><p id="p0349" num="0349"> . . . GO:0044255 cellular lipid metabolic *** X </p><p id="p0350" num="0350"> process </p><p id="p0351" num="0351"> . . . GO:0051186 cofactor metabolic ** </p><p id="p0352" num="0352"> process </p><p id="p0353" num="0353"> . . . . GO;0006732 coenzyme metabolic </p><p id="p0354" num="0354"> process </p><p id="p0355" num="0355"> . . . GO:0006082 organic acid metabolic * X </p><p id="p0356" num="0356"> process </p><p id="p0357" num="0357"> . . GO:0019748 secondary metabolic * </p><p id="p0358" num="0358">process </p><p id="p0359" num="0359"> . . . GO:0006582 melanin metabolic X </p><p id="p0360" num="0360">process </p><p id="p0361" num="0361"> . . . GO:0006629 lipid metabolic process **** X </p><p id="p0362" num="0362"> GO:0008202 steroid metabolic X </p><p id="p0363" num="0363">process </p><p id="p0364" num="0364"> GO:0006694 steroid biosynthetic ** X ; </p><p id="p0365" num="0365">process </p><p id="p0366" num="0366"> GO:0016126 sterol biosynthetic ** X </p><p id="p0367" num="0367">process </p><p id="p0368" num="0368"> GO:0006695 cholesterol *» X </p><p id="p0369" num="0369">biosynthetic process </p><p id="p0370" num="0370"> GO:0016125 sterol metabolic * X </p><p id="p0371" num="0371">process </p><p id="p0372" num="0372"> (30:0008610 lipid biosynthetic ; **** X </p><p id="p0373" num="0373">process </p><p id="p0374" num="0374"> . . GO:0044281 small molecule metabolic **** </p><p id="p0375" num="0375">process </p><p id="p0376" num="0376"> . . . GO:0044283 small molecule * </p><p id="p0377" num="0377">biosynthetic process </p><p id="p0378" num="0378"> . . . GO:0006066 alcohol metabolic * </p><p id="p0379" num="0379">process </p><p id="p0380" num="0380"> . . GO:00551 14 oxidation reduction ** </p><p id="p0381" num="0381"><sup>1</sup> Statistical significance is as described in Table 4. </p><p id="p0382" num="0382"> The theme analysis of the genes regulated in intrinsic aging, like that for photo-aging, revealed that the up- and down-regulated genes were associated with very different processes. The down-regulated genes in intrinsic skin aging were associated with a number of processes related to the epidermis and keratinocytes. Most dominant were terms related to lipid biosynthetic pathways that are involved in the synthesis of lipids important in epidermal barrier 
<!-- EPO <DP n="54"/>-->
 function. A more specific term related to epithelial biology, "ectoderm development," was associated with the down-regulated genes. The related term "'epidermal development" (p&lt; 0.001 ) was not included in the table because it did not make the p value cutoff, but it was also associated with the down-regulated genes. Terms related to regulation of pigmentation (melanogenesis), which is an epidermal function, were also significant for the down list analysis. As seen in the analysis of photo-aging, up-regulated themes included various developmental processes related to mesenchymal cells. The appearance of terms such as "ossification," which may seem irrelevant to skin, was due to the fact that various regulatory pathways and related genes are involved in a number of processes associated with cell lineages. Bone matrix cells are of mesenchymal origin. The term "regulation of mesenchymal cell proliferation" (highly significant in the photo-aging analysis) was not included in the table because it did not make the p value cutoff, but was significant at p&lt;0.001 for the up list in intrinsic aging. </p><p id="p0383" num="0383"> The Intrinsic Aging 600 signature gene lists (described in Example 3 and defined as the top 300 up- and down-regulated genes set forth in Tables A and B) were also subjected to theme analysis (not shown), which revealed a pattern of significant terms similar to that obtained with the entire intrinsic aging data set. The up-regulated gene list contains genes involved in biological processes associated with fibroblasts or mesenchymal cells, and the down-regulated list contained genes more closely associated with epidermal processes and keratinocytes. The results of these theme analyses suggest a rationale for the strong connectivity of fibroblasts to the intrinsic aging up-regulated gene expression signature and their preferential linkage to the overall signature, as well as the preferential connectivity of keratinocyte instances to the down-regulated gene expression signature. Overall, the intrinsic aging signatures reflect the biology in intrinsic aging. </p><p id="p0384" num="0384"> The biological theme analyses performed on the genes regulated in photo-aging and intrinsic aging demonstrate differences in the dominant biology in these two aspects of skin aging. The major differences related to an apparently greater down-regulation of processes associated with keratinocyte differentiation in intrinsic aging. These analyses further support the value of using signatures for both photo-aging and intrinsic aging in querying the C-map database to identify cosmetic materials to treat aging skin. These analyses also further support the non- intuitive finding that fibroblasts cell lines are more useful than keratinocyte cell lines for identifying cosmetic agents to improve photo-aged skin. The studies described herein also demonstrate that cell type-specific signals can be detected from full thickness biopsies using the C-map method and system. 
<!-- EPO <DP n="55"/>-->
 Example 6 </p><p id="p0385" num="0385"> Connectivity Map Results for Artichoke Leaf Extract and Carob Seed Extract In this example, 20 materials that were candidates for an anti-aging facial benefit study were tested in fibroblasts and keratinocytes. A microarray analysis was conducted for each sample compound and ordered lists of the probe set IDs were stored as instances in a database. Photo-aging and intrinsic aging gene expression signatures were compared against the instances and connectivity scores were derived. </p><p id="p0386" num="0386"> Of the 20 candidates screened, 2 showed consistent connections to the photo-aging gene expression signatures when tested in BJ fibroblasts. The detailed results for these materials, artichoke leaf extract and carob seed extract, are shown in Table 6. Since both intrinsic aging and photo-aging are considered adverse conditions, it is preferential to find materials that tend to reverse one or both of the gene expression signatures. Such materials will have negative connectivity score, and the more negative the score the stronger the negative connection. It can be seen in Table 6 that all fibroblast instances of artichoke leaf extract consistently linked negatively to the 3 photo-aging gene expression signatures. Artichoke leaf extract also consistently scored negatively with the intrinsic aging signatures when tested in fibroblasts, but the scores were weaker and there were some null or zero scores. Null scores are not considered inconsistent with other scores all showing the same directionality. When tested in keratinocytes, artichoke leaf extract showed generally weak positive connections to both the photo-aging and intrinsic aging gene expression signatures. Therefore, the testing in fibroblasts and keratinocytes gave inconsistent results. Similarly, carob seed extract fibroblast instances showed a pattern of negative connections to the photo-aging gene expression signatures and inconsistent results were obtained with keratiocyte instances with both sets of gene signatures. </p><p id="p0387" num="0387"> Table 6. </p><p id="p0388" num="0388"> C-MAP scores for two cosmetic supplier materials, Biobenefity™ and Glyco-repair™, tested in fibroblasts and keratinocytes. </p><p id="p0389" num="0389"> Intrinsic Aging Clinical Photo-aging Clinical Signatures Signatures</p><p id="p0390" num="0390">GeneChip ID Material Cell Line Intrinsic Intrinsic Intrinsic Photo- Photo- Photo- Utilized for 200 400 600 aging aging aging Instance 200 400 600 Data </p><p id="p0391" num="0391"> CMP_62_1 3 Artichoke BJ -0.403 0 -0.333 -0.551 -0.553 -0.547</p><p id="p0392" num="0392">CMP_62_1 4 <sup>Leaf</sup> <sub>?</sub> fibroblasts .Q 21 1 -0.1 98 -0.235 I -0.251 -0.298 -0.299 </p><p id="p0393" num="0393"> Extract </p><p id="p0394" num="0394"> CMP_65_51 0 -0.222 0 -0.31 -0.264 -0.295 CMP_ 61„1 3 Telomerized- 0 0 0 0 0 0.19</p><p id="p0395" num="0395">C P 61 14 : keratinocytes Q 401 0.346 0.316 0.293 <sup>;</sup> 0.268 0.284 
<!-- EPO <DP n="56"/>-->
 CMP 68A 27 -0.251 0 0.137 0.209 0.156 0.149 </p><p id="p0396" num="0396">CMP_62„23 Carob BJ 0 0 0 -0.342 -0.288 -0.325</p><p id="p0397" num="0397">CMP 62 24 <sup>Seed</sup> , fibroblasts <sub>0 0 0</sub> _<sub>0 41</sub> -0.327 -0.325</p><p id="p0398" num="0398"><sup>~</sup> — Extract </p><p id="p0399" num="0399"> CMP_65_55 0 0 0.151 0 0 0</p><p id="p0400" num="0400">CMP_61_23 Telomerized- -0.321 -0.286 -0.248 -0.44 Ϊ-0.438 -0.404</p><p id="p0401" num="0401">CMP_61_24 keratinocytes o <sub>27 0 25</sub> 0.226 -0.374 -0.349 0</p><p id="p0402" num="0402">CMP_68A_31 0.287 0.263 0.268 0.347 0.348 0.346</p><p id="p0403" num="0403"><sup>1</sup> Test compositions were prepared using a concentration of 0.01 % of one of artichoke leaf extract or carob seed extract. </p><p id="p0404" num="0404"><sup>2</sup> One example of Artichoke leaf extract is available from Ichimaru Pharcos, Japan under the tradename Biobenifity™ </p><p id="p0405" num="0405">3 One example of carob seed extract is available from Silab, France under the tradename Glyco- Repair™ </p><p id="p0406" num="0406"> In view of the discovery that there is a strong preferential linkage of the skin aging gene expression signatures to instances derived from fibroblasts, additional gene expression signatures optimized for the fibroblast linkage were also generated to screen the cosmetic materials. Only the photo-aging data from the aging skin genomics study in Example 2 were used because the fibroblast linkage to the photo-aging gene expression signature was stronger than that to intrinsic aging gene expression signature. The modified gene expression signatures were generated similarly to the photo-aging signatures in Example 3, except that the microarray probe sets were also filtered for genes selected from a microarray analysis of BJ fibroblast cells that had &gt;10% Present calls, wherein the microarray analysis of the BJ fibroblast cells was derived from data from 30 control and chemically-treated cultures. This filter was added so that the modified gene expression signature would only contain probes complementary to genes actually expressed in the fibroblasts. Additionally, the probes used in the modified gene expression signature were identified using the following filters. </p><p id="p0407" num="0407"> (i) "Signature 1" Filtered on log t-test rank; best ranked 100 up-regulated and</p><p id="p0408" num="0408">100 down-regulated probe sets in the arm old to young comparison.</p><p id="p0409" num="0409">(ii) "Signature 2" Filtered on log t-test rank; best ranked 150 up-regulated and 150 down-regulated probe sets in the arm old to young comparison.</p><p id="p0410" num="0410">(iii) "Signature 3" (identifiers set forth in Table I) Filtered on log t-test rank; best ranked 200 up-regulated and 200 down-regulated probe sets in the arm old to young comparison. </p><p id="p0411" num="0411"> Table 7 
<!-- EPO <DP n="57"/>-->
 Connectivity scores derived from a comparison of artichoke leaf extract and carob seed extract instances tested in fibroblast cells compared to the fibroblast-optimized photo-aging signatures. </p><p id="p0412" num="0412">Photo-aging signatures </p><p id="p0413" num="0413"> optimized for fibroblasts </p><p id="p0414" num="0414"> GeneChip Material Cell Line Signature Signature Signature </p><p id="p0415" num="0415"> ID <sup>1</sup> 1 2 3 </p><p id="p0416" num="0416">CMP. _62. _13 Artichoke BJ -0.721 -0.707 -0.684 </p><p id="p0417" num="0417"> CMP. _62. <sub>1</sub>4 leaf fibroblasts -0.341 -0.366 -0.375 </p><p id="p0418" num="0418"> extract </p><p id="p0419" num="0419"> CMP<sub>.</sub> _65. <sub>.</sub>51 -0.417 -0.38 -0.365 </p><p id="p0420" num="0420"> CMP_ -62. <sub>.</sub>23 Carob BJ -0.482 -0.43 -0.415 </p><p id="p0421" num="0421"> CMP_ -62. 24 seed fibroblasts -0.48 -0.41 -0.416 </p><p id="p0422" num="0422"> extract </p><p id="p0423" num="0423"> CMP_ 65_ 55 0 0 0 </p><p id="p0424" num="0424"> The C-map instances are the same as in Table 6. Only results with fibroblasts are shown. </p><p id="p0425" num="0425"> The results set forth in Table 7 are similar to those for the photo-aging signatures shown in Table 6 except that the scores are stronger. </p><p id="p0426" num="0426"> An overall weighting of the C-map scores was used to determine whether the materials tested were considered hits against the gene expression signatures. For each signature in a category (e.g. photo-aging or intrinsic aging), the hits were identified and given a weight using the criteria in Table 8. The desired directionality of the scores depends on whether the analysis is intended to identify materials that will ameliorate a condition like photo-aging (negative scores) or that are similar to a known benefit agent (positive scores). This heuristic approach was applied because of the limited number of replicates available for the materials in the C-map database. </p><p id="p0427" num="0427"> Table 8 </p><p id="p0428" num="0428"> Weight Criteria </p><p id="p0429" num="0429"> 3 At least 2 instances in the top 5% of all C-map instances<sup>1</sup> based on C-map score, all instances with correct directionality or null. Non-null instances &gt;50%. </p><p id="p0430" num="0430"> 2 At least 1 instance in the top 5% of all C-map instances based on C-map score, all </p><p id="p0431" num="0431"> instances with correct directionality or null. Non-null instances &gt;50%. </p><p id="p0432" num="0432"> 2 At least 2 instances in the top 10% of all C-map instances based on C-map score, all instances with correct directionality or null. Non-null instances &gt;50%. </p><p id="p0433" num="0433"> 1 = 1 instance in the top 5% of all C-map instances, all instances with correct directionality or null. Non-null instances &gt;40 AND &lt;50%.. </p><p id="p0434" num="0434">1 There were more than 4000 chemical instances in the C-map database when these analyses were done. </p><p id="p0435" num="0435"> The average weight was calculated for each set of signatures (e.g. the 3 photo-aging signatures described in Example 2 and derived from Tables C and D). Materials were considered a hit if their average weights across signatures were as described in Table 9. 
<!-- EPO <DP n="58"/>-->
 Table 9 </p><p id="p0436" num="0436"> Weighting of hits Average hit weigh </p><p id="p0437" num="0437"> Strong hit value = 3 </p><p id="p0438" num="0438"> Hit 2 &lt; value &lt; 3 </p><p id="p0439" num="0439"> Weak hit 1 &lt; value &lt; 2 </p><p id="p0440" num="0440"> Weak linkage 0 &lt; value &lt; 1 </p><p id="p0441" num="0441"> The results of the weighted analysis for artichoke leaf extract and carob seed extract are shown in Table 10. Based on the average hit weights artichoke leaf extract was considered an overall negative hit against the photo-aging signatures and a weak negative hit against the intrinsic aging signatures when tested in fibroblasts. Carob seed extract was a weak negative hit against the photo-aging signatures optimized for fibroblasts. Considering the strong preferential linkage of the photo-aging signatures to instances derived from fibroblasts (described above), the keratinocyte data were discounted and only the fibroblast data were used as part of the weight of evidence to determine whether artichoke leaf extract and carob seed extract should be advanced to in vivo testing. </p><p id="p0442" num="0442">Table 10. </p><p id="p0443" num="0443"> Weighting of the C-map scores from Table 6 and Table 7 to determine hits. </p><p id="p0444" num="0444"> Average hit weights </p><p id="p0445" num="0445">Material Cell Line Intrinsic Photo-aging Fibroblast </p><p id="p0446" num="0446"> Aging Signatures Optimized </p><p id="p0447" num="0447"> Signatures (P200, P400, Photo-aging </p><p id="p0448" num="0448"> (1200, 1 400, P600) Signatures </p><p id="p0449" num="0449"> 1600) (Signatures 1 - 3) </p><p id="p0450" num="0450"> Artichoke leaf BJ fibroblasts 1.33 </p><p id="p0451" num="0451"> extract Telomerized- 0 </p><p id="p0452" num="0452"> keratinocytes </p><p id="p0453" num="0453"> Carob seed extract BJ fibroblasts 0 1.33 </p><p id="p0454" num="0454"> Telomerized- keratinocvtes </p><p id="p0455" num="0455">Example 7 </p><p id="p0456" num="0456">In vitro and in vivo Results for Artichoke Leaf Extract and Carob Seed Extract </p><p id="p0457" num="0457"> C-map is a hypothesis-generating tool whose predictiveness for identifying agents that can improve aging skin should be validated through clinical testing. Artichoke leaf extract and carob seed extract were subjected to in vitro testing to establish a weight of evidence before 
<!-- EPO <DP n="59"/>-->
 submitting them for clinical tests. Skin equivalent cultures were treated with the materials as described below and assayed for endpoints related to cosmetic benefits including: procollagen, hyaluronic acid, fibronectin, and inhibition of matrix metal loprotease 1 (MMP1 ) activity. </p><p id="p0458" num="0458">In vitro Testing Procedures: </p><p id="p0459" num="0459"> Human skin equivalent cultures (EFT-400 Full-Thickness Skin Model, MatTek</p><p id="p0460" num="0460">Corporation, Ashland MA) were equilibrated overnight at 37°C and 5% C0<sub>2</sub>. Cultures were treated topically with 40 μΐ of test material for 24 hours. The test materials evaluated were aqueous solutions of 3.0% of a commercial preparation of hydrolyzed carob seed extract or 3.5% of a commercial preparation of artichoke leaf extract. Control cultures were treated with water vehicle alone. After treatment with test material, the cultures were rinsed with PBS. A 5-mm punch biopsy sample was taken for procollagen and hyaluronic acid measurements and the remaining quantities of each culture were used for cell viability (MTT) analysis. </p><p id="p0461" num="0461"> Cultures to be tested for cell viability were transferred to new six-well plates containing 2 ml of MTT solution (MTT kit, MatTek Corporation) in each well and incubated for 3 hours. Cultures were then removed from wells, blotted dry, and transferred to new six-well plates containing 3 ml of extraction solution in each well. One ml of extraction solution was added topically to each culture, and the plates were placed on a shaker for 2 hours at room temperature. An aliquot (200 μΐ) of extraction solution was removed from each culture well, transferred to a 96-well flat bottom plate, and read at A570. </p><p id="p0462" num="0462"> Culture samples for procollagen and hyaluronic acid analysis were incubated with 1 ml of mild protein extraction reagent (T-per, Pierce Protein Research Products, Thermo Fisher Scientific Inc., Rockford, IL), then homogenized with a mixer mill (Model MM 300, Qiagen Inc., Valencia, CA) for 6 minutes. Samples were then centrifuged at 10,000 rpm for 15 minutes at 4°C and the soluble fractions collected. Supernatants were analyzed with a Micro BCA Protein Assay Kit (Pierce Protein Research Products, Thermo Fisher Scientific Inc., Rockford, IL) to quantify protein concentrations. For analysis of procollagen 1 , supernatant samples were diluted 1 :5 in assay buffer and analyzed with a commercially available ELISA kit (Takara Bio Inc., Shiga, Japan). For hyaluronic acid analysis, supernatant samples were diluted 1 :300 in assay buffer and analyzed with a commercially available ELISA kit (Corgenix, Broomfield CO). Procollagen and hyaluronic acid were normalized to protein levels for each culture, and expressed as a % of the vehicle control. Statistical comparisons to vehicle control were made using the Students f-test. </p><p id="p0463" num="0463">In vitro Testing Results: </p><p id="p0464" num="0464"> Table 1 1 
<!-- EPO <DP n="60"/>-->
 In vitro Skin Biomarker Responses </p><p id="p0465" num="0465"> Compound Level Hyaluronic Acid Procollagen Other </p><p id="p0466" num="0466"> (%) (% control) (% control) (% control)</p><p id="p0467" num="0467">Carob Seed Extract 3.0 139* 354* </p><p id="p0468" num="0468"> Artichoke Leaf Extract 3.5 160* 270* MMP- 1 : 64*</p><p id="p0469" num="0469">* indicates p &lt; 0.05; nc = no change vs Control </p><p id="p0470" num="0470"> These results indicate that human skin cultures treated with 3.0% of a commercial preparation of hydrolyzed carob seed extract significantly (p &lt; 0.05) increased expression of procollagen (the precursor of dermal matrix collagens) and hyaluronic acid (a matrix component that binds water and hydrates the skin). Cultures treated with 3.5% of a commercial preparation of artichoke leaf extract produced significantly increased expression of procollagen and hyaluronic acid, and also significantly reduced MMP- 1 expression (an enzyme increased in skin aging and inflammation that damages dermal matrix). In vivo Testing Procedures </p><p id="p0471" num="0471"> The study design was a 13-week, randomized, double-blinded, vehicle controlled, split- face study to evaluate fine lines and wrinkles in 40 to 65 year old women, Fitzpatrick skin type I to III, with moderate to moderately-severe photo-aged facial skin. The duration of the study included 1-week preconditioning with vehicle product, followed by 12 weeks of test product application to the facial skin twice each day. High density digital images of subject facial skin were captured with a Fuji S2 Pro digital SLR camera with a 60mm Nikon lens. Images were taken at baseline, 4, 8 and 12 weeks. Coded images were evaluated on a 0 to 8 grading scale by expert graders to determine the degree of change in eye area fine lines and wrinkles at 4, 8 or 12 weeks as compared to the matching baseline image for each subject. </p><p id="p0472" num="0472"> The test products used by the panelists contained a commercial preparation of 3.0% hydrolyzed carob seed extract or 3.5% artichoke leaf extract, each prepared in an oil-in-water formulation. The control was the oil-in-water formulation alone. </p><p id="p0473" num="0473">In vivo Test Results: </p><p id="p0474" num="0474"> Table 12. </p><p id="p0475" num="0475"> Eye Area Fine Lines &amp; Wrinkle Grades at 4, 8 and 12 Weeks of Test Product Use </p><p id="p0476" num="0476"> 8 Weeks 12 Weeks </p><p id="p0477" num="0477">Facial Product Level FLW Statistical p value FLW Statistical p value vs </p><p id="p0478" num="0478"> ;(%) Grade <sub>:</sub> Grouping vs Grade : Grouping Vehicle </p><p id="p0479" num="0479"><sub>:</sub> Vehicle </p><p id="p0480" num="0480"> Vehicle - 0.137 a - 0.230 <sup>'</sup> a ! 
<!-- EPO <DP n="61"/>-->
 Carob Seed 3.0% : 0.741 be 0.0302 0.799 be 0.0213 extract </p><p id="p0481" num="0481"> Artichoke Leaf 3.5% 0.503 ab 0.1207 0.924 c 0.0059 extract </p><p id="p0482" num="0482"> These results indicate that test product containing 3.0% of a commercial preparation of carob seed extract produced a significant (p &lt; 0,05) improvement in eye area fine lines and wrinkles as compared to the concurrent vehicle control product at 4, 8 and 12 weeks. Test product containing 3.5% of a commercial preparation of artichoke leaf extract produced a significant improvement in eye area fine lines and wrinkles as compared to the concurrent vehicle control product at 12 weeks. Overall, the in vivo test results demonstrate the predictiveness of the methods described here to identify skin anti-aging agents. </p><p id="p0483" num="0483"> Every document cited herein is hereby incorporated herein by reference in its entirety unless expressly excluded or otherwise limited. The citation of any document is not an admission that it is prior art with respect to any invention disclosed or claimed herein or that it alone, or in any combination with any other reference or references, teaches, suggests or discloses any such invention. Further, to the extent any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition assigned to that term in this document shall govern. </p><p id="p0484" num="0484"> The values disclosed herein are not to be understood as being strictly limited to the exact numerical values recited. Instead, unless otherwise specified, each such value is intended to mean both the recited value and a functionally equivalent range surrounding that value. </p><p id="p0485" num="0485"> The present invention should not be considered limited to the specific examples described herein, but rather should be understood to cover all aspects of the invention. Various modifications, equivalent processes, as well as numerous structures and devices to which the present invention may be applicable will be readily apparent to those of skill in the art. Those skilled in the art will understand that various changes may be made without departing from the scope of the invention, which is not to be considered limited to what is described in the specification. Some examples of the invention are described in the following clauses: </p><p id="p0486" num="0486">1. A method for constructing a data architecture for use in identifying connections between perturbagens and genes associated with one or more skin aging conditions, comprising:</p><p id="p0487" num="0487">(a) providing a gene expression profile for a control human dermal fibroblast cell;</p><p id="p0488" num="0488">(b) generating a gene expression profile for a human dermal fibroblast cell exposed to at least one perturbagen; </p><p id="p0489" num="0489"> (c) identifying genes differentially expressed in response to the at least one </p><p id="p0490" num="0490"> perturbagen by comparing the gene expression profiles of (a) and (b); 
<!-- EPO <DP n="62"/>-->
 (d) creating an ordered list comprising identifiers representing the differentially expressed genes, wherein the identifiers are ordered according to the differential expression of the genes; </p><p id="p0491" num="0491"> (e) storing the ordered list as a fibroblast instance on at least one computer readable medium; and </p><p id="p0492" num="0492"> (f) constructing a data architecture of stored fibroblast instances by repeating (a) through (e), wherein the at least one perturbagen of step (a) is different for each fibroblast instance. </p><p id="p0493" num="0493">A method according to clause 1 , comprising using a programmable computer to perform one or more of steps (c), (d), (e) and (f). </p><p id="p0494" num="0494">A method according to clause 1 , wherein the ordered list comprises the ordered list of identifiers in association with a numerical ranking for the identifier corresponding to its rank in the ordered list. </p><p id="p0495" num="0495">A method according to clause 1 , wherein the step of generating is performed by extracting a biological sample from the treated cell and subjecting the biological sample to microarray analysis. </p><p id="p0496" num="0496">A method according to clause 1, wherein the biological sample comprises mRNA. </p><p id="p0497" num="0497">A method according to clause 1 , wherein the microarray is a global microarray or a specific microarray, wherein the specific rnieroarray comprises oligonucleotides which hybridize to genes corresponding to a gene expression signature for a cellular phenotype. </p><p id="p0498" num="0498">A method according to clause 1 , wherein the step of constructing the data architecture of stored instances by repeating steps (a) through (e) comprises repeating steps (a) through (e) for between about 50 and about 50,000 instances. </p><p id="p0499" num="0499">A method according to clause 7, wherein the step of constructing a gene expression data bases of stored instances comprises repeating steps (a) through (e) for between about 1000 and about 20,000 instances. </p><p id="p0500" num="0500">A method according to clause 1 , wherein the at least one perturbagen is a cosmetic agent. </p><p id="p0501" num="0501">A method according to clause 1 , wherein each of the different perturbagens is a cosmetic agent. 
<!-- EPO <DP n="63"/>-->
 A method according to clause 1 , wherein the identifiers are selected from the group consisting of gene names, gene symbols, microarray probe set ID values, and </p><p id="p0502" num="0502"> combinations thereof. </p><p id="p0503" num="0503">A method according to clause 1 , wherein the ordered list is arranged so that an identifier associated with a most up-regulated gene is positioned at the top of the ordered list and an identifier associated with a most down-regulated gene is positioned at the bottom of the ordered list. </p><p id="p0504" num="0504">A method according to clause 12, wherein the ordered list of each instance is airanged so that an identifier associated with each gene that is not differentially expressed is positioned between the identifier associated with the most up-regulated gene and the identifier associated with the most down-regulated gene. </p><p id="p0505" num="0505">A method according to clause 1 , wherein each instance comprises between about 1 ,000 and about 50,000 identifiers. </p><p id="p0506" num="0506">A method according to clause 1 , wherein each instance comprises metadata for the at least one perturbagen associated with the instance. </p><p id="p0507" num="0507">A method according to clause 1 , further comprising; </p><p id="p0508" num="0508"> (a) providing a gene expression profile for a control human keratinocyte cell; </p><p id="p0509" num="0509"> (b) generating a gene expression profile for a human keratinocyte cell exposed to at least one perturbagen; </p><p id="p0510" num="0510"> (c) identifying genes differentially expressed in response to the at least one </p><p id="p0511" num="0511"> perturbagen by comparing the gene expression profiles of (g) and (h); </p><p id="p0512" num="0512"> (d) creating an ordered list comprising identifiers representing the differentially </p><p id="p0513" num="0513"> expressed genes, wherein the identifiers are ordered according to the differential expression of the genes identified in (i); </p><p id="p0514" num="0514"> (e) storing the ordered list created in step (j) as a keratinocyte instance on the at least one computer readable medium; and </p><p id="p0515" num="0515"> (f) constructing a data base of stored keratinocyte instances by repeating (g) through (k), wherein the at least one perturbagen of step (h) is different for each keratinocyte instance. </p><p id="p0516" num="0516">A method according to clause 16, wherein the at least one perturbagen of step (a) is the same as the at least one perturbagen of step (g). 
<!-- EPO <DP n="64"/>-->
 A method according to clause 1 , wherein the at least one perturbagen is a botanical. A method according to clause 18, wherein the botanical is derived from one or more of a root, stem, bark, leaf, seed, or fruit of a plant. A method according to clause 1 , wherein the at least one perturbagen is selected from the group consisting of a vitamin compound, a sugar amine, a phytosterol, hexamidine. a hydroxy acid, a ceramide, an amino acid, and a polyol. A method according to clause 20, wherein the vitamin compound is selected from the group consisting of a vitamin B3 compound, a vitamin B5 compound, a vitamin B6 compound, a vitamin B9 compound, a vitamin A compound, a vitamin C compound, a vitamin E compound, and derivatives and combinations thereof. A method according to clause 20, wherein the vitamin compound is selected from the group consisting of retinol, retinyl esters, niacinamide, folic acid, panthenol, ascorbic acid, tocopherol, and tocopherol acetate. A method for implementing the data architecture according to claim 1 to generate connections useful for identifying cosmetic agents effective for treating aged skin, the method comprising querying the data architecture with at least one skin aging gene expression signature, wherein querying comprises comparing the at least one skin aging gene expression signature to each stored fibroblast instance, wherein the skin aging gene expression signature represents genes differentially expressed in association with at least one skin aging condition. A method according to clause 23, wherein the comparison of the at least one skin aging gene expression signature to each stored fibroblast instance is performed by a programmable computer. A method according to clause 23, wherein the at least one skin aging condition is selected from intrinsic skin aging conditions; photo-aging skin conditions; and combinations thereof. A method according to clause 23, wherein the at least one skin aging gene expression signature is constructed by a method comprising (i) identifying genes having up- regulated expression in the at least one skin aging condition when compared to a control; (ii) identifying genes having down-regulated expression in the at least one skin aging 
<!-- EPO <DP n="65"/>-->
 condition when compared to a control; (iii) creating one or more gene expression signature lists associated with the at least one skin aging gene expression signature comprising identifiers corresponding to a plurality of the genes identified in (i) and (ii); and storing the one or more gene expression signature lists on the at least one computer readable medium. </p><p id="p0517" num="0517">A method according to clause 26, wherein the number of genes having up-regulated expression in the at least one skin aging condition is between about 10 and about 400, and the number of genes down-regulated in the at least one skin aging condition is between about 10 and about 400. </p><p id="p0518" num="0518">A method according to clause 27 wherein the identifiers for from between about 80% and about 100% of the up-regulated genes are set forth as in Table C and wherein identifiers for from between about 80% and about 100% of the down-regulated genes are set forth in Table D. </p><p id="p0519" num="0519">A method according to clause 23, wherein the identifiers representing the genes identified in (i) and (ii) are selected from the group consisting of gene names, gene symbols, and microarray probe set ID values. </p><p id="p0520" num="0520">A method according to clause 26, wherein the one or more gene expression signature lists comprises a first list representing a plurality of the up-regulated genes identified in (i) and a second list representing a plurality of down-regulated genes identified in (ii). </p><p id="p0521" num="0521">A method according to clause 26, wherein at least one skin sample is taken from a human subject exhibiting the at least one skin condition, a biological sample is extracted from the skin sample, and a gene expression profile of the at least one skin sample is generated prior to at least one of the steps (i) and (ii). </p><p id="p0522" num="0522">A method according to clause clause 31 , wherein the at least one human subject is between the ages of about 1 8 and about 80. </p><p id="p0523" num="0523">A method according to clause 31. wherein the skin sample comprises cells from epidermal and dermal layers of the human subject. </p><p id="p0524" num="0524">A method according to clause 23, wherein the comparison further comprises assigning a connectivity score to each of plurality of instances. 
<!-- EPO <DP n="66"/>-->
 A method according to clause 34, wherein a plurality of connectivity scores represents a positive correlation and a plurality of the connectivity scores represents a negative correlation. A method according to clause 34, wherein the connectivity score has a value between +2 and -2. A method for formulating a skin care composition by identifying connections between perturbagens and genes associated with one or more skin aging conditions, comprising: </p><p id="p0525" num="0525">(a) accessing a plurality of instances stored on at least one computer readable </p><p id="p0526" num="0526"> medium, wherein each instance is associated with a perturbagen and a skin cell type and wherein each instance comprises an ordered list comprising a plurality of identifiers representing a plurality of up-regulated and a plurality of down regulated genes; </p><p id="p0527" num="0527">(b) accessing at least one skin aging gene expression signature stored on the at least one computer readable medium, wherein the at least one skin aging gene expression signature comprises one or more lists comprising a plurality of identifiers representing a plurality of up-regulated genes and a plurality of down- regulated genes associated with a skin aging condition; c) comparing the at least one skin aging gene expression signature to the plurality of the instances, wherein the comparison comprises comparing each identifier in the one or more gene expression signature lists with the position of the same identifier in the ordered lists for each of the plurality of instances; </p><p id="p0528" num="0528">(d) assigning a connectivity score to each of the plurality of instances; and </p><p id="p0529" num="0529">(e) formulating a skin care composition comprising a dermatologically acceptable carrier and at least one perturbagen, wherein the connectivity score of the instance associated with the at least one perturbagen has a negative correlation. A method according to clause 37. further comprising applying the skin care compositiono a plurality of human subjects having the skin aging condition. 
<!-- EPO <DP n="67"/>-->
 A method according to clause 38, wherein the skin care composition improves the appearance of facial fine lines or wrinkles of one or more of the plurality of human subjects. A method according to clause 37, wherein the identifiers are selected from the group consisting of gene names, gene symbols, and microarray probe set ID values. A method according to clause 37, wherein each instance comprises between about 50 and about 400 identifiers. A method according to clause 37, wherein the plurality of instances comprises between about 50 and about 50,000 instances. A method according to clause 37, wherein the plurality of instances comprises between about 1000 and about 20,000 instances. A method according to clause 37, wherein the at least one perturbagen is a cosmetic agent. A method according to clause 37, wherein the at least one perturbagen is a botanical. A method according to clause 45, wherein the botanical is derived from one or more of a root, stem, bark, leaf, seed, or fruit of a plant. A method according to clause 37 wherein one or more of steps (a), (b), (c), and (d) are performed by a programmable computer. A method according to clause 37, wherein the at least one skin aging gene expression signature comprises a plurality of skin aging gene expression signatures and each of the plurality of instances has a connectivity score assigned thereto for each of the plurality of skin aging gene expression signatures. A method according to clause 48, wherein the connectivity score for each of the plurality of instances is a combination of the connectivity scores assigned to each instance for each of the plurality of skin aging gene expression signatures. </p><p id="p0530" num="0530">A method according to clause 49. wherein the plurality of skin aging gene expression signatures comprises a plurality of photo-aging gene expression signatures. 
<!-- EPO <DP n="68"/>-->
 A method according to clause 49. wherein the plurality of skin aging gene expression signatures comprises a plurality of intrinsic aging gene expression signatures. A method according to clause 49, wherein the plurality of skin aging gene expression signatures comprises a plurality of photo-aging gene expression signatures and a plurality of intrinsic aging gene expression signatures. A method according to clause 52, wherein each of the plurality of the intrinsic aging gene expression signatures comprises one or more gene expression signature lists comprising a plurality of identifiers representing a plurality of up-regulated genes and a plurality of down-regulated genes, wherein an identifier for between about 80% and about 100% of the up-regulated genes are set forth in Table A and wherein an identifier for between about 80% and about 100% of the down-regulated genes are set forth in Table B. A method according to clause 49, wherein each connectivity score assigned to the instance associated with the at least one perturbagen of the skin care composition has a negative correlation. A method according to clause 37, wherein the plurality of instances are stored in a database on the at least one computer readable medium. A method according to clause 55, wherein the plurality of instances comprises a plurality of instances associated with a first skin cell type and a plurality of instances associated with a second skin cell type, A method according to clause 56, wherein the first skin cell type is a human dermal fibroblast and the second skin cell type is a human keratinocyte. A method according to clause 55. wherein each of the plurality of instances further comprises metadata associated with the skin cell type and the perturbagen associated therewith. A method according to clause 58. wherein the metadata comprises a name for the skin cell type and a name for the perturbagen. A method according to clause 37, wherein the plurality of instances are stored in a first digital file and the at least one skin aging gene expression signature is stored in a second digital file. 
<!-- EPO <DP n="69"/>-->
 A skin care composition formulated according to the method of clause 37. A method for generating a gene expression signature for use in identifying connections between perturbagens and genes associated with one or more skin aging conditions, comprising: </p><p id="p0531" num="0531">(a) providing a gene expression profile for a reference sample of human skin cells; </p><p id="p0532" num="0532">(b) generating a gene expression profile for at least one sample of human skin cells from a subject exhibiting at least one skin aging condition, </p><p id="p0533" num="0533">(c) comparing the expression profiles of (a) and (b) to determine a gene expression signature comprising a set of genes differentially expressed in (a) and (b); </p><p id="p0534" num="0534">(d) assigning an identifier to each gene constituting the gene expression signature and ordering the identifiers according to the direction of differential expression to create one or more gene expression signature lists; </p><p id="p0535" num="0535">(e) storing the one or more gene expression signature lists on at least one computer readable medium. The method according to clause 62, wherein the human skin cells derive from either an epidermal or dermal layer of skin and the human subject is between the age of about 18 to about 80 years. A gene expression signature determined according to clause 62 having from about 50 to about 400 genes differentially up-regulated in the at least one skin aging condition and about 50 to about 400 differentially down-regulated in the at least one skin aging condition. A method according to clause 62, wherein the identifiers are selected from the group consisting of gene names, gene symbols, and microarray probe set IDs. A method according to clause 62, wherein the at least one sample of human skin cells comprises a plurality of samples and wherein one of the plurality of skin samples is taken from a sun exposed location and one of the plurality of skin samples is taken from sun protected location. 
<!-- EPO <DP n="70"/>-->
 A method according to clause 66, wherein the sun exposed location is a on a forearm and the sun protected location is on a buttock. A system for identifying connections between perturbagens and genes associated with one or more skin aging conditions, comprising: </p><p id="p0536" num="0536">(a) at least one computer readable medium having stored thereon a plurality of </p><p id="p0537" num="0537"> instances, and at least one skin aging gene expression signature, wherein the instances and the gene expression signature are derived from a human dermal fibroblast cell, wherein each instance comprises an instance list of rank-ordered identifiers of differentially expressed genes, and wherein the at least one skin aging gene expression signature comprises one or more gene expression signature lists of identifiers representing differentially expressed genes associated with a skin aging condition; </p><p id="p0538" num="0538"> (b) a programmable computer comprising computer-readable instructions that cause the programmable computer to execute one or more of the following: </p><p id="p0539" num="0539"> (i) accessing the plurality of instances and the at least one skin aging gene expression signature stored on the computer readable medium; </p><p id="p0540" num="0540"> (ii) comparing the at least one skin aging gene expression signature to the plurality of the instances, wherein the comparison comprises comparing each identifier in the gene expression signature list with the position of the same identifier in the instance list for each of the plurality of instances; and</p><p id="p0541" num="0541">(iii) assigning a connectivity score to each of the plurality of instances. A system according to clause 68, further comprising a plurality of instances and at least one gene expression signature derived from a human keratinocyte cell. A system according to clause 68, further comprising: a microarray scanner for receiving a sample comprising human dermal fibroblast cells and/or human keratinocyte cells; and a second programmable computer for transmitting gene expression data from the scanner to the first programmable computer. A system according to clause 70, further comprising an array of perturbagens for application to the dermal fibroblast cells and the keratinocyte cells. 
<!-- EPO <DP n="71"/>-->
 A system according to clause 68, wherein the plurality of instances comprises between about 50 and about 50,000 instances. A system according to clause 68, wherein the plurality of instances comprises between about 1 ,000 and about 20,000 instances. A gene expression signature for intrinsically aged skin consisting of genes selected from the genes set forth in Tables A and B. An immobilized array of oligonucleotides which hybridize to the genes selected for the gene expression signature according to clause 74. A gene expression signature according to clause 74 stored on a memory device accessible by a programmable computer. A gene expression signature according to clause 74, comprising from 50-300 genes identified to be up-regulated in Table A. A gene expression signature according to clause 74, comprising from 50-300 genes identified to be down-regulated in Table B. A gene expression signature according to clause 74, comprising a set of genes identified to be up-regulated and a set of genes identified to be down-regulated. A gene expression signature for photo-aged skin consisting of genes selected from the genes set forth in Tables C and D. An immobilized array of oligonucleotides which hybridize to the genes selected for the gene expression signature according to clause 80. A gene expression signature according to clause 80 stored on a memory device accessible by a programmable computer. A gene expression signature according to clause 80, comprising from 50-300 genes identified to be up-regulated in Table C. A gene expression signature according to clause 80, comprising from 50-300 genes identified to be down-regulated in Table D. 
<!-- EPO <DP n="72"/>-->
 A gene expression signature according to clause 80, comprising a set of genes identified to be up-regulated and a set of genes identified to be down-regulated. </p><p id="p0542" num="0542">A computer readable medium, comprising: a data architecture comprising a digital file stored in a spreadsheet file format, a word processing file format, or a database file format suitable to be read by a respective spreadsheet, word processing, or database computer program, the first digital file comprising data arranged to provide one or more gene expression signature lists comprising a plurality of identifiers when read by the respective spreadsheet, word processing, or database computer program; and wherein each identifier is selected from the group consisting of a microarray probe set ID, a human gene name, a human gene symbol, and combinations thereof representing a gene set forth in any of Tables A-D wherein each of the one or more gene expression signature lists comprises between about 50 and about 600 identifiers. </p><p id="p0543" num="0543">The computer readable medium of clause 86, further comprising computer readable instructions for reading the digital file. 
<!-- EPO <DP n="73"/>-->
</p><p id="p0544" num="0544">Table_A </p><p id="p0545" num="0545"> Probe set ID Gene symbol Gene Name Representative Public ID </p><p id="p0546" num="0546"> value </p><p id="p0547" num="0547"> 212134_at PHLDBl pleckstrin homology-l ke domain family B member 1 </p><p id="p0548" num="0548">AB014538 2 . 5989E-07 </p><p id="p0549" num="0549"> 203384_s_at GOLGAl golgi autoantigen golgin subfamily a 1 NM_002077 </p><p id="p0550" num="0550"> 8.8180E-07 </p><p id="p0551" num="0551"> 203812_at null AB011538 2 . 6720E-06 </p><p id="p0552" num="0552"> 218418_s_at ANK2 KN motif and ankyrin repeat domains 2 NM_015493 </p><p id="p0553" num="0553"> 2.9847E-06 </p><p id="p0554" num="0554"> 210619_s^.at HYAL1 hyaluronoglucosaminidase 1 AF173154 4.4879E-06 213891_s_at TCF4 transcription factor 4 AI927067 7.1351E-06 </p><p id="p0555" num="0555">40665_at FM03 flavin containing monooxygenase 3 M83772 7.4313E-06 218007_s_at RPS27L ribosomal protein S27-like NNL015920 9.9049E-06 218986_s_at DDX60 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 N _017631 1.3762E-05 </p><p id="p0556" num="0556">204112_s_at HNMT histamine N-methyl transferase N _006895 1.5543E-05 202510_s_at TNFAIP2 tumor necrosis factor alpha-induced protein 2 NM_006291 1.5736E-05 </p><p id="p0557" num="0557">205236_x_at SOD3 superoxide dismutase 3 extracellular NM_003102 </p><p id="p0558" num="0558">2.1085E-05 </p><p id="p0559" num="0559">204940_at PLN phospholamban NM_002667 2 .4429E-05 </p><p id="p0560" num="0560">204742_s_at PDS5B PDS5 regulator of cohesion maintenance homolog B (S. </p><p id="p0561" num="0561">cerevi siae) NM_015032 3.5542E-05 </p><p id="p0562" num="0562">217721_at null BE551361 3.9171E-05 </p><p id="p0563" num="0563">61732_r_at IFT74 intraflagellar transport 74 homolog (chlamydomonas) </p><p id="p0564" num="0564">AI610355 4.0031E-05 </p><p id="p0565" num="0565">220276_at RERGL RERG/RAS-like NM_024730 4.0141E-05 </p><p id="p0566" num="0566">210147_at ART3 ADP-ribosyl transferase 3 U47054 4.0793E-05 </p><p id="p0567" num="0567">203874_s_at SMARCAl SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily a member 1 N _003069 4.2533E-05 </p><p id="p0568" num="0568">218718_at PDGFC platelet derived growth factor C NM_016205 </p><p id="p0569" num="0569">4.7811E-05 </p><p id="p0570" num="0570">216321_s_at NR3C1 nuclear receptor subfamily 3 group C member 1 </p><p id="p0571" num="0571">(glucocorticoid receptor) X03348 4. 8089E-05 </p><p id="p0572" num="0572">203083_at THBS2 thrombospondin 2 NMJ303247 4.9034E-05 </p><p id="p0573" num="0573">212798_s_at A KMY2 ankyrin repeat and MYND domain containing 2 AK001389 4.9281E-05 </p><p id="p0574" num="0574">213435_at SATB2 SATB homeobox 2 AB028957 5.2665E-05 </p><p id="p0575" num="0575">212796_s_at TBC1D2B TBCl domain family member 2B BF195608 5.3819E-05 218901_at PLSCR4 phospholipid scramblase 4 ΝΜ_020353 5.3859E-05 208792_s_at CLU clusterin M25915 5.5727E-05 </p><p id="p0576" num="0576">204457_s_at GASl growth arrest-specific 1 NM_002048 5.9563E-05 203906_at IQSEC1 IQ motif and Sec7 domain 1 AI652645 6.1904E-05 204963_at SSPN sarcospan (Kras oncogene-associ ated gene) AL136756 6.1925E-05 </p><p id="p0577" num="0577">218854_at DSE dermatan sulfate epimerase NM_013352 6.4684E-05 200771_at LAMC1 lamini gamma 1 (formerly LA B2) NM_002293 </p><p id="p0578" num="0578">6. 7641E-05 </p><p id="p0579" num="0579">212195_at IL6ST interleukin 6 signal transducer (gpl30 oncostatin M receptor) AL049265 6.9132E-05 </p><p id="p0580" num="0580">212914_at CBX7 chromobox homolog 7 AV648364 7.2463E-05 </p><p id="p0581" num="0581">204719„at ABCA8 ATP bi ndi ng cassette sub-family A (ABCl) member 8 </p><p id="p0582" num="0582">N _007168 7.2719E 05 </p><p id="p0583" num="0583">213397_x_at RNASE4 ribonuclease RNase A family 4 AI761728 7.3945E-05 209613_s_at ADHlB alcohol dehydrogenase IB (class I) beta polypeptide</p><p id="p0584" num="0584"> 21692 7.4466E- <sup>■</sup>05 </p><p id="p0585" num="0585">205361_s_at PFDN4 prefoldin subunit 4 AI718295 7.5317E-05 </p><p id="p0586" num="0586">212 13_at MFAP4 m crofi bri liar-associated protein 4 R72286 7.5567E-05 218285_s_at BDH2 3-hydroxybutyrate dehydrogenase type 2 NM_020139 </p><p id="p0587" num="0587">7.8227E-05 </p><p id="p0588" num="0588">65472..at c2orf68 chromosome 2 open reading frame 68 AI161338 </p><p id="p0589" num="0589">8.0285E-05 </p><p id="p0590" num="0590">221747_at TNSl tens n 1 AL046979 8.1012E-05 
<!-- EPO <DP n="74"/>-->
 Table_A </p><p id="p0591" num="0591"> 204944_at PTP G protein tyrosine phosphatase receptor type G NM_002841 8.5062E-05 </p><p id="p0592" num="0592"> 205803_s_at TRPCI transient receptor potential cation channel subfamily C member 1 NM_003304 9.1121E-05 </p><p id="p0593" num="0593"> 202664_at IPF1 AS/WASL interacting protein family member 1 AW058622 9.5200E-05 </p><p id="p0594" num="0594"> 212386_at TCF4 transcription factor 4 BF592782 9 . 6608E-05 </p><p id="p0595" num="0595"> 202598_at S100A13 S100 calcium binding protein A13 NM_005979 </p><p id="p0596" num="0596"> 9.9951E-05 </p><p id="p0597" num="0597"> 209375„at XPC xeroderma pigmentosum complementation group C D21089 1.0203E-04 </p><p id="p0598" num="0598"> 221611_s_at PHF7 PHD finger protein 7 AY014283 1.0523E-04 </p><p id="p0599" num="0599"> 203638_s_at FGFR2 fibroblast growth factor receptor 2 NM_022969 </p><p id="p0600" num="0600"> 1.1006E-04 </p><p id="p0601" num="0601"> 209990_s_at GABBR2 gamma-ami nobutyric acid (GABA) B receptor 2 AF056085 1.1153E-04 </p><p id="p0602" num="0602"> 204446_s_at ALOX5 arachi donate 5-lipoxygenase N _000698 1.1577E-04 212530_at NEK7 NIMA (never in mitosis gene a)-related kinase 7 AL080111 1.2283E-04 </p><p id="p0603" num="0603">211675_s_at MDFIC yoD family inhibitor domain containing AF054589 </p><p id="p0604" num="0604">1.3221E-04 </p><p id="p0605" num="0605">222103_at ATFl activating transcription factor 1 AI434345 </p><p id="p0606" num="0606">1.3421E-04 </p><p id="p0607" num="0607">209763_at CHRDLl chordin-like 1 AL049176 1.3715E-04 </p><p id="p0608" num="0608">216840_s_at LAMA2 laminin alpha 2 AK026829 1.3816E-04 </p><p id="p0609" num="0609">210664_s_at TFPI tissue factor pathway inhibitor (1 i poprotei n-associ ated coagulation inhibitor) AF021834 1.3910E-04 </p><p id="p0610" num="0610">222043_at CLU clusterin AI982754 1. 5732 E-04 </p><p id="p0611" num="0611">208747_s_at CIS complement component 1 s subcomponent M18767 1. 6336E-04 210129_s_at TTLL3 tubulin tyrosine ligase-like family member 3 AF078842 1.6579E-04 </p><p id="p0612" num="0612">204136_at COL7A1 collagen type VII alpha 1 NM_000094 1 . 6678E-04 218168_s_at CABCl chape rone ABC1 activity of bcl complex homolog (S. pombe) N _020247 1.6820E-04 </p><p id="p0613" num="0613">212690_at DDHD2 DDHD domain containing 2 AB018268 1.6898E-04 203799_at CD302 CD302 molecule NM_014880 1 . 7414E-04 </p><p id="p0614" num="0614">209086_x_at MCAM melanoma cell adhesion molecule BE964361 1 . 7613 E-04 206227_at CILP cartilage intermediate layer protein nucleotide </p><p id="p0615" num="0615">pyrophosphohyd rolase NM_003613 1.7709E-04 </p><p id="p0616" num="0616">205498_at GHR growth hormone receptor NM_000163 1 . 8023 E-04 </p><p id="p0617" num="0617">204939_s_at PLN phospholamban NM_002667 1.8529E-04 </p><p id="p0618" num="0618">209737_at MAGI 2 membrane associated guanylate kinase WW and PDZ domain containing 2 AB014605 1.9535E-04 </p><p id="p0619" num="0619">207606_s_at ARHGAP12 Rho GTPase activating protein 12 NM_018287 1.9567E-04 </p><p id="p0620" num="0620">206502_s_at INSMl insulinoma -associated 1 NM_002196 2 . 0132 E-04 </p><p id="p0621" num="0621">201811_x_at SH3BP5 SH 3 -domain binding protein 5 (BTK-associated) NM_004844 2.0465E-04 </p><p id="p0622" num="0622">221530_s_at BHLHE41 basic helix-loop-helix family member e41 BE857425 2.0872E-04 </p><p id="p0623" num="0623">203177_x_at TFAM transcription factor A mitochondrial NM_003201 </p><p id="p0624" num="0624">2.1048E-04 </p><p id="p0625" num="0625">202142_at COPS8 COP9 constitutive photomorphogen c homolog subuni t 8 (Arabidopsis) BC003090 2 . 1440E-04 </p><p id="p0626" num="0626">221950_at EMX2 empty spiracles homeobox 2 AI478455 2. 1866E-04 205116_at LAMA2 laminin alpha 2 NM_000426 2 . 2469E-04 </p><p id="p0627" num="0627">218456_at CAPRI 2 caprin family member 2 NM_Q23925 2 . 2868E-04 </p><p id="p0628" num="0628">211340_s_at MCAM melanoma eel 1 adhesion molecule M28882 2 . 3165 E-04 </p><p id="p0629" num="0629">213247_at SVEPl sushi von Willebrand factor type A EGF and pentraxi n domai n containing 1 AA716107 2. 3856E-04 </p><p id="p0630" num="0630">209210_s_at FERMT2 fermitin family homolog 2 (Drosophila) Z24725 2. 4012 E-04 201313_at EN02 enolase 2 (gamma neuronal) NM_001975 2 . 4732 E 04 203884_s_at RAB11FIP2 RABll family interacting protei n 2 (class I) 
<!-- EPO <DP n="75"/>-->
 Table_A </p><p id="p0631" num="0631"> NM_014904 2.6635E-04 </p><p id="p0632" num="0632"> 204853_at ORC2L origin recognition complex subunit 2-1 ike Cyeast) NM_006190 2.6654E-04 </p><p id="p0633" num="0633"> 221230_s_at ARID4B AT rich interactive domain 4B (RBPl-like) NM_016374 2.6997E-04 </p><p id="p0634" num="0634"> 212970_at APBB2 amyloid beta (A4) precursor protein-binding family B member 2 AI694303 3.0394E-04 </p><p id="p0635" num="0635"> 203446_s_at OCRL oculocerebrorenal syndrome of Lowe NM_000276 </p><p id="p0636" num="0636"> 3.0709E-04 </p><p id="p0637" num="0637"> 203217_s_at ST 3 GAL 5 ST 3 beta-gal actosi de alpha-23-sialyltransferase 5 </p><p id="p0638" num="0638"> NM_003896 3.1215E-04 </p><p id="p0639" num="0639"> 221748_s_at TNS1 tensin 1 AL046979 3.1441E-04 </p><p id="p0640" num="0640"> 218087_s_at SORBSl sorbin and SH3 domain containing 1 NM_015385 </p><p id="p0641" num="0641"> 3.1579E-04 </p><p id="p0642" num="0642"> 203689_s_at FMR1 fragile X mental retardation 1 AI743037 3.1785E-04 221218_s_at TPK1 thiamin pyrophosphoki nase 1 NM_022445 3.2805E-04 208669_s_at EIDl EP300 interacting inhibitor of differentiation 1 </p><p id="p0643" num="0643">AF109873 3.6197E-04 </p><p id="p0644" num="0644"> 212736_at Cl6orf45 chromosome 16 open reading frame 45 BE299456 3.6201E-04 </p><p id="p0645" num="0645"> 218204_s_at FYCOl FYVE and coiled-coil domain containing 1 NM_024513 3.8403E-04 </p><p id="p0646" num="0646"> 213 7 _s_at CASP8 caspase 8 apoptosis-related cysteine peptidase BF439983 3.8971E-04 </p><p id="p0647" num="0647"> 218625_at NRNl neuritin 1 NM_016588 4.0450E-04 </p><p id="p0648" num="0648">210788_s_at DHRS7 dehydrogenase/reductase (SDR family) member 7 AF126782 4.1440E-04 </p><p id="p0649" num="0649">205612_at M RNl multimerin 1 NMJ307351 4.1487E-04 </p><p id="p0650" num="0650">209335_at DCN decorin AI281593 4.1933E-04 </p><p id="p0651" num="0651">213519_s_at LAMA2 laminin alpha 2 AI078169 4.2572E-04 </p><p id="p0652" num="0652">217504_at ABCA6 ATP-binding cassette sub-family A (ABCl) member 6 </p><p id="p0653" num="0653">AA099357 4.3088E-04 </p><p id="p0654" num="0654">203983_at TSNAX transl in-associated factor x NM_005999 4.3798E-04 202979_s_at CREBZF CREB/ATF bziP transcript on factor NM_021212 </p><p id="p0655" num="0655">4.3846E-04 </p><p id="p0656" num="0656">207317_s_at CASQ2 cal sequestrin 2 (cardiac muscle) NM_001232 </p><p id="p0657" num="0657">4.4266E-04 </p><p id="p0658" num="0658">213480_at VAMP4 vesicle-associated membrane protein 4 AF052100 </p><p id="p0659" num="0659">4.4528E-04 </p><p id="p0660" num="0660">203661_s_at TMODl tropomodulin 1 BC002660 4.4930E-04 </p><p id="p0661" num="0661">212764_at ZEBl zinc finger E-box binding homeobox 1 AI806174 </p><p id="p0662" num="0662">4.5363E-04 </p><p id="p0663" num="0663">209332_s_at MAX MYC associated factor X BC003525 4.6003E-04 </p><p id="p0664" num="0664">209732_at CLEC2B C-type lectin domain family 2 member B BC005254 </p><p id="p0665" num="0665">4.7151E-04 </p><p id="p0666" num="0666">201648_at JAKl Janus kinase 1 (a protein tyrosine kinase) AL039831 4.7270E-04 </p><p id="p0667" num="0667">214151_s_at CCPG1 cell cycle progression 1 AU144243 4.8468E-04 221958_s<sub>^</sub>at GPR177 G protein-coupled receptor 177 AA775681 4.9941E-04 212805_at PRUNE2 prune homolog 2 (Drosophila) AB002365 5.0295E-04 213415_at CLIC2 chloride intracellular channel 2 AI768628 </p><p id="p0668" num="0668">5.1005E-04 </p><p id="p0669" num="0669">213262_at SACS spastic ataxia of Charlevoi x-Saguenay (sacsi n) AI932370 5.1009E-04 </p><p id="p0670" num="0670">39582_at CYLD cyl i ndromatosi s (turban tumor syndrome) AL050166 </p><p id="p0671" num="0671">5.1801E-04 </p><p id="p0672" num="0672">209265_s_at ETTL3 methyl transferase like 3 BC001650 5.2345E-04 201581_at T X4 thioredoxin domain containing 13 BF572868 </p><p id="p0673" num="0673">5.3682E-04 </p><p id="p0674" num="0674">213429_at Biccl bi caudal c homolog 1 (Drosophila) AW025579 </p><p id="p0675" num="0675">5.4069E-04 </p><p id="p0676" num="0676">203662_s_at TMODl tropomodulin 1 NM_003275 5.4629E 04 </p><p id="p0677" num="0677">206496_at FM03 f lavi n containing monooxygenase 3 NM_ 
<!-- EPO <DP n="76"/>-->
 Table_A </p><p id="p0678" num="0678"> 5.4990E-04 </p><p id="p0679" num="0679"> 40446„at PHFl PHD finger protein 1 AL021366 5.5428E-04 </p><p id="p0680" num="0680"> 209467_s_at MKNKI MAP kinase interacting serine/threonine kinase 1 </p><p id="p0681" num="0681"> BC002755 5.5795E-04 </p><p id="p0682" num="0682"> 219949_at LR C2 leucine rich repeat containing 2 NM_024512 </p><p id="p0683" num="0683"> 5.6098E-04 </p><p id="p0684" num="0684"> 218957_s_at PAAF1 proteasomal ATPase-associated factor 1 NM_025155 </p><p id="p0685" num="0685"> 5.6482E-04 </p><p id="p0686" num="0686"> 201237_at CAPZA2 capping protein (actin filament) muscle z-line alpha 2</p><p id="p0687" num="0687">AV685920 5.9285E-04 </p><p id="p0688" num="0688"> 209568_s_at RGLl ral guanine nucleotide dissociation stimulator-like 1</p><p id="p0689" num="0689">AF186779 5.9347E-04 </p><p id="p0690" num="0690"> 212163_at KIDINS220 kinase D-i nteracti ng substrate 220kDa AB033076</p><p id="p0691" num="0691">5.96O5E-04 </p><p id="p0692" num="0692"> 221757_at PIK3IP1 phosphoinositide-3-kinase interacting protein 1 BE042976</p><p id="p0693" num="0693">6.0094E-04 </p><p id="p0694" num="0694"> 204779_s_at HOXB7 homeobox B7 NM_004502 6.0694E-04 </p><p id="p0695" num="0695"> 221139_s_at CSAD cysteine sulfinic acid decarboxylase NM_015989</p><p id="p0696" num="0696">6.1189E-04 </p><p id="p0697" num="0697"> 218946_at NFUl NFUl iron-sulfur cluster scaffold homolog (S. cerevisiae)</p><p id="p0698" num="0698">NM_015700 6.2140E-04 </p><p id="p0699" num="0699"> 201753_s_at ADD3 adducin 3 (gamma) NM_019903 6.2561E-04</p><p id="p0700" num="0700">219895_at FAM70A family with sequence similarity 70 member A NM_017938</p><p id="p0701" num="0701">6.2596E-04 </p><p id="p0702" num="0702"> 202074_s_at OPTN optineurin NM_021980 6.2626E-04 </p><p id="p0703" num="0703"> 221556_at CDC14B CDC14 cell division cycle 14 homolog B (s. cerevisiae)</p><p id="p0704" num="0704">BF792631 6.3179E-04 </p><p id="p0705" num="0705"> 213194_at ROBOl roundabout axon guidance receptor homolog 1 (Drosophila)</p><p id="p0706" num="0706">BF059159 6.3295E-04 </p><p id="p0707" num="0707"> 205986_at AATK apoptosis-associated tyrosine kinase NM_004920 </p><p id="p0708" num="0708"> 6.4921E-04 </p><p id="p0709" num="0709"> 212558_at SPRYl sprouty homolog 1 antagonist of FGF signaling (Drosophila)</p><p id="p0710" num="0710">BF508662 6.5829E-04 </p><p id="p0711" num="0711"> 209787_s_at HMGN4 high mobility group nucleosomal binding domain 4 </p><p id="p0712" num="0712"> BC001282 6.6274E-04 </p><p id="p0713" num="0713"> 205083„at AOXl aldehyde oxidase 1 NM_001159 6.6633E-04 </p><p id="p0714" num="0714"> 203427_at ASFlA ASFl anti -silencing function 1 homolog A (S. cerevisiae)</p><p id="p0715" num="0715">NM_014034 6.6918E-04 </p><p id="p0716" num="0716"> 209822_s_at VLDLR very low density lipoprotein receptor L22431 6.7088E-04</p><p id="p0717" num="0717">217967_s_at FAM129A family with sequence similarity 129 member A AF288391</p><p id="p0718" num="0718">6.7923E-04 </p><p id="p0719" num="0719"> 203131_at PDGFRA platelet-derived growth factor receptor alpha polypeptide</p><p id="p0720" num="0720">NM_006206 6.9010E-04 </p><p id="p0721" num="0721"> 210150_s_at LAMAS laminin alpha 5 BC003355 6.9685E-04 </p><p id="p0722" num="0722"> 212675_s_at CEP68 centrosomal protein 68kDa AB011154 6.9915E-04</p><p id="p0723" num="0723">219700_at PLXDCl plexin domain containing 1 NM_020405 7.0728E-04</p><p id="p0724" num="0724">47608_at TDAPl tight junction associated protein 1 (peripheral) </p><p id="p0725" num="0725"> AI697401 7.1269E-04 </p><p id="p0726" num="0726"> 218288_s_at CCDC90B co 1 ed-coi 1 domain containing 90B NM_021825 </p><p id="p0727" num="0727"> 7.1308E-04 </p><p id="p0728" num="0728"> 209285 s_.at C3orf63 chromosome 3 open reading frame 63 N38985 7.1497E-04</p><p id="p0729" num="0729">?15245_x_at FMRl f ragi le X mental retardation 1 AA830884 7.1688E-04</p><p id="p0730" num="0730">212913._at c6orf26 chromosome 6 open reading frame 26 BE674960 </p><p id="p0731" num="0731"> 7.3457E-04 </p><p id="p0732" num="0732"> 214086_s_at PARP2 poly (ADP-ribose) polymerase 2 A 001980 7.4675E-04</p><p id="p0733" num="0733">218656_s_at LHFP lipoma HMGIC fusion partner NM_005780 7.5779E-04</p><p id="p0734" num="0734">213800_at CFH complement factor H X04697 7.6114E-04 </p><p id="p0735" num="0735"> 212126_at CBX5 chromobox homolog 5 (HPI alpha homolog Drosophila) </p><p id="p0736" num="0736"> BG391282 7.6440E-04 </p><p id="p0737" num="0737"> 206958_s_at UPF3A UPF3 regulator of nonsense transcri pts homolog A (yeast)</p><p id="p0738" num="0738">AF318575 7.6790E-04 </p><p id="p0739" num="0739"> 219848_s_at ZNF432 zinc finger protein 432 NM„014650 7.6977E-04 </p><p id="p0740" num="0740"> 212653_s_at EHBPl EH domain binding protein 1 AB020710 7.7156E-04 
<!-- EPO <DP n="77"/>-->
 Table_A </p><p id="p0741" num="0741"> 216044_x_at FAM69A family with sequence similarity 69 member A AK027146</p><p id="p0742" num="0742">7.7784E-04 </p><p id="p0743" num="0743"> 219161_s_at C LF chemokine-like factor NM_016951 7.8299E-04 </p><p id="p0744" num="0744"> 210102_at VWA5A von willebrand factor A domain containing 5A BC001234</p><p id="p0745" num="0745">7.9257E-04 </p><p id="p0746" num="0746"> 210155_at MYOC myocilin trabecular meshwork inducible glucocorticoid response D88214 7.9752E-04 </p><p id="p0747" num="0747"> 202409_at IGF2 insulin-like growth factor 2 (somatomedin A) X07868</p><p id="p0748" num="0748">8.0081E-04 </p><p id="p0749" num="0749"> 218501_at ARHGEF3 Rho guanine nucleotide exchange factor (GEF) 3 NM_019555</p><p id="p0750" num="0750">8.2089E-04 </p><p id="p0751" num="0751"> 212535_at MEF2A myocyte enhancer factor 2A AA142929 8.2429E-04</p><p id="p0752" num="0752">214453_s_at IFI44 interferon-induced protein 44 N _006417 8.4432E-04</p><p id="p0753" num="0753">212368_at ZNF292 zinc finger protein 292 AA972711 8.4711E-04 </p><p id="p0754" num="0754"> 205011_at VWA5A von wi lebrand factor A domain containing 5A NM_014622</p><p id="p0755" num="0755">8.5033E-04 </p><p id="p0756" num="0756"> 214684_at MEF2A myocyte enhancer factor 2A X63381 8.5065E-04 </p><p id="p0757" num="0757"> 208683_at CAPN2 calpain 2 (m/ll) large subunit M23254 8.5570E-04 </p><p id="p0758" num="0758"> 205547_s_at TAGLN transgelin NM_003186 8.6781E-04 </p><p id="p0759" num="0759"> 218303_x_at KRCC1 lysine- rich coiled-coi 1 NM_016618 8.7453E-04</p><p id="p0760" num="0760">201384_s_at LOC100133166 similar to neighbor of BRCAl gene 1 NM_005899</p><p id="p0761" num="0761">8.8284E-04 </p><p id="p0762" num="0762"> 212589_at RRAS2 related RAS viral (r-ras) oncogene homolog 2 AI753792</p><p id="p0763" num="0763">8.8349E-04 </p><p id="p0764" num="0764"> 201034_at ADD3 adducin 3 (gamma) BE545756 8.8904E-04 </p><p id="p0765" num="0765"> 205158_at RNASE4 ribonuclease RNase A family 4 NM_002937 8.9603E-04</p><p id="p0766" num="0766">204793_at GPRASPl G protein-coupled receptor associated sorting protein 1</p><p id="p0767" num="0767">NM_014710 8.9876E-04 </p><p id="p0768" num="0768"> 202928_s_at PHFl PHD finger protein 1 NM_024165 8.9963E-04 </p><p id="p0769" num="0769"> 203717_at DPP4 dipeptidyl -peptidase 4 NM_001935 9.1050E-04 </p><p id="p0770" num="0770"> 206157_at PTX3 pentraxin-re ated gene rapidly induced by iL-1 beta</p><p id="p0771" num="0771">N _002852 9.2166E-04 </p><p id="p0772" num="0772"> 219 55_at CXorf57 chromosome X open reading frame 57 NM_018015 </p><p id="p0773" num="0773"> 9.2632E-04 </p><p id="p0774" num="0774"> 204070_at RARRES3 retinoic acid receptor responder (tazarotene induced) 3</p><p id="p0775" num="0775">NM_004585 9.2641E-04 </p><p id="p0776" num="0776"> 204428_s_at LCAT lecithin-cholesterol acyltransferase N _000229 </p><p id="p0777" num="0777"> 9.4980E-04 </p><p id="p0778" num="0778"> 204897_at PTGER4 prostaglandin E receptor 4 (subtype EP4) AA897516</p><p id="p0779" num="0779">9.5926E-04 </p><p id="p0780" num="0780"> 209612_s_at ADH1B alcohol dehydrogenase IB (class I) beta polypeptide</p><p id="p0781" num="0781">M24317 9.7983E-04 </p><p id="p0782" num="0782">222001_x_at LOC728855 hypothetical LOC728855 AI160126 9.8111E-04</p><p id="p0783" num="0783">218486_at LFll ruppel-like factor 11 AA149594 9.8974E-04 217816_s_at PCNP PEST proteolytic signal containing nuclear protein </p><p id="p0784" num="0784">NM_020357 9.9522E-04 </p><p id="p0785" num="0785">209780_at PHTF2 putative homeodomain transcription factor 2 AL136883 1.0108E-03 </p><p id="p0786" num="0786">214683„s at CL 1 CDC- like k nase 1 AI251890 1.O113E-03 216620_s_at ARHGEF10 Rho guanine nucleotide exchange factor (GEF) 10 AF009205 1.0159E-03 </p><p id="p0787" num="0787">213158_at null AA045174 1.0352E-03 </p><p id="p0788" num="0788">210273_at PCDH7 protocadherin 7 AB006757 1.0391E-03 </p><p id="p0789" num="0789">212793_at DAAM2 dishevelled associated activator of morphogenes s 2 </p><p id="p0790" num="0790">BF513244 1.0515E-03 </p><p id="p0791" num="0791">205545_x_at DNA3C8 DnaJ (Hsp40) homolog subfamily C member 8 NV_014280 1.0523E-03 </p><p id="p0792" num="0792"> 204310_s_at NPR2 natriuretic peptide receptor B/guanylate cyclase B (atr onatriuretic peptide receptor B) NM_003995 1.0523E-03 </p><p id="p0793" num="0793">216250_s_at LPXN leupaxin X77598 1.0558E-03 </p><p id="p0794" num="0794"> 202748_at GBP2 cjuanyl ate binding protein 2 i nte r eron-i nduci bl e </p><p id="p0795" num="0795"> N _004120 1.0592E-03 </p><p id="p0796" num="0796"> 208248_x_at APLP2 amyloid beta (A4) precursor-like protein 2 NM_ 
<!-- EPO <DP n="78"/>-->
 Table_A </p><p id="p0797" num="0797"> 1.06O2E-03 </p><p id="p0798" num="0798"> 216973_s_at HOXB7 homeobox B7 S49765 1.0759E-03 </p><p id="p0799" num="0799"> 221044_s__at TRIM6 tripartite motif-containing 34 NM_021616 1.0950E-03</p><p id="p0800" num="0800">217853_at TNS3 tensin 3 NM_022748 1.0951E-03 </p><p id="p0801" num="0801"> 209009„at ESD esterase D/formylgl utathi one hydrolase BC001169 </p><p id="p0802" num="0802"> 1.0953E-03 </p><p id="p0803" num="0803"> 220127_s_at FBXL12 F-box and leucine- rich repeat protein 12 NM_017703</p><p id="p0804" num="0804">1. 0997E-03 </p><p id="p0805" num="0805"> 218196_at OSTMl osteopetrosis associated transmembrane protein 1 </p><p id="p0806" num="0806"> NM_014028 1. 1047E-03 </p><p id="p0807" num="0807"> 200986_at SERPING1 serpin peptidase inhibitor clade G (CI inhibitor) member 1 NM._000062 1 . 1056E-03 </p><p id="p0808" num="0808"> 214044_at RYR2 ryanodine receptor 2 (cardiac) BE968750 1 . 1145 E-03</p><p id="p0809" num="0809">205549_at PCP4 Purkinje cell protein 4 NM_006198 1.1168E-03 </p><p id="p0810" num="0810"> 212761_at TCF7L2 transcription factor 7-like 2 (τ-cell specific HMG-box)</p><p id="p0811" num="0811">AI949687 1.1230E-03 </p><p id="p0812" num="0812"> 204994_at MX 2 myxovi rus (influenza virus) resistance 2 (mouse) </p><p id="p0813" num="0813"> NM_002463 1 . 1250E-03 </p><p id="p0814" num="0814"> 218919_at ZFAND1 zinc finger ANl-type domain 1 NNL024699 1 . 1391E-03</p><p id="p0815" num="0815">204438_at MRC1L1 mannose receptor C type 1 NM_002438 1 . 1392 E-03</p><p id="p0816" num="0816">218146_at GLT8D1 glycosyl transferase 8 domain containing 1 NM_018446</p><p id="p0817" num="0817">1.1414E-03 </p><p id="p0818" num="0818"> 222229_x_at RPL26P37 60S ribosomal protein L26 pseudogene AL121871</p><p id="p0819" num="0819">1. 1749 E-03 </p><p id="p0820" num="0820"> 212509_s_at MXRA7 matrix- remodel ling associated 7 BF968134 1.1781E-03</p><p id="p0821" num="0821">204938_s_at PLN phospholamban M60411 1.1841E-03 </p><p id="p0822" num="0822"> 216241_s_at TCEAl transcr tion elongation factor A (Sll) 1 X57198</p><p id="p0823" num="0823">1.1997E-03 </p><p id="p0824" num="0824"> 214703_s_at AN2B2 mannosidase alpha class 2B member 2 AW954107 </p><p id="p0825" num="0825"> 1.2028E-03 </p><p id="p0826" num="0826"> 203336_s_at ITGBlBPl integrin beta 1 binding protein 1 AL548363</p><p id="p0827" num="0827">1. 2099E-03 </p><p id="p0828" num="0828"> 65718_at GPR124 G protein-coup ed receptor 124 AI655903 1.2271E-03</p><p id="p0829" num="0829">211679_x_at GABBR2 gamma-ami nobutyric acid (GABA) B receptor 2 AF095784</p><p id="p0830" num="0830">1.2692E-03 </p><p id="p0831" num="0831"> 202552_s_at CRIMl cysteine rich transmembrane BMP regulator 1 (chordin-like)</p><p id="p0832" num="0832">NM_016441 1.2732E-03 </p><p id="p0833" num="0833"> 202853_s_at RYK RYK receptor-like tyrosine kinase NM_002958 </p><p id="p0834" num="0834"> 1.3008E-03 </p><p id="p0835" num="0835"> 213703_at LOC150759 hypothetical protein LOC150759 W95043 1.3148E-03</p><p id="p0836" num="0836">206167_s_at ARHGAP6 Rho GTPase activating protein 6 NM_001174 1.3166E-03</p><p id="p0837" num="0837">213294_at EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2</p><p id="p0838" num="0838">AV755522 1. 3257E-03 </p><p id="p0839" num="0839"> 212343_at YIPF6 Yipl domain family member 6 AL117461 1.3337E-03</p><p id="p0840" num="0840">212586_at CAST calpastatin AA195244 1.3533E-03 </p><p id="p0841" num="0841"> 212077_at CALD1 caldesmon 1 AL583 520 1. 3697E-03 </p><p id="p0842" num="0842"> 213309_at PLCL2 phospholipase C like 2 AL117515 1.3761E-03 </p><p id="p0843" num="0843"> 203774_at MTR 5 -methyl tetrahydrofol ate-honocystei ne methyl transferase</p><p id="p0844" num="0844">NM.000254 1.4049E-03 </p><p id="p0845" num="0845"> 209621 s_at PDLIM3 PDZ and LIM doma n 3 AF002280 1.4120E-03 </p><p id="p0846" num="0846"> 203249„at EZHl enhancer of zeste homolog 1 (Drosoph la) AB002386</p><p id="p0847" num="0847">1.4127E-03 </p><p id="p0848" num="0848"> 201784' s cit Cllorf58 chromosome 11 open reading frame 58 NM„014267</p><p id="p0849" num="0849">1.4222E-03 </p><p id="p0850" num="0850"> 203156_at AKAPll A kinase (PRKA) anchor protein 11 NM_016248 </p><p id="p0851" num="0851"> 1.4238E-03 </p><p id="p0852" num="0852"> 213165_at CEP350 centrosomal protein 350kDa AI041204 1.4348E-03</p><p id="p0853" num="0853">212984_at ATF2 activating transcription factor 2 BE786164 </p><p id="p0854" num="0854"> 1.4415E 03 </p><p id="p0855" num="0855"> 202907„s_at NBN nibrin NM_002485 1.4488E 03 </p><p id="p0856" num="0856"> 205260_s_at ACYPl acylphosphatase 1 erythrocyte (common) type NM_001107</p><p id="p0857" num="0857">1.4518E-03 </p><p id="p0858" num="0858"> 206332_s_at IFI16 interferon gamma-i nducible protein 16 NM_005531 
<!-- EPO <DP n="79"/>-->
 Table„A </p><p id="p0859" num="0859"> 1.4578E-03 </p><p id="p0860" num="0860"> 212390_at LOC727893 similar to phosphodiesterase 4D interacting protein (myomegalin) AB007923 1. 4580E-03 </p><p id="p0861" num="0861"> 212455_at YTHDC1 YTH domain containing 1 N36997 1.4597E-03 </p><p id="p0862" num="0862"> 209337_at PSIP1 PC4 and SFRSl interacting protein 1 AF063020 </p><p id="p0863" num="0863"> 1 . 4630E-03 </p><p id="p0864" num="0864"> 213375_s_at N4BP2L1 NEDD4 binding protein 2-1 ike 1 N80918 1.4697E-03 </p><p id="p0865" num="0865"> 34031_i_at KRITl KRIT1 ankyrin repeat containing U90269 1.4716E-03 </p><p id="p0866" num="0866"> 210538_s_at BIRC3 baculoviral IAP repeat-containing 3 U37546 1.4849E-03 216949_s„at PKDl polycystic kidney disease 1 (autosomal dominant) </p><p id="p0867" num="0867"> L 39891 1.4913E-03 </p><p id="p0868" num="0868"> 219778_at ZFPM2 zinc finger protein multitype 2 NM_012082 1.4980E-03</p><p id="p0869" num="0869">203505_at ABCAl ATP-binding cassette sub-family A (ABCl) member 1 </p><p id="p0870" num="0870"> AF285167 1.4984E-03 </p><p id="p0871" num="0871"> 202328_s_at PKDl polycystic kidney disease 1 (autosomal dominant) </p><p id="p0872" num="0872"> NM_000296 1.5072E-03 </p><p id="p0873" num="0873"> 219820_at SLC6A16 solute carrier family 6 member 16 N _014037 </p><p id="p0874" num="0874"> 1 . 5190E-03 </p><p id="p0875" num="0875"> 207558_s_at PITX2 paired-like homeodomain 2 NM_000325 1.5248E-03</p><p id="p0876" num="0876">209236_at SLC23A2 solute carrier family 23 (nucleobase transporters) member 2</p><p id="p0877" num="0877">AL389886 1 . 5384E-03 </p><p id="p0878" num="0878"> 201038_s_at ANP32A Cerebellar leucine rich acidic nuclear protein (LANP) </p><p id="p0879" num="0879">T67821 1 . 5626E-03 </p><p id="p0880" num="0880"> 205407_at RECK reversion-inducing-cysteine-rich protein with kazal motifs NM_021111 1 . 5697E-03 </p><p id="p0881" num="0881">203281_s_at UBA7 ubiquitin-like modifier activating enzyme 7 NM_003 3 35 1. 5792E-03 </p><p id="p0882" num="0882">206201_s_at EOX2 mesenchyme homeobox 2 NM_005924 1.5832E-03 </p><p id="p0883" num="0883">209815_at PTCH1 patched homolog 1 (Drosophila) BG054916 1.5922E-03 213295_at CYLD cylindromatosis (turban tumor syndrome) AA555096 </p><p id="p0884" num="0884">1. 6088E-03 </p><p id="p0885" num="0885">211742_s_at EVI2B ecotropic viral integration site 2B BC005926 </p><p id="p0886" num="0886">1 . 6282E-03 </p><p id="p0887" num="0887">20303 5_s_at PIAS3 protein inhibitor of activated STAT 3 NM_006099 </p><p id="p0888" num="0888">1 . 6319E-03 </p><p id="p0889" num="0889">21223 3_at MAPlB mi crotubul e-associ ated protein IB AL523076 </p><p id="p0890" num="0890">1 . 6369E-03 </p><p id="p0891" num="0891">211743_s_at PRG2 proteoglycan 2 bone marrow (natural killer cell activator eosinophil granule major basic protein) BC005929 1.6770E-03 </p><p id="p0892" num="0892">213388_at PDE4DIP phosphodiesterase 4D interacting protein H15535 </p><p id="p0893" num="0893"> 1.6837E-03 </p><p id="p0894" num="0894"> 206159_at GDF10 growth differentiation factor 10 NN_004962 </p><p id="p0895" num="0895"> 1. 6866E-03 </p><p id="p0896" num="0896"> 219654_at PTPLA protein tyrosine phosphatase-! i ke (proline instead of catalytic arginine) member A NM_014241 1.6959E-03 </p><p id="p0897" num="0897"> 210312_s_at I FT20 i ntrafl agell ar transport 20 homolog (Chlamydomonas) </p><p id="p0898" num="0898">BC002640 1. 7097E-03 </p><p id="p0899" num="0899">210794_s_at MEG3 maternally expressed 3 (non-protein coding) AF119863 1. 7106E-03 </p><p id="p0900" num="0900">202136_at ZMYNDll z nc finger MYND domain contai ni ng 11 BE250417 </p><p id="p0901" num="0901">1.7169E -03 </p><p id="p0902" num="0902">201395. _at RBM5 RNA bind ng motif rotein 5 NM. 005778 1.7384E-03 2038Sl_s_at DMD dystrophin NM_004010 1.7474E-03 </p><p id="p0903" num="0903">20886J s_at ATRX a I pha thai as semi a/mental retardation syndrome x-1 inked</p><p id="p0904" num="0904">( AD 54 homolog s. cerevisiae) U72937 1.7816E-03 </p><p id="p0905" num="0905"> 202104_s_at SPG7 spasti c paraplegia 7 (pure and complicated autosomal </p><p id="p0906" num="0906">recessive) NM_003119 1.7951E-03 </p><p id="p0907" num="0907">2Q9656_s_at TME 47 transmembrane protein 47 AL136550 1.7975E-03 210644_s_at LAIRI leukocyte-associated immunoglobul i n-1 ke receptor 1 </p><p id="p0908" num="0908">AF109683 1.8453E-03 </p><p id="p0909" num="0909">213849_s_at PPP2R2B protein phosphatase 2 (formerly 2A) regulatory subuni t B beta i soform AA974416 1.8555E-03 </p><p id="p0910" num="0910">212547_at BRD3 bromodomain containing 3 N34842 1.8672E-03 
<!-- EPO <DP n="80"/>-->
 Table_A </p><p id="p0911" num="0911"> 213880_at LG 5 leucine-rich repeat-containing G protein-coupled receptor 5 AL524520 1.8699E-03 </p><p id="p0912" num="0912">212698_s_at SEPT10 septin 10 BF966021 1. 8766E-03 </p><p id="p0913" num="0913">204215_at C7orf23 chromosome 7 open reading frame 23 NM_024315 </p><p id="p0914" num="0914">1. 8796E-03 </p><p id="p0915" num="0915">204277_s_at TK2 thymidine kinase 2 mitochondrial BE895437 </p><p id="p0916" num="0916">1.8964E-03 </p><p id="p0917" num="0917">217954_s_at PHF3 PHD finger protein 3 NM_015153 1.9020E-03 </p><p id="p0918" num="0918">207845_s_at ANAPCIO anaphase promoting complex subunit 10 NM_014885 </p><p id="p0919" num="0919">1 . 9148E-03 </p><p id="p0920" num="0920">2 13071_at DPT dermatopontin AL049798 1.9353E-03 </p><p id="p0921" num="0921">210829_s_at SSBP2 s ngle-stranded DNA binding protein 2 AF077048 </p><p id="p0922" num="0922">1. 9382 E-03 </p><p id="p0923" num="0923">217989_at HSD17B11 hydroxysteroid (17-beta) dehydrogenase 11 </p><p id="p0924" num="0924">N _016245 1.9516E-03 </p><p id="p0925" num="0925">219862_s_at NARF nuclear prelamin A recognition factor NM_012336 </p><p id="p0926" num="0926">1.9592E-03 </p><p id="p0927" num="0927">212726_at PHF2 PHD finger protein 2 AB014562 1.9691E-03 </p><p id="p0928" num="0928">205933_at SETBPl SET binding protein 1 NM_015559 1.9781E-03 </p><p id="p0929" num="0929">204894_s_at AOC3 amine oxidase copper containing 3 (vascular adhesion protein 1) NM_003734 1.9794E-03 </p><p id="p0930" num="0930">209894_at LEPR leptin receptor U50748 1.9798E-03 </p><p id="p0931" num="0931">202363_at SPOCKl sparc/osteonecti n cwcv and kazal-like domains proteoglycan (testican) 1 AF231124 1.9920E-03 </p><p id="p0932" num="0932">202265_at BMil B Il polycomb ring finger oncogene NM_005180 </p><p id="p0933" num="0933">1.9971E-03 </p><p id="p0934" num="0934">214494_s_at SPG7 spastic paraplegia 7 (pure and complicated autosomal </p><p id="p0935" num="0935">recessive) NM_005200 2.0054E-03 </p><p id="p0936" num="0936">218518_at FAM13B family with sequence similarity 13 member Bl NM_016603 2. 0060E-03 </p><p id="p0937" num="0937">210105_s_at FYN FYN oncogene related to SRC FGR YES 14333 2.0099E-03 
<!-- EPO <DP n="81"/>-->
</p><p id="p0938" num="0938">Table_B </p><p id="p0939" num="0939"> Probe set ID Gene symbol Gene Name Representative Public ID </p><p id="p0940" num="0940"> value </p><p id="p0941" num="0941"> 213 30„s_at STIP1 stress-induced-phosphoprotein 1 BE886580 1 . 9219 E-07 213887_s_at P0LR2E polymerase (RNA) II (DNA directed) polypeptide E 25kDa AI554759 5.9774E- 07 </p><p id="p0942" num="0942"> 20163 l_s_at IER3 immediate early response 3 NM_003897 8 . 6381E-07 221610_s_at STAP2 signal transducing adaptor family member 2 BC000795 3.7342E-06 </p><p id="p0943" num="0943"> 205847_at PRSS22 protease serine 22 NM__022119 4.7883E-06 </p><p id="p0944" num="0944"> 208928_at POR P450 (cytochrome) ox doreductase AF258341 </p><p id="p0945" num="0945"> 5.1845E-06 </p><p id="p0946" num="0946"> 201530_x_at EIF4A1 eukaryotic translation initiation factor 4A isoform 1 </p><p id="p0947" num="0947"> NM_001416 1.0859E- 05 </p><p id="p0948" num="0948"> 217835_x_at C20orf24 chromosome 20 open reading frame 24 NM_018840 1.0871E-05 </p><p id="p0949" num="0949"> 222231_s_at LRRC59 leucine rich repeat containing 59 AK025328 </p><p id="p0950" num="0950"> 1.1501E-05 </p><p id="p0951" num="0951"> 201118_at PGD phosphogl uconate dehydrogenase N _002631 1.1705E-05 206426_at MLANA melan-A NM_005511 1.4820E-05 </p><p id="p0952" num="0952">210719_s_at HMG20B high-mobility group 20B BC002552 1.5452E-05 </p><p id="p0953" num="0953">208909_at UQCRFSl ubiquinol-cytochrome c reductase Rieske iron-sulfur polypeptide 1 BC000649 1.8592E-05 </p><p id="p0954" num="0954">208336_s_at GPSN2 glycoprotein synaptic 2 NM_004868 2.3068E-05 </p><p id="p0955" num="0955">201195_s_at SLC7A5 solute carrier family 7 (cationic amino acid transporter y+ system) member AB018009 2.3348E-05 </p><p id="p0956" num="0956">211787_s_at EIF4A1 eukaryotic translation initiation factor 4A isoform 1 BC006210 2.8418E- 05 </p><p id="p0957" num="0957">202435„s_at CYPlBl cytochrome P450 family 1 subfamily B polypeptide 1 </p><p id="p0958" num="0958">AU154504 2.9878E-05 </p><p id="p0959" num="0959">204039_at CEBPA CCAAT/enhancer b nding protein (C/EBP) al ha N _004364 3.0309E-05 </p><p id="p0960" num="0960">212070_at GPR56 G protein-coupled receptor 56 AL 554008 3 . 6504E-05 209126_x_at KRT6B keratin 6B L42612 3 . 7302 E-05 </p><p id="p0961" num="0961">220174_at LRRC8E leucine rich repeat containing 8 family member E </p><p id="p0962" num="0962">NM_025061 4.2418E- 05 </p><p id="p0963" num="0963">219402<sub>^</sub>s_at DERLl Deri-l ke doma n family member 1 NM_024295 </p><p id="p0964" num="0964">5.1192E-05 </p><p id="p0965" num="0965">212858_at PAQR4 progestin and adipoQ receptor family member iv AL 520675 5.2306E-05 </p><p id="p0966" num="0966">203702_s_at TTLL4 tubulin tyrosine ligase-like family member 4 AL043927 5.8383E-05 </p><p id="p0967" num="0967">217854_s_at POLR2E polymerase (RNA) II (DNA directed) polypeptide E 25kDa </p><p id="p0968" num="0968">N _002695 5.8400E-05 </p><p id="p0969" num="0969">201287_s_at SDC1 syndecan 1 N _002997 5.8419E-05 </p><p id="p0970" num="0970">212041_at ATP6V0D1 ATPase H+ transporting lysosomal 38kDa v0 subunit dl AL566172 6.4338E-05 </p><p id="p0971" num="0971"> 212531 ctt LCN2 li ocalin 2 NM_005564 6.5499E-05 </p><p id="p0972" num="0972"> 220013_at ABHD9 abhydrolase domain containing 9 NM_024794 6.8876E-05 209792 ,s_at L 10 kail kre n- related peptidase 10 BC002710 6.9165E-05 212085_at SLC25A6 solute carrier fami 1 y 25 (mitochondrial carrier; adenine nucleotide translocator) member 6 AA916851 7.4951E-05 </p><p id="p0973" num="0973">213680_at KRT6B ke at n 6B AI831452 7.5036E-05 </p><p id="p0974" num="0974">210020_x_at CALML3 calmodul in-like 3 M58026 7.9243E-05 </p><p id="p0975" num="0975">208002_s_at ACOT7 acyl-CoA thioesterase 7 NM ..00 274 8.1836L-05 </p><p id="p0976" num="0976">216607_s_at CYP51A1 cytochrome P450 family 51 subfamily A polypeptide 1 </p><p id="p0977" num="0977">U40053 8.3548E 05 </p><p id="p0978" num="0978">202005_at ST14 suppression of tumori gem<sup>*</sup> city 14 (colon carcinoma) </p><p id="p0979" num="0979"> NM_021978 8.4956E-05 </p><p id="p0980" num="0980"> 216512_s_at DCT dapac.hr orre tautorr.e rase (dopachrorre delta-i some rase </p><p id="p0981" num="0981">tyrosine- related protein 2) AL139318 9.5957E-05 </p><p id="p0982" num="0982"> 2Q4331_s__at MRPS12 mitochondrial r bosomal protein S12 NMJ321107 </p><p id="p0983" num="0983">1.0048E-04 </p><p id="p0984" num="0984"> 213571_s_at EIF4E2 eukaryotic translation initiation fa 4E family member 2 
<!-- EPO <DP n="82"/>-->
 Table_B </p><p id="p0985" num="0985"> BF516289 1.0230E-04 </p><p id="p0986" num="0986"> 212075_s_at CSN 2A1 casein kinase 2 alpha 1 polypeptide AI161318 </p><p id="p0987" num="0987"> 1. 1634E-04 </p><p id="p0988" num="0988"> 212501_at CEBPB CCAAT/enhancer binding protein (c/EBP) beta AL564683</p><p id="p0989" num="0989">1.1968E-04 </p><p id="p0990" num="0990"> 203663_s_at cox5A cytochrome c oxidase subunit va NM„004255 1.2510E-04</p><p id="p0991" num="0991">36994_at ATP6vOC ATPase H+ transporting lysosomal 16kDa VO subunit c </p><p id="p0992" num="0992"> M62762 1.2780E-04 </p><p id="p0993" num="0993"> 201976_s_at YO10 myosin X NM„012334 1.3176E-04 </p><p id="p0994" num="0994"> 209502_s_at BAIAP2 BAIl-associated protein 2 BC002495 1.4026E-04 200658„s_at PHB prohibitin AL 560017 1.4366E-04 </p><p id="p0995" num="0995"> 206630„at TYR tyrosinase (oculocutaneous albinism IA) N _000372 </p><p id="p0996" num="0996"> 1.4525E-04 </p><p id="p0997" num="0997"> 200895_s_at FKBP4 FK506 binding protein 4 59kDa NM_002014 1.4549E-04 204532_x_at UGTlAlO UDP glucuronosyltransferase 1 family polypeptide Al </p><p id="p0998" num="0998"> N _021027 1.5004E-04 </p><p id="p0999" num="0999"> 221676_s_at COROlC coronin actin binding protein lc BC002342 </p><p id="p1000" num="1000"> 1. 5064E-04 </p><p id="p1001" num="1001">204132_s_at FOX03 forkhead box 03 NM_001455 1.5795E-04 </p><p id="p1002" num="1002">217999_s_at PHLDAl pleckstrin homology-1 i ke domain family A member 1 </p><p id="p1003" num="1003">NM_007350 1.6252E-04 </p><p id="p1004" num="1004">206498_at OCA2 oculocutaneous albinism II NM_000275 1.6286E-04 201310_s_at C5orfl3 chromosome 5 open reading frame 13 NM_004772 </p><p id="p1005" num="1005">1.6328E-04 </p><p id="p1006" num="1006">209125_at KRT6A keratin 6A J00269 1.6608E-04 </p><p id="p1007" num="1007">209149_s_at TM9SF1 transmembrane 9 superfamily member 1 BE899402 </p><p id="p1008" num="1008">1.6635E-04 </p><p id="p1009" num="1009">206427_s_at MLANA melan-A U06654 1.6829E-04 </p><p id="p1010" num="1010">219752_at RASALl RAS protein activator like 1 (GAPl like) NM_004658 1. 7105E-04 </p><p id="p1011" num="1011">201322_at ATP5B ATP synthase H+ transporting mitochondrial Fl complex beta polypeptide NM_001686 1.7170E-04 </p><p id="p1012" num="1012">208918_s_at NAD NAD kinase AI334128 1.7531E-04 </p><p id="p1013" num="1013">218548_x_at TEX264 testis expressed 264 N _015926 1.7787E-04 </p><p id="p1014" num="1014">206595_at CST6 cystatin E/M N _001323 1.8189E-04 </p><p id="p1015" num="1015">217947_at CMTM6 C LF-like MARVEL transmembrane domain containing 6 </p><p id="p1016" num="1016">NM_017801 1.9994E-04 </p><p id="p1017" num="1017">218028_at ELOVLl elongation of very long chain fatty acids (FENl/Elo2 SUR4/Elo3 yeast)-like 1 NM_016031 2. 0196E-04 </p><p id="p1018" num="1018">202068_S_at LDLR low density lipoprotein receptor NM_000527 </p><p id="p1019" num="1019">2 . 1143 E-04 </p><p id="p1020" num="1020"> 221295_at CIDEA cell death-inducing DFFA-1 ke effector a NM_001279 2.1176E-04 </p><p id="p1021" num="1021"> 209482_at POP7 processing of precursor 7 ribonuclease P/MRP subunit (S. cerevis ae) BC001430 2.1329E-04 </p><p id="p1022" num="1022">214580_x_at KRT6C keratin 6A AL569511 2 . 1776E-04 </p><p id="p1023" num="1023">201131_s_at CDHl cadheri n 1 type 1 E-cadheri n (epithelial) NM_004360 2.2275E-04 </p><p id="p1024" num="1024">206094_x_at UGTlAlO UDP gl ucu ronosyl t ransfe rase 1 fami l y pol ypepti de Al </p><p id="p1025" num="1025">NM_001072 2. 2335 E-04 </p><p id="p1026" num="1026">208906_at BSCL2 Be rna rdi n el 1 i - sei p congenital lipodystrophy 2 (seipin) BC004911 2 , 2965E-04 </p><p id="p1027" num="1027">207986_x_at CYB561 cytochrome b-561 N _001915 2.3248E-04 </p><p id="p1028" num="1028">222138_s_at DR13 WD repeat domai n 13 AF158978 2.5149E-04 </p><p id="p1029" num="1029">201577_at NMEl non -metastat i c ee l 1 s 1 p rotei n (NM23A) expressed i n </p><p id="p1030" num="1030">NM_000269 2.5496E 04 </p><p id="p1031" num="1031">210613_s_at SYNGRl synaptogy r n 1 BC000731 2.5878E-04 </p><p id="p1032" num="1032">206445_s_at PRMTl p rotei n a rg i n i ne methyl transferase 1 NM_001536 </p><p id="p1033" num="1033">2.6001E-04 </p><p id="p1034" num="1034">57163_at ELOVLl e l ongati on of ve ry l ong chai n fatty aci ds (FENl/El o2 SUR4/El o3 yeast)-! ike 1 H93026 2.6427E-04 </p><p id="p1035" num="1035"> 218368_s_at TNFRSF12A tumor necrosis factor receptor superfamily member</p><p id="p1036" num="1036">12A NM_016639 2.7727E-04 
<!-- EPO <DP n="83"/>-->
 Table_B </p><p id="p1037" num="1037"> 218897_at TMEM177 transmembrane protein 177 NM_030577 2.7927E-04 205749„at CYPlAl cytochrome P450 family 1 subfamily A polypeptide 1 </p><p id="p1038" num="1038"> NM_000499 2.8164E-04 </p><p id="p1039" num="1039"> 203287_at LADl ladinin 1 NM_005558 2.9269E-04 </p><p id="p1040" num="1040"> 218189_s_at NANS N-acetyl neuraminic acid synthase NM_018946 </p><p id="p1041" num="1041"> 2.9981E-04 </p><p id="p1042" num="1042"> 201489_at PPIF peptidylprolyl isomerase F BC005020 3.0445E-04 202799_at CLPP ClpP caseinolytic peptidase ATP-dependent proteolytic subunit homolog (E. coli) NM_006012 3.1644E-04 </p><p id="p1043" num="1043"> 215206_at null AK025143 3.1867E-04 </p><p id="p1044" num="1044"> 208700_s_at T T transketolase L12711 3.2294E-04 </p><p id="p1045" num="1045"> 207126_x_at UGTlAlO UDP glucuronosyltransferase 1 family polypeptide Al </p><p id="p1046" num="1046"> NM_000463 3.2300E-04 </p><p id="p1047" num="1047"> 204941_s_at ALDH3B2 aldehyde dehydrogenase 3 family member B2 AA071510 3.2381E-04 </p><p id="p1048" num="1048"> 212826_s_at SLC25A6 solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator) member 6 AI961224 3.2556E-04 </p><p id="p1049" num="1049"> 218739_at ABHD5 abhydrolase domain containing 5 NM_016006 3.2819E-04 209208_at PDUl mannose-P-dolichol utilization defect 1 AF059752 </p><p id="p1050" num="1050"> 3.3424E-04 </p><p id="p1051" num="1051"> 200846_s_at PPPlCA protein phosphatase 1 catalytic subunit alpha isoform N _002708 3.5337E-04 </p><p id="p1052" num="1052"> 200750<sub>^</sub>s_at RAN RAN member RAS oncogene family AF054183 3.5383E-04 201739_at SG l serum/g ucocorticoid regulated kinase 1 NM_005627 </p><p id="p1053" num="1053"> 3.5459E-04 </p><p id="p1054" num="1054"> 212165_at T E 183B transmembrane protein 183A AF070537 </p><p id="p1055" num="1055"> 3.5638E-04 </p><p id="p1056" num="1056">218756_s_at DHRSll dehydrogenase/reductase (SDR family) member 11 NM_024308 3.6110E-04 </p><p id="p1057" num="1057">204733_at KLK6 kallikrein-related peptidase 6 N _002774 3.8374E-04 213726_x_at TUBB2C tubulin beta 2C AA515698 3.9114E-04 </p><p id="p1058" num="1058">214549_x„at SPRRlA small proline-rich protein 1A NM_005987 3.9410E-04 211800_s_at USP4 ubiquitin specific peptidase 4 (proto-oncogene) AF017306 4.0198E-04 </p><p id="p1059" num="1059">202712_s_at LOC100133623 creatine kinase mitochondrial 1A NM_020990 4.0457E-04 </p><p id="p1060" num="1060">213796_at SPRRlA small proline-rich protein lA AI923984 4.1153E-04 209036_s_at MDH2 malate dehydrogenase 2 NAD (mitochondrial) BC001917 4.1608E-04 </p><p id="p1061" num="1061">31846_at RHOD ras homolog gene fami y member D AW003733 </p><p id="p1062" num="1062">4.1843E-04 </p><p id="p1063" num="1063">217140_s_at LOC100133724 similar to Voltage-dependent anion-sel ecti ve channel protein 1 (VDAC-l) (hVDACl) (Outer mitochondrial membrane protein porin 1) </p><p id="p1064" num="1064">(Plasmalemmal porin) (Porin 31HL) (Porin 31HM) AJ002428 4.1935E-04 </p><p id="p1065" num="1065"> 207367_at ATP12A ATPase H+/K+ transporting nongastric alpha polypeptide NM_001676 4.1960E-04 </p><p id="p1066" num="1066">203109_at UBE2M ubi u ti n-con jugati ng enzyme E2M (UBC12 homolog yeast) NKJ303969 4.2473F-04 </p><p id="p1067" num="1067">202421. at IGSF3 immunoglobulin superfamily member 3 AB007935 </p><p id="p1068" num="1068">4.2745E-04 </p><p id="p1069" num="1069">208977_x„at TUBB2C tubulin beta 2c BC004188 4.2872E-04 </p><p id="p1070" num="1070">201231_s_at ENOl enolase 1 (alpha) N _001428 4.3258E-04 </p><p id="p1071" num="1071">207507_s_.at ATP5G3 ATP synthase H+ transporti ng mi tochondri al F0 complex subunit C3 ubuni t 9) NM_001689 4.3401E-04 </p><p id="p1072" num="1072">217973_at DCXR d carbonyl/L- xylulose reductase NM_016286 4.3576E-04 213132_s_at MCAT malonyl CoA :ACP acyl ransfe ase (mitochondrial) AL022237 4.3749E-04 </p><p id="p1073" num="1073">212236_x_at KRT17 keratin 17 219574 4.3848E-04 </p><p id="p1074" num="1074">207192_at DNASE1L2 deoxyri bonucl ease i-like 2 NM_001374 </p><p id="p1075" num="1075">4.4267E-04 </p><p id="p1076" num="1076">202376_at SERPINA3 serpin peptidase inhibitor clade A (alpha-1 antiprotei nase antitrypsin) member 3 NM_001085 4.4762E-04 </p><p id="p1077" num="1077">208813_at GOTl glutamic-oxaloacetic transaminase 1 soluble (aspartate 
<!-- EPO <DP n="84"/>-->
 Table_B </p><p id="p1078" num="1078"> aminotransferase 1) BC000498 4.5160E-04 </p><p id="p1079" num="1079"> 205157_s_at KRT17 keratin 17 NM_000422 4.5700E-04 </p><p id="p1080" num="1080"> 200862_at DHCR24 24-dehydrocholesterol reductase N _014762 4.6729E-04 205293_x_at BAIAP2 BAil-associated protein 2 AB017120 4.6882E-04 202436_s_at CYP1B1 cytochrome P450 family 1 subfamily B polypept de 1 AU144855 4.7083E-04 </p><p id="p1081" num="1081"> 220994_s_at STXBP6 syntaxin binding protein 6 (ami syn) NM_014178 </p><p id="p1082" num="1082"> 4.7382E-04 </p><p id="p1083" num="1083"> 216475_at null AL133269 4.8343 E- 04 </p><p id="p1084" num="1084"> 204341_at TRIM16 tripartite mot f-conta n ng 16 NNL006470 4.8792E-04 201175_at TMX2 thioredoxin domain containing 14 NM_015959 </p><p id="p1085" num="1085"> 5.0497E-04 </p><p id="p1086" num="1086"> 203462_x_at EIF3B eukaryotic translation initiation factor 3 subunit B N _003751 5.1683E-04 </p><p id="p1087" num="1087"> 205064_at SPRRlB small proline-rich protein IB (cornifin) NM_003125 5.3559E-04 </p><p id="p1088" num="1088"> 210959_s_at SRD5A1 steroi d-5-al pha-reductase alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1) AF113128 5.3596E-04 </p><p id="p1089" num="1089">220976_s_at LOC728946 keratin associated protein 1-1 NM_030967 </p><p id="p1090" num="1090"> 5.3814E-04 </p><p id="p1091" num="1091">215626_at null AU144887 5.4582E-04 </p><p id="p1092" num="1092">209800_at RT16 keratin 16 AF061812 5.4918E-04 </p><p id="p1093" num="1093">206714_at ALOX15B arachi donate 15-lipoxygenase type B NM_001141 </p><p id="p1094" num="1094">5.5543E-04 </p><p id="p1095" num="1095">206302_s_at NUDT4 nudix (nucleoside diphosphate linked moiety X)-type motif 4 NM_019094 5.6492E-04 </p><p id="p1096" num="1096">212861_at MF5D5 major facilitator superfamily domain containing 5 </p><p id="p1097" num="1097">BF690150 5.7171E-04 </p><p id="p1098" num="1098">208756_at EIF3I eukaryotic translation initiation factor 3 subunit I</p><p id="p1099" num="1099">U36764 5.8834E-04 </p><p id="p1100" num="1100"> 205338_s_at DCT dopachrome tautomerase (dopachrome del ta-i some rase tyrosine-related protein 2) N _001922 5.9284E-04 </p><p id="p1101" num="1101"> 205436_s_at H2AFX H2A hi stone family member X NM_002105 5 </p><p id="p1102" num="1102">215952_s_at OAZl ornithine decarboxylase antizyme 1 AF090094 </p><p id="p1103" num="1103">5.9942E-04 </p><p id="p1104" num="1104">2101 0_s_at TM7SF2 transmembrane 7 superfamily member 2 AF096304 </p><p id="p1105" num="1105">6.0308E-04 </p><p id="p1106" num="1106">215100_at C6orfl05 chromosome 6 open reading frame 105 AL022724 6.1457E-04 </p><p id="p1107" num="1107">205417_s_at DAGl dystroglycan 1 (dystrophin-associated glycoprotein 1) N _004393 6.2276E-04 </p><p id="p1108" num="1108">216237_s_at MCM5 mini chromosome maintenance complex component 5 AA807529 6.2290E-04 </p><p id="p1109" num="1109">201113_at TUFM Tu translation elongation factor mitochondrial NM_003321 6.2822E-04 </p><p id="p1110" num="1110">205694_at TYRPl tyrosinase-related protein 1 NM_000550 6.3022E-04 202315_s_at BCR breakpoint cluster region N _004327 6.3140E-04 203391_at FKBP2 FK506 bind ng protein 2 13kDa NM_004 70 6.3385E-04 218880_at FOSL2 FOS-1 i ke antigen 2 N36408 6.3536E-04 </p><p id="p1111" num="1111">2?0978_at kerati n associated protein 1-3 N _030966 </p><p id="p1112" num="1112">6.3713F-04 </p><p id="p1113" num="1113">207670_at KRT85 keratin 85 NM_002283 6.4259E-04 </p><p id="p1114" num="1114">201463_s_at LOC100133665 s milar to transaldol ase NM_.006755 </p><p id="p1115" num="1115">6.4937E-04 </p><p id="p1116" num="1116">210589_s__at GBA glucosidase beta; aci d (includes gl ucosyl erami dase) D13287 6.6217E-04 </p><p id="p1117" num="1117">219395__at ESRP2 RNA binding mot f protein 35B NM_024939 6.6704E-04 204675_at SRD5A1 steroi d-5~al pha-reductase alpha polypeptide 1 (3-oxo-5 al ha-steroid delta 4-dehydrogenase alpha 1) NM_001047 6.6827E-04 215808_at KLKlO kalli krei n-rel ated peptidase 10 AK026045 6.7220E-04</p><p id="p1118" num="1118">33646_g_at GM2A GM2 gangl ios de activator X61094 6.8424E-04 </p><p id="p1119" num="1119"> 207508...at ATP5G3 ATP synthase H+ transporting mitochondrial FO complex subunit C3 (subunit 9) NM 001689 6.8567E-04 
<!-- EPO <DP n="85"/>-->
 Table_B </p><p id="p1120" num="1120"> 214370_at S100A8 calcium-binding protein in macrophages (MRP-8) macrophage migration inhibitory factor (MIF)- related protein AW238654 6.8779E-04</p><p id="p1121" num="1121">200803_s_at TMBIM6 transmembrane BAX inhibitor motif containing 6 AF033095 6.8912E-04 </p><p id="p1122" num="1122"> 221872_at RARRESl retinoic acid receptor responder Ctazarotene induced) 1</p><p id="p1123" num="1123">AI669229 6.9158E-04 </p><p id="p1124" num="1124"> 207088_s_at SLC25A11 solute carrier family 25 (mitochondrial carrier; oxoqlutarate carrier) member 11 NM_003 562 6.9700E-04 </p><p id="p1125" num="1125"> 219412_at RAB38 RAB38 member RAS oncogene family NM_022337 </p><p id="p1126" num="1126"> 7.0409E-04 </p><p id="p1127" num="1127"> 218893_at ISOC2 isochorismatase domain containing NM_024710 </p><p id="p1128" num="1128"> 7.1390E-04 </p><p id="p1129" num="1129"> 202917_s_at S100A8 S100 calcium binding protein A8 N _002964 7.1637E-04 220970_s_at LOC6443 50 keratin associated protein 2. IB NM_030977 </p><p id="p1130" num="1130"> 7.2209E-04 </p><p id="p1131" num="1131"> 219911_s_at LOC100134295 similar to Solute carrier organic anion transporter family member NM_016354 7.2592E-04 </p><p id="p1132" num="1132"> 200894_s_at FKBP4 F 506 binding protein 4 59kDa AA894574 7.3446E-04 206709_x_at GPT glutamic-pyruvate transaminase (alanine aminotransferase) NM_005309 7.3607E-04 </p><p id="p1133" num="1133"> 219723_x_at AGPAT 3 l-acylglycerol-3-phosphate o-acyltransferase 3 NM_020132 7.4330E-04 </p><p id="p1134" num="1134"> 209372_x_at TUBB2B tubulin beta 2A BF971587 7.4649E-04 </p><p id="p1135" num="1135"> 203535_at S100A9 S100 calcium binding protein A9 NM_002965 7.6032E-04 218214_at Cl2orf44 chromosome 12 open reading frame 44 NM_021934 7.6225E-04 </p><p id="p1136" num="1136"> 206391_at RARRESl retinoic acid receptor responder (tazarotene induced) 1 NM_002888 7.6289E-04 </p><p id="p1137" num="1137"> 206605_at Pll 26 serine protease NM_006025 7.7125E-04 </p><p id="p1138" num="1138">201490_s_at PPIF pept dyl prolyl isomerase F NM_005729 7.7571E-04 219850_s_at EHF ets homologous factor NM_012153 7.7583E-04 </p><p id="p1139" num="1139">221256„s_at HDHD3 haloacid dehalogenase-l ke hydrolase domain containing 3 NM_031219 7.7612E-04 </p><p id="p1140" num="1140">218105_s_at MRPL4 mitochondrial ribosomal protein l_4 NM_015956 </p><p id="p1141" num="1141">7.8720E-04 </p><p id="p1142" num="1142">216810_at KRTAP4-7 keratin associated protein 4-7 AJ406939 </p><p id="p1143" num="1143">7.9938E-04 </p><p id="p1144" num="1144">218556_at ORMDL2 ORMl-like 2 (s. cerevisiae) NM_014182 8.2452E-04 201286_at SDCl syndecan 1 Z48199 8. 2815 E-04 </p><p id="p1145" num="1145">211715_s_at BDHl 3-hydroxybutyrate dehydrogenase type 1 BC005844 </p><p id="p1146" num="1146">8.2925E-04 </p><p id="p1147" num="1147">220189_s_at MGAT4B mannosyl (alpha-13-) -gl coprotein </p><p id="p1148" num="1148">beta-14-N-acetylglucosaminyl transferase isozyme B NM_014275 8.3956E-04</p><p id="p1149" num="1149">217208_s_at DLGl discs large homolog 1 (Drosophil ) AL121981 </p><p id="p1150" num="1150"> 8.4322E-04 </p><p id="p1151" num="1151">208653_s_at CD164 CD164 molecule sialomucin AF263279 8.4956E-04 207065_at KRT75 keratin 75 NM_004693 8.5476E-04 </p><p id="p1152" num="1152">202122_s_at M6PRBP1 mannose-6-phosphate receptor binding protein 1 N _005817 8.6534E-04 </p><p id="p1153" num="1153">221561_at SOATl sterol o-acyltransferase 1 L21934 8 . 6953 E-04 </p><p id="p1154" num="1154">203119_at CCDC86 coi 1 ed-coi 1 domain containing 86 NM_024098 </p><p id="p1155" num="1155">8.7851E-04 </p><p id="p1156" num="1156">20343Ls_at RICS Rho GTPase-activating protein NM_014715 8 . 7902 E-04 208699_x_at T T transketolase BF696840 8. 8246E-04 </p><p id="p1157" num="1157">206392_s_at RARRESl retinoic acid receptor responder (tazarotene induced) 1 NM_002888 8.8393E-04 </p><p id="p1158" num="1158">210715_s_at SPINT2 ser ne peptidase i nhi bi tor Kunitz type 2 AF027205 8.9891E-04 </p><p id="p1159" num="1159">200837_at BCAP31 B-cel 1 receptor-associated protein 31 NM_005745 </p><p id="p1160" num="1160">9 . 0194E-04 </p><p id="p1161" num="1161">20902 5_s_at SYNCRIP synaptotagmin binding cytoplasmi c RNA interacting protein AF037448 9.0260E-04 </p><p id="p1162" num="1162">211047_x_at AP2S1 adaptor-related protein complex 2 sigma 1 subunit 
<!-- EPO <DP n="86"/>-->
 Table_B </p><p id="p1163" num="1163"> BC006337 9.0723E-04 </p><p id="p1164" num="1164"> 204942_s_at ALDH3B2 aldehyde dehydrogenase 3 family member B2 NM_000695 9.1058E-04 </p><p id="p1165" num="1165"> 208919_s_at NADK NAD kinase BC001709 9.1552E-04 </p><p id="p1166" num="1166"> 210074_at CTSL2 cathepsin L2 AF070448 9.3602E-04 </p><p id="p1167" num="1167"> 208963_x_at FAD sl fatty acid desaturase 1 BG165833 9.5738E-04 </p><p id="p1168" num="1168"> 208799_at PSMB5 proteasome (prosome macropain) subunit beta type 5 </p><p id="p1169" num="1169"> BC004146 9.6091E-04 </p><p id="p1170" num="1170"> 219429_at FA2H fatty acid 2-hydroxylase NM_024306 9.6450E-04 36475_at GCAT glycine Oacetyltransferase (2-amino-3-ketobutyrate coenzyme A ligase) Z97630 9.6676E-04 </p><p id="p1171" num="1171"> 215093_at NSDHL NAD(P) dependent steroid dehydrogenase-li ke U82671 </p><p id="p1172" num="1172"> 9.6805E-04 </p><p id="p1173" num="1173"> 215189_at LOC100134394 keratin 86 X99142 9.7401E-04 </p><p id="p1174" num="1174"> 209078_s_at TXN2 thioredoxin 2 AF276920 9.7751E-04 </p><p id="p1175" num="1175"> 208852_s_at CANX calnexin AI761759 9.7992E-04 </p><p id="p1176" num="1176"> 204253_s_at VDR vitamin D (125- dihydroxyvitamin D3) receptor AA454701 9.8319E-04 </p><p id="p1177" num="1177"> 209457_at DUSP5 dual specificity phosphatase 5 U16996 9.9441E-04 207595_s_at BMPl bone morphogenetic protein 1 NM_006132 1.0199E-03 211752_s_at NDUFS7 NADH dehydrogenase (ubiquinone) Fe-S protein 7 20kDa </p><p id="p1178" num="1178"> (NADH-coenzyme Q reductase) BC005954 1.0313E-03 </p><p id="p1179" num="1179"> 219843_at IPP i ntraci sternal A particle-promoted polypeptide NM_005897</p><p id="p1180" num="1180">1.0419E-03 </p><p id="p1181" num="1181"> 218582_at MARCH 5 membrane-associated ring finger (C3HC4) 5 NM_017824 1.0479E-03 </p><p id="p1182" num="1182"> 201119_s_at COX 8 A cytochrome c oxidase subunit 8A (ubiquitous) N _004074 1.0583E-03 </p><p id="p1183" num="1183"> 210334_x_at BIRC5 baculoviral IAP repeat-containing 5 AB028869 </p><p id="p1184" num="1184"> 1.0585E-03 </p><p id="p1185" num="1185"> 201201_at CSTB cystatin B (stefin B) NM_000100 1.0624E-03 </p><p id="p1186" num="1186">207787_at KRT33B keratin 33B NM_002279 1.0655E-03 </p><p id="p1187" num="1187">208688_x_at EIF3B eukaryotic translation initiation factor 3 subunit B </p><p id="p1188" num="1188">U78525 1.1028E-03 </p><p id="p1189" num="1189">201433_s_at PTDSSl phosphatidyl serine synthase 1 NM_014754 1.1096E-03</p><p id="p1190" num="1190">91684_g_at EXOSC4 exosome component 4 AI571298 1.1230E-03 213288_at MBOAT2 membrane bound O-acyl transferase domain containing 2 </p><p id="p1191" num="1191">AI761250 1.1339E-03 </p><p id="p1192" num="1192">206074_s_at HMGAl high mobility group AT-hook 1 NM_002131 1.1423E-03 220486_x_at LOC100130886 hypothetical protein LOC100130886 NM_017698 1.1621E-03 </p><p id="p1193" num="1193">200734_s_at ARF3 ADP-ribosylation factor 3 BG341906 1.1713E-03 203971_at SLC31A1 solute carrier family 31 (copper transporters) member 1 NM_001859 1.1747E-03 </p><p id="p1194" num="1194">201284_s_at APEH N-acyl ami noacyl -peptide hydrolase NM_001640 </p><p id="p1195" num="1195">1.1833E-03 </p><p id="p1196" num="1196">204014_at DUSP4 dual specificity phosphatase 4 NM_001394 1.1864E-03 217806_s_at POLDIP2 polymerase (DNA di rected) delta interacting protein 2 NM_015584 1.1923E-03 </p><p id="p1197" num="1197">210236_at PPFIA1 protein tyrosi ne phosphatase receptor type f pol ypept de (PTPRF) interacting protein (liprin) alpha 1 U22815 1.2081E-03 </p><p id="p1198" num="1198">208527_x<sub>^</sub>at HIST1H2BG hi stone cluster 1 H2bc NM_003523 1.2099E-03</p><p id="p1199" num="1199">208962_s...at FADSl fatty acid desaturase 1 BE540552 1.2236E-03 </p><p id="p1200" num="1200">206873_at CA6 carbonic anhydrase VI NM_001215 1.2902E-03 </p><p id="p1201" num="1201">212048_s_at YARS tyrosyl-tRNA synthetase AW245400 1.3124E-03 </p><p id="p1202" num="1202">205916_at S100A7 S100 calcium binding protein A 7 N _002963 1.3187E-03 210655„s_at FOX03 forkhead box 03 AF041336 1.3616E-03 </p><p id="p1203" num="1203">220163_s_at HR hai rless homolog (mouse) NM_018411 1.3692E-03 204836_at GLDC glycine dehydrogenase (decarboxyl ating) NM_000170 </p><p id="p1204" num="1204">1.4104E-03 </p><p id="p1205" num="1205">202218_s_at FADS2 fatty acid desaturase 2 NM„004265 1.4192E-03 </p><p id="p1206" num="1206">214786_at MAP3K1 mi togen-acti ated protei n kinase kinase ki nase 1 </p><p id="p1207" num="1207">AA361361 1.4341E-03 
<!-- EPO <DP n="87"/>-->
 Table_B </p><p id="p1208" num="1208"> 211906_s_at SERPINB4 serpin peptidase inhibitor clade B (ovalbumin) member 4 AB046400 1.4392E-03 </p><p id="p1209" num="1209"> 220615_s_at FAR2 fatty acy CoA reductase 2 NM_018099 1.4407E-03</p><p id="p1210" num="1210">205759_s_at SULT2B1 sulfotransferase family cytosolic 2B member 1 NM_004605</p><p id="p1211" num="1211">1.4410E-03 </p><p id="p1212" num="1212"> 209605_at TST thiosulfate sulfurtransferase (rhodanese) D87292</p><p id="p1213" num="1213">1.4493E-03 </p><p id="p1214" num="1214"> 212218_s_at FASN fatty acid synthase AI954041 1.4565E-03 </p><p id="p1215" num="1215"> 206465_at ACSBGl acyl-COA synthetase bubblegum family member 1 BE856376</p><p id="p1216" num="1216">1.4571E-03 </p><p id="p1217" num="1217"> 205661_s_at FLADl FADl flavi adenine di nucleotide synthetase homolog (S. cerevi siae) NM_025207 1.4794E-03 </p><p id="p1218" num="1218"> 218062_x_at CDC42EP4 CDC42 effector protein (Rho GTPase binding) 4</p><p id="p1219" num="1219">NM_012121 1.4836E-03 </p><p id="p1220" num="1220"> 205783_at LK13 ka likrein- related peptidase 13 N _015596 1.4883E-03</p><p id="p1221" num="1221">212807_s_at SORTl sortilin 1 BF447105 1.5110E-03 </p><p id="p1222" num="1222"> 210816_s_at CYB561 cytochrome b-561 BC000021 1.5129E-03 </p><p id="p1223" num="1223"> 205856_at SLC14A1 solute carrier family 14 (urea transporter) member 1 (Kidd blood group) NM_015865 1.5262E-03 </p><p id="p1224" num="1224"> 204471_at GAP43 growth associated protein 43 NM_002045 1.5287E-03</p><p id="p1225" num="1225">208708_x_at EIF5 eukaryotic translation initiation factor 5 AL080102</p><p id="p1226" num="1226">1.5349E-03 </p><p id="p1227" num="1227"> 202826_at SPINT1 serine peptidase inhibitor Kunitz type 1 NNL003710</p><p id="p1228" num="1228">1.5419E-03 </p><p id="p1229" num="1229"> 200971_s_at SERPl stress-associated endoplasmic reticulum protein 1 </p><p id="p1230" num="1230"> NM_014445 1.5589E-03 </p><p id="p1231" num="1231"> 201695_s_at NP nucleoside phosphorylase NM_000270 1.5658E-03</p><p id="p1232" num="1232">201760_s_at WSB2 WD repeat and SOCS box-containing 2 NM_018639</p><p id="p1233" num="1233">1.5795E-03 </p><p id="p1234" num="1234"> 209624_s_at CCC2 methyl crotonoyl -Coenzyme A carboxylase 2 (beta) AB050049</p><p id="p1235" num="1235">1.6326E-03 </p><p id="p1236" num="1236"> 216396_s_at EI24 etoposide induced 2.4 mRNA AF131850 1.6335E-03</p><p id="p1237" num="1237">209832_s_at CDTl chromatin licensing and DNA replication factor 1 </p><p id="p1238" num="1238"> AF321125 1.6426E-03 </p><p id="p1239" num="1239"> 215066_at PTPRF protein tyrosine phosphatase receptor type F AU158443</p><p id="p1240" num="1240">1.6528E-03 </p><p id="p1241" num="1241"> 207114_at LY6G6C lymphocyte antigen 6 complex locus G6c N _025261 </p><p id="p1242" num="1242"> 1.6553E-03 </p><p id="p1243" num="1243"> 202671_s_at PDXK pyridoxal (pyridox ne vitamin B6) kinase NM_003681</p><p id="p1244" num="1244">1.6560E-03 </p><p id="p1245" num="1245"> 214665_s_at CHP calcium binding protein P22 AK000095 1.6605E-03</p><p id="p1246" num="1246">219369_s_at OTUB2 OTU domain ubiquitin aldehyde binding 2 NM_023112</p><p id="p1247" num="1247">1.6717E-03 </p><p id="p1248" num="1248"> 219272_at TRIM62 tripartite motif-containing 62 NM_018207 1.6780E-03</p><p id="p1249" num="1249">209093_s_at GBA glucosidase beta; acid (includes glucosylceramidase) 02920 1.6857E 03 </p><p id="p1250" num="1250"> 212088_at PMPCA peptidase (mitochondrial processing) alpha BF570122</p><p id="p1251" num="1251">1.6997E-03 </p><p id="p1252" num="1252"> 218580_x at AURKAIPl aurora kinase A interacting protein 1 N _ 017900</p><p id="p1253" num="1253">1.7063E-03 </p><p id="p1254" num="1254"> 220972_s_at KRTAP9-9 keratin associated protei n 9-4 N _030 75 </p><p id="p1255" num="1255"> 1.7166E-03 </p><p id="p1256" num="1256"> 201274_at PSMA5 proteasome (prosome macropain) subunit alpha type 5 </p><p id="p1257" num="1257"> NM_002790 1.7264E-03 </p><p id="p1258" num="1258"> 202788_at MAPKAPK3 mi togen-acti vated protein kinase-act ated protei n ki nase 3 N _004635 1.7807E-03 </p><p id="p1259" num="1259"> 2166 1_s_at LADl ladinin 1 U58994 1.7904E-03 </p><p id="p1260" num="1260"> 201277_s_at HNRNPAB heterogeneous nuclear ribonucleoprotein A/B NM_004499</p><p id="p1261" num="1261">1.7905E-03 </p><p id="p1262" num="1262"> 205942_s„at ACSM3 acyl-COA synthetase medium-chain family member 3 </p><p id="p1263" num="1263"> NM_005622 1.7973E-03 </p><p id="p1264" num="1264"> 217188_s ..at cl4orfl chromosome 14 open reading frame 1 AC007182</p><p id="p1265" num="1265">1.8045E-03 
<!-- EPO <DP n="88"/>-->
 Table_B </p><p id="p1266" num="1266"> 201879_at ARIHl ariadne homolog ubi qui tin-conjugating enzyme E2 binding protein 1 (Drosophila) AI694332 1.8359E-03 </p><p id="p1267" num="1267"> 200890_s_at SSRl signal sequence receptor alpha AW006345 1.8454E-03 210337_s_at ACLY ATP citrate lyase U18197 1.8472E-03 </p><p id="p1268" num="1268">208301__at null NM_025033 1.8565E-03 </p><p id="p1269" num="1269">202831_at GPX2 glutathione peroxidase 2 (gastrointestinal) NM_002083 1.8811E-03 </p><p id="p1270" num="1270">208351_s_at MAPKl mi togen-activated protein kinase 1 NM_002745 </p><p id="p1271" num="1271">1.8879E-03 </p><p id="p1272" num="1272">202418_at YlFlA Yipl interacting factor homolog A (S. cerevisiae) </p><p id="p1273" num="1273">NM_020470 1.9069E-03 </p><p id="p1274" num="1274">216979_at NR4A3 nuclear receptor subfamily 4 group A member 3 X89894 1.9090E-03 </p><p id="p1275" num="1275">219980„at C4orf29 chromosome 4 open reading frame 29 NM_025097 </p><p id="p1276" num="1276">1.9117E-03 </p><p id="p1277" num="1277">207457_s_at LY6G6D lymphocyte antigen 6 complex locus G6D NM_021246 </p><p id="p1278" num="1278">1.9129E-03 </p><p id="p1279" num="1279">209885_at RHOD ras homolog gene family member D BC001338 </p><p id="p1280" num="1280">1.9191E-03 </p><p id="p1281" num="1281">220431_at TMPRSSllE transmembrane protease serine HE NM_014058 1.9354E-03 </p><p id="p1282" num="1282">213553_x_at APOCl apoli oprotein C-I W79394 1.9760E-03 </p><p id="p1283" num="1283">200824_at GSTP1 glutathione S-transferase pi 1 N _000852 1.9764E-03 221934_s_at LOC100133719 DALR anticodon binding domain containing 3 </p><p id="p1284" num="1284">BF941492 1.9812E-03 </p><p id="p1285" num="1285">206969_at KRT34 keratin 34 NM_021013 1.9840E-03 </p><p id="p1286" num="1286">213059_at CREB3L1 CAMP responsive element binding protein 3-1 ike 1 </p><p id="p1287" num="1287">AF055OO9 1.9924E-03 </p><p id="p1288" num="1288">218951_s_at PLCXDl phosphatidyl inositol-specific phosphol i pase c x domain containing 1 NM_018390 1.9969E-03 </p><p id="p1289" num="1289">21913 Lat UBlADl Ubi A prenyl transferase domain containing 1 IMM_013319 2.0022E-03 </p><p id="p1290" num="1290">39729_at PRDX2 peroxi redoxin 2 L19185 2.0334E-03 </p><p id="p1291" num="1291">220675_s_at PNPLA3 patatin-like phospholipase domain containing 3 NM_025225 2.0480E-03 </p><p id="p1292" num="1292">211695_x_at MUCl mucin 1 cell surface associated AF348143 2.0496E-03 206027_at S100A3 S100 calcium b nding protein A3 NM_002960 2.0599E-03 208660_at CS citrate synthase BC000105 2.0731E-03 </p><p id="p1293" num="1293">218018_at PDXK pyridoxal (pyridoxine vitamin B6) kinase A 449022 2.0955E-03 
<!-- EPO <DP n="89"/>-->
</p><p id="p1294" num="1294">Tabl e_C </p><p id="p1295" num="1295"> probe set ID Gene symbol Gene Name Rep resentati ve Publ i c ID </p><p id="p1296" num="1296"> value </p><p id="p1297" num="1297"> 205236_x_at SOD3 supe roxi de di stnutase 3 ext racel l ul ar NM_00 102 </p><p id="p1298" num="1298"> 4.1207E-10 </p><p id="p1299" num="1299"> 213247_at SVEP1 sushi von willebrand factor type A EGF and pentraxin domain containing 1 AA716107 5.1550E-10 </p><p id="p1300" num="1300"> 212796_s_at TBC1D2B TBCl domain family member 2B BF195608 3.6373E-09 213113_s_at SLC43A3 solute carrier family 43 member 3 AI630178 </p><p id="p1301" num="1301"> 1.0187E-08 </p><p id="p1302" num="1302"> 202510_s_at TNFAIP2 tumor necrosis factor alpha-induced protein 2 NM_006291 2.4861E-08 </p><p id="p1303" num="1303"> 213364_s_at SNX1 sorting nexin 1 AI052536 2.7627E-08 </p><p id="p1304" num="1304"> 202291_s_at MGP matrix Gla protein NM_000900 6.9902E-08 </p><p id="p1305" num="1305"> 219304_s_at PDGFD platelet derived growth factor D NM_025208 </p><p id="p1306" num="1306"> 7.2053E-08 </p><p id="p1307" num="1307"> 213258_at TFPI tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) BF511231 7.6953E-08 </p><p id="p1308" num="1308"> 213071_at DPT dermatopontin AL049798 8.6564E-08 </p><p id="p1309" num="1309"> 202912_at ADM adrenomedullin NNL.001124 1.1154E-07 </p><p id="p1310" num="1310"> 202363_at SPOC l sparc/osteonectin cwcv and kazal-like domains proteoglycan</p><p id="p1311" num="1311">Ctestican) 1 AF231124 1.3816E-07 </p><p id="p1312" num="1312"> 212067_s_at ClR complement component 1 r subcomponent AL573058 </p><p id="p1313" num="1313"> 1. 7318E-07 </p><p id="p1314" num="1314"> 203088_at FBLN5 fibulin 5 NVL006329 1.8181E-07 </p><p id="p1315" num="1315"> 212589_at RRAS2 related RAS viral (r-ras) oncogene homolog 2 ΑΙ753792 2. 0143 E-07 </p><p id="p1316" num="1316"> 202994_s_at FBLNl fibulin 1 Z95331 2.4381E-07 </p><p id="p1317" num="1317"> 213164_at SLC5A3 solute carrier family 5 (sodi um/myo-i nosi tol cotransporter) member 3 AI867198 3.0577E-07 </p><p id="p1318" num="1318"> 212761_at TCF7L2 transcription factor 7-1 ike 2 (T-ce l specific HMG-box) AI949687 3.3288E-07 </p><p id="p1319" num="1319"> 216620_s_at ARHGEF10 Rho guanine nucleotide exchange factor (GEF) 10 AF009205 3.6027E-07 </p><p id="p1320" num="1320"> 217800_s_at NDFIPl Nedd4 family interacting protein 1 N _030571 </p><p id="p1321" num="1321"> 3.8336E-07 </p><p id="p1322" num="1322">206157_at PTX3 pentraxin- related gene rapidly induced by IL-I beta </p><p id="p1323" num="1323">NM_002852 4.0587E-07 </p><p id="p1324" num="1324">209763_at CHRDLl chordin-like 1 AL049176 4.1288E-07 </p><p id="p1325" num="1325">207606_s_at ARHGAP12 Rho GTPase activating protein 12 NM_018287 4.3253E-07 </p><p id="p1326" num="1326">213348_at CDKNlc cycl in-dependent kinase inhibitor 1C (p57 Kip2) N33167 </p><p id="p1327" num="1327">4.6161E-07 </p><p id="p1328" num="1328">208747_s_at CIS complement component 1 s subcomponent M18767 4.8744E-07 213150_at HOXA10 homeobox AlO BF792917 4.9645E-07 </p><p id="p1329" num="1329">210155_at YOC myocilin trabecular meshwork inducible glucocorticoid response D88214 5.0664E-07 </p><p id="p1330" num="1330">212558_at SPRYl sprouty homolog 1 antagonist of FGF signaling (Drosophila) BF508662 5.2222E-07 </p><p id="p1331" num="1331">205794_s_at NOVAl neuro-oncological ventral antigen 1 NM_002515 </p><p id="p1332" num="1332">5.5567E-07 </p><p id="p1333" num="1333"> 200785_s_at LOClOOl 34190 similar to low density lipoprotein-related protein 1 Calpha-2-macroglobulin receptor) N _002332 6.7345E 07 </p><p id="p1334" num="1334"> 205422_s_at iTGBLl integrin beta-like 1 (with EGF like repeat domains) </p><p id="p1335" num="1335"> N ._004791 6.8540E-07 </p><p id="p1336" num="1336">204749_at NAP1L3 nucleosome assembly prote n 1-1 ike 3 NM_004538 </p><p id="p1337" num="1337">7.3357E-07 </p><p id="p1338" num="1338">204963_at sarcospan (Kras oncogene-associated gene) AL136756 7.4308E-07 </p><p id="p1339" num="1339">220327_at VGLL3 vestigial like 3 (Drosophila) NM_016206 9.2218E-07 217853_at TNS3 tens n 3 NM_022748 9.6113E-07 </p><p id="p1340" num="1340">213068_at DPT dermatopontin AI146848 9.9396E-07 </p><p id="p1341" num="1341">212944_at SLC5A3 solute carrier family 5 (sodi um/myo-i nosi tol cotransporter) member 3 AK024896 1.0012E-06 
<!-- EPO <DP n="90"/>-->
 Table_C </p><p id="p1342" num="1342"> 209335_at DCN decorin AI281593 1.0494E-06 </p><p id="p1343" num="1343"> 200986_at SERPlNGl serpin peptidase nhibitor clade G (Cl inhibitor) member 1 NM_000062 1.0535E-06 </p><p id="p1344" num="1344"> 201842_s_at EFEMPl EGF-containing fibulin-like extracellular matrix protein 1</p><p id="p1345" num="1345">AI826799 1.1054E-06 </p><p id="p1346" num="1346"> 212224_at ALDHlAl aldehyde dehydrogenase 1 family member Al NM_000689</p><p id="p1347" num="1347">1.1206E-06 </p><p id="p1348" num="1348"> 221950_at EMX2 empty spiracles homeobox 2 AI478455 1.1299E-06</p><p id="p1349" num="1349">203939_at NT5E 5'-nucleotidase ecto (CD73) NM_002526 1.1852E-06</p><p id="p1350" num="1350">217904„s_at BACEl beta-site APP-cleaving enzyme 1 NM_012104 1.2008E-06</p><p id="p1351" num="1351">213568_at 0SR2 odd-skipped related 2 (Drosophila) AI811298 </p><p id="p1352" num="1352"> 1.2131E-06 </p><p id="p1353" num="1353"> 212419_at ZCCHC24 zinc finger CCHC domain containing 24 AA131324 </p><p id="p1354" num="1354"> 1.2940E-06 </p><p id="p1355" num="1355"> 204846_at CP ceruloplasmin (ferroxidase) NM_000096 1.3807E-06</p><p id="p1356" num="1356">203217_s_at ST3GAL5 ST 3 beta-galactoside al pha-23-sialyltransferase 5 </p><p id="p1357" num="1357"> NM_003896 1.4759E-06 </p><p id="p1358" num="1358"> 206373_at ZIC1 zic family member 1 (odd-paired homolog Drosophila)</p><p id="p1359" num="1359">NM_003412 1.4967E-06 </p><p id="p1360" num="1360"> 202897_at SIRPA signal-regulatory protein alpha AB023430 1.6045E-06</p><p id="p1361" num="1361">201787_at LOC100133843 fibulin 1 NM_001996 1.6142E-06 </p><p id="p1362" num="1362"> 218505_at WDR59 WD repeat domain 59 NM_024673 1.6525E-06 </p><p id="p1363" num="1363"> 221019_s_at COLEC12 col lectin sub-family member 12 NM_030781 1.6596E-06</p><p id="p1364" num="1364">201744_s_at LUM lumican NM_002345 1.7389E-06 </p><p id="p1365" num="1365"> 220037_s„at LYVEl lymphatic vessel endothelial hyaluronan receptor 1 </p><p id="p1366" num="1366"> NM_016164 1.7506E-06 </p><p id="p1367" num="1367"> 213429_at BICC1 bi caudal C homolog 1 (Drosophila) AW025579 </p><p id="p1368" num="1368"> 1.7710E-06 </p><p id="p1369" num="1369"> 218901_at PLSCR4 phospholipid scramblase 4 N _020353 1.8289E-06</p><p id="p1370" num="1370">221016_s_at TCF7L1 transcription factor 7-1 ike 1 (τ-cell specific HMG-box)</p><p id="p1371" num="1371">NM_031283 1.8590E-06 </p><p id="p1372" num="1372"> 213800_at CFH complement factor H X04697 2.0989E-06 </p><p id="p1373" num="1373"> 202995_s_at FBLNl fibulin 1 NM_006486 2.1038E-06 </p><p id="p1374" num="1374"> 207977_s_at DPT dermatopontin N _001937 2.1423E-06 </p><p id="p1375" num="1375"> 205612_at MMRNl multimerin 1 NM_007351 2.1544E-06 </p><p id="p1376" num="1376"> 201811_x_at SH3BP5 SH3-domain binding protein 5 (BTK-associated) N _004844</p><p id="p1377" num="1377">2.2599E-06 </p><p id="p1378" num="1378"> 201792_at AEBPl AE binding protein 1 NM_001129 2.2845E-06 </p><p id="p1379" num="1379"> 202664_at iPFl WAS/WASL interacting protein family member 1 AW058622</p><p id="p1380" num="1380">2.3077E-06 </p><p id="p1381" num="1381"> 214494_s_at SPG7 spastic paraplegia 7 (pure and complicated autosomal recessive) NM_005200 2.3371E-06 </p><p id="p1382" num="1382"> 202729_s_at LTBPl latent transforming growth factor beta binding protein 1</p><p id="p1383" num="1383">NM_000627 2.3760E-06 </p><p id="p1384" num="1384"> 201843_s_at EFEMPl EGF-contain ng fibulin-like extracellular matrix protein 1</p><p id="p1385" num="1385">NM_004105 2.4011E-06 </p><p id="p1386" num="1386"> 218418_s_at KANK2 KN motif and ankyri n repeat domains 2 NM_015493 </p><p id="p1387" num="1387"> 2.4190E-06 </p><p id="p1388" num="1388"> 205407_at RECK reversi on-i nduci ng-cyste ne ri ch prote n with kazal moti s</p><p id="p1389" num="1389">N _021111 2.4567E-06 </p><p id="p1390" num="1390"> 210135 s at SHOX2 short stature homeobox 2 AF022654 2.4688E-06</p><p id="p1391" num="1391">?15116_s_at DNMl dynamin 1 AF035321 2.5340E-06 </p><p id="p1392" num="1392"> 221556„at CDC 148 CDC 14 cell divi si on cycle 14 homolog B (S. cerevisiae)</p><p id="p1393" num="1393">BF792631 2.5893E-06 </p><p id="p1394" num="1394"> 205011_at VWA5A von willebrand factor A domain containing A NM_014622</p><p id="p1395" num="1395">2.6449E-06 </p><p id="p1396" num="1396"> 200771_at LAMC1 laminin gamma 1 (formerly LAMB2) NM_002293 </p><p id="p1397" num="1397"> 2.6594E-06 </p><p id="p1398" num="1398"> 203083_at THBS2 thrombospondin 2 NM_003247 2.7220E-06 </p><p id="p1399" num="1399"> 201116_s_at CPE carboxypeptidase E ΑΙ922855 2.7262E-06 </p><p id="p1400" num="1400"> 205802_at TRPCl transient receptor potential cation channel subfamily C member 1 NM_003304 2.7777E-06 </p><p id="p1401" num="1401"> 200945_s_at SEC31A SEC31 homolog A (5. cerevisiae) NM_014933 2.8298E-06 
<!-- EPO <DP n="91"/>-->
 Tab e_C </p><p id="p1402" num="1402"> 203813_s SLIT3 slit homolog ί (Drosophila) NM_003062 2.9973E-06 200784_s. LOC100134190 similar to low density lipoprotein- related protein (alpha-2 globulin receptor) BF304759 3.1301E-06 </p><p id="p1403" num="1403"> 201818_at LPCAT1 lysophosphatidylcholine acyltransferase 1 NM_024830 3.1321E-06 </p><p id="p1404" num="1404"> 205382_s_at CFD complement factor D (adipsin) NM_001928 3.3053E-06 210105_s_at FYN FYN oncogene related to SRC FGR YES M14333 3.3891E-06 221796_at NTRK2 neurotrophic tyrosine kinase receptor type 2 AA707199 3.4378E-06 </p><p id="p1405" num="1405"> 219173_at MY015B myosin XVB pseudogene NM_024957 3.4389E-06 </p><p id="p1406" num="1406"> 218276_s„at SAVl Salvador homolog 1 (Drosophila) N _021818 3.5175E-06 211743_s_at PRG2 proteoglycan 2 Bone marrow (natural killer cell activator eosinophil granule major basic protein) BC005929 3.5818E-06 </p><p id="p1407" num="1407"> 218162_at 0LFML3 olfactomedin-like 3 NM_020190 3.6798Ε-06 </p><p id="p1408" num="1408"> 202202_s_at LAMA4 laminin alpha 4 N _002290 3.6835E-06 </p><p id="p1409" num="1409"> 213249_at FBXL7 F-box and leucine- rich repeat protein 7 AU145127 </p><p id="p1410" num="1410"> 3.7131E-06 </p><p id="p1411" num="1411"> 202220_at KIAA0907 KIAA0907 NM_014949 3.8586E- 06 </p><p id="p1412" num="1412"> 212736_at Cl6orf45 chromosome 16 open reading frame 45 BE299456 3.9881E-06 </p><p id="p1413" num="1413">209550_at NDN necdin homolog (mouse) U35139 4.0364E-06 </p><p id="p1414" num="1414">213422_s_at MXRA8 matrix-remodelling associated 8 AW888223 4.0854E-06 209568_s_at RGLl ral guanine nucleotide dissociation st mulator-like 1 AF186779 4.1032E -06 </p><p id="p1415" num="1415">212713_at MFAP4 microfibrillar-associated protein 4 R72286 4.2791E-06 203131_at PDGFRA platelet-derived growth factor receptor alpha polypeptide ΝΜ_006206 4.2993E <sup>■</sup>06 </p><p id="p1416" num="1416">204140_at TPST1 tyrosylprotei n sulfotransferase 1 NM_003596 </p><p id="p1417" num="1417">4.4001E-06 </p><p id="p1418" num="1418">209265_s_at METTL3 methyl transferase like 3 BC001650 4.6265E- 06 218715_at UTP6 UTP6 small subunit (ssu) processome component homolog</p><p id="p1419" num="1419">(yeast) NM_018428 4.6383E-06 </p><p id="p1420" num="1420">204671_s_at ANKRD6 ankyrin repeat domain 6 BE677131 4.7769E-06 </p><p id="p1421" num="1421">201535_at UBL3 ubi qui tin-like 3 NM_007106 4.8034E-06 </p><p id="p1422" num="1422">218146_at GLT8D1 glycosyl transferase 8 domain containing NM_018446 4.8282E-06 </p><p id="p1423" num="1423"> 204042_at WASF3 WAS protein family member 3 AB020707 4.8795Ε-06 204345_at COL16A1 collagen type xvi alpha 1 NM_001856 4.9731E-06 216033_s_at FYN FYN oncogene related to SRC FGR YES S74774 5.0274E-06 36030_at IFFOI intermediate filament family orphan AL080214 </p><p id="p1424" num="1424">5.0956E-06 </p><p id="p1425" num="1425">218718_at PDGFC platelet derived growth factor c NM_016205 </p><p id="p1426" num="1426">5.1266E-06 </p><p id="p1427" num="1427">203706_s_at FZD7 frizzled homolog 7 (Drosophila) NM_003507 5.4817E-06 219093_at PIDl phosphotyrosine interaction domain containing 1 N _017933 5.7633E-06 </p><p id="p1428" num="1428">203583_at UNC50 unc-50 homolog (C elegans) NM_014044 5.7712E-06 205609_at ANGPTl angiopoietin 1 NM_001146 5.7795E 06 </p><p id="p1429" num="1429">204457_s_at GAS1 growth arrest-specific 1 NM_002048 5.7891E- 06 205083_at AOXl aldehyde oxidase 1 NM_001159 5.9671E-06 </p><p id="p1430" num="1430">203812_at null AB011538 6.2204E-06 </p><p id="p1431" num="1431">212621_at T EM194A transmembrane protein 194A AB006624 </p><p id="p1432" num="1432">6.3362E-06 </p><p id="p1433" num="1433">206404_at FGF9 fibroblast growth factor 9 (g a-activat ng factor) </p><p id="p1434" num="1434">NM_002010 6.5054E-06 </p><p id="p1435" num="1435">204606_at CCL21 chemok ne (C-C motif) ligand 21 N _002989 6.5807E-06 201117„s__at CPE carboxypeptidase E NM_001873 6 8179E-06 </p><p id="p1436" num="1436">213802_at null AI810767 7.0439E-06 </p><p id="p1437" num="1437"> 212486_s_at FYN FYN oncogene related to SRC FGR YES N20923 7.2524E-06 201278_at DAB2 disabled homolog 2 m togen- responsive phosphoprotein (Drosophila) N21202 7.7092E-06 </p><p id="p1438" num="1438">218656_s_at LHFP l poma HMGIC fusion partner NM_005780 7.9930E-06 212230_at PPAP2B phosphatidi c aci d phosphatase type 2B AV725664 
<!-- EPO <DP n="92"/>-->
 Table<sub>^</sub>c </p><p id="p1439" num="1439"> 8.1114E-06 </p><p id="p1440" num="1440"> 221760_at MANlAl CDNA: FLJ21946 f i s clone HEP04860 highly similar to HSHUM 9 Homo sapiens HUMM9 m NA BG287153 8.1833E-06 </p><p id="p1441" num="1441"> 210139_s„at PMP22 peripheral myelin protein 22 L03203 8.8249E-06 </p><p id="p1442" num="1442"> 212877_at LCl kinesin light chain 1 AA284075 9.1329E-06 </p><p id="p1443" num="1443"> 217767_at C3 complement component 3 NM_000064 9.1495E-06 </p><p id="p1444" num="1444"> 212503_s_at DIP2C DIP2 disco-interacting protein 2 homolog C (Drosophila) N22859 9.3817E<sup>•</sup>06 </p><p id="p1445" num="1445"> 218204_s_at FYCOl FYVE and co 1 ed-coi 1 domain containing 1 NM_024513 9.6526E-06 </p><p id="p1446" num="1446"> 212793_at DAAM2 dishevelled associated activator of morphogenesis 2 </p><p id="p1447" num="1447"> BF513244 1.0235E-05 </p><p id="p1448" num="1448"> 202920_at AN 2 ankyrin 2 neuronal BF726212 1.0636E-05 </p><p id="p1449" num="1449"> 203476_at TPBG trophoblast glycoprotein NM_006670 1.0681E-05 217122_s_at LOC728661 similar to solute carrier family 35 member E2 AL031282 1.0828E-05 </p><p id="p1450" num="1450">211896_s_at DCN decorin AF138302 1.0835E-05 </p><p id="p1451" num="1451">204453_at ZNF84 zinc finger protein 84 NM_003428 1.0897E-05 </p><p id="p1452" num="1452">211535_s_at FGFR1 fibroblast growth factor receptor 1 M60485 1.1017E-05 211548_s_at HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) 305594 </p><p id="p1453" num="1453">1.1089E-05 </p><p id="p1454" num="1454">213880_at LGR5 leucine-rich repeat-containing G protein-coupled receptor 5 AL524520 1.1094E-05 </p><p id="p1455" num="1455">202273_at PDGFRB platelet-derived growth factor receptor beta polypeptide NM_002609 1.1180E-05 </p><p id="p1456" num="1456">207808_s_at PROSl protein S (alpha) NM_000313 1.1272E-05 </p><p id="p1457" num="1457">220744_s_at IFT122 intraflagellar transport 122 homolog (Chlamydomonas) NM_018262 1.2426E-05 </p><p id="p1458" num="1458">205542_at STEAPl six transmembrane epithelial antigen of the prostate 1 N _012449 1.2639E-05 </p><p id="p1459" num="1459">205933_at SETBPl SET binding protein 1 NM_015559 1.2646E-05 </p><p id="p1460" num="1460">214323_s_at UPF3A UPF3 regulator of nonsense transcripts homolog A (yeast)</p><p id="p1461" num="1461">N36842 1.2818E-05 </p><p id="p1462" num="1462"> 212597_s_at HMGXB4 HMG box domain containing 4 AL079310 1.2979E-05</p><p id="p1463" num="1463">204112_s_at HNMT histamine N-methyl transferase NM_006895 1.3109E-05</p><p id="p1464" num="1464">213652_at PCS 5 Protease PC6 isoform A (PCSK5) AU152579 1.3167E-05</p><p id="p1465" num="1465">215388_s_at CFH complement factor H X56210 1.3176E-05 </p><p id="p1466" num="1466"> 204036_at L ARl lysophosphatidic acid receptor L AW269335 </p><p id="p1467" num="1467"> 1.3211E-05 </p><p id="p1468" num="1468"> 209884_s_at SLC4A7 solute carrier family 4 sodium bicarbonate cotransporter member 7 AF047033 1.4144E-05 </p><p id="p1469" num="1469"> 205452_at PIGB phosphatidyl inositol glycan anchor biosynthesis class B</p><p id="p1470" num="1470">NM_004855 1.4354E-05 </p><p id="p1471" num="1471"> 207177_at PTGFR prostaglandin F receptor (FP) NM_000959 1.4808E-05</p><p id="p1472" num="1472">219059_s_at LYVEl lymphatic vessel endothelial hyaluronan receptor 1 </p><p id="p1473" num="1473"> AL574194 1.4902E-05 </p><p id="p1474" num="1474"> 201150_s_at TIMP3 TIMP metal lopeptidase inhibitor 3 NM_000362 </p><p id="p1475" num="1475"> 1.4957E-05 </p><p id="p1476" num="1476"> 200770__s_at LA Cl laminin gamma 1 (formerly LAMB2) 303202 1.5246E-05</p><p id="p1477" num="1477">212327 ci"t LlMCHl LIM and calponin homology domains AK026815 </p><p id="p1478" num="1478"> 1.6143E-05 </p><p id="p1479" num="1479"> 206958_s„at UPF3A UPF3 regulator of nonsense transcripts homolog A (yeast)</p><p id="p1480" num="1480">AF318575 1.6235E-05 </p><p id="p1481" num="1481"> 39650_s_at PCNXL2 pecanex-l ke 2 (Drosophila) AB007895 1.6512E-05</p><p id="p1482" num="1482">207417_s_at ZNF177 zinc finger protein 177 NM_003451 1.6676E-05 </p><p id="p1483" num="1483"> 213293_s_at TRI 22 tripartite motif-containing 22 AA083478 1.6798E-05</p><p id="p1484" num="1484">218686_s_at RHBDFl rhomboid 5 homo log 1 (Drosophila) NM_022450 </p><p id="p1485" num="1485"> 1.7255E-05 </p><p id="p1486" num="1486"> 212195_at IL6ST interleukin 6 signal transducer (gpl30 oncostatin M receptor) AL049265 1.7471E-05 </p><p id="p1487" num="1487"> 202598_at S100A13 S100 calcium binding protein A13 NM_005979 </p><p id="p1488" num="1488"> 1.7872E-05 </p><p id="p1489" num="1489"> 203893_at TAF9 TAF9 RNA polymerase II TATA box binding protein 
<!-- EPO <DP n="93"/>-->
 Tabl e_C </p><p id="p1490" num="1490"> (TBP) -associated factor 32kDa NM_016283 1. 7916E 05 </p><p id="p1491" num="1491"> 218093_s__at ANKRDlO ankyrin repeat domain 10 NM_017664 1. 8440E-05 216840_s_at LA A2 laminin alpha 2 AK026829 1.8901E-05 </p><p id="p1492" num="1492"> 219552_at SVEPl sushi von willebrand factor type A EGF and pentraxin domain containing 1 NM_024500 1. 9057E-05 </p><p id="p1493" num="1493"> 203914_x_at HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) NM__000860 1 . 9929E-05 </p><p id="p1494" num="1494"> 218793„s_at SCMLl sex comb on midleg-like 1 (Drosophila) N _006746 </p><p id="p1495" num="1495"> 2.0086E-05 </p><p id="p1496" num="1496"> 209612_s_at ADHlB alcohol dehydrogenase IB (class I) beta polypeptide </p><p id="p1497" num="1497"> M24317 2.0211E-05 </p><p id="p1498" num="1498"> 209580_s_at MBD4 methyl -cpG binding domain protein 4 AF114784 </p><p id="p1499" num="1499"> 2.0320E-05 </p><p id="p1500" num="1500"> 221897_at TRIM52 tripartite motif-containing 52 AA205660 2.0818E-05</p><p id="p1501" num="1501">21928 _at ClGALTlCl ClGALTl-specific chape rone 1 NM_014158 </p><p id="p1502" num="1502"> 2 . 1265 E-05 </p><p id="p1503" num="1503"> 202478_at TRIB2 tribbles homolog 2 (Drosophila) N _021643 2.1280E-05</p><p id="p1504" num="1504">214703_s_at MAN2B2 mannosidase alpha class 2B member 2 AW954107 </p><p id="p1505" num="1505"> 2.1437E-05 </p><p id="p1506" num="1506"> 59375„at MY015B myosin XVB pseudogene AI825877 2.1605E-05 </p><p id="p1507" num="1507"> 204719_at ABCA8 ATP-binding cassette sub-family A (ABCl) member 8 </p><p id="p1508" num="1508"> NM_007168 2.1721E- 05 </p><p id="p1509" num="1509"> 211675_s_at MDFIC MyoD family inhibitor domain containing AF054589 </p><p id="p1510" num="1510"> 2.1807E-05 </p><p id="p1511" num="1511"> 213161_at c9orf97 chromosome 9 open reading frame AI583393 </p><p id="p1512" num="1512"> 2.2081E-05 </p><p id="p1513" num="1513"> 202951_at ST 38 serine/threonine kinase 38 BE048506 2.2195E-05</p><p id="p1514" num="1514">213519_s_at LA A2 laminin alpha 2 AI078169 2.2351E-05 </p><p id="p1515" num="1515"> 209409_at GRB10 growth factor receptor-bound protein 10 D86962 2.2881E-05</p><p id="p1516" num="1516">201034_at ADD3 adducin 3 (gamma) BE545756 2.3091E-05 </p><p id="p1517" num="1517"> 206227_at CILP cartilage intermediate layer protein nucleotide </p><p id="p1518" num="1518">pyrophosphohydrol ase NM_003613 2.3220E-05 </p><p id="p1519" num="1519"> 212651_at RHOBTBl Rho-related BTB domain containing AB018283 </p><p id="p1520" num="1520">2 . 3246E-05 </p><p id="p1521" num="1521">215016_x_at DST dystonin BC004912 2.3884E-05 </p><p id="p1522" num="1522">212958_x_at PAM peptidyl glycine al pha-ami dati ng monooxygenase AI022882 2.4348E-05 </p><p id="p1523" num="1523">219949_at LRRC2 leucine rich repeat containing 2 NM_024512 </p><p id="p1524" num="1524">2. 4451E-05 </p><p id="p1525" num="1525">219639_x_at PARP6 poly (ADP-ribose) polymerase family member 6 NM_020213 2.4585E-05 </p><p id="p1526" num="1526">220992_s_at Clorf25 chromosome 1 open reading frame 25 NM_030934 </p><p id="p1527" num="1527">2.4860E-05 </p><p id="p1528" num="1528">203600_s_at C4orf8 chromosome 4 open reading frame 8 N _003704 </p><p id="p1529" num="1529">2.5273E-05 </p><p id="p1530" num="1530">219729_at PRRX2 paired related homeobox 2 NM_016307 2.5432E-05 212855_at DCUN1D4 DCNl defective in cull in neddyl ati on 1 domain containing 4 (S. cerev si ae) D87466 2.5564E-05 </p><p id="p1531" num="1531">212328_at LI CHl LIM and cal poni n homo ogy domains 1 AB029025 </p><p id="p1532" num="1532">2.6031E-05 </p><p id="p1533" num="1533">201395_at RB 5 RNA b nd ng motif protein 5 NM. .005778 2.6282E- 05 203139_at DAPK1 death-associated protei n kinase 1 NM_004938 </p><p id="p1534" num="1534">2.6335E-05 </p><p id="p1535" num="1535">222043_at CLU c usteri n AI982754 2.6684E-05 </p><p id="p1536" num="1536">203886„s_at FBLN2 fibulin 2 NM_001998 2.7202E-05 </p><p id="p1537" num="1537">212979„s_at FAM115A famil with sequence similarity 115 member AW293343 2.7293E-05 </p><p id="p1538" num="1538">209220_at GPC3 glypican 3 I 47125 2.7421E-05 </p><p id="p1539" num="1539">212148_at PBXl pre-B-cell leukemia homeobox 1 AL049381 2.7560E-05 202142_at COPS8 COP9 constitutive photoniorphogen c homolog subunit 8 </p><p id="p1540" num="1540">(Arabidopsis) BC003090 2.7754E-05 </p><p id="p1541" num="1541">22223 5_s_at CSGALNACT2 chondro tin su fate </p><p id="p1542" num="1542"> N-acetyl gal actosami nyl transfe rase 2 2.8031E-05 
<!-- EPO <DP n="94"/>-->
 Table_C </p><p id="p1543" num="1543"> 212764_at ZEBl zinc finger E-box binding homeobox 1 AI806174 </p><p id="p1544" num="1544"> 2.8104E-05 </p><p id="p1545" num="1545"> 2147 9_s_at AR CX6 armadillo repeat containing x-1 inked 6 AK000818 </p><p id="p1546" num="1546"> 2.8574E-05 </p><p id="p1547" num="1547"> 201944_at HEXB hexosaminidase B (beta polypeptide) NM_000521 </p><p id="p1548" num="1548"> 2.8860E<sup>^</sup>05 </p><p id="p1549" num="1549"> 205515_at PRSS12 protease serine 12 (neurotrypsin motopsin) NM_003619 2.8866E-05 </p><p id="p1550" num="1550"> 213698_at LOC100130633 similar to ZMYM6 protein AI805560 </p><p id="p1551" num="1551"> 2.8874E-05 </p><p id="p1552" num="1552"> 203824_at TSPAN8 tetraspanin 8 NM_004616 2 . 9175 E-05 </p><p id="p1553" num="1553"> 203117_s_at PA 2 PA 2 poly(A) specific ribonuc ease subunit homolog (S. cerevi siae) N _014871 3 . 0053 E-05 </p><p id="p1554" num="1554"> 204605_at CGRRFl cell growth regulator with ring finger domain 1 NM_006568 3 . 0162 E-05 </p><p id="p1555" num="1555"> 219778_at ZFPM2 zinc finger protein multitype 2 NM_012082 3. 0400E-05 217892_s_at LlMAl LIM domain and actin binding 1 NM_016357 3. 0815 E-05 212681_at EPB41L3 erythrocyte membrane protein band 4.1-like 3 AI770004 3.0884E-05 </p><p id="p1556" num="1556">204085_s_at CLN5 ceroid-lipofuscinosis neuronal 5 NM_006493 </p><p id="p1557" num="1557">3 . 0907E-05 </p><p id="p1558" num="1558">210102_at VWA5A von willebrand factor A domain containing 5A BC001234 3.0936E-05 </p><p id="p1559" num="1559">220351_at CCRLl chemokine (c-C motif) receptor-like 1 NM_016557 </p><p id="p1560" num="1560">3.1140E-05 </p><p id="p1561" num="1561">210406_s_at RAB6A RAB6A member RAS oncogene family AL136727 </p><p id="p1562" num="1562">3 . 1167E-05 </p><p id="p1563" num="1563">221569_at AHI1 Abel son helper integration site 1 AL136797 </p><p id="p1564" num="1564">3 . 1574E-05 </p><p id="p1565" num="1565">219550_at R0B03 roundabout axon guidance receptor homolog 3 (Drosophila) NM_022370 3.1855E-05 </p><p id="p1566" num="1566">200762_at DPYSL2 dihydropyrimidinase-like 2 N _001386 3.1884E-05 201086_x_at SON SON DNA binding protein NM_003103 3.2222E-05 </p><p id="p1567" num="1567">218285_s_at BDH2 3-hydroxybutyrate dehydrogenase type 2 NM_020139 </p><p id="p1568" num="1568">3 . 2876E-05 </p><p id="p1569" num="1569">213397_x_at RNASE4 ribonuclease RNase A family 4 AI 761728 3 . 3089E-05 219908_at DKK2 dickkopf homolog 2 (xenopus laevis) NM_014421 </p><p id="p1570" num="1570">3 . 4237E-05 </p><p id="p1571" num="1571">213262_at SACS spastic ataxia of Charlevoix-Saguenay (sacsin) AI932370 3 . 4386E-05 </p><p id="p1572" num="1572">208944_at TGFBR2 transforming growth factor beta receptor II (70/80kDa) D50683 3.4404E-05 </p><p id="p1573" num="1573">209946_at VEG vascular endothelial growth factor C U58111 3.4474E-05 219700_at PLXDCl plexin domain containing 1 NM_020405 3.4923E-05 213737_x_at G0LGA9P golgi autoantigen golgin subfamily a 9 pseudogene </p><p id="p1574" num="1574">AI620911 3.5009E-05 </p><p id="p1575" num="1575">201669_s_at MARCKS myri stoyl ated alanine-rich protein kinase C substrate NM_002 56 3.5037E-05 </p><p id="p1576" num="1576">204897_at PTGER4 prostagland n E receptor 4 (subtype EP4) AA897516 3.5257E-05 </p><p id="p1577" num="1577">220642_x_at GPR89B G protein-coupled receptor 89A NM_016334 3.5976E-05 206159_at GDF10 g owth differentiation factor 10 N.v_004962 </p><p id="p1578" num="1578">3.6140E-05 </p><p id="p1579" num="1579">201798_s_at MYOF myoferlin NM_013451 3.7082E-05 </p><p id="p1580" num="1580">215000_s_at FEZ2 fasciculation and elongation protein zeta 2 (zygin II) AL117593 3.7115E-05 </p><p id="p1581" num="1581">212985_at APBB2 amyloid beta (A4) precursor protei n-bi ndi ng fami ly B member 2 BF115739 3.7441E-05 </p><p id="p1582" num="1582"> 209101_at CTGF connective tissue growth factor M92934 3.7465E-05 </p><p id="p1583" num="1583"> 22144 „s_at GLT8D2 glycosyltransferase 8 domain containing 2 NM_031302</p><p id="p1584" num="1584">3.7495E-05 </p><p id="p1585" num="1585"> 218303_x_at KRCC1 lysine- rich coiled-coil 1 N _016618 3.7642E-05 203241_at UVRAG uv radiation resistance associated gene NM 003369 
<!-- EPO <DP n="95"/>-->
 Table_c </p><p id="p1586" num="1586"> 3.7762E-05 </p><p id="p1587" num="1587"> 209659_s_at CDC16 cell division cycle 16 homolog (S. cerevisiae) AF164598 3.8581E-05 </p><p id="p1588" num="1588"> 216321_s_at NR3C1 nuclear receptor subfamily 3 group C member 1 </p><p id="p1589" num="1589"> (glucocorticoid receptor) X03348 3.8658E-05 </p><p id="p1590" num="1590"> 201063_at RCNl reticulocalbin 1 EF-hand calcium binding domain N _002901</p><p id="p1591" num="1591">3.8695E-05 </p><p id="p1592" num="1592"> 202304_at FNDC3A fibronectin type ill domain containing 3A NM_014923 3.9178E-05 </p><p id="p1593" num="1593"> 206484_s_at XPNPEP2 x-prolyl aminopeptidase (aminopeptidase P) 2 membrane-bound NM_003399 3.9464E-05 </p><p id="p1594" num="1594"> 210312_s<sub>^</sub>_at IFT20 intraflagellar transport 20 homolog (Chlamydomonas) </p><p id="p1595" num="1595"> BC002640 4.0492E-05 </p><p id="p1596" num="1596"> 220065_at TN D tenomodulin NM_022144 4.0580E-05 </p><p id="p1597" num="1597"> 209356_x_at EFEMP2 EGF-containing fibulin-li ke extracellular matrix protein 2 AB030655 4.0584E-05 </p><p id="p1598" num="1598"> 2023 6_s_at PAM peptidy glycine alpha-ami dating monooxygenase NM_000919 4.0770E-05 </p><p id="p1599" num="1599"> 208669_s_at EIDl EP300 interacting inhibitor of differentiation 1 </p><p id="p1600" num="1600">AF109873 4.1682E-05 </p><p id="p1601" num="1601"> 202446_s_at PLSCRl phospholipid scramblase 1 AI825926 4.1757E-05 209497_s_at RBM4B RNA binding motif protein 4B BC003503 4.1986E-05 201139_s_at SSB Sjogren syndrome antigen B (autoantigen La) NM_003142 4.2098E-05 </p><p id="p1602" num="1602"> 212169__at F BP9 FK506 binding protein 9 63 kDa AL050187 4.2116E-05 201753_s_at ADD 3 adducin 3 (gamma) NM_019903 4.2645E-05 </p><p id="p1603" num="1603">217525_at OLF Ll olfactomedin-like 1 AW305097 4.2856E-05 </p><p id="p1604" num="1604">218616_at INTS12 integrator complex subunit 12 NM_020395 4.3996E-05 205100_at GFPT2 glutamine-fructose-6-phosphate transaminase 2 NM_005110 4.4073E-05 </p><p id="p1605" num="1605">218801_at UGCGL2 UDP-glucose ceramide glucosyltransferase-like 2 NM_020121 4.4535E-05 </p><p id="p1606" num="1606">201398_s_at TRAMl translocation associated membrane protein 1 BC000687 4.4699E-05 </p><p id="p1607" num="1607">213455_at FAM114A1 family with sequence similarity 114 member Al W87466 4.4874 </p><p id="p1608" num="1608">219493_at SHCBPl SHC SH2-domain binding protein 1 N _024745 </p><p id="p1609" num="1609">4.5019E-05 </p><p id="p1610" num="1610">219073_s_at OSBPL10 oxysterol binding protein-like 10 NM_017784 </p><p id="p1611" num="1611">4.5703E-05 </p><p id="p1612" num="1612">216044_x_at FA 69A family with sequence similarity 69 member A AK027146 4.6409E-05 </p><p id="p1613" num="1613">208986_at TCF12 transcription factor 12 AL559478 4.6942E-05 </p><p id="p1614" num="1614">205792_at WISP2 WNTl inducible signaling pathway protein 2 NM_003881 4.7104E-05 </p><p id="p1615" num="1615">204735_at PDE4A phosphodiesterase 4A cA P-specific (phosphodiesterase E2 dunce homolog Drosophila )) NNMM„„000066220022 44..77115533EE--0055 </p><p id="p1616" num="1616"> 202382_s_at GNPDAl gl ucosami ne-6-phosphate deaminase 1 NM_005471 </p><p id="p1617" num="1617">4.7273E-05 </p><p id="p1618" num="1618">214434.at HSPA12A heat shock 70kDa protein 12A ΑΒ007877 4.8185E-05</p><p id="p1619" num="1619">211864_s_at MYOF myoferlin AF207990 4.9709E-05 </p><p id="p1620" num="1620">211719_x„at FN1 fibronectin 1 BC005858 5.0797E-05 </p><p id="p1621" num="1621">205728_at null AL022718 5.1523E-05 </p><p id="p1622" num="1622"> GALNT12 UDP-N-acetyl -al pha-D-gal actosami ne : pol ypepti d</p><p id="p1623" num="1623">N-ace tyl gal actosaminyl transferase 12 (GalNAc-Tl2) NM_024642 5.1829E-05</p><p id="p1624" num="1624">218076_s_at ARHGAP17 Rho GTPase acti vati ng protein 17 NM„018054</p><p id="p1625" num="1625">5.2424E-05 </p><p id="p1626" num="1626"> 217792_at SNX5 sorting nexin 5 NM_014426 5.2561E-05 </p><p id="p1627" num="1627"> 212779_at KIAA1109 KIAA1109 AB029032 5.2993E-05 </p><p id="p1628" num="1628"> 212254_s_at DST dystonin AI798790 5.3772E-05 </p><p id="p1629" num="1629"> 202863_at SP100 SP100 nuclear antigen NM_003113 5.4231E-05 </p><p id="p1630" num="1630"> 218084_x_at FX YD5 FXYD domain contai ning ion transport regul ator 5 </p><p id="p1631" num="1631"> NM_014164 5.4271E-05 
<!-- EPO <DP n="96"/>-->
 Table_C </p><p id="p1632" num="1632"> 205573_s_at SNX7 sorting nexin 7 NM_015976 5.4748E-05 </p><p id="p1633" num="1633"> 221020_s_at SLC25A32 solute carrier family 25 member 32 NM_030780</p><p id="p1634" num="1634">5.5194E-05 </p><p id="p1635" num="1635"> 202104_s_at SPG7 spastic paraplegia 7 (pure and complicated autosomal recessi e) NM_003119 5.5970E-05 </p><p id="p1636" num="1636"> 201780_s„at RNF13 ring finger protein 13 NM„007282 5.6181E-05 </p><p id="p1637" num="1637"> 204093_at CCNH cyclin H N _001239 5.6217E-05 </p><p id="p1638" num="1638"> 208016_s_at AGTRl angiotensin II receptor type 1 NM_004835 5.6967E-05</p><p id="p1639" num="1639">221773_at EL 3 EL 3 ETS-domain protein (SRF accessory protein 2) mRNA (CDNA clone MGC:13551 IMAGE : 4287696) AW575374 5.7036E-05 </p><p id="p1640" num="1640"> 213392_at IQCK IQ motif containing κ AW070229 5.7402E -05 </p><p id="p1641" num="1641"> 212 98_s_at AN MY2 ankyrin repeat and MYND domain containing 2 AK001389</p><p id="p1642" num="1642">5.7754E-05 </p><p id="p1643" num="1643"> 221645_s_at ZNF83 zinc finger protein 83 27877 5.9654E-05 </p><p id="p1644" num="1644"> 218999_at TMEM140 transmembrane protein 140 NM_018295 5.9756E-05</p><p id="p1645" num="1645">203799_at CD302 CD302 molecule NM_014880 5.9942E-05 </p><p id="p1646" num="1646"> 214093_s_at FUBPl far upstream element (FUSE) binding protein 1 AA156865</p><p id="p1647" num="1647">6.0566E-05 </p><p id="p1648" num="1648"> 202958_at PTPN9 protein tyrosine phosphatase non-receptor type 9 </p><p id="p1649" num="1649"> NM_002833 6.1062E-05 </p><p id="p1650" num="1650"> 203903_s„at HEPH hephaestin NM_014799 6.1829E-05 </p><p id="p1651" num="1651"> 210495_x_at FNl fibronectin 1 AF130095 6.1983E-05 </p><p id="p1652" num="1652"> 218007_s_at RPS27L ribosomal protein S27- ike NM_015920 6.2147E-05</p><p id="p1653" num="1653">205139_s_at UST uronyl-2-sulfotransferase NM_005715 6.2337E-05 
<!-- EPO <DP n="97"/>-->
</p><p id="p1654" num="1654">Tab e_D </p><p id="p1655" num="1655"> Probe set ID Gene Symbol Gene Name Representati e Public ID </p><p id="p1656" num="1656"> value </p><p id="p1657" num="1657"> 212291_at HIPKI homeodomain interacting protein kinase 1 AI393355 1 . 4712 E-08 </p><p id="p1658" num="1658"> 205187_at S AD5 SMAD fam ly member 5 AF010601 2 . 3661E-08 </p><p id="p1659" num="1659"> 216022_at null AL049278 1 . 5264E-07 </p><p id="p1660" num="1660"> 211074_at FOLR1 folate receptor 1 (adult) AF000381 2. 3573 E-07 208711_s_at CCNDl cyclin Dl BC000076 2.4510E-07 </p><p id="p1661" num="1661"> 214265_at ITGA8 integrin alpha 8 AI193623 3.5683E-07 </p><p id="p1662" num="1662"> 202102_s_at BRD4 bromodomain containing 4 BF718610 4. 5386E-07 222024_s_at A AP13 A kinase (PRKA) anchor protein 13 AK022014 </p><p id="p1663" num="1663"> 6 . 873 7E-07 </p><p id="p1664" num="1664"> 210717_at null AF116659 .8389E-07 </p><p id="p1665" num="1665"> 211081_s_at MAP4 5 mitogen-<sup>■</sup>activated protein kinase kinase kinase kinase 5 Z25426 1. 0560E -06 </p><p id="p1666" num="1666"> 215024_at c7orf28B chromosome 7 open reading frame A 000993 1. 0617E-06 </p><p id="p1667" num="1667"> 209936_at RBM5 RNA binding motif protein 5 AF107493 1.2081E-06 206061_s_at DICERl dicer 1 ribonuclease type in N _030621 1 . 5719 E-06 217649_at ZFAND5 zinc finger ANl-type domain 5 AV702306 1.6384E-06 216858_x_at null AL080112 2.8178E- 06 </p><p id="p1668" num="1668"> 220071_x_at CEP27 centrosomal protein 27kDa NM_018097 2.8584E-06 216187_x_at null AF222691 2.8639E- 06 </p><p id="p1669" num="1669"> 214041_x_at RPL37A Ribosomal protein L37a BE857772 2.9005E-06 </p><p id="p1670" num="1670"> 209088_s_at UBNl ubinuclein 1 T70262 3.0772E-06 </p><p id="p1671" num="1671"> 210807_s_at SLC16A7 solute carrier family 16 member 7 (monocarboxylic acid transporter 2) AF049608 3.7623E-06 </p><p id="p1672" num="1672">214153_at ELOVL5 ELOVL family member 5 elongation of long chain fatty acids (FENl/Elo2 SUR4/Elo3-like yeast) BE467941 3.8401E-06 </p><p id="p1673" num="1673">212057_at KIAA0182 KIAA0182 AA206161 3.8589E-06 </p><p id="p1674" num="1674">213718_at RB 4 RNA binding motif protein 4 BE222257 3.9440E-06 207291_at PRRG4 proline rich Gla (G-carboxygl utamic acid) 4 (transmembrane) NM_024081 4.4222E-06 </p><p id="p1675" num="1675">203742_s_at LOC645233 thymine-DNA glycosylase pseudogene BF674842 4.5161E-06 </p><p id="p1676" num="1676">221943_x_at RPL38 Ribosomal protein i_38 mRNA (CDNA clone MGC </p><p id="p1677" num="1677">IMAGE .-3346447) A 303136 4.7760E-06 </p><p id="p1678" num="1678">204881_s_at UGCG UDP-glucose ceramide glucosyl transferase NM_003358 4. 9560E-06 </p><p id="p1679" num="1679">206036_s_at REL v-rel reticuloendotheliosis vi al oncogene homolog (avi NM_002908 5.0576E 06 </p><p id="p1680" num="1680">202940_at WNKl KIAA0344 gene NM_014823 5.0700E- 06 </p><p id="p1681" num="1681">217538_at SGSM2 small G protein signaling modulator 2 BF347113 </p><p id="p1682" num="1682">5.3480E-06 </p><p id="p1683" num="1683">212492_s_at 3MJD2B jumonji domain containing 2B AW237172 5.3779E-06 211503_s_at RAB14 RAB14 member RAS oncogene family AF112206 </p><p id="p1684" num="1684">6.0532E-06 </p><p id="p1685" num="1685">203803_at PCYOXl prenyl cyste ne oxidase 1 N45309 6.5416E-06 </p><p id="p1686" num="1686">211993_at WNKl WNK lysine deficient protein kinase 1 AI768512 </p><p id="p1687" num="1687">6.7386E-06 </p><p id="p1688" num="1688">202040_s_at JARlDlA jumonji AT rich interactive domain 1A NM_005056 </p><p id="p1689" num="1689">6.7560E-06 </p><p id="p1690" num="1690">214807_at null AI278204 7.1860E -06 </p><p id="p1691" num="1691">201195_s_at SLC7A5 solute carrier family 7 (cati oni c amino ac d transporter system) member 5 AB018009 7.2298E-06 </p><p id="p1692" num="1692">213517_at PCBP2 poly(rc) bi ndi ng protei n 2 AW103422 7.3423E-06 201299_s_at MOBKLIB MOBl Mps One Binder kinase activator-like IB (yeast) NM_018221 7.3742E -06 </p><p id="p1693" num="1693">63825__at ABHD2 abhydrolase domain containing 2 AI557319 7.6414E-06 214902_x_at null AL080232 7.8481E-06 </p><p id="p1694" num="1694">221664_s_at FllR Fll receptor AF154005 8.1916E-06 </p><p id="p1695" num="1695">212659_s_at ILlRN inter! eukin 1 receptor antagonist AW083357 </p><p id="p1696" num="1696">8.3955E-06 
<!-- EPO <DP n="98"/>-->
 Table_D </p><p id="p1697" num="1697"> 219024_at PLEKHAI pl eckst ri n homo l ogy domai n contai ni ng fami l y A </p><p id="p1698" num="1698"> Cphosphoi nosi ti de bi ndi ng speci fi c) member 1 NM_021622 8.6942E-06 </p><p id="p1699" num="1699"> 204524_at PDPKl 3-phosphoi nosi ti de dependent p rotei n ki nase-1 NM_002613 9.1327E-06 </p><p id="p1700" num="1700"> 203318_s„at ZNF148 zinc finger protein 148 NM_021964 9.1431E-06 </p><p id="p1701" num="1701"> 213229_at DICERI dicer 1 ribonuclease type III BF590131 9.7278E-06 214422_at LOC131185 similar to RAD23B protein T93562 9.7480E-06 209945_s_at GSK3B glycogen synthase kinase 3 beta BC000251 1.0201E-05 205 22_s_at MTF1 metal-regulatory transcription factor 1 AW182367 </p><p id="p1702" num="1702"> 1.O323E-05 </p><p id="p1703" num="1703"> 204181_s_at ZBTB43 zinc finger and BTB domain containing 43 T90308 1.0792E-05 </p><p id="p1704" num="1704"> 203321_s_at ADNP2 ADNP homeobox 2 AK022688 1.1043E-05 </p><p id="p1705" num="1705">201901_s_at YYl YYl transcription factor Z14077 1.1154E-05 </p><p id="p1706" num="1706">212525_s_at H2AFX H2A histone family member x AA760862 1.1321E-05 201917_s_at SLC25A36 solute carrier family 25 member 36 AI694452 1.1789E-05 </p><p id="p1707" num="1707">211337_s_at TUBGCP4 tubulin gamma complex associated protein 4 BC000966 1.1823E-05 </p><p id="p1708" num="1708">215179_x_at PGF Placenta growth factor 2 (PlGF-2) AK023843 </p><p id="p1709" num="1709">1.2046E-05 </p><p id="p1710" num="1710">205967_at HIST1H4A histone cluster 1 H4a NM_003542 1.2155E-05 210943_s_at LYST lysosomal trafficking regulator U84744 1.2287E-05 </p><p id="p1711" num="1711">221753_at SSHl slingshot homolog 1 (Drosophila) AI651213 </p><p id="p1712" num="1712">1.2405E-05 </p><p id="p1713" num="1713">221705_s_at SI E suppressor of IKK epsilon BC005934 1.3958E-05 215892_at ZNF440 zinc finger protein 440 mRNA (CDNA clone MGC:46665 </p><p id="p1714" num="1714">IMAGE: 5556302) AK021474 1.4065E-05 </p><p id="p1715" num="1715">208624_s_at EIF4G1 eukaryotic translation initiation factor 4 gamma 1 </p><p id="p1716" num="1716">BE966878 1.4201E-05 </p><p id="p1717" num="1717">208610_s_at SRRM2 seri ne/argi ni ne repetitive matrix 2 AI655799 </p><p id="p1718" num="1718">1.4389E-05 </p><p id="p1719" num="1719">222366_at null W86781 1.4392E-05 </p><p id="p1720" num="1720">220085_at HELLS helicase lymphoid-speci ic NM_018063 1.4498E-05 207657_x_at TNPOl transport! n 1 NM_002270 1.4524E-05 </p><p id="p1721" num="1721">214815_at TRI 33 tripartite motif-containing 33 AU136587 1.5331E-05 212520_s_at SMARCA4 swi/SNF related matrix associated actin dependent regulator of chromatin subf<sup>"</sup>amily a member 4 AI684141 1.5496E-05 </p><p id="p1722" num="1722">221986_s_at KLHL24 kelch-like 24 (Drosophila) AW006750 1.5586E-05 217007_s_at ADAM15 ADAM metall opepti dase domain 15 AK000667 1.5851E-05</p><p id="p1723" num="1723">210479_s_at RORA RAR-related orphan receptor A L14611 1.6006E-05 </p><p id="p1724" num="1724">20402l_s_at PURA purine- rich element binding protein A NM_005859 </p><p id="p1725" num="1725">1.7428E-05 </p><p id="p1726" num="1726"> 220572_at DKFZp547Gl83 hypothetical LOC55525 NM_018705 1.8600E-05</p><p id="p1727" num="1727">206462_s_at NTRK3 neurotrophic tyrosine kinase receptor type 3 NM_002530</p><p id="p1728" num="1728">1.8602E-05 </p><p id="p1729" num="1729"> 207057_at SLC16A7 solute carr er fami 1 y 16 member 7 (monocarboxyl i c acid transporter NM._004731 1.9146E-05 </p><p id="p1730" num="1730"> 207911_s_at TGM5 transglutaminase 5 NM_004245 1.9378E-05 </p><p id="p1731" num="1731"> 207730_x_at null NVL017932 1.9989E-05 </p><p id="p1732" num="1732"> 217620_s_at PIK3CB phosphoi nosi t i de-3-ki nase catalyti c beta polypeptide</p><p id="p1733" num="1733">AA805318 2.0764E-05 </p><p id="p1734" num="1734"> 208345_s„at POU3F1 POU class 3 homeobox 1 NM_002699 2.1059E-05 </p><p id="p1735" num="1735"> 220795„x_at SLC35E1 solute carrier family 35 member El NM_024881 </p><p id="p1736" num="1736"> 2.1364E-05 </p><p id="p1737" num="1737"> 210613_s_at SYNGRl synaptogyrin 1 BC000731 2.1806E-05 </p><p id="p1738" num="1738"> 214305_s_at SF3B1 splicing factor 3b subunit 1 155kDa AW003030 </p><p id="p1739" num="1739"> 2.2116E-05 </p><p id="p1740" num="1740"> 201867_s_at TBLlx transduci n (beta) -1 i ke lx-linked AW968555 </p><p id="p1741" num="1741"> 2.2119E-05 </p><p id="p1742" num="1742"> 213748_at TRIM66 tri partite moti f-contai ni ng 66 A 271713 2.2307E-05</p><p id="p1743" num="1743">220688_s_at MRT04 mRNA turnover 4 homolog (S. cerevi siae) NM.016183 </p><p id="p1744" num="1744"> 2.2339F-05 
<!-- EPO <DP n="99"/>-->
 Table_D </p><p id="p1745" num="1745"> 204180_s_at ZBTB43 zinc finger and BTB domain containing 43 AI745225 2.2691E-05 </p><p id="p1746" num="1746"> 202669__s_at EFNB2 ephrin-B2 U16797 2.2926E-05 </p><p id="p1747" num="1747"> 208003_s„at NFAT5 nuclear factor of activated T-cells 5 toni city-responsive NNL006599 2.3205E-05 </p><p id="p1748" num="1748"> 212106„at FAF2 Fas associated factor family member 2 BF116183 </p><p id="p1749" num="1749"> 2.3380E-05 </p><p id="p1750" num="1750"> 211921_x_at PT A prothymosin alpha AF348514 2.3625E-05 </p><p id="p1751" num="1751"> 22090 l_at GPR157 G protein-coupled receptor 157 NM_024980 2.4153E-05 218930_s_at TMEM106B transmembrane protein 106B NM_018374 </p><p id="p1752" num="1752"> 2.4608E-05 </p><p id="p1753" num="1753"> 211992_at WNKl WNK lysine deficient protein kinase 1 AI445745 </p><p id="p1754" num="1754"> 2.4613E-05 </p><p id="p1755" num="1755"> 215206_at null AK025143 2.4978E-05 </p><p id="p1756" num="1756"> 203181_x_at SRPK2 SFRS protein kinase 2 AW149364 2.5494E-05 </p><p id="p1757" num="1757"> 209030_s_at CAD 1 cell adhesion molecule 1 NM_014333 2.5571E-05 211316_x_at CFLAR CASP8 and FADD-like apoptosis regulator AF009616 </p><p id="p1758" num="1758"> 2.6699E-05 </p><p id="p1759" num="1759"> 211387_x_at RNGTT RNA guanylyltransferase and 5 ' -phosphatase AB012143 2.7582E-05 </p><p id="p1760" num="1760"> 219633_at TTPAL tocopherol (alpha) transfer protein-like NM_024331 2.8430E-05 </p><p id="p1761" num="1761"> 2006 7_s_at PTPRF protein tyrosine phosphatase receptor type F AI762627 2.8541E-05 </p><p id="p1762" num="1762"> 213298_at NFIC nuclear factor i/c (CCAAT-binding transcription factor) X12492 2.8753E-05 </p><p id="p1763" num="1763"> 212079_s_at MLL myeloid/ ymphoid or mixed-l neage leukemia (tri thorax homolog Drosophila) AA715041 2.9516E-05 </p><p id="p1764" num="1764"> 219235_s_at PHACTR4 phosphatase and actin regulator 4 N _023923 </p><p id="p1765" num="1765">3.0091E-05 </p><p id="p1766" num="1766">212229_s_at FBX021 F-box protein 21 AK001699 3.0649E-05 </p><p id="p1767" num="1767">220720_x_at FAM128B family with sequence similarity 128 member B NM_025029 3.1771E-05 </p><p id="p1768" num="1768">219717_at C4orf 0 chromosome 4 open reading frame NM_017741 </p><p id="p1769" num="1769">3.4671E-05 </p><p id="p1770" num="1770">210426_x_at RORA RAR-related orphan receptor A U04897 3.5549E-05 </p><p id="p1771" num="1771">207382_at TP63 tumor protein p63 NM_003722 3.6289E-05 </p><p id="p1772" num="1772">202082_s_at SEC14L1 SEC14-Iike 1 (S. cerevis ae) AV748469 3.6797E-05 215628_x_at null AL049285 3.6881E-05 </p><p id="p1773" num="1773">210057_at SMGl SMGl homolog phosphatidyl inositol 3-ki nase-rel ated kinase (C. elegans) U32581 3.7071E-05 </p><p id="p1774" num="1774">212808_at NFATC2IP nuclear factor of activated T-cells cytoplasmic calcineurin-dependent 2 interacting protein AI884627 3.9473E-05 </p><p id="p1775" num="1775">215066_at PTPRF protein tyrosine phosphatase receptor type F AU158443</p><p id="p1776" num="1776">3.9879E-05 </p><p id="p1777" num="1777">20537O_x_at DBT di hydro! ipoam de branched chain transacylase E2 NM_001918 4.0073E-05 </p><p id="p1778" num="1778">218489_s__at ALAD aminolevulinate delta- dehydratase NM_000031 </p><p id="p1779" num="1779">4.1739E-05 </p><p id="p1780" num="1780">209024_s_at SYNCRIP synaptotagmi n binding cytoplasmic RNA i nteracti ng protein AI472757 4.1961E-05 </p><p id="p1781" num="1781">210407_at PPMlA protei n phosphatase lA (formerly 2C) magnesium-dependent alpha i so form AF070670 4.2137E-05 </p><p id="p1782" num="1782">204290_s_at ALDH6A1 aldehyde dehydrogenase 6 family member Al NM_005589 4.2320E-05 </p><p id="p1783" num="1783">33646_g_at GM2A GM2 ganglioside activator X61094 4.2372E-05 </p><p id="p1784" num="1784">201606_s_at PWPl PWPl homolog (S. cerevisiae) BE796924 4.3138E-05 208485_x_at CFLAR CASP8 and FADD-l ke apoptos s regulator NM_003879 </p><p id="p1785" num="1785">4.3820E-05 </p><p id="p1786" num="1786">215428_at AL109707 4.4947E-05 </p><p id="p1787" num="1787">201918_at SLC25A36 solute carrier fami ly 25 member 36 AI927944 4.5232E-05 </p><p id="p1788" num="1788">221416_at PLA2G2F phospholipase A2 group IIF NM__022819 4.5850E-05 
<!-- EPO <DP n="100"/>-->
 Table_D </p><p id="p1789" num="1789"> 221006_s_at SNX27 sorting nexin family member 27 ΝΜ„030918 4.6187E-05</p><p id="p1790" num="1790">209065„at UQCRB ubi qui nol -cytochrome c reductase binding protein </p><p id="p1791" num="1791"> BC005230 4.6351E-05 </p><p id="p1792" num="1792"> 219910_at FICD FIC domain containing NM_007076 4.6518E-05 </p><p id="p1793" num="1793"> 210130_s_at TM7SF2 transmembrane 7 superfamily member 2 AF096304 </p><p id="p1794" num="1794"> 4.6563E-05 </p><p id="p1795" num="1795"> 216189_at null BC002465 4.7282E-05 </p><p id="p1796" num="1796"> 39313_at NKl IAA0344 gene AB002342 4.8130E-05 </p><p id="p1797" num="1797"> 208930„s_at ILF3 inter leukin enhancer binding factor 3 90kDa BG032366</p><p id="p1798" num="1798">4.8427E-05 </p><p id="p1799" num="1799"> 208549_x_at PTMAP7 prothymosin alpha pseudogene 7 NM_016171 4.9816E-05</p><p id="p1800" num="1800">20163L_s_at IER3 immediate early response 3 NM_003897 5.0093E-05</p><p id="p1801" num="1801">210701_at CFDP1 craniofacial development protein 1 D85939 5.0154E-05</p><p id="p1802" num="1802">213998_s_at DDX17 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 A 188131</p><p id="p1803" num="1803">5.0660E-05 </p><p id="p1804" num="1804"> 214972_at MGEA5 Meningioma expressed antigen 5 (hyaluronidase) mRNA (CDNA clone MGC:48750 IMAGE : 5558183) AU144791 5.0939E-05 </p><p id="p1805" num="1805"> 220113_x_at POLR1B polymerase (RNA) polypeptide B 128kDa NM_019014 </p><p id="p1806" num="1806"> 5.1800E-05 </p><p id="p1807" num="1807">209203_s_at BICD2 bicaudal D homolog 2 (Drosophila) BC002327 </p><p id="p1808" num="1808"> 5.2918E-05 </p><p id="p1809" num="1809">209508_x_at CFLAR CASP8 and FADD-like apoptosis regulator AF005774 </p><p id="p1810" num="1810"> 5.4720E-05 </p><p id="p1811" num="1811">208120_x_at FKSG49 FKSG49 NM_031221 5.4869E-05 </p><p id="p1812" num="1812">201683_x_at TOX4 TOX high mobility group box family member 4 BE783632 5.5472E-05 </p><p id="p1813" num="1813">201548_s_at 3ARID1B umonji AT rich interactive domain IB W02593 5.7057E-05 216175_at null AK025276 5.8353E-05 </p><p id="p1814" num="1814">209225_x_at TNPOl transportin 1 AI653355 5.8424E-05 </p><p id="p1815" num="1815">212629_s_at PKN2 protein kinase N2 AI633689 5.8864E-05 </p><p id="p1816" num="1816">214843_s_at USP33 ubiquitin specific peptidase 33 AK022864 5.8995E-05 212840_at UBXN7 UBX domain protein 7 BG339560 5.9251E-05 </p><p id="p1817" num="1817">2143 4_s_at PPFlBPl PTPRF interacting protein binding protein 1 (liprin beta 1) AI962377 5.9916E-05 </p><p id="p1818" num="1818">212807_s_at SORTl sortilin 1 BF447105 6.1077E-05 </p><p id="p1819" num="1819">201879_at ARIHl ariadne homolog ubiquitin-conjugating enzyme E2 binding protein 1 (Drosophila) AI694332 6.1735E-05 </p><p id="p1820" num="1820">202844_s_at RALBPl ralA binding protein 1 AW025261 6.2362E-05 </p><p id="p1821" num="1821">203176_s_at TFAM transcription factor A mitochondrial BE552470 </p><p id="p1822" num="1822">6.3943E-05 </p><p id="p1823" num="1823">202867_s_at DNA3B12 DnaD (Hsp40) homolog subfamily B member 12 NM_017626 6.5775E-05 </p><p id="p1824" num="1824">217593_at ZSCAN18 zinc finger and SCAN domain containing 18 AI375002 6.6413E-05 </p><p id="p1825" num="1825"> 201846_s_at RYBP RlNGl and YYl binding protein NM_012234 6.6541E-05 210734_x_at MAX MYC associated factor x M64240 6.7154E-05 </p><p id="p1826" num="1826">221985_at KLHL24 kelch-like 24 (Drosophila) AW006750 6.8295E-05 213506_at F2RL1 coagulation factor n (thrombin) receptor 1 </p><p id="p1827" num="1827">BE965369 6.9457E-05 </p><p id="p1828" num="1828">219915_s_at SLC16A10 solute carrier family 16 member 10 (aromati c amino acid transporter) NM..018593 7.0225E-05 </p><p id="p1829" num="1829">216243_s_at ILIRN i nterleuk n 1 receptor antagoni st BE563442 </p><p id="p1830" num="1830">7.0801E-05 </p><p id="p1831" num="1831">210679_x_at null BC002629 7.1307E-05 </p><p id="p1832" num="1832">204863_s_at IL6ST interleukin 6 signal transducer (gpl30 oncostati n M receptor) BE856546 7.2636E-05 </p><p id="p1833" num="1833">209750_at NR1D2 nuclear receptor subfamily 1 group D member 2 N32859 7.4546E-05 </p><p id="p1834" num="1834">204680_s_at RAPGEF5 Rap guanine nucleotide exchange factor (GEF) 5 AI263837 7.6949E-05 </p><p id="p1835" num="1835">205809_s_at ASL Wiskott-Aldrich syndrome-like ΒΕ504979 7.7732E 05 217370_x_at FUS fusion (i nvol ved in t(12 ; 16) in malignant 1 i posarcoma)</p><p id="p1836" num="1836">S75762 7.8524E-05 
<!-- EPO <DP n="101"/>-->
 Tab! e„D </p><p id="p1837" num="1837"> 201085_s_at SON SON DNA binding protein AA664291 8.0308E-05 </p><p id="p1838" num="1838"> 2175 50_at ATF6 ATF family member ATF6 (ATF6) AA576497 8. 1358E-05 213299_at ZBTB7A zinc finger and BTB domain containing 7A AW027070 8 . 2767E-05 </p><p id="p1839" num="1839"> 217152_at null AK024136 8.4186E-05 </p><p id="p1840" num="1840"> 204358_s_at FLRT2 fibronectin leucine rich transmembrane protein 2 </p><p id="p1841" num="1841"> AF169676 8.5719E-05 </p><p id="p1842" num="1842"> 201996_s_at SPEN spen homolog transcriptional regulator (Drosophila) AL 524033 8.8224E-05 </p><p id="p1843" num="1843"> 213446_s„at IQGAPl IQ motif containing GTPase activating protein 1 AI679073 8.8686E-05 </p><p id="p1844" num="1844"> 214001_x_at RPS10 Ribosomal protein S10 A 302047 8.9790E-05 </p><p id="p1845" num="1845"> 211317_s_at CFLAR CASP8 and FADD-like apoptosis regulator AF041461 </p><p id="p1846" num="1846"> 9 . 0579E-05 </p><p id="p1847" num="1847"> 204131_s_at FOX03 forkhead box 03 N25732 9.2446E-05 </p><p id="p1848" num="1848"> 202971_s_at DYR 2 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 NM_006482 9.2687E-05 </p><p id="p1849" num="1849"> 209807_s_at NFIX nuclear factor I/X (CCAAT-b ndi ng transcription factor) U18759 9.3413E-05 </p><p id="p1850" num="1850"> 222180_at null AU147889 9.4177E-05 </p><p id="p1851" num="1851"> 216711_s_at TAFl TAFl RNA polymerase II TATA box binding protein </p><p id="p1852" num="1852"> (TBP) -associated factor 250kDa M73444 9 . 4219E-05 </p><p id="p1853" num="1853"> 214912_at null AK022067 9.4601E-05 </p><p id="p1854" num="1854">203899_s_at CRCP CGRP receptor component NM_014478 9.4951E-05 </p><p id="p1855" num="1855">208336_s_at GPSN2 glycoprotein synaptic 2 NM_004868 9.7951E-05 </p><p id="p1856" num="1856">200616_s_at LEC malectin BC000371 1.0015E-04 </p><p id="p1857" num="1857">219963_at DUSP13 dual specificity phosphatase 13 NM_016364 1.0195E-04 222263_at SLC35E1 solute carrier family 35 member El BE904333 </p><p id="p1858" num="1858">1.0454E-04 </p><p id="p1859" num="1859">202045_s_at GRLFl glucocortico d receptor DNA binding factor 1 AI670100 1.0659E-04 </p><p id="p1860" num="1860">213650_at GOLGA8A golgi autoantigen golgin subfamily a 8A AW006438 </p><p id="p1861" num="1861">1.0835E-04 </p><p id="p1862" num="1862">220675_s_at PNPLA3 patatin-like phospholi pase domain containing 3 NM_025225 1.0928E-04 </p><p id="p1863" num="1863">211000_s_at IL6ST interleukin 6 signal transducer (gpl30 oncostatin M </p><p id="p1864" num="1864">receptor) AB015706 1.1061E-04 </p><p id="p1865" num="1865">208114_s_at ISG20L2 interferon stimulated exonuclease gene 20kDa-like 2 </p><p id="p1866" num="1866">NM_030980 1.1075E-04 </p><p id="p1867" num="1867">203515_s_at P VK phosphomevalonate kinase NM_006556 1.1168E-04 209890_at TSPAN 5 tetraspanin 5 AF065389 1.1232E-04 </p><p id="p1868" num="1868">203027_s_at VD mevalonate Cdiphospho) decarboxylase AI189359 </p><p id="p1869" num="1869">1.1424E-04 </p><p id="p1870" num="1870">210251_s_at RUFY3 RUN and FYVE domain containing 3 AF112221 </p><p id="p1871" num="1871">1.1432E-04 </p><p id="p1872" num="1872">207993_s_at CHP calcium binding protein P22 NM_007236 1.1696E-04 212007_at UBXN4 UBX domain protein 4 AI927512 1.1705E- 04 </p><p id="p1873" num="1873">218150 at ARI..5A ADP-ribosylation factor-like 5A M_012097 1. 1723 E-04 202035_s_at SFRPl secreted frizzled-related protein 1 AI 332407 </p><p id="p1874" num="1874">1.1931E-04 </p><p id="p1875" num="1875">221765_at UGCG UDP-gl ucose ce rami de glucosyl transferase AI 378044 1.1935E-04 </p><p id="p1876" num="1876">201183_s_at CHD4 chromodomai n he case DNA bi ndi ng protei n 4 AI613273 1.2057E-04 </p><p id="p1877" num="1877">213579_s_at ΕΡ300 ElA binding protein p300 AI459462 1 . 2 148E-04 210598_at null AF130051 1.2242E-04 </p><p id="p1878" num="1878">208042_at AGGFl angiogeni c factor with G patch and FHA domai ns 1 </p><p id="p1879" num="1879">NM_013303 1.2 329 E-04 </p><p id="p1880" num="1880">208699_x_at TKT transketolase BF696840 1.2417E-04 </p><p id="p1881" num="1881">204463_s_at EDNRA endothelin receptor type A AU118882 1. 2584E-04 216316. x_at. GK glycerol kinase X78713 1.2804E-04 </p><p id="p1882" num="1882">203542._s_at LF9 Kruppel-like factor 9 AI690205 1.2986E-04 </p><p id="p1883" num="1883">214833_at TMEM63A transmembrane protein 63A AB007958 1. 339 E-04 
<!-- EPO <DP n="102"/>-->
 Table_D </p><p id="p1884" num="1884"> ?01072_s_at SMARCCl SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily c member 1 AW152160 1.3391E-04 </p><p id="p1885" num="1885"> 217813_s_at SPINl spindlin 1 NM_006717 1.3414E-04 </p><p id="p1886" num="1886"> 200635„s_at PTPRF protein tyrosine phosphatase receptor type AU145351 1.3466E-04 </p><p id="p1887" num="1887"> 209069_s_at H3F3A H3 hi stone family 3A BC001124 1.3652E-04 </p><p id="p1888" num="1888"> 35436_at GOLGA2 golgi autoantigen golgin subfamily a 2 L.06147 1.3653 E-04 201287_s_at SDCl syndecan 1 NN_002997 1.3732E-04 </p><p id="p1889" num="1889"> 214670_at ZKSCANl zinc finger with RAB and SCAN domains 1 AA653300 1.4190E-04 </p><p id="p1890" num="1890"> 222214_at null AK024988 1.4292E 04 </p><p id="p1891" num="1891"> 219428_s_at PXMP4 peroxisomal membrane protein 4 24kDa BF057649 </p><p id="p1892" num="1892"> 1.4316E-04 </p><p id="p1893" num="1893"> 20 524_s_at mercaptopyruvate sulfurtransferase NM_021126 </p><p id="p1894" num="1894"> 1.4351E-04 </p><p id="p1895" num="1895"> 213805_at ABHD5 abhydrolase domain containing 5 AI692428 1.4397E-04 209193_at PlMl pim-1 oncogene M24779 1.4475E-04 </p><p id="p1896" num="1896"> 218724_s_at TGIF2 TGFB-induced factor homeobox 2 NM_021809 1.4720E-04 219723_x_at AGPAT 3 1-acyl glycerol -3- phosphate o-acyl transferase NM_020132 1.4809E-04 </p><p id="p1897" num="1897"> 220178_at Cl9orf28 chromosome 19 open reading frame 28 NM_021731 1.4817E-04 </p><p id="p1898" num="1898">222036_s_at MCM4 mi ni chromosome maintenance complex component 4 AI859865 1.4881E-04 </p><p id="p1899" num="1899">203975_s_at CHAFlA chromatin assembly factor 1 subunit A (pl50) BF000239 1.4883E-04 </p><p id="p1900" num="1900">214352_s_at RAS v-Ki-ras2 Ki rsten rat sarcoma v ral oncogene homolog BF673699 1.4977E- 04 </p><p id="p1901" num="1901">205783_at KLK13 kallikrein-related peptidase 13 NM_015596 1.5104E-04 211040_X_at GTSEl G-2 and S-phase expressed 1 BC006325 1.5322E-04</p><p id="p1902" num="1902">207700_s_at NCOA3 nuclear receptor coactivator 3 NM_006534 1.5903E-04 215986_at null AU146999 1.5936E-04 </p><p id="p1903" num="1903">222284_at null AI734111 1.6225E-04 </p><p id="p1904" num="1904"> 215355_at POU2F3 CDNA FLJ61459 complete cds highly similar to POU domain class 2 transcript on factor 3 AI686582 1.6659E-04 </p><p id="p1905" num="1905"> 204712_at WlFl WNT inhibitory factor 1 NM_007191 1.6699E-04 </p><p id="p1906" num="1906">204074_s_at KIAA0562 KIAA0562 AI936976 1.6713E-04 </p><p id="p1907" num="1907">204710_s_at WIPI2 WD repeat domain phosphoinositide interacting 2 NM_016003 1.6842E-04 </p><p id="p1908" num="1908">203007_x_at LYPLAl lysophospholipase I AF077198 1.6870E-04 </p><p id="p1909" num="1909">218155_x_at TSRl TSRl 20S rRNA accumulation homolog (s. cerevisiae) </p><p id="p1910" num="1910">AK026565 1.6954E-04 </p><p id="p1911" num="1911">204941_s_at ALDH3B2 aldehyde dehydrogenase 3 family member B2 AA071510 1.7220E-04 </p><p id="p1912" num="1912">213936_x_at SFTPB surfactant protein B A 276646 1.7285E-04 </p><p id="p1913" num="1913">217713_x_at null AA126763 1.7423E-04 </p><p id="p1914" num="1914">91920_at BCAN brevican AI205180 1.7852E-04 </p><p id="p1915" num="1915">216641_s_at LADl ladinin 1 U58994 1.7900E 04 </p><p id="p1916" num="1916">202028_s_at RPL38 ribosomal protein L38 BC000603 1.8201E-04 </p><p id="p1917" num="1917"> 200842_s at EPRS gl utamyl - rolyl -tRNA synthetase AI475965 1.8206E-04 150 2_at RREBl ras responsive element binding protein 1 AK022442 1.8444E-04 </p><p id="p1918" num="1918"> 2! 11944 3,t BAT2D1 BAT2 domain containing 1 BE729523 1.8445E-04</p><p id="p1919" num="1919">215780_s_at SET SET translocation (myeloid leukemia-associated) pseudogene Z95126 1.8450E-04 </p><p id="p1920" num="1920">209136_s_at USP10 ubiqui ti n speci fi c peptidase 10 BG390445 1.8544E-04 201035_s_at HADH hydroxyacyl -Coenzyme A dehydrogenase BC000306 </p><p id="p1921" num="1921">1.8556E-04 </p><p id="p1922" num="1922">205338_s_at DCT dopachrome tautomerase (dopachrome del ta-i some rase tyrosine-related protein 2) NM_001922 1.8650E-04 </p><p id="p1923" num="1923">219392_x_at PRRll proline rich 11 NM_018304 1.8715E-04 </p><p id="p1924" num="1924">214682_at LOC399491 LOC399491 protein A 023376 1.8746E-04</p><p id="p1925" num="1925">221419_s_at null NM_013307 1.8781E-04 
<!-- EPO <DP n="103"/>-->
 Table_D </p><p id="p1926" num="1926"> 201411_s_at PLEKHB2 pleckstrin homology domain containing family B (evectins) member 2 NM_017958 1.9071E-04 </p><p id="p1927" num="1927"> 202053„s_at ALDH3A2 aldehyde dehydrogenase 3 family member A2 L47162 1.9195E-04 </p><p id="p1928" num="1928"> 215029_at null AL117451 1.9204E-04 </p><p id="p1929" num="1929"> 217482_at null AK021987 1.9253E-04 </p><p id="p1930" num="1930"> 218521_s_at UBE2W ubiqui tin-conjugating enzyme E2w (putative) N _018299 1.9276E-04 </p><p id="p1931" num="1931"> 208200_at ILlA interleukin 1 alpha NM_000575 1.9377E-04 </p><p id="p1932" num="1932"> 200727_s_at ACTR2 ARP2 actin-related protein 2 homolog (yeast) ΑΑ699583 1.9730E-04 </p><p id="p1933" num="1933"> 215069_at NMT2 N-myri stoy transferase 2 ΑΚ025065 1.9771E-04 215067_x_at PRDX2 peroxi redoxin 2 AU 147942 2.0142E-04 </p><p id="p1934" num="1934"> 201294_s_at WSB1 WD repeat and SOCS box-containing 1 N24643 2.0215E-04 201205_at null AF006751 2.0372E-04 </p><p id="p1935" num="1935"> 214734_at EXPH5 exophilin 5 AB014524 2.0781E 04 </p><p id="p1936" num="1936"> 210513_s_at VEGFA vascular endothelial growth factor A AF091352 </p><p id="p1937" num="1937"> 2.0886E-04 </p><p id="p1938" num="1938"> 209167_at GP 6B glycoprotein M6B AI419030 2.1021E- 04 </p><p id="p1939" num="1939"> 206551_x_at LHL24 kelch-like 24 (Drosophila) NM_017644 2.1048E- 04 221830_at RAP2A RAP2A member of RAS oncogene family AI302106 </p><p id="p1940" num="1940"> 2.1126E-04 </p><p id="p1941" num="1941"> 204675_at SRDSAI steroid-5-alpha-reductase alpha polypeptide 1 (3-oxo-5 al pha-steroid delta 4-dehydrogenase alpha 1) N _001047 2.1270E-04 </p><p id="p1942" num="1942"> 212468_at SPAG9 sperm associated antigen 9 AK023512 2.1355Ε 213228_at PDE8B phosphodiesterase 8B AK023913 2.1410E-04 </p><p id="p1943" num="1943"> 206929_s_at NFIC nuclear factor i/c (CCAAT-bind ng transcription factor) NM_005597 2.1412E-04 </p><p id="p1944" num="1944"> 204347_at A 3L1 adenylate kinase 3-like 1 AI653169 2.1420E-04 204387_x_at RP63 mitochondrial ribosomal protein 63 NM..024026 </p><p id="p1945" num="1945">2.1456E-04 </p><p id="p1946" num="1946"> 212290_at SLC7A1 solute carrier family 7 (cationic amino acid transporter y+ system) member 1 AA527433 2.1475E-04 </p><p id="p1947" num="1947">210282_at Z YM2 zinc finger MYM-type 2 AL136621 2.1681E-04 </p><p id="p1948" num="1948">216503<sub>^</sub>s_at MLLTIO myeloid/lymphoid or mixed-lineage leukemia (tri thorax homolog Drosophila); translocated to 10 AF060927 2.1739E-04 </p><p id="p1949" num="1949">216512_s_at DCT dopachrome tautomerase (dopachrome de ta-i somerase tyrosine-related protein 2) AL139318 2.2002E-04 </p><p id="p1950" num="1950"> 220011_at Clorfl35 chromosome J open reading frame 135 NM_024037 2.2283E-04 </p><p id="p1951" num="1951">217703_x_at null AA401963 2.2444E-04 </p><p id="p1952" num="1952">202122_s_at M6PRBP1 mannose- -6-phosphate receptor binding protein 1 N _005817 2.2502E-04 </p><p id="p1953" num="1953">219789_at NPR3 natriuretic peptide receptor c/guanylate cyclase C </p><p id="p1954" num="1954"> (atrionatr uretic peptide receptor c) AI628360 .2627E-04 </p><p id="p1955" num="1955"> 208615_s_at PTP4A2 protein tyrosine phosphatase type IVA member 2 BF795101 2.2678E-04 </p><p id="p1956" num="1956"> 219341_at CLN8 ceroid-lipofuscinosis neuronal 8 (epilepsy progressive mental retardation) NM_018941 2.3705E-04 </p><p id="p1957" num="1957"> 33148_at ZFR zinc finger RNA binding protein AI459274 2.3899E-04 ?14383_x_at KLHDC3 kelch domai n containing 3 BF063121 2.3941E-04 1053_at RFC2 replication factor c (activator 1) 2 40kDa M 2.4024E-04 215620_at RREBl ras responsive element binding protein 1 AU147182 2.4784E-04 </p><p id="p1958" num="1958">214715_x_at ZNF160 zinc finger protein 160 A 024789 2.5344E-04 </p><p id="p1959" num="1959">205538_at COR02A coroni n actin binding protein 2A N _003389 </p><p id="p1960" num="1960">2.5574E 04 </p><p id="p1961" num="1961">202975_s_at RHOBTB3 Rho-rel ated BTB domain contain ng 3 N21138 2.5588E-04 221479_s_at BNIP3L BCL2/adenovi rus E1B 19kDa interacting protein 3- li ke </p><p id="p1962" num="1962">AF060922 2.5978E- 04 </p><p id="p1963" num="1963">215600_x_at FBXW12 CDNA FLJ40275 f s clone TESTI2027185 AK022174 </p><p id="p1964" num="1964">2.6324E-04 </p><p id="p1965" num="1965">204375_at CLST 3 calsyntenin 3 N _014718 2.6950E-04 
<!-- EPO <DP n="104"/>-->
 Table_D </p><p id="p1966" num="1966"> 217862_at PIASl protein inhibitor of activated STAT 1 N24868 2.6992E-04</p><p id="p1967" num="1967">215604_x_at null A 023783 2.7098E-04 </p><p id="p1968" num="1968"> 213209_at TAF6L TAF6-like RNA polymerase II p300/CBP-associated factor</p><p id="p1969" num="1969">(PCAF) -associated factor 65kDa BF058726 2.7694E-04 
<!-- EPO <DP n="105"/>-->
</p><p id="p1970" num="1970">Tabl e_E probe Set ID CMP 62_13 CMapRank </p><p id="p1971" num="1971"> 33579_i _at 1 </p><p id="p1972" num="1972"> 205182_s_at 2 </p><p id="p1973" num="1973"> 216001_at 3 </p><p id="p1974" num="1974"> 222160_at 4 </p><p id="p1975" num="1975"> 202OO5_at 5 </p><p id="p1976" num="1976"> 211197_s_at 6 </p><p id="p1977" num="1977"> 209325_s_at 7 </p><p id="p1978" num="1978"> 208725_at 8 </p><p id="p1979" num="1979"> 207675_x_at 9 </p><p id="p1980" num="1980"> 204 97_at 10 </p><p id="p1981" num="1981"> 217516_x_at 11 </p><p id="p1982" num="1982"> 207136_at 12 </p><p id="p1983" num="1983"> 204466_s_at 13 </p><p id="p1984" num="1984"> 212823_s_at 14 </p><p id="p1985" num="1985"> 202616_s_at 15 </p><p id="p1986" num="1986"> 219853_at 16 </p><p id="p1987" num="1987"> 217171_at 17 </p><p id="p1988" num="1988"> 221176_x_at 18 </p><p id="p1989" num="1989"> 208349_at 19 </p><p id="p1990" num="1990"> 215292_s_at 20 </p><p id="p1991" num="1991"> 208340_at 10100 </p><p id="p1992" num="1992"> 214046_at 10101 </p><p id="p1993" num="1993"> 219159_s_at 10102 </p><p id="p1994" num="1994"> 207402_at 10103 </p><p id="p1995" num="1995"> 215757_at 10104 </p><p id="p1996" num="1996"> 217026_at 10105 </p><p id="p1997" num="1997"> 210163_at 10106 </p><p id="p1998" num="1998"> 207659_s_at 10107 </p><p id="p1999" num="1999"> 214470_at 10108 </p><p id="p2000" num="2000"> 203703_s_at 10109 </p><p id="p2001" num="2001"> 222114_x_at 10110 </p><p id="p2002" num="2002"> 208515_at 10111 </p><p id="p2003" num="2003"> 207369_at 10112 </p><p id="p2004" num="2004"> 206865_at 10113 </p><p id="p2005" num="2005"> 214067_at 10114 </p><p id="p2006" num="2006"> 214059_at 10115 </p><p id="p2007" num="2007"> 206498_at 10116 </p><p id="p2008" num="2008"> 206957_at 10117 </p><p id="p2009" num="2009"> 206434_at 10118 </p><p id="p2010" num="2010"> 221391_at 10119 </p><p id="p2011" num="2011"> 211701_s_at 10120 </p><p id="p2012" num="2012"> 213075_at 22193 </p><p id="p2013" num="2013"> 219784_at 22194 </p><p id="p2014" num="2014"> 214283_at 22195 </p><p id="p2015" num="2015"> 215233_at 22196 </p><p id="p2016" num="2016"> 219752_at 22197 </p><p id="p2017" num="2017"> 208987„s_at 22198 </p><p id="p2018" num="2018"> 203836. 5. at 22199 </p><p id="p2019" num="2019"> 216025_x_at 22200 </p><p id="p2020" num="2020"> 220178_at 22201 </p><p id="p2021" num="2021"> 210126_at 22202 </p><p id="p2022" num="2022"> 216320_x_at 22203 </p><p id="p2023" num="2023"> 222015_at 22204 </p><p id="p2024" num="2024"> 214372_x_at 22205 </p><p id="p2025" num="2025"> 205875_s_at 22206 </p><p id="p2026" num="2026"> 218720_x_at 22207 </p><p id="p2027" num="2027"> 211573_x_at 22208 </p><p id="p2028" num="2028"> 219640_at 22209 </p><p id="p2029" num="2029"> 204701_s_at 22210 </p><p id="p2030" num="2030"> 204484_at 22211 
<!-- EPO <DP n="106"/>-->
 Tabl e_E</p><p id="p2031" num="2031">209547_s_at 22212 </p><p id="p2032" num="2032">209876_at 22213 </p><p id="p2033" num="2033">219664_s_at 22214 
<!-- EPO <DP n="107"/>-->
</p><p id="p2034" num="2034">Table_F probe set ID CMP 61_13 CMapRank </p><p id="p2035" num="2035"> 216074_x_at 1 </p><p id="p2036" num="2036"> 217391_x_at 2 </p><p id="p2037" num="2037"> 219807_x_at 3 </p><p id="p2038" num="2038"> 220538_at 4 </p><p id="p2039" num="2039"> 205654_at 5 </p><p id="p2040" num="2040"> 213710_s_at 6 </p><p id="p2041" num="2041"> 202099_s_at 7 </p><p id="p2042" num="2042"> 2O4307_at 8 </p><p id="p2043" num="2043"> 213141_at 9 </p><p id="p2044" num="2044"> 210974_s_at 10 </p><p id="p2045" num="2045"> 217723_x_at 11 </p><p id="p2046" num="2046"> 202991_at 12 </p><p id="p2047" num="2047"> 218272_at 13 </p><p id="p2048" num="2048"> 219057_at 14 </p><p id="p2049" num="2049"> 212487_at 15 </p><p id="p2050" num="2050"> 206485_at 16 </p><p id="p2051" num="2051"> 206289_at 17 </p><p id="p2052" num="2052"> 202669_s_at 18 </p><p id="p2053" num="2053"> 205182_s_at 19 </p><p id="p2054" num="2054"> 216472_at 20 </p><p id="p2055" num="2055"> 220630_s_at 10100 </p><p id="p2056" num="2056"> 211333_s_at 10101 </p><p id="p2057" num="2057"> 203547_at 10102 </p><p id="p2058" num="2058"> 210889_s_at 10103 </p><p id="p2059" num="2059"> 221159_at 10104 </p><p id="p2060" num="2060"> 208253_at 10105 </p><p id="p2061" num="2061"> 216188_at 10106 </p><p id="p2062" num="2062"> 216879_at 10107 </p><p id="p2063" num="2063"> 205949_at 10108 </p><p id="p2064" num="2064"> 216763_at 10109 </p><p id="p2065" num="2065"> 215186_at 10110 </p><p id="p2066" num="2066"> 221141_x_at 10111 </p><p id="p2067" num="2067"> 209145_s_at 10112 </p><p id="p2068" num="2068"> 206731_at 10113 </p><p id="p2069" num="2069"> 217514_at 10114 </p><p id="p2070" num="2070"> 213162_at 10115 </p><p id="p2071" num="2071"> 217429_at 10116 </p><p id="p2072" num="2072"> 206645_s_at 10117 </p><p id="p2073" num="2073"> 37201_at 10118 </p><p id="p2074" num="2074"> 217706_at 10119 </p><p id="p2075" num="2075"> 207167_at 10120 </p><p id="p2076" num="2076"> 21035 _s_at 22194 </p><p id="p2077" num="2077"> 222362_at 22195 </p><p id="p2078" num="2078"> 213303_x_at 22196 </p><p id="p2079" num="2079"> 211112_at 22197 </p><p id="p2080" num="2080"> 214879_x_at 22198 </p><p id="p2081" num="2081"> 210739_x._at 22199 </p><p id="p2082" num="2082"> 216042_at 22200 </p><p id="p2083" num="2083"> 209436._al 22201 </p><p id="p2084" num="2084"> 206063_x_at 22202 </p><p id="p2085" num="2085"> 213521 st 22203 </p><p id="p2086" num="2086"> 209926_at 22204 </p><p id="p2087" num="2087"> 218965_s_at 22205 </p><p id="p2088" num="2088"> 206911_at 22206 </p><p id="p2089" num="2089"> 222167_at 22207 </p><p id="p2090" num="2090"> 221061_at 22208 </p><p id="p2091" num="2091"> 214893_x_at 22209 </p><p id="p2092" num="2092"> 202685_s_at 22210 </p><p id="p2093" num="2093"> 218599_at 22211 </p><p id="p2094" num="2094"> 215595_x_at 22212 
<!-- EPO <DP n="108"/>-->
221992_at 22213 215015_at 22214 
<!-- EPO <DP n="109"/>-->
</p><p id="p2095" num="2095">Tab1e_G probe Set ID CMP 62 24 CMapRank </p><p id="p2096" num="2096"> 21292 5_at 1 </p><p id="p2097" num="2097"> 214542„x_at 2 </p><p id="p2098" num="2098"> 206739__at 3 </p><p id="p2099" num="2099"> 214223_at 4 </p><p id="p2100" num="2100"> 222013_x_at 5 </p><p id="p2101" num="2101"> 221010_s_at 6 </p><p id="p2102" num="2102"> 205648„at 7 </p><p id="p2103" num="2103"> 207346_at 8 </p><p id="p2104" num="2104"> 208040„s_at 9 </p><p id="p2105" num="2105"> 214054_at 10 </p><p id="p2106" num="2106"> 204776_at 11 </p><p id="p2107" num="2107"> 205950_s_at 12 </p><p id="p2108" num="2108"> 221270_s_at 13 </p><p id="p2109" num="2109"> 216293_at 14 </p><p id="p2110" num="2110"> 206994_at 15 </p><p id="p2111" num="2111"> 222210_at 16 </p><p id="p2112" num="2112"> 216940_x_at 17 </p><p id="p2113" num="2113"> 215736_at 18 </p><p id="p2114" num="2114"> 205275_at 19 </p><p id="p2115" num="2115"> 222375_at 20 </p><p id="p2116" num="2116"> 217583_at 11000 </p><p id="p2117" num="2117"> 214025_at 11001 </p><p id="p2118" num="2118"> 210392_x_at 11002 </p><p id="p2119" num="2119"> 216673_at 11003 </p><p id="p2120" num="2120"> 220911_s_at 11004 </p><p id="p2121" num="2121"> 207873_x_at 11005 </p><p id="p2122" num="2122"> 219572_at 11006 </p><p id="p2123" num="2123"> 214329_x_at 11007 </p><p id="p2124" num="2124"> 213683_at 11008 </p><p id="p2125" num="2125"> 208385_at 11009 </p><p id="p2126" num="2126"> 211336_x_at 11010 </p><p id="p2127" num="2127"> 205380_at 11011 </p><p id="p2128" num="2128"> 204855_at 11012 </p><p id="p2129" num="2129"> 208593_x_at 11013 </p><p id="p2130" num="2130"> 214952_at 11014 </p><p id="p2131" num="2131"> 220893_at 11015 </p><p id="p2132" num="2132"> 215228_at 11016 </p><p id="p2133" num="2133"> 205814_at 11017 </p><p id="p2134" num="2134"> 210121_at 11018 </p><p id="p2135" num="2135"> 208208_at 11019 </p><p id="p2136" num="2136"> 215465_at 11020 </p><p id="p2137" num="2137"> 209794_at 22194 </p><p id="p2138" num="2138"> 221810_at 22195 </p><p id="p2139" num="2139"> 217107_at 22196 </p><p id="p2140" num="2140"> 212611_at 22197 </p><p id="p2141" num="2141"> 217135_x„at 22198 </p><p id="p2142" num="2142"> 221077_at 22199 </p><p id="p2143" num="2143"> 211241 at 22200 </p><p id="p2144" num="2144"> 212153_at 22201 </p><p id="p2145" num="2145"> 210126_at 22202 </p><p id="p2146" num="2146"> 212475_at 22203 </p><p id="p2147" num="2147"> 209547_s_at 22204 </p><p id="p2148" num="2148"> 208987_s_at 22205 </p><p id="p2149" num="2149"> 216320_x_at 22206 </p><p id="p2150" num="2150"> 212713_at 22207 </p><p id="p2151" num="2151"> 204484_at 22208 </p><p id="p2152" num="2152"> 214880_x_at 22209 </p><p id="p2153" num="2153"> 206764__x_at 22210 </p><p id="p2154" num="2154"> 219636_s_at 22211 </p><p id="p2155" num="2155"> 210933_s_at 22212 
<!-- EPO <DP n="110"/>-->
219664„s_at 22213 219018_s_at 22214 
<!-- EPO <DP n="111"/>-->
</p><p id="p2156" num="2156">Tab! e_H probe Set ID CMP_61_23 CMapRank </p><p id="p2157" num="2157"> 209547_s_at 1 </p><p id="p2158" num="2158"> 210974_s_at 2 </p><p id="p2159" num="2159"> 210348„at 3 </p><p id="p2160" num="2160"> 219807_x_at 4 </p><p id="p2161" num="2161"> 205743_at 5 </p><p id="p2162" num="2162"> 216243_s_at 6 </p><p id="p2163" num="2163"> 215195_at 7 </p><p id="p2164" num="2164"> 214320_x_at 8 </p><p id="p2165" num="2165"> 220940_at 9 </p><p id="p2166" num="2166"> 220694_at 10 </p><p id="p2167" num="2167"> 210325_at 11 </p><p id="p2168" num="2168"> 205950_s_at 12 </p><p id="p2169" num="2169"> 201808_s_at 13 </p><p id="p2170" num="2170"> 220319_s_at 14 </p><p id="p2171" num="2171"> 220243_at 15 </p><p id="p2172" num="2172"> 220028_at 16 </p><p id="p2173" num="2173"> 336_at 17 </p><p id="p2174" num="2174"> 215757_at 18 </p><p id="p2175" num="2175"> 207670_at 19 </p><p id="p2176" num="2176"> 211304_x_at 20 </p><p id="p2177" num="2177"> 221866_at 11000 </p><p id="p2178" num="2178"> 208534_s_at 11001 </p><p id="p2179" num="2179"> 211643_x_at 11002 </p><p id="p2180" num="2180"> 219890_at 11003 </p><p id="p2181" num="2181"> 216655_s_at 11004 </p><p id="p2182" num="2182"> 216065_at 11005 </p><p id="p2183" num="2183"> 213945_s_at 11006 </p><p id="p2184" num="2184"> 215048_at 11007 </p><p id="p2185" num="2185"> 211232_x_at 11008 </p><p id="p2186" num="2186"> 220687_at 11009 </p><p id="p2187" num="2187"> 215770_at 11010 </p><p id="p2188" num="2188"> 204915_s_at 11011 </p><p id="p2189" num="2189"> 203325_s_at 11012 </p><p id="p2190" num="2190"> 212706_at 11013 </p><p id="p2191" num="2191"> 205948_at 11014 </p><p id="p2192" num="2192"> 205852_at 11015 </p><p id="p2193" num="2193"> 205155_s_at 11016 </p><p id="p2194" num="2194"> 222089_s_at 11017 </p><p id="p2195" num="2195"> 203071_at 11018 </p><p id="p2196" num="2196"> 221784_at 11019 </p><p id="p2197" num="2197"> 210794_s_at 11020 </p><p id="p2198" num="2198"> 205918_at 22194 </p><p id="p2199" num="2199"> 208347_at 22195 </p><p id="p2200" num="2200"> 215845_x_at 22196 </p><p id="p2201" num="2201"> 205662_at 22197 </p><p id="p2202" num="2202"> 20830L_at 22198 </p><p id="p2203" num="2203"> 212559_at 22199 </p><p id="p2204" num="2204"> 211088_s. at 22200 </p><p id="p2205" num="2205"> 20903 Lat 22201 </p><p id="p2206" num="2206"> 216532_x_at 22202 </p><p id="p2207" num="2207"> 213755_s„at 22203 </p><p id="p2208" num="2208"> 211112_at 22204 </p><p id="p2209" num="2209"> 207953_at 22205 </p><p id="p2210" num="2210"> 202497_x_at 22206 </p><p id="p2211" num="2211"> 209035_at 22207 </p><p id="p2212" num="2212"> 215849_x_at 22208 </p><p id="p2213" num="2213"> 210201_x_at 22209 </p><p id="p2214" num="2214"> 219847_at 22210 </p><p id="p2215" num="2215"> 202328„s_at 22211 </p><p id="p2216" num="2216"> 219664_s_at 22212 
<!-- EPO <DP n="112"/>-->
204757_s_at 22213 216822_x_at 22214 
<!-- EPO <DP n="113"/>-->
</p><p id="p2217" num="2217">Table_i </p><p id="p2218" num="2218"> Probe set ID Gene Symbol Gene Name Representative Public ID Log t-ttestRank </p><p id="p2219" num="2219"> 205236_x_at SOD3 superoxide dismutase 3 extracellular NM_003102 1 213113_s_at SLC43A3 solute carrier family 43 member 3 AI630178 3 212796_s_at TBC1D2B TBC1 domain family member 2B BF195608 4 </p><p id="p2220" num="2220"> 213364_s_at SNXl sorting nexin 1 AI052536 7 </p><p id="p2221" num="2221"> 202510_s_at TNFAIP2 tumor necrosis factor al ha-induced protein 2 NM_006291 8 </p><p id="p2222" num="2222"> 213258_at TFPI tissue factor pathway inhibitor (l poprotein-associated coagulation inhibitor) BF511231 9 </p><p id="p2223" num="2223"> 202291_s_at MGP matrix Gla protein NM_000900 13 </p><p id="p2224" num="2224"> 219304_s_at PDGFD platelet derived growth factor D NM_025208 14 202994_s_at FBLNl fibul in 1 Z95331 15 </p><p id="p2225" num="2225"> 212589_at RRAS2 related RAS viral (r-ras) oncogene homolog 2 AI753792 16 </p><p id="p2226" num="2226"> 202912_at ADM adrenomedullin NM_001124 17 </p><p id="p2227" num="2227"> 203088_at FBLN5 fibul in 5 NM_006329 20 </p><p id="p2228" num="2228"> 216620_s_at ARHGEFlO Rho guanine nucleotide exchange factor (GEF) 10 AF009205 21 </p><p id="p2229" num="2229"> 212067_s_at ClR complement component 1 r subcomponent AL573058 22 202363_at SPOC l sparc/osteonecti n cwcv and kazal-like domains proteoglycan (testican) 1 AF231124 23 </p><p id="p2230" num="2230"> 206157_at PTX3 pentraxin-related gene rapidly induced by IL-I beta </p><p id="p2231" num="2231"> N _002852 24 </p><p id="p2232" num="2232"> 208747_s_at CIS complement component 1 s subcomponent M18767 29 </p><p id="p2233" num="2233"> 209763_at CHRDLl chordin- ike 1 AL049176 30 </p><p id="p2234" num="2234"> 200785_s_at LOC100134190 similar to low density lipoprotein-related protein 1</p><p id="p2235" num="2235">(alpha-2-macroglobuli n receptor) NM_002332 31 </p><p id="p2236" num="2236"> 206373_at ZICl Zic family member 1 (odd-paired homolog Drosophila) </p><p id="p2237" num="2237">NM_003412 </p><p id="p2238" num="2238">213164_at SLC5A3 solute carrier family 5 (sodium/myo-inos tol cotransporter) member 3 AI867198 34 </p><p id="p2239" num="2239">202897_at SIRPA signal -regulatory protein alpha AB023430 36 </p><p id="p2240" num="2240">201787_at LOC100133843 fibul in 1 NM_001996 37 </p><p id="p2241" num="2241">213348_at CDKNlc cyclin-dependent kinase inhibitor 1C (p57 Kip2) N33167 38 201842_s_at EFEMPl EGF-contai ning fibul in-like extracellular matrix protein 1 AI826799 39 </p><p id="p2242" num="2242">217800_s_at NDFiPl Nedd4 family interacting protein 1 NM_030571 40 212761_at TCF7L2 transcription factor 7-Tike 2 (τ-cell specific HMG-box) AI949687 41 </p><p id="p2243" num="2243">212944_at SLC5A3 solute carrier family 5 (sodium/myo-inositol cotransporter) member 3 AK024896 43 </p><p id="p2244" num="2244">217904_s_at BACEl beta-s te APP-cleaving enzyme 1 NM_012104 44 </p><p id="p2245" num="2245">209335_at DCN decorin AI281593 45 </p><p id="p2246" num="2246">213568_at OSR2 odd-skipped related 2 (Drosoph la) AI811298 49 205422_s_at ITGBLl integrin beta-like 1 (with EGF-like repeat domains) </p><p id="p2247" num="2247">NM_004791 </p><p id="p2248" num="2248">200771_at LAMC1 laminin gamma 1 (formerly LAMB2) NM_002293 51 207606_s_at ARHGAP12 Rho GTPase activat ng protein 12 NM_018287 52 </p><p id="p2249" num="2249"> 213150_at ΗΟΧΑ10 homeobox A10 BF792917 53 </p><p id="p2250" num="2250"> 214494_s_at SPG7 spastic paraplegia 7 (pure and complicated autosomal recessive) NM_005200 54 </p><p id="p2251" num="2251"> 205802_at TRPCl transient receptor potential cation channel subfamily c member 1 NM_003304 55 </p><p id="p2252" num="2252"> 212558_at SPRYl sprouty homolog 1 antagonist of FGF signaling (Drosophila)</p><p id="p2253" num="2253">BF508662 57 </p><p id="p2254" num="2254"> 218901_at PLSCR4 phospholipid scramblase 4 NM_020353 58 </p><p id="p2255" num="2255"> 200986_at SERPING1 serpin peptidase inhibitor clade G (CI inhibitor) member 1 NM_000062 59 </p><p id="p2256" num="2256"> 204963_at SSPN sarcospan (Kras oncogene -assoc ated gene) AL136756</p><p id="p2257" num="2257">60 </p><p id="p2258" num="2258"> 203939_at NT5E 5 ' -nucleotidase ecto (CD73) NM_002526 63 
<!-- EPO <DP n="114"/>-->
 Table_l </p><p id="p2259" num="2259"> 201843_s_at EFEMPl EGF-contai ning fibulin-like extracellular matrix protein 1</p><p id="p2260" num="2260">NM_004105 64 </p><p id="p2261" num="2261"> 202995„s_at FBLNl fibulin 1 NM_006486 65 </p><p id="p2262" num="2262"> 204749_at NAP1L3 nucleosome assembly protein 1-1 ike 3 NM_004538 66</p><p id="p2263" num="2263">212419_at ZCCHC24 zinc finger CCHC domain containing 24 AA131324 67</p><p id="p2264" num="2264">203217„s_at ST3GAL5 ST3 beta-galactos de al pha-23-siaiyl transferase 5 </p><p id="p2265" num="2265"> NM_003896 68 </p><p id="p2266" num="2266"> 218418_s_at AN 2 KN motif and ankyrin repeat domains 2 NM_015493 69</p><p id="p2267" num="2267">220327_at VGLL3 vestigial like 3 (Drosophila) NM_016206 72 </p><p id="p2268" num="2268"> 205612_at MMRNl multimerin 1 NM_007351 73 </p><p id="p2269" num="2269"> 218276_s_at SAVl Salvador homolog 1 (Drosophila) NM_021818 76 </p><p id="p2270" num="2270"> 212224_at ALDHlAl aldehyde dehydrogenase 1 family member Al NM_000689</p><p id="p2271" num="2271">78 </p><p id="p2272" num="2272"> 221950__at E X2 empty spiracles homeobox 2 AI478455 79 </p><p id="p2273" num="2273"> 205407_at RECK reversion-inducing-cysteine-rich protein with kazal motifs</p><p id="p2274" num="2274">NML021111 80 </p><p id="p2275" num="2275"> 221016_s_at TCF7L1 transcription factor 7-1 i ke 1 (r-cell specific HMG-box)</p><p id="p2276" num="2276">NM_031283 83 </p><p id="p2277" num="2277"> 201535_at UBL3 ubi qui tin-like 3 N _007106 87 </p><p id="p2278" num="2278"> 213429_at BICCl bi caudal C homolog 1 (Drosophila) AW025579 88</p><p id="p2279" num="2279">217853_at TNS3 tensin 3 NM_022748 90 </p><p id="p2280" num="2280"> 201811_x_at SH3BP5 SH3-domain binding protein 5 (BTK-associated) N _004844</p><p id="p2281" num="2281">91 </p><p id="p2282" num="2282"> 205011_at VWA5A von Willebrand factor A domain containing 5A N _014622 92 </p><p id="p2283" num="2283"> 202220_at KIAA0907 ΚΙΑΑ0907 NM__014949 95 </p><p id="p2284" num="2284"> 221019_s_at COLEC12 collectin sub-family member 12 NM_030781 97 </p><p id="p2285" num="2285"> 218162_at OLFML3 olfactomedi n-1 i ke 3 NM_020190 98 </p><p id="p2286" num="2286"> 201744_s_at LUM lumican NM_002345 99 </p><p id="p2287" num="2287"> 202664_at WIPFl WAS/WASL interacting protein family member 1 AW058622</p><p id="p2288" num="2288">101 </p><p id="p2289" num="2289"> 210135_s_at SHOX2 short stature homeobox 2 AF022654 102 </p><p id="p2290" num="2290"> 203083_at THBS2 thrombospondi n 2 NNL003247 104 </p><p id="p2291" num="2291"> 201792_at AEBPl AE binding protein 1 N _001129 105 </p><p id="p2292" num="2292"> 209265_s_at METTL.3 methyltransferase like 3 BC001650 106 </p><p id="p2293" num="2293"> 204457_s_at GASl growth arrest-specific 1 NM_002048 109 </p><p id="p2294" num="2294"> 213249_at FBXL7 -box and leuc ne- rich repeat protein 7 AU145127 111</p><p id="p2295" num="2295">201818_at LPCATl lysophosphatidyl choline acyl transferase 1 NMJ324830</p><p id="p2296" num="2296">112 </p><p id="p2297" num="2297"> 203583_at UNC50 unc-50 homolog (c. elegans) N _014044 113 </p><p id="p2298" num="2298"> 212486_s_at FYN FYN oncogene related to SRC FGR YES N20923 114 </p><p id="p2299" num="2299"> 205609_at A GPT1 angiopoietin 1 NM_001146 117 </p><p id="p2300" num="2300"> 202729_s_at LTBPl latent transforming growth factor beta binding protein 1</p><p id="p2301" num="2301">N _000627 119 </p><p id="p2302" num="2302"> 36030_at IFFOl intermediate filament family orphan 1 AL080214 123</p><p id="p2303" num="2303">204140_at TPSTl tyrosyl protein sulfotransferase 1 NM_003596 124</p><p id="p2304" num="2304">217122_s_at LOC728661 similar to sol ute carrier fami ly 35 member E2</p><p id="p2305" num="2305">AL031282 125 </p><p id="p2306" num="2306"> 200945_s_at SEC31A SE homolog A (S . cerevisiae) M_014 33 126 </p><p id="p2307" num="2307"> 21262Lat T EM194A transmembrane protein 194A AB006624 127</p><p id="p2308" num="2308">203131_at PDGFRA platelet-derived growth factor receptor alpha polypeptide</p><p id="p2309" num="2309">NM_006206 129 </p><p id="p2310" num="2310"> 218 X5 St. UTP6 UTP6 small subunit (SSU) processome component homolog</p><p id="p2311" num="2311">(yeast) HM_01i 428 132 </p><p id="p2312" num="2312">212877_at KLCl kinesi light chain 1 AA284075 134 </p><p id="p2313" num="2313">218204_s_at FYCOl FYVE and coi 1 ed-coi 1 domain containing NM_024513 138 </p><p id="p2314" num="2314"> 203812_at null AB011538 140 </p><p id="p2315" num="2315">213422_s_at MXRA8 matrix-remodelling associated 8 AW888223 141 </p><p id="p2316" num="2316">212736_at Cl6orf45 chromosome 16 open reading frame 45 BE299456 142 </p><p id="p2317" num="2317"> 212230_at PPAP2B phosphati di c acid phosphatase type 2B AV725664 146 209550 at NDN necdin homolog (mouse) U35139 147 
<!-- EPO <DP n="115"/>-->
 W </p><p id="p2318" num="2318"> 114 </p><p id="p2319" num="2319">Tabl e. .1 </p><p id="p2320" num="2320"> 221556_at CDC14B CDC14 cell division cycle 14 homolog B (S. cerevi siae)</p><p id="p2321" num="2321">BF792631 148 </p><p id="p2322" num="2322"> 213802_at null AI810767 149 </p><p id="p2323" num="2323"> 218718_at PDGFC platelet derived growth factor C NM_016205 150</p><p id="p2324" num="2324">218146_at GLT8D1 glycosyl transferase 8 domain containing 1 NM_018446</p><p id="p2325" num="2325">153 </p><p id="p2326" num="2326"> 205083_at AOX1 a dehyde oxidase 1 NM_001159 154 </p><p id="p2327" num="2327"> 213161_at C9orf97 chromosome 9 open reading frame 97 AI583393 155</p><p id="p2328" num="2328">212597_s_at HMGXB4 HMG box domain containing 4 AL079310 159 </p><p id="p2329" num="2329"> 210105<sub>^</sub>s_at FYN FYN oncogene related to SRC FGR YES M14333 160 </p><p id="p2330" num="2330"> 203706_s_at FZD7 frizzled homolog 7 (Drosophila) NM_003507 163 </p><p id="p2331" num="2331"> 202202_s_at LAMA4 laminin alpha 4 N _002290 165 </p><p id="p2332" num="2332"> 216033_s_at FYN FYN oncogene related to SRC FGR YES S74774 167 </p><p id="p2333" num="2333"> 221897_at TRIM52 tripartite motif-containing 52 AA205660 169 </p><p id="p2334" num="2334"> 218656_s_at LHFP lipoma HMGIC fusion partner NM_005780 173 </p><p id="p2335" num="2335"> 204112_s_at HN T histamine N-methyltransferase NM_006895 175 </p><p id="p2336" num="2336"> 204042_at ASF3 WAS protein family member 3 AB020707 177 </p><p id="p2337" num="2337"> 209568_s_at RGLl ra guanine nucleotide dissociation stimulator like </p><p id="p2338" num="2338"> AF186779 179 </p><p id="p2339" num="2339"> 209884_s_at SLC4A7 ssoolluuttee carrier family 4 sodium bicarbonate cotransporter member 7 AF047033 180 </p><p id="p2340" num="2340"> 201395_at RBM5 RNA binding motif protein 5 NM_ 005778 185 </p><p id="p2341" num="2341"> 219552_at SVEPl sushi von illebrand factor type A EGF and pentraxin domain containing 1 NM_024500 188 </p><p id="p2342" num="2342"> 214323_s_at UPF3A UPF3 regulator of nonsense transcripts homolog A (yeast)</p><p id="p2343" num="2343">N36842 189 </p><p id="p2344" num="2344"> 219093_at PIDl phosphotyrosine interaction domain containing 1 NM_017933</p><p id="p2345" num="2345">191 </p><p id="p2346" num="2346"> 204345_at COL16A1 collagen type xvi alpha 1 NM_001856 198 </p><p id="p2347" num="2347"> 203476_at TPBG trophoblast glycoprotein NM_006670 202 </p><p id="p2348" num="2348"> 203117_s_at PAN2 PAN2 poly(A) specific ribonuclease subunit homolog (S. </p><p id="p2349" num="2349">cerevi siae) N J314871 208 </p><p id="p2350" num="2350"> 204453_at ZNF84 zinc finger protein 84 NM_003428 209 </p><p id="p2351" num="2351"> 203600_s_at C4orf8 chromosome 4 open reading frame 8 NM_003704 210</p><p id="p2352" num="2352">221760_at A lAl CDNA: FL321946 fis clone HEP04860 highly similar to HSHUMM9</p><p id="p2353" num="2353">Homo sapiens HU 9 mRNA BG287153 211 </p><p id="p2354" num="2354"> 218793_s_at SCMLl sex comb on midleg-like 1 (Drosophila) N _006746 213</p><p id="p2355" num="2355">205542_at STEAPl six transmembrane epithelial antigen of the prostate </p><p id="p2356" num="2356"> NM_012449 215 </p><p id="p2357" num="2357"> 215388_s_at CFH complement factor H X56210 217 </p><p id="p2358" num="2358"> 201278_at DAB2 disabled homolog 2 mitogen-responsi ve phosphoprotein </p><p id="p2359" num="2359"> (Drosophila) N21202 218 </p><p id="p2360" num="2360"> 206958_s_at UPF3A UPF3 regulator of nonsense transcripts homolog A (yeast)</p><p id="p2361" num="2361">AF318575 219 </p><p id="p2362" num="2362"> 202273_at PDGFRB platelet-derived growth factor receptor beta polypeptide</p><p id="p2363" num="2363">NM_002609 224 </p><p id="p2364" num="2364"> 218686_s_at RHBDFl rhomboid 5 homolog 1 (Drosophila) NM_022450 227</p><p id="p2365" num="2365">39650_s_at PCNXL2 pecanex-1 i ke 2 (Drosophila) AB007895 228 </p><p id="p2366" num="2366"> 219639_x_at PARP6 poly (ADP-ribose) polymerase family member 6 NM_020213</p><p id="p2367" num="2367">231 </p><p id="p2368" num="2368"> 222235_s_at CSGALNACT2 chondroitin sulfate </p><p id="p2369" num="2369"> N-acetyl gal actosami ny 1 transfe rase 2 AL139812 232 </p><p id="p2370" num="2370"> 209580_s_at MBD4 methyl -CpG binding domain protein 4 AF114784 234 212651_at RHOBTB1 Rho-related BTB domain containing 1 AB018283 236 207177_at PTGFR prostaglandin F receptor (FP) NM_000959 239 </p><p id="p2371" num="2371">205452_at PIGB phosphatidyl inositol glycan anchor biosynthesis class NM__004855 241 </p><p id="p2372" num="2372">212195_at IL.6ST interleukin 6 signal transducer (gpl30 oncostatin M receptor) AL049265 242 </p><p id="p2373" num="2373">220351_.at CCRL1 chemokine (C-C motif) receptor-like 1 NM_016557 243 212503__s__at DIP2C DIP2 disco-interacting protein 2 homo og C (Drosophil ) N22859 246 </p><p id="p2374" num="2374">218093_s_at A KRDIO ankyrin repeat domain 10 NM 017664 248 
<!-- EPO <DP n="116"/>-->
 Table__i </p><p id="p2375" num="2375"> 207808_s_at PROSl protein S laipna) NM_000313 249 </p><p id="p2376" num="2376"> 201034_at ADD3 adducin 3 (gamma) BE545756 251 </p><p id="p2377" num="2377"> 212327_at LIMCHl LIM and calponin homology domains 1 AK026815 2</p><p id="p2378" num="2378">212979_s_at FAM115A family with sequence similarity 115 member A AW293343</p><p id="p2379" num="2379">253 </p><p id="p2380" num="2380"> 212855_at DCUN1D4 DCNl defective in cullin neddylation 1 domain containing 4 (S. cerevisiae) D87466 257 </p><p id="p2381" num="2381"> 219283_at ClGALTlCl clGALTl-specific chaperone 1 NM_014158 259 211896_s_at DCN decorin AF138302 260 </p><p id="p2382" num="2382"> 210139_s_at PMP22 peripheral myelin protein 22 L03203 263 </p><p id="p2383" num="2383"> 207417„s_at ZNF177 zinc finger protein 177 NM_003451 265 </p><p id="p2384" num="2384"> 200770_s_at LAMCl laminin gamma 1 (formerly LAMB2) 303202 266 </p><p id="p2385" num="2385">202920_at ANK2 ankyrin 2 neuronal BF726212 267 </p><p id="p2386" num="2386">221569„at AHIl Abel son helper integration site 1 AL136797 268 213737_x_at GOLGA9P golgi autoantigen golgin subfamily a 9 pseudogene </p><p id="p2387" num="2387">AI620911 269 </p><p id="p2388" num="2388">202142_at COPS8 COP9 constitutive photomorphogenic homolog subunit 8 (Arabidopsis) BC003090 270 </p><p id="p2389" num="2389">202951_at STK38 serine/threonine kinase 38 BE048506 272 </p><p id="p2390" num="2390">201139_s_at SSB Sjogren syndrome antigen B (autoantigen La) NM_003142 274 </p><p id="p2391" num="2391"> 213293_s_at TRIM22 tripartite motif-containing 22 AA083478 276 </p><p id="p2392" num="2392">218285_s_at BDH2 3-hydroxybutyrate dehydrogenase type 2 NM_020139 278 213262_at SACS spastic ataxia of Charlevoix-Saguenay (sacsin) AI932370 281 </p><p id="p2393" num="2393"> 203893_at TAF9 TAF9 RNA polymerase II TATA box binding protein </p><p id="p2394" num="2394">(TBP) -associated factor 32kDa NM_016283 282 </p><p id="p2395" num="2395">201086_x_at SON SON DNA binding protein N _003103 283 </p><p id="p2396" num="2396">204085_s_at CLN5 ceroid-lipofuscinosis neuronal 5 NM_006493 287 204897_at PTGER4 prostaglandin E receptor 4 (subtype EP4) ΑΑ897516 288 </p><p id="p2397" num="2397"> 212793_at DAAM2 dishevelled associated activator of morphogenesis 2 </p><p id="p2398" num="2398">BF513244 289 </p><p id="p2399" num="2399">204036_at LPARl lysophosphatidi c acid receptor 1 AW269335 291 212958_x_at PAM peptidyl glycine al ha-ami dating monooxygenase AI022882 292 </p><p id="p2400" num="2400"> 211535_s_at FGFRl fibroblast growth factor receptor 1 M60485 295 </p><p id="p2401" num="2401">212764_at ZEBl zinc finger E-box binding homeobox 1 AI806174 298 221645_s_at ZNF83 zinc finger protein 83 M27877 300 </p><p id="p2402" num="2402">208922_s_at NXFI nuclear RNA export factor 1 BC004904 301 </p><p id="p2403" num="2403">203139_at DAPKl death-associated prote n kinase 1 NM_004938 302 220992_s_at Clorf25 chromosome 1 open reading frame 25 NM_030934 306 214703_s_at MAN2B2 mannosidase alpha class 2B member 2 AW954107 307 214749_s_at ARMCX6 armadillo repeat containing x-1 inked 6 AK000818 308 201150_s_at TIMP3 TIMP metal lopept dase inhibitor 3 NM_000362 309 213455_at FAM114A1 family with sequence similarity 114 member Al W87466 310 </p><p id="p2404" num="2404">203886„s_at FBLN2 fibulin 2 NM_ .001998 313 </p><p id="p2405" num="2405">202104_s_at SPG7 spastic paraplegia 7 (pure and complicated autosomal recessive) NM_003119 316 </p><p id="p2406" num="2406">201669_s_at MARCKS myri stoylated alanine-rich protei n ki nase C substrate NM_002356 318 </p><p id="p2407" num="2407"> 2 X7792 3t SNXS sorting nexin 5 NM_014 26 319 </p><p id="p2408" num="2408"> 204093_at CCNH cyclin H NM_001239 320 </p><p id="p2409" num="2409">208669_s_at EIDl EP300 i nteracti ng nhibitor of differentiation </p><p id="p2410" num="2410">AF109873 326 </p><p id="p2411" num="2411">204605_at CGRRF1 cell growth regulator with ri ng finger domai n 1 NM_006568 328 </p><p id="p2412" num="2412"> 211675_s_at MDFIC MyoD family inhibitor domain containing AF054589 331 209101_at CTGF connective tissue growth factor M92934 332 </p><p id="p2413" num="2413">201798„s_at YOF myoferl i n NM_013451 334 </p><p id="p2414" num="2414">206876 at SIMl single-minded homolog 1 (Drosophila) AL121948 338 209946_at VEGFC vascular endothelial growth factor C U58111 339 
<!-- EPO <DP n="117"/>-->
 Table_i </p><p id="p2415" num="2415"> 216840_s_at LAMA2 laminin aipna 2 A 026829 340 </p><p id="p2416" num="2416"> 208848_at ADH5 alcohol dehydrogenase 5 (class Hi) chi polypeptide </p><p id="p2417" num="2417"> M30471 343 </p><p id="p2418" num="2418"> 218014_at NUP85 nucleoporin 85kDa NM_024844 345 </p><p id="p2419" num="2419"> 202478_at TRIB2 tribbles homolog 2 (Drosophila) NM_021643 346 </p><p id="p2420" num="2420"> 201063_at RCNl reticulocalbin 1 EF-hand calcium binding domain NM_002901</p><p id="p2421" num="2421">347 </p><p id="p2422" num="2422"> 209409_at GRB10 growth factor receptor-bound protein 10 D86962 348 </p><p id="p2423" num="2423">212681_at EPB41L.3 erythrocyte membrane protein band 4.1-like 3 AI770004 349 </p><p id="p2424" num="2424"> 202598_at S100A13 S100 calcium binding protein A13 NM_005979 351</p><p id="p2425" num="2425">209497_s„at RBM4B RNA binding motif protein 4B BC003503 352 </p><p id="p2426" num="2426"> 219949_at LRRC2 leucine rich repeat containing 2 NM_024512 353</p><p id="p2427" num="2427">210312_s_at IFT20 i ntrafl agel lar transport 20 homolog (Chlamydomonas) </p><p id="p2428" num="2428"> BC002640 354 </p><p id="p2429" num="2429"> 213266_at TUBGCP4 Tubulin gamma complex associated protein 4 mRNA (CDNA clone</p><p id="p2430" num="2430">MGC:2720 IMAGE: 2821891) BF592982 355 </p><p id="p2431" num="2431"> 219778_at ZFPM2 zinc finger protein multitype 2 NM_012082 357 </p><p id="p2432" num="2432"> 210406_s_at RAB6A RAB6A member RAS oncogene family AL136727 358</p><p id="p2433" num="2433">212148_at PBXl pre-B-cell leukemia homeobox 1 AL049381 359 </p><p id="p2434" num="2434"> 203241_at UVRAG uv radiation resistance associated gene NM_003369 360</p><p id="p2435" num="2435">218076_s_at ARHGAP17 Rho GTPase activating protein 17 NM_018054</p><p id="p2436" num="2436">361 
<!-- EPO <DP n="118"/>-->
</p><p id="p2437" num="2437">Table_J </p><p id="p2438" num="2438"> Probe set ID Gene Symbol Gene Name Representative public ID Log t-testRank </p><p id="p2439" num="2439"> 205187_at SMAD5 SMAD family member 5 AF010601 </p><p id="p2440" num="2440"> 201702_s_at PPP1R10 protein phosphatase 1 regulatory (inhibitor) subunit 10 AI492873 11 </p><p id="p2441" num="2441"> 211074_at FOLR1 folate receptor 1 (adult) AF000381 19 </p><p id="p2442" num="2442"> 202102_s_at BRD4 bromodomain conta ning 4 BF718610 25 </p><p id="p2443" num="2443"> 214265_at ITGA8 inteqrin alpha 8 AI193623 26 </p><p id="p2444" num="2444"> 208711_s_at CCNDl cyclin Dl BC000076 27 </p><p id="p2445" num="2445"> 222024_s_at AKAP13 A kinase (PRKA) anchor protein 13 AK022014 28 210717_at null AF116659 35 </p><p id="p2446" num="2446"> 206061_s_at DICERl dicer 1 ribonuclease type III NM_030621 42 </p><p id="p2447" num="2447"> 209936_at RBM5 RNA binding motif protein 5 AF107493 46 </p><p id="p2448" num="2448"> 211081_s_at MAP4K5 mitogen-activated protein kinase kinase kinase kinase 5 Z25426 56 </p><p id="p2449" num="2449"> 217649_at ZFAND5 zinc finger ANl-type domain 5 AV702306 70 </p><p id="p2450" num="2450"> 209088_s_at UBN1 ubinuc em 1 T70262 81 </p><p id="p2451" num="2451"> 210807_s_at SLC16A7 solute carrier family 16 member 7 (monocarboxyl ic acid transporter 2) AF049608 84 </p><p id="p2452" num="2452"> 220071_x_at CEP27 centrosomal protein 27kDa NM_018097 85 </p><p id="p2453" num="2453"> 214153_at ELOVL5 ELOVL family member 5 elongation of long chain fatty acids CFENl/Elo2 SUR4/Elo3-like yeast) BE467941 89 </p><p id="p2454" num="2454"> 211993_at WNKl WNK lysine deficient protein kinase 1 AI768512 100 21 718_at RBM4 RNA binding motif protein 4 BE222257 103 </p><p id="p2455" num="2455"> 216858_x_at null AL080112 116 </p><p id="p2456" num="2456"> 212057_at IAA0182 KIAA0182 AA206161 121 </p><p id="p2457" num="2457"> 214041_x_at RPL37A Ribosomal protein L37a BE857772 130 </p><p id="p2458" num="2458">209945_s_at GSK3B glycogen synthase kinase 3 beta BC000251 131 </p><p id="p2459" num="2459">216187_x_at null AF222691 133 </p><p id="p2460" num="2460">221943_x_at RPL38 Ribosomal protein L38 RNA (cDNA clone MGC:1637 </p><p id="p2461" num="2461">IMAGE: 3346447) AW303136 136 </p><p id="p2462" num="2462">217538_at SGSM2 small G protein signaling modulator 2 BF347113 137 203803_at PCYOXl prenyl cysteine oxidase 1 N45309 139 </p><p id="p2463" num="2463">202040_s_at JARlDlA jumonji AT rich interactive domain 1A NM_005056 143 211503_s_at RAB14 RAB14 member RAS oncogene family AF112206 145 210479_s_at RORA RAR-related orphan receptor A L14611 151 </p><p id="p2464" num="2464">205967_at HIST1H4A hi stone cluster 1 H4a NM_003542 156 </p><p id="p2465" num="2465">201195_s_at SLC7A5 solute carrier family 7 (cationic amino acid transporter y+ system) member 5 AB018009 158 </p><p id="p2466" num="2466">204881_s_at UGCG UDP-glucose ceramide gl ucosyltransferase NMJ03358 161 </p><p id="p2467" num="2467"> 201867_s_at TBLlX transducin (beta) -like lx-l inked AW968555 162 201901_s_at YY1 YYl transcript on factor Z14077 164 </p><p id="p2468" num="2468">211337_s_at TUBGCP4 tubulin gamma complex associated protein 4 BC000966 166 </p><p id="p2469" num="2469"> 214422_at LOC131185 similar to RAD23B protein T93562 168 </p><p id="p2470" num="2470"> 206036_s_at REL v- reti culoendotheliosis viral oncogene ho olog (avian)</p><p id="p2471" num="2471">NM_002908 170 </p><p id="p2472" num="2472"> 203742_s_at LOC645233 thymine-DNA glycosylase pseudogene BF674842</p><p id="p2473" num="2473">171 </p><p id="p2474" num="2474"> 213517_at PCBP2 poly(rc) binding protein 2 AW103422 174 </p><p id="p2475" num="2475"> 203318 s_at ZNF148 zinc finger protein 148 NM_021964 176 </p><p id="p2476" num="2476"> 214815_at TRI 33 t partite mot f-contain ng 33 AU136587 178 </p><p id="p2477" num="2477"> 212492_s_.at 3MJD2B jumonji domain containing 2B AW237172 181 </p><p id="p2478" num="2478"> 207657„x_at T POl transport! n 1 NM_002270 184 </p><p id="p2479" num="2479"> 213229_at DICERl dicer 1 ribonuclease type ill BF590131 186 </p><p id="p2480" num="2480"> 221705_s_at SI E suppressor of IKK epsi Ion BC005934 187 </p><p id="p2481" num="2481"> 210943_s_at LYST lysosomal trafficking regulator U84744 190 </p><p id="p2482" num="2482"> 212525_s_at H2AFX H2A hi stone family member x AA760862 194 </p><p id="p2483" num="2483"> 208624_s_at EIF4G1 eukaryoti c translation ini tiation factor 4 gamma 1 </p><p id="p2484" num="2484"> BE966878 196 </p><p id="p2485" num="2485"> 201917_s_at SLC25A36 solute carrier family 25 member 36 AI694452</p><p id="p2486" num="2486">197 
<!-- EPO <DP n="119"/>-->
 Table_j </p><p id="p2487" num="2487"> 212229_s_at FBX021 F-box protein 21 AK001699 199 </p><p id="p2488" num="2488"> 204181_s_at ZBTB43 zinc finger and BTB domain containing 43 T90308 200 204524_at PDPKI 3-phosphoinositide dependent protein kinase-: NM_002613 201 </p><p id="p2489" num="2489"> 63825_at ABHD2 abhydrolase domain containing 2 AI557319 203 </p><p id="p2490" num="2490"> 221753„at SSH1 slingshot homolog 1 (Drosophila) AI651213 204</p><p id="p2491" num="2491">214902_x_at null AL080232 207 </p><p id="p2492" num="2492"> 211387_x_at RNGTT RNA guanylyltransferase and 5 ' -phosphatase AB012143</p><p id="p2493" num="2493">212 </p><p id="p2494" num="2494"> 201299„s_at MOBKLIB MOBl Mps One Binder kinase activator-like IB (yeast) </p><p id="p2495" num="2495"> NM_018221 214 </p><p id="p2496" num="2496"> 205322_s_at MTFl metal -regulatory transcription factor 1 AW182367 216 215892_at ZNF440 zinc finger protein 440 mRNA (cDNA clone MGC:46665 </p><p id="p2497" num="2497"> IMAGE: 5556302) AK021474 220 </p><p id="p2498" num="2498"> 220085_at HELLS helicase lymphoid-specific NM_018063 223 </p><p id="p2499" num="2499"> 212520_s_at SMARCA4 S I/SNF related matrix associated actin dependent regulator of chromat n subfamily a member 4 AI684141 226 </p><p id="p2500" num="2500">202940_at WNKl KIAA0344 gene NM_014823 233 </p><p id="p2501" num="2501">222366_at null 86781 238 </p><p id="p2502" num="2502">210426_x_at RORA RAR-re ated orphan receptor A U04897 240 </p><p id="p2503" num="2503">215179_x_at PGF Placenta growth factor 2 (P1GF-2) AK023843 244 221986_s_at KLHL24 kelch-like 24 (Drosophila) AW006750 245 </p><p id="p2504" num="2504">207057_at SLC16A7 solute carrier family 16 member 7 (monocarboxyl i c acid transporter 2) NM_004731 247 </p><p id="p2505" num="2505">203321_s_at ADNP2 ADNP homeobox 2 AK022688 250 </p><p id="p2506" num="2506">20402l_s_at PURA purine-rich element binding protein A NM_005859 2 54 220901_at GPR157 G prote n-coupled receptor 157 NM_024980 25 </p><p id="p2507" num="2507">218930_s_at TMEM106B transmembrane protein 106B NM_018374 258 207730_x_at null NM_017932 261 </p><p id="p2508" num="2508">211316_x_at CFLAR CASP8 and FADD-1 i ke apoptosis regulator AF009616 262 208610_s_at SRRM2 serine/arginine repetitive matrix 2 AI655799 264 219024_at PLEKHAl pleckstrin homology domain containing family A </p><p id="p2509" num="2509"> (phosphoinositide binding specific) member 1 NM_021622 271 </p><p id="p2510" num="2510"> 212079_s_at MLL myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog Drosophila) AA715041 273 </p><p id="p2511" num="2511"> 210613_s_at SYNGRl synaptogyrin 1 BC000731 280 </p><p id="p2512" num="2512">219235_s_at PHACTR4 phosphatase and actin regulator 4 NM_023923 284 220688_s_at MRT04 mRNA turnover 4 homolog (S. cerevisiae) NM_016183 290 212106_at FAF2 Fas associated factor family member 2 BF116183 293 201606_s_at PWPl PWPl homolog (s . cerevisiae) BE796924 294 </p><p id="p2513" num="2513">211992_at WNKl WNK lysine deficient protein kinase 1 AI445745 296 208003_s_at NFAT5 nuclear factor of activated T-cells 5 tonicity-responsi ve NM_006599 297 </p><p id="p2514" num="2514">220572_at DKFZp547Gl83 hypothetical L0C55525 NM_018705 303 </p><p id="p2515" num="2515">211921_x_at PTMA prothymosin a <sup>"</sup>lp <sup>'</sup>ha AF348514 304 </p><p id="p2516" num="2516">209065_at UQCRB ubiquinol -cytochrome c reductase binding protein </p><p id="p2517" num="2517">BC005230 305 </p><p id="p2518" num="2518">213998_s_at DDX17 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 AW188131 311 </p><p id="p2519" num="2519"> 213298_at NFIC nuclear factor I/C (CCAAT-bi nding transcription factor)</p><p id="p2520" num="2520">X12492 312 </p><p id="p2521" num="2521"> 209030<sub>^</sub>s<sub>^</sub>at CADM1 cell adhesion molecule 1 NM_014333 315 </p><p id="p2522" num="2522"> 214305_s_at SF3B1 splicing factor 3b subunit 1 155kDa AW003030 317</p><p id="p2523" num="2523">219910_at FICD Fic domain containing NM_007076 322 </p><p id="p2524" num="2524"> 20163 l_s_at IER3 immediate early response 3 NM_003897 323 </p><p id="p2525" num="2525"> 208120_x_at FKSG49 FKSG49 NM_031221 327 </p><p id="p2526" num="2526"> 204180__s_at ZBTB43 zinc finger and BTB domain containing 43 AI745225</p><p id="p2527" num="2527">330 </p><p id="p2528" num="2528"> 210057_at SMG1 SMGl homolog phosphatidyl inositol 3-kinase- related kinase (c. elegans) U32581 335 </p><p id="p2529" num="2529">219717_at C4orf30 chromosome 4 open reading frame 30 NM_017741 336 203181_x_at SRPK2 SFRS protein kinase 2 AW149364 337 </p><p id="p2530" num="2530">216175„at null AK025276 341 
<!-- EPO <DP n="120"/>-->
 Table_j </p><p id="p2531" num="2531"> 202669„s_at EFNB2 ephn<sup>'</sup>n-B2 U16797 344 </p><p id="p2532" num="2532"> 220720_x_at FAM128B family with sequence similarity 128 member NM_025029 350 </p><p id="p2533" num="2533"> 212807_s_at SORTl sortilin 1 BF447105 356 </p><p id="p2534" num="2534"> 201918_at SLC25A36 solute carrier family 25 member 36 AI927944 368 </p><p id="p2535" num="2535"> 204290_s_at ALDH6A1 aldehyde dehydrogenase 6 family member Al NM_005589 369 </p><p id="p2536" num="2536"> 200637_s_at PTPRF protein tyrosine phosphatase receptor type AI762627 371 </p><p id="p2537" num="2537"> 33646_g_at GM2A GM2 ganglioside activator X61094 381 </p><p id="p2538" num="2538"> 220796_x_at SLC35E1 solute carrier family 35 member El NM_024881 386 212808_at NFATC2IP nuclear factor of activated τ-cells cytoplasmic calcineurin-dependent 2 interacting protein AI884627 389 </p><p id="p2539" num="2539"> 21963 _at TTPAL tocopherol (alpha) transfer protein-like NM_024331 395 </p><p id="p2540" num="2540"> 215628_x__at null AL049285 399 </p><p id="p2541" num="2541"> 221006_s_at SNX27 sorting nexin family member 27 NM_030918 400 </p><p id="p2542" num="2542"> 214972_at MGEA5 Meningioma expressed antigen 5 (hyaluronidase) m NA (CDNA clone MGC: 48750 IMAGE : 5558183) AU144791 403 </p><p id="p2543" num="2543"> 209203_s_at BICD2 bi caudal D homolog 2 (Drosophila) BC002327 405 217620_s_at PIK3CB phosphoinositide-3-kinase catalytic beta polypeptide </p><p id="p2544" num="2544">AA805318 407 </p><p id="p2545" num="2545"> 200616_s_at MLEC malectin BC000371 411 </p><p id="p2546" num="2546"> 215206_at null AK025143 414 </p><p id="p2547" num="2547">212629_s_at PKN2 protein kinase N2 AI633689 417 </p><p id="p2548" num="2548">214374_s_at PPFIBPl PTPRF interacting protein binding protein 1 (liprin beta 1) AI962377 418 </p><p id="p2549" num="2549">202867_s_at DNAJB12 Dnaj (Hsp40) homolog subfamily B member 12 NM„017626 423 </p><p id="p2550" num="2550"> 210407_at PPMlA protein phosphatase 1A (formerly 2c) magnesium-dependent alpha isoform AF070670 427 </p><p id="p2551" num="2551"> 201846_s_at RYBP RING1 and YYl binding protein NM_012234 428 </p><p id="p2552" num="2552"> 20413l_s_at FOX03 forkhead box 03 N25732 429 </p><p id="p2553" num="2553"> 213748_at TRIM66 tripartite moti -contain ng 66 A 271713 431 </p><p id="p2554" num="2554"> 210130_s_at TM7SF2 transmembrane 7 superfamily member 2 AF096304 436</p><p id="p2555" num="2555">204863_s_at IL6ST interleukin 6 signal transducer (gpl30 oncostatin M receptor) BE856546 440 </p><p id="p2556" num="2556"> 201879_at ARIH1 ariadne homolog ub qui tin-conjugating enzyme E2 binding protein 1 (Drosophila) AI694332 442 </p><p id="p2557" num="2557"> 209225_x_at TNPOl transportin 1 AI653355 446 </p><p id="p2558" num="2558">209750_at NR1D2 nuclear receptor subfamily 1 group D member 2 N32859 447 205370_x_at DBT dihydrolipoamide branched chain transacylase E2 NM_001918 449 </p><p id="p2559" num="2559"> 209024_s_at SYNCRIP synaptotagmin binding cytoplasmic RNA interacting protein</p><p id="p2560" num="2560">AI472757 451 </p><p id="p2561" num="2561"> 201548_s_at JARIDlB AT r ch interactive domain IB 452 </p><p id="p2562" num="2562"> 216315_x_at LLOOCCI10O0OI133558 similar to hCGl642170 AL121873 454 </p><p id="p2563" num="2563"> 210701_at CFDPl crani ofaci al development protein 1 D85939 462 </p><p id="p2564" num="2564"> 202844_s_at RALBP1 ralA binding protein 1 AW025261 466 </p><p id="p2565" num="2565"> 208930_s_at ILF3 interleukin enhancer binding factor 90kDa BG032366</p><p id="p2566" num="2566">467 </p><p id="p2567" num="2567"> 212840_at UBXN7 UBX domain protein 7 BG339560 473 </p><p id="p2568" num="2568"> 220113_x_.at POLRlB polymerase (RNA) I pol peptide B 128kDa NM_019014 477</p><p id="p2569" num="2569">207993_s_at CHP calc um binding protein P22 NM_007236 484 </p><p id="p2570" num="2570"> 201085__s_at SON SON DNA binding protein AA664291 489 </p><p id="p2571" num="2571"> 200727_s__at ACTR2 ARP2 actin-re lated protein 2 homolog (yeast) AA699583</p><p id="p2572" num="2572">498 </p><p id="p2573" num="2573"> 209508_x_at CFLAR CASP8 and FADD-1 i ke apoptosis regulator AF005774 502 214843_s_at USP33 ubiquitin specific peptidase 33 AK022864 503 </p><p id="p2574" num="2574">201183_s_at CHD4 chromodomai n helicase DNA binding protein 4 AI613273</p><p id="p2575" num="2575">504 </p><p id="p2576" num="2576"> 221985_at LHL24 kelch-like 24 (Drosophila) AW006750 509 
<!-- EPO <DP n="121"/>-->
 Table_J </p><p id="p2577" num="2577"> 217370_x_at FUS fusion (involved in t(12;16) in malignant liposarcoma)</p><p id="p2578" num="2578">S75762 511 </p><p id="p2579" num="2579"> 219428_s_at PXMP4 peroxisomal membrane protein 4 24kDa BF057649 522</p><p id="p2580" num="2580">208485_x_at CFLAR CASP8 and FADD-like apoptosis regulator NM_003879 523</p><p id="p2581" num="2581">203515_s_at PMVK phosphomevalonate kinase NM_006556 532 </p><p id="p2582" num="2582"> 208549„x_at PTMAP7 prothymosin alpha pseudogene 7 NM_016171 535 </p><p id="p2583" num="2583"> 205809_s_at ASL Wiskott-Aldrich syndrome-l ke BE504979 543 </p><p id="p2584" num="2584"> 217152_at null AK024136 551 </p><p id="p2585" num="2585"> 214001_x„at RPS10 Ribosomal protein S10 AW302047 555 </p><p id="p2586" num="2586"> 202035_s_at SFRPl secreted f rizz ed-related protein 1 AI332407 556</p><p id="p2587" num="2587">202082_s_at SEC14L1 SECl4-like 1 (S. cerevisiae) AV748469 565 </p><p id="p2588" num="2588"> 219723_x_at AGPAT 3 l-acylglycerol-3-phosphate O-acyltransferase 3 NM_020132</p><p id="p2589" num="2589">569 </p><p id="p2590" num="2590"> 201072_s_at SMARCCl swi/SNF related matrix associated actin dependent regulator of chromatin subfamily c member 1 AW152160 570 </p><p id="p2591" num="2591"> 203176_s_at TFAM transcription factor A mitochondrial BE552470 575</p><p id="p2592" num="2592">217550_at ATF6 ATF family member ATF6 (ATF6) AA576497 576 </p><p id="p2593" num="2593"> 204358_s_at FLRT2 fibronectin leucine rich transmembrane protein 2 </p><p id="p2594" num="2594"> AF169676 577 </p><p id="p2595" num="2595"> 204074__s_at KIAA0562 KIAA0562 AI936976 578 </p><p id="p2596" num="2596"> 201035_s_at HADH hydroxyacy -Coenzyme A dehydrogenase BC000306 579</p><p id="p2597" num="2597">210679_x_at null BC002629 580 </p><p id="p2598" num="2598"> 201683_x_at TOX4 TOX high mobility group box family member 4 BE783632</p><p id="p2599" num="2599">587 </p><p id="p2600" num="2600"> 222284_at null AI734111 591 </p><p id="p2601" num="2601">221765_at UGCG UDP-glucose ceramide gl ucosyltransferase AI 378044 596 </p><p id="p2602" num="2602"> 210251_s_at RUFY3 RUN and FYVE domain containing 3 AF112221 600</p><p id="p2603" num="2603">218150_at ARL5A ADP-ribosylation factor-like 5A NMJD12097 604 </p><p id="p2604" num="2604"> 201294_s_at WSBl WD repeat and SOCS box-containing 1 N24643 609 </p><p id="p2605" num="2605"> 35436_at GOLGA2 golgi autoantigen golg n subfamily a 2 L06147 610 </p><p id="p2606" num="2606"> 201996_s_at SPEN spen homolog transcriptional regulator (Drosophila) </p><p id="p2607" num="2607"> AL524033 612 </p><p id="p2608" num="2608"> 210734_x_at MAX MYC associated factor X M64240 615 </p><p id="p2609" num="2609"> 203542_s_at KLF9 Kruppe -like factor 9 AI690205 621 </p><p id="p2610" num="2610"> 214670_at ZKSCANl zinc finger with KRAB and SCAN domains 1 AA653300</p><p id="p2611" num="2611">626 </p><p id="p2612" num="2612"> 208699_x_at TKT transketolase BF696840 627 </p><p id="p2613" num="2613"> 217703_x_at null AA401963 628 </p><p id="p2614" num="2614"> 222214_at null AK024988 630 </p><p id="p2615" num="2615"> 212007_at UBXN4 UBX domain protein 4 AI927512 631 </p><p id="p2616" num="2616"> 209890_at TSPAN5 tetraspanin 5 AF065389 634 </p><p id="p2617" num="2617"> 208200_at ILIA interleukin 1 alpha NM_000575 637 </p><p id="p2618" num="2618"> 213579_s_at EP300 E1A binding protein p300 AI459462 641 </p><p id="p2619" num="2619"> 213650_at GOLGA8A golgi autoantigen golgin subfamily a 8A AW006438 644</p><p id="p2620" num="2620">203975_s_at CHAFlA chromatin assembly factor 1 subunit A (pl50) BF000239</p><p id="p2621" num="2621">647 </p><p id="p2622" num="2622"> 39313_at WNKl KIAA0344 gene AB002342 650 </p><p id="p2623" num="2623"> 215069_at NMT2 NN--mmyyrrii ssttooyyll ttrraannssffeerraassee 22 AAKK002255006655 652 </p><p id="p2624" num="2624"> 219392„x_at PRRll proline rich 11 NM_018304 653 </p><p id="p2625" num="2625"> 213506_at F2RL1 coagulation factor II (thrombin) receptor-like 1 </p><p id="p2626" num="2626"> BE965369 658 </p><p id="p2627" num="2627"> 211000__s_,at IL6ST interleukin 6 signal transducer (gpl30 oncostatin M receptor) AB015706 660 </p><p id="p2628" num="2628"> 222036_s_at MCM4 mi n chromosome maintenance compl ex component 4 AI 859865</p><p id="p2629" num="2629">662 </p><p id="p2630" num="2630"> 218155_x_at TSRl TSRl 20s rRNA accumulation homolog (S. cerevisiae) </p><p id="p2631" num="2631">AK026565 670 </p><p id="p2632" num="2632">200635_s_at PTPRF protein tyrosine phosphatase receptor type F AU145351 674 </p><p id="p2633" num="2633"> 210686_x_at SLC25A16 sol ute carri er f ami 1 y 25 (m tochondrial carrier; Graves di seas e autoantigen) member 16 BC001407 678 </p><p id="p2634" num="2634">66053_at HNRNPUl 2 heterogeneous nucl ear r bonucl eoprotei n u-1 i ke 2 
<!-- EPO <DP n="122"/>-->
 Tabled </p><p id="p2635" num="2635"> AI738452 693 </p><p id="p2636" num="2636"> 213299_at ZBTB7A zinc finger and BTB domain containing 7A AW027070</p><p id="p2637" num="2637">696 </p><p id="p2638" num="2638"> 208336_s_at GPSN2 glycoprotein synaptic 2 NM_004868 698 </p><p id="p2639" num="2639">218521_s_at UBE2W ubi qui tin-conjugating enzyme E2w (putative) NM_018299 700 </p><p id="p2640" num="2640"> 1053_at RFC2 replication factor c (activator 1) 2 40kDa M87338 702 </p><p id="p2641" num="2641"> 211 17_s_at CFLAR CASP8 and FADD-like apoptosis regulator AF041461 705</p><p id="p2642" num="2642">201205_at null AF006751 706 </p><p id="p2643" num="2643"> 222180_at null AU147889 707 </p><p id="p2644" num="2644"> 221419_s_at null NN_013307 709 </p><p id="p2645" num="2645"> 217813_s_at SPIN1 spindl n 1 N _006717 710 
</p></description><claims mxw-id="PCLM44725900" ref-ucid="WO-2012116081-A2" lang="EN" load-source="patent-office"><claim-statement><!-- EPO <DP n="123"/>-->CLAIMS What is claimed is: </claim-statement><claim id="clm-0001" num="1"><claim-text> 1 . A method for constructing a data architecture for use in identifying connections between perturbagens and genes associated with one or more skin aging conditions, comprising:</claim-text><claim-text>(a) providing a gene expression profile for a control human dermal fibroblast cell;</claim-text><claim-text>(b) generating a gene expression profile for a human dermal fibroblast cell exposed to at least one perturbagen; </claim-text><claim-text> (c) identifying genes differentially expressed in response to the at least one </claim-text><claim-text> perturbagen by comparing the gene expression profiles of (a) and (b); </claim-text><claim-text> (d) creating an ordered list comprising identifiers representing the differentially </claim-text><claim-text> expressed genes, wherein the identifiers are ordered according to the differential expression of the genes; </claim-text><claim-text> (e) storing the ordered list as a fibroblast instance on at least one computer readable medium; and </claim-text><claim-text> (f) constructing a data architecture of stored fibroblast instances by repeating (a) through (e), wherein the at least one perturbagen of step (a) is different for each fibroblast instance. </claim-text></claim><claim id="clm-0002" num="2"><claim-text>2. The method according to claim 1 , further comprising; </claim-text><claim-text> (a) providing a gene expression profile for a control human keratinocyte cell ; </claim-text><claim-text> (b) generating a gene expression profile for a human keratinocyte cell exposed to at least one perturbagen; </claim-text><claim-text> (c) identifying genes differentially expressed in response to the at least one </claim-text><claim-text> perturbagen by comparing the gene expression profiles of (g) and (h);</claim-text><claim-text>(d) creating an ordered list comprising identifiers representing the differentially </claim-text><claim-text> expressed genes, wherein the identifiers are ordered according to the differential expression of the genes identified in (i); </claim-text><claim-text> (e) storing the ordered list created in step (j) as a keratinocyte instance on the at least one computer readable medium; and </claim-text><claim-text> (f) constructing a data base of stored keratinocyte instances by repeating (g) through (k), wherein the at least one perturbagen of step (h) is different for each keratinocyte instance. <!-- EPO <DP n="124"/>--> </claim-text></claim><claim id="clm-0003" num="3"><claim-text>3. The method according to claim 1 or claim 2, comprising using a programmable computer to perform one or more of steps (c), (d), (e), (f)<sub>&gt;</sub> (0. Q), (k) and (1). </claim-text></claim><claim id="clm-0004" num="4"><claim-text>4. The method according to any of claims 1 to 3, wherein the step of generating is performed by extracting a biological sample from the treated cell and subjecting the biological sample to microarray analysis. </claim-text></claim><claim id="clm-0005" num="5"><claim-text>5. The method according to claim 4, wherein the microarray analysis comprises a global microarray or a specific microarray, wherein the specific microarray comprises oligonucleotides which hybridize to genes corresponding to a gene expression signature for a cellular phenotype. </claim-text></claim><claim id="clm-0006" num="6"><claim-text>6. A method for implementing the data architecture according to any of claims 1 to 5, to generate connections useful for identifying cosmetic agents effective for treating aged skin, the method comprising querying the data architecture with at least one skin aging gene expression signature, wherein querying comprises comparing the at least one skin aging gene expression signature to each stored fibroblast instance, wherein the skin aging gene expression signature represents genes differentially expressed in association with at least one skin aging condition. </claim-text></claim><claim id="clm-0007" num="7"><claim-text>7. The method according to claim 6, wherein the at least one skin aging gene expression signature is constructed by a method comprising (i) identifying genes having up-regulated expression in the at least one skin aging condition when compared to a control; (ii) identifying genes having down-regulated expression in the at least one skin aging condition when compared to a control; (iii) creating one or more gene expression signature lists associated with the at least one skin aging gene expression signature comprising identifiers corresponding to a plurality of the genes identified in (i) and (ii); and storing the one or more gene expression signature lists on the at least one computer readable medium. </claim-text></claim><claim id="clm-0008" num="8"><claim-text>8. The method according to claim 7. wherein at least one skin sample is taken from a human subject exhibiting the at least one skin condition, a biological sample is extracted from the skin sample, and a gene expression profile of the at least one skin sample is generated prior to at least one of the steps (i) and (ii). </claim-text></claim><claim id="clm-0009" num="9"><claim-text>9. A method according to claim 8. wherein the skin sample comprises cells from epidermal and dermal layers of the human subject. <!-- EPO <DP n="125"/>--> </claim-text></claim><claim id="clm-0010" num="10"><claim-text>10. The method according to any of claims 6 to 9, wherein the comparison further comprises assigning a connectivity score to each of a plurality of instances. </claim-text></claim><claim id="clm-0011" num="11"><claim-text>1 1 . The method according to claim 10 further comprising formulating a skin care composition comprising a dermatologically acceptable carrier and at least one perturbagen, wherein the connectivity score of the instance associated with the at least one perturbagen has a negative correlation. </claim-text></claim><claim id="clm-0012" num="12"><claim-text>12. The method according to any of claims 1 to 5, further comprising: providing a microarray scanner for receiving a sample comprising human dermal fibroblast cells and/or human keratinocyte cells; and configuring a first programmable computer for transmitting gene expression data from the scanner to a second programmable computer containing the at least one computer readable medium. </claim-text></claim><claim id="clm-0013" num="13"><claim-text>13. The method of any of claims 6 to 1 1 wherein the at least one skin aging gene expression signature consists of genes selected from the genes set forth in Tables A and B. </claim-text></claim><claim id="clm-0014" num="14"><claim-text>14. The method of any of claims 6 to 1 1 wherein the at least one skin aging gene expression signature consists of genes selected from the genes set forth in Tables C and D. </claim-text></claim><claim id="clm-0015" num="15"><claim-text>15. The method of any of claims 1 to 14 wherein each identifier is selected from the group consisting of a microaiTay probe set ID. a human gene name, a human gene symbol, and combinations thereof representing a gene set forth in any of Tables A-D wherein each of the one or more gene expression signature lists comprises between about 50 and about 600 identifiers. </claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
